Development of a Pathogen Profiling Approach for Detecting and Dissecting Markers of Pathogenicity and Hyper-Variability in Group B Streptococci by Loy, Richard Paul
Open Research Online
The Open University’s repository of research publications
and other research outputs
Development of a Pathogen Profiling Approach for
Detecting and Dissecting Markers of Pathogenicity and
Hyper-Variability in Group B Streptococci
Thesis
How to cite:
Loy, Richard Paul (2013). Development of a Pathogen Profiling Approach for Detecting and Dissecting Markers of
Pathogenicity and Hyper-Variability in Group B Streptococci. PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2013 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
Development of a pathogen profiling approach for 
detecting and dissecting markers of pathogenicity 
and hyper-variability in group B streptococci.
R.P. Loy BSc.
Submitted for Doctorate of Philosophy 
Faculty of Life Sciences 
The Open University 
September 2012
cP  ; • .vv .ac.:e r* 2 5  »<*'£■
£>AT<£. o1,-- ft ; .gft
ProQuest Number: 13835942
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com plete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13835942
Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States Code
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
Acknowledgments
This is probably the most overused cliche in the writing of acknowledgments but this section of 
the thesis is both the easiest and hardest section to write with so many people to thank for their 
help in completing this thesis. First of all I would like to thank my supervisors Julie Logan, Kirstin 
Edwards and Christine McCartney for their help, support and probably most importantly patience. 
I would also like to thank Saheer Gharbia, mostly for her scientific input but also for providing a 
number of well-timed pushes throughout this project. For the bioinformatics work I would like to 
thank Antony Underwood and Raju Misra for support and training, they were very important in 
developing my bioinformatics skills to the level they are now at and particular thanks go to Nadia 
Ahmod who provided the initial scripts that formed the basis of a large part of this project as well 
as helping develop my skills. Unfortunately she passed away after a long illness before this project 
could be completed. It is a great shame that no one else will be able to receive the benefit of her 
wisdom in the future. For the laboratory work I would like to thank Chloe Bishop, Sally Langham, 
Dunstan Rajendram, the staff of NCTC for training and assistance as well as the rest of the staff of 
DBHT. Last but not least I would like to thank my wife Megan, mainly for putting up with me 
throughout the PhD process and also for providing a more or less never-ending supply of coffee 
and toast, without this support, it is unlikely this thesis would ever have been completed.
2
Abstract
Sequence typing is a rapidly evolving field and offers improved analysis into the genetic 
background and lineages of organisms compared to serological or DNA banding pattern based 
analysis. However, the resolution of molecular typing schemes varies between organisms and 
often loci used in sequence typing lack discriminatory power and give limited information into the 
evolution of .the organism. This is particularly true of group B streptococci (GBS), where the same 
sequence types appear worldwide, which is unlikely for such a pathogen.
This project aimed to develop a two component pathogen profiling approach which accurately 
reflected the phylogeny of GBS isolates, using elements of the core genome and elements of the 
variable genome. To address this a bioinformatic approach which selected loci for sequence 
typing based on predicting genes which evolve in the same manner as the average for the core 
genomes was adapted from a previously applied study for designing genus level sequence typing 
schemes. This informed the selection of candidate loci which were then experimentally verified, 
using a collection of 135 GBS clinical isolates. It was demonstrated that it was possible to obtain 
greater resolution and accuracy using only three unique genes that are intelligently selected, 
rather than using seven known housekeeping genes that are selected at random.
Sources of hyper variability within the genome, in particular the presence of mononucleotide 
repeats (MNR) were investigated in non-coding DNA. It was postulated that these regions of DNA 
are more prone to mutation due to the lack of selective pressures, the presence of MNR repeats 
make these regions more unstable during replication and that in core genes these regions may be 
involved in genomic regulation by slipped strand mispairing. Results did confirm that non-coding 
DNA containing MNR repeats were more variable than DNA without them but these did not 
match the discriminatory power of MLST typing or the new three gene typing scheme. However, it 
was observed that one MNR tract was an insertion site for one of two insertion sequences and 
that typing using the presence/absence of these insertion sequences further enhanced
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discriminatory power in addition to the 3 gene scheme and may yet prove to be an indicator of 
virulence in clinical GBS isolates.
As well as demonstrating that sequence typing can be more informative if sequence typing 
markers are intelligently selected, this project also showed the importance of developing 
computational methods to analyse pathogen genome sequences that are being released in ever 
increasing numbers thanks to new and constantly improving technologies. For example, methods- 
used here to determine the core and pan-genome of any given set of genomes are becoming 
increasingly important to the study of pathogen evolution, virulence and population dynamics.
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Chapter 1 
Introduction
1.0 Introduction
1.1 Streptococcus agalactiae
1.1.1 Biology
The genus Streptococcus are Gram positive bacteria with spherical or ovoid cells arranged in 
chains or pairs (figure 1.1). All species are non-motile, non-spore forming and have complex 
nutritional requirements. They, are obligate parasites of mucosal membranes. Some Streptococcus 
species are members of the commensal microflora and others are highly pathogenic. 
Streptococcus agalactiae (group B streptococcus or GBS) is a combination of the two, it can 
colonise the gastrointestinal and genitourinary tract without causing symptoms but if it becomes 
established in a normally non-sterile site it can cause severe invasive disease (112). It was first 
isolated from cattle as the cause of bovine mastitis with other pathogenic streptococci and first 
differentiated into group B streptococci in 1934 by Rebecca Lancefield (126). GBS emerged as a 
serious human pathogen in the 1970s and transfer of virulence genes from group A streptococcus 
has been presented as one possible explanation for its sudden emergence
Figure 1.1: Scanning electron micrograph o f the chains o f GBS bacterium
Source: Craig Rubens, University of Washington
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1.1.2 Epidemiology, Pathogenesis and Clinical Disease
1.1.2.1 Trends in GBS Incidence in the UK 
Incidence of bacteraemia caused by GBS in the UK increased substantially between 2005 to 2006 
from 1249 to 1442 (15% increase), after a slight decrease in incidence between 2006-2007 (1442 
to 1403). A further increase was observed between 2007-2008 from 1403 to 1550 (10% increase). 
2008-2009 also showed an increase from 1550 to 1571 (1.3% increase) and the latest year for 
which figures are available 2009-2010 showed an increase from 1571 to 1610 (2.5% increase) ' 
making the total increase from 2004-2010 of 27% meaning the disease burden caused by GBS is 
on a long upward trend in the UK. As shown in Figure 1.2 the increased incidence of bacteraemia 
caused by GBS combined with a decrease in incidence of bacteraemia caused by group A 
streptococci (GAS) between 2004 and 2010 (1754 to 1574) make GBS bacteraemia the current 
leading cause of pyogenic streptococcal bacteraemia in England, Wales and Northern Ireland (85)
Figure 1.2: Bacteraemia caused by pyogenic streptococci (group A streptococci, GAS, group B 
streptococci, GBS, group C streptococci, GCS and group G streptococci, GGS) in England, Wales 
and Northern Ireland 2004-2008.
2000
1800
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1200
1000
800
600
400
200
2004 2005 20072006 2008 2009 2010
Source: Pyogenic and non-pyogenic streptococcal bacteraemia, England, Wales and Northern
Ireland: 2010, Health Protection Agency
The overall rate of GBS bacteraemia in 2010 for England, Wales and Northern Ireland was 2.8 per
100,000 population the same rates are observed in Wales and England although Northern Ireland 
has a much higher level of incidence (3.4/100,000 population). Within England, rates vary 
considerably by region with the lowest rates being observed in the North East and South East 
(both 2.0/100,000) and the highest rates outside of Northern Ireland being the West Midlands. 
(3.3/100,000). Rates of GBS bacteraemia were highly concentrated in infants, 71 per 100,000 
population <ly, with higher rates in males than females with the exception of 15-44 year olds (2.0 
and 0.6 in females and males respectively). Untreated, mortality rates are high (50%) and many 
survivors showed permanent neurological sequelae. Use of intrapartum antibiotic prophylaxis 
administered during labour reduces mortality rates to ~15% (209).
1.1.2.2 Epidem iology o f  E arly  Onset and Late Onset Disease 
In the UK early onset disease (EOD) is more common than late onset disease (LOD) with 
0.39/1000 live births opposed to 0.27/1000 live births (85) (Table 1.1). However, the incidence of 
LOD is more commonly associated with the onset of meningitis with 43% of cases presenting with 
meningitis compared to 11% for cases of EOD. Conversely, septicaemia is more prevalent in EOD 
(63%) than LOD (41%) (128). Of the number of cases developing meningitis, half develop long 
term disability including mental retardation and loss of vision (13) and since meningitis is more 
common in LOD the majority of long-term disability is caused by LOD even accounting for the 
lower number of cases, whilst EOD has a higher case fatality rate of 10% compared to 8% for LOD 
(86). However, it is worth noting that these rates may be overestimated since the UK has no 
universal screening system and less severe cases of EOD or LOD may be missed (128)
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Table 1.1: The onset o f GBS bacteraemia split according to age a t onset and the 95% confidence 
interval (Cl)
Number Rate/1000 Live Births 95% Cl
Total Cases (0-90 Days) 506 0.69 0.63-0.76
Early Onset (0-6 Days) 302 0.41 0.37-0.46
Late Onset (7-90 Days) 204 0.28 ....0.24-0.32
Source: Pyogenic and non-pyogenic streptococcal bacteraemia, England, Wales and Northern
Ireland: 2010, Health Protection Agency
1.1.2.3 Pathogenesis o f E arly  Onset Disease 
Research into GBS has focused on the organism's ability to cause invasive disease in neonates 
since this is the most common form of the disease. Disease in neonates can be split into two 
forms, early onset (<7 days) and late onset (7-90 days) which is less common. Pathogenesis of 
early onset invasive neonatal disease occurs first through asymptomatic colonisation of the 
genitourinary tract of a pregnant mother, shown in 38% of adult women (64) followed by 
transmission to the neonate which occurs in 50-70% of births (167). Acquisition by the infant may 
occur by one of two mechanisms: 1) exposure in utero after ascending infection of the placental 
membranes and amniotic fluid; or 2) transmission through passage of an infected birth canal. In 
the first stage of infection GBS enters the lung causing infected neonates to present with 
respiratory symptoms. Autopsies of early onset fatalities show 80% have histological evidence of 
lobar or multilobar pneumonia. From the lung GBS traverses three host barriers, the alveolar 
epithelium, the pulmonary interstitium and the pulmonary endothelium, which damages lung 
tissue and allows GBS entry to the blood stream. The host immune response to GBS in the blood 
causes sepsis syndrome and in some cases septic shock, which is clinically indistinguishable from  
Gram-negative endotoxemia. From the blood, GBS can cross the blood brain barrier resulting in 
meningitic incidence (167).
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  _ 1.1.2 A  Pathogenesis o f LateO nset Disease   r
Whereas the mode of infection for early onset GBS infection is relatively well understood, the 
mode of infection for late onset disease in less well understood. A number of potential modes of 
infection have been postulated including acquisition of the organism vertically during vaginal 
delivery, or postnatally from maternal/carer contact, infected breastmilk (168) or nosocomial 
sources (177). As with early onset disease premature delivery is still considered a risk factor (187). 
It may be possible to identify the most likely level of transmission in individual cases by 
considering the method of delivery (vaginal or caesarean), the infection status of the mother or 
method of feeding i.e. breast or formula (45).
After infection, pathogenesis is broadly similar to early onset disease except that meningitis is 
more commonly associated with late onset disease. Either because the host immune system is 
more developed and therefore more likely to trigger inflammation around the brain or the fact 
that early onset disease shows more severe pneumonia and sepsis syndrome causing fatality 
before meningitis sets in (167).
1.1.2.S A dult Infection
GBS has also been shown to cause disease in adult patients, the most common presentation being 
skin and soft tissue infections but urinary tract infections (239), meningitis and bacterial sepsis 
have been documented. Cases in adult populations more frequently affect the elderly and 
immunocompromised but cases in patients with no known risk factors have been described. One 
study of GBS soft tissue infections showed that as high as 24% of patients had no obvious 
underlying conditions, mortality rates reached 7% and 11% of patients lost limbs through 
infection (130). The pathogenesis of GBS in adult infections usually relies on failures in the host 
immune system, for example one risk factor for GBS soft tissue infection is cutaneous ulceration 
demonstrating that disruption to the skin allows infection to become established and in some 
cases proceed into the blood stream (130). It is also possible that a combination of physical injury,
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pre-existing conditions and mixed infections can contribute to cause skin infections, one example 
being Necrotizing Fasciitis caused by Streptococcus agalactiae, Arcanobocterium haemolyticum, 
and Finegoldia mogna in a dog-bitten patient with diabetes (131). In patients with no known risk 
factors novel modes of transmission have been observed for example GBS entering the blood 
stream through lesions in the oral cavity caused by tooth brushing (71).
Pregnant women as well as being at risk of passing on the infection to neonates can also develop 
symptoms from infection including fever, premature labour and symptoms associated with a 
urinary tract infection and these symptoms can be used as risk factors of transmission to the 
neonate (128).
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1.1.3 Detection and Identifica tion
1.1.3.1 Culture
Standard laboratory identification o f GBS is performed by culture, cells are grown on blood agar 
and GBS identification is positive if: (3-haemolysis occurs on a Columbia agar plate containing 5% 
horse blood (figure 1.3), Gram staining shows Gram-positive cocci in pairs or short chains, there is 
a negative reaction w ith catalase reagent (figure 1.4), and Lancefield grouping w ith type B 
antisera is shown (207). Additionally the Christie Atkins Munch-Petersen (CAMP) test can identify 
GBS strains by showing lysis o f sheep or ox cells when grown in the proxim ity o f Staphylococcus 
aureus strains under anaerobic conditions (figure 1.5). Detection in a clinical setting is commonly 
performed by selective culturing on enriched medium tha t w ill allow preferential growth o f GBS 
when inoculated w ith  samples taken from  vaginal or rectal swabs. For example the StrepB carrot 
broth (Hardy Diagnostics, Santa Maria CA, USA) is a pigmented enrichment broth which positively 
identifies GBS if there is a positive colour change (figure 1.6).
Figure 1.3: (3-haemolytic activity o f GAS, GBS, GFS and GGS.
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Source: CDC Laboratory Slide Set
Figure 1,4: Negative catalase reagent test
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Figure 1.5: Positive CAMP test
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Figure 1.6: Positive GBS test using the Strep B carrot broth
Pigmented Broth — Positive Result
Positive color change
Source: CDC Laboratory Slide Set
1.1,3.2 Im m u n o lo g ic a l D etection  
GBS carries the Lancefield group B antigen and detection methods using latex agglutination and 
immunoassays fo r the detection o f this antigen have been developed (215) (figure 1.7). The HPA 
Streptococcus Reference Laboratory uses the Streptex kit (Remel, Lenexa KS, USA) to  confirm  the 
identity o f cultures. This assay requires culturing o f GBS prior to  perform ing the test and can 
therefore only be used to  confirm  culture-based identification. Two early studies on similar 
immunological assays have been carried out to  assess the ir sensitivity and specificity when 
applied directly to  clinical samples which showed that when comparing selective broth culturing 
to  immunoassays fo r identification of GBS direct from  vagino-rectal swabs, sensitivity o f between 
only 4%-37% was observed (8,257). However, the prevailing view is tha t latex agglutination assays 
give a high level o f false positive and false negative results (51). Therefore these tests can only be 
used to  confirm culture identification or identify heavily colonised patients (180).
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Figure 1.7: Positive and Negative latex agglutination tests fo r  GBS
Commercial Agglutination Tests
Positive agglutination Negative agglutination
G 55 is present G55 is not presen t
Source: CDC Laboratory Slide Set
1 .1 3 3  M o le c u la r  D e tec tion  
The Polymerase Chain reaction (PCR) was developed by Kary Mullis in 1983 and is a molecular 
biology technique to amplify from  a small number o f copies o f a piece o f DNA, generating 
thousands to  millions o f copies o f a particular DNA sequence selected by the use o f target specific 
primers and thermostable enzymes.
PCR has been used fo r the identification o f GBS where loci unique to  GBS have been amplified by 
conventional or real-time PCR (54). There is a w ide array o f assays fo r clinical diagnosis and 
research which amplify d ifferent genomic targets e.g the genes cfb, encoding CAMP factor and 
scpB which encodes segregation and condensation protein B (110,190).
Diagnostic assays are moving towards using real-time PCR (39,54,106,166,190,227,238) in which 
amplification is measured in real-time by using sequence-specific probes or dyes tha t fluoresce 
when they bind to or intercalate w ith  double stranded DNA. The interaction o f the probes or
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fluorescent dyes with double stranded DNA is measured at each cycle and used to calculate the 
amount of DNA in the reaction. Real-time PCR has several advantages over conventional PCR, it is 
faster, it can be carried out in a closed tube system preventing carry over contamination and 
results are immediately accessible since no post amplification visualisation of product is required.
Identification using a PCR assay offers several advantages over culture. DNA can be isolated 
* directly from vaginal and/or rectal swabs of pregnant women eliminating the need for time 
consuming culture (238). Using PCR can determine the GBS colonisation status of mothers and 
identify infection in neonates faster than culture based methods, and it could even be used as a 
point of care test speeding up detection further. PCR methods have also been shown to be 
superior in identifying colonisation than culture. For example, Natarajan et al. showed that a real­
time PCR assay for the cfb gene had a sensitivity of 90% and detected GBS carriage in 51% of 
women tested compared to culture which only identified colonisation in 17% of women (166). 
However, PCR may overestimate the rates of colonisation because PCR cannot distinguish 
between live and dead bacteria and since PCR is more sensitive that culture, low level colonisation 
that may not be able to cause disease can also be identified, leading to overuse of prophylactic 
antibiotics.
Finally, generic real-time PCR assays targeting the 16s rRNA fragments have been developed to 
distinguish bacterial septicaemic disease from other causes of neonatal illness such as asphyxia or 
complications of prematurity. These have been used with varying success in the analysis of whole 
blood for neonatal sepsis, specificity is generally high but sensitivity can be as low as 40% 
(106,107).
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1.1.3.4 Novel Methods  
Although not a method used for diagnosing GBS infection, surface-enhanced-laser-desorption- 
ionization time of flight mass spectrometry (SELDI-TOF MS) has been successfully used to identify 
four amniotic fluid proteomic biomarkers, namely human neutrophil defensins two and one and 
calgranulins C and A. These have been shown to be strongly predictive for neonatal sepsis and 
neonates born to women, with three out of four of these biomarkers shown to have an 
association with increased incidence of sepsis (25,26). Using SELDI-TOF MS in this manner has 
advantages and disadvantages. It's advantages include being a rapid catch all for neonatal sepsis 
allowing treatment to be rapidly applied. Conversely, since this method is diagnosing sepsis rather 
than a specific infection no causative agent is known meaning organism specific qualities such as 
antibiotic resistance could be missed.
1.1.4 Treatment and Prevention/Diagnosis
1.1.4.1 T reatm ent
If GBS is detected prior to birth or risk factors such as prolonged rupture of membranes or fever in 
labour may indicate infection, treatment is intrapartum antibiotics given to the mother during 
labour. If transmission to the neonate is not prevented and the neonate shows signs of infection 
intravenous antibiotics and intensive care treatment are used. The standard antibiotic used for 
treatment for GBS infection is penicillin, with clindamycin or erythromycin used in patients allergic 
to penicillin. Figures for the UK from 2003 to 2010 show an increase in resistance to erythromycin 
from 7% to 15%, while clindamycin levels fluctuate around 8-9% when figures where last available 
(85). There are two main mechanisms conferring resistance to these antibiotics. The first is 
erythromycin ribosomal methylase (mediated by ermB, ermA, ermTR or ermCgene variants) 
which confers cross-resistance to macrolides, lincosamides and streptogramin B (77). The second 
is a macrolide efflux pump (mediated by mef) which confers resistance to 14 and 15 member 
macrolides only (27).
It has been suggested that.the use of intrapartum antibiotics could lead to an increase in the 
prevalence of resistant organisms and cause adverse effects in neonates. For example, Stoll et al. 
showed that increased antibiotic use in neonates has led to decreased rates of early onset GBS 
infection but also led to a rise in early onset E. coli sepsis leaving overall rates of early onset sepsis 
in neonates stable (226). However, this conclusion is far from the consensus. Cousens et al. 
showed that intrapartum antibiotic use has decreased the level of complications from preterm 
delivery, reduced rates of neonatal infections and reduced overall neonatal mortality (36) and 
Balter et al. showed that neonates born to mothers treated with intrapartum antibiotics were no 
more or less likely to undergo invasive procedures or to receive further antibiotic treatments (10).
1.1.4.2 Prevention/D iagnosis
1.1.4.2.1 Risk Factor Based Screening 
In the UK national policy dictates prevention of GBS infection in neonates by a risk factor-based 
screening approach for infection in pregnant women using five risk factors, preterm labour, 
prolonged rupture of the membranes, fever in labour, GBS bacteriuria detected during the 
current pregnancy and previous baby affected by GBS infection (196), with the first three risk 
factors considered to be the most important (128). It is predicted that this risk factor based 
approach is 67% effective at preventing early onset GBS disease with a 17% false positive rate 
(128). However, despite national guidelines being issued in 2003 they have not yet been 
implemented nationally and only 34 of 227 maternity units could be shown to be following 
national guidelines exactly (38).
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1.1.4.2.2  Culture Screening
In the US, Centers for Disease Control and Prevention (CDC) guidelines recommend culture 
screening all pregnant women between 35-37 weeks gestation (207). Culture methods identify 
more cases of GBS colonisation that risk factor screening with 90% GBS positive mothers 
identified by culture compared to 67% by risk factor screening alone (128). There are weaknesses 
in this approach, costs are high, GBS colonisation can be transient so results at the time of testing 
may not reflect colonisation status during labour and rupture of membranes caused by GBS can 
trigger premature labour which can put birth before the 35 week mark when culture tests would 
be performed. However, culture based methods are still an improvement on a risk factor based 
approach since it can be shown on a national level that GBS incidence rates have fallen in the USA 
since the introduction of CDC guidelines recommending the introduction of culture screening 
between 35-37 weeks gestation. This is shown in figure 1.8 and can be compared to the increasing 
levels of GBS infection in the UK shown in figure 1.2.
Figure 1.8: The decrease in GBS incidence in the USA after introduction o f CDC guidelines
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1.1.4.2.3 PCR versus Immunological screening 
Although there are no national guidelines that use either PCR or immunological methods as a 
standard method for GBS screening there have been a number of studies to suggest these 
methods may be more effective than culture. Firstly, PCR based assays are faster than culture and 
can be performed in either a laboratory setting with appropriate equipment or theoretically in a 
ward or field setting using portable real-time PCR system such as the RAZOR EX (Idaho Technology 
Inc, Salt Lake City UT, USA) which would overcome some of the drawbacks of culture-based 
screening.
The sensitivity and specificity of PCR based assays has been shown to be either comparable to 
culture screening, for example the RiboSEQ GBS test was shown to be 96.4% sensitive and 95.8% 
specific compared to culture screening (252) or superior to culture. For example, Rallu et al 
showed that PCR assays for the scpB and cfb genes had sensitivity and specificity rates of 99.6% 
and 100% and 75.3% and 100% respectively, compared to a sensitivity of 42.3% and specificity of 
100% for the standard CDC culture method (190). This study also compared the PathoDX (remel) 
culture identification method and found an improvement on the CDC culture screening but was 
not as sensitive or specific as either of the PCR methods with a sensitivity of 57.3% and a 
specificity of 99.5%. However, each of these three methods were carried out on cultured 
organisms, not directly from patient swabs. Another study found that real-time PCR screening was 
able to identify three times more cases of GBS colonisation in pregnant women with 51% of 
women assessed by real-time PCR opposed to 17% assessed by culture being identified as 
colonised by GBS as the time of delivery. This study showed that real-time PCR would be a useful 
clinical tool in the management of infants potentially at risk of invasive GBS infection. (166).
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1.1.5 Vaccination
In theory vaccination would eliminate infection and the need for screening programs. However, 
since in practice uptake of vaccines is never 100% and herd immunity is unlikely to be applicable 
to an organism that is for the most part a commensal organism even vaccination would not 
completely remove the burden of GBS disease. Antibody levels in the neonate remain constant for 
up to three months after birth and therefore would also protect against late onset disease. It 
would remove the need for antibiotics preventing an increased risk of allergic reactions later in 
life and prevent the removal of penicillin sensitive organisms allowing increased growth of 
antibiotic resistant bacteria (128). Natural immunity to GBS can be conferred by transmission of 
capsular polysaccharide (CPS) serotype specific IgG antibodies across the placenta (9). Because of 
this a number of vaccines are composed of capsular polysaccharides conjugated to a protein 
which improve the carbohydrates immunogenicity (76). For example, a tetravalent vaccine 
containing tetanus toxid conjugated to CPS la, lb, II and III is predicted to prevent 90% of cases of 
invasive neonatal disease (176). However CPS vaccines would require updating as new serotypes 
emerge in human disease. Sequencing of GBS genomes has also allowed reverse vaccinology 
(100,192) research to develop a vaccine based on universal cell surface protein antigens which 
may overcome this problem (147,211). Other advantages include the reduced time of vaccine 
development, theoretically reducing development time from 5-15 years to 1-2 years (100). Other 
problems with vaccine development are political and economic, such as reluctance to develop 
products for use during pregnancy for the fear of teratogenicity despite at least one vaccine being 
proved non-teratogenic in rabbits (174) and perceived limited returns due to scepticism 
surrounding vaccines in general (128).
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1.2 Genomics of GBS
1.2.1 Typing Methods
1.2.1.1 Serotyping
GBS can be classified by serotyping (126) on the basis often type specific capsularpolysaccharides 
(CPS) IA, IB, II, III, IV, V, VI, VII, VII and the recently proposed IX (216). They can be further 
classified according to three cell surface localised protein antigens C, X and R. A recent meta­
analysis has shown that the most common serotypes worldwide are serotypes la, III and V which, 
account for 72% of GBS isolates (95). Serotyping is most commonly performed by latex 
agglutination using antibodies specific to each CPS and protein antigen (215). Serotyping via latex 
agglutination has been used since it is a rapid, simple method for typing GBS. Serotyping may 
have been superseded by molecular methods that better differentiate GBS isolates but serotyping 
is still used for historical reasons since this method has been used since the discovery of GBS in 
1934 and by maintaining this method all GBS clinical isolates that have been serotyped are 
comparable. Secondly vaccine development is looking at CPS variants as vaccine candidates so the 
serotypes in the population must be monitored to select the most appropriate candidate(s) for 
vaccination (20,251). However, there are limitations to serotyping including non-typeable isolates, 
one study showed 12% of isolates were nontypeable by latex agglutination (116) and some 
serotypes show cross-reactivity resulting in a non-conclusive result. Finally it has been shown that 
there is significant genetic variation between isolates of the same serotype as shown by MLST and 
PFGE (58,103,191), meaning that serotypes do not reflect genetic diversity.
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1.2.1,2 M olecu lar Methods
1 2 .1 2 .1  Random Amplification of Polymorphic DNA  
Random Amplification of Polymorphic DNA (RAPD) was originally developed in 1990 by Williams 
et al. (255) and is a method to construct genetic maps without prior knowledge of DNA sequence. 
In this method random 8-12 nucleotide primers are used to amplify regions of chromosomal DNA, 
resulting in the amplification of a number of different size PCR products which are visualised by 
agarose gel electrophoresis. Polymorphisms are identified by the presence/absence of each band 
and so RAPD can be used to place isolates into clusters. Using RAPD, Duarte et al. showed 
relationships between GBS isolates from cows of the same herd (48) and Martinez et al. showed 
that human isolates clustered separately from bovine isolates (154). It can also be used to identify 
regions of the genome that are linked to pathogenic traits, since missing or additional bands can 
indicate insertions and deletions that render priming sites too distant to allow amplification, or 
insertions/deletions that change the size of a DNA segment without preventing its amplification 
(255). For example, van der Mee-Marquet et al. used RAPD to identify prophagic DNA fragments 
associated with virulent GBS strains (244).
RAPD has largely been replaced by other profiling methods such as PFGE and MLST for typing of 
GBS clinical isolates. However a number of research groups still use RAPD. The most common use 
of RAPD is in epidemiological studies measuring transmission of isolates between defined patient 
groups and it has been used to show direct transmission or lack of direct transmission between 
patients (52,53,82,243). It has also been used for confirmation of results generated using other 
profiling methods (151).
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1.2.1.2.2 Pulsed Field Gel Electrophoresis 
Pulsed Field Gel Electrophoresis (PFGE) was developed as a method to view large DNA molecules 
of up to 2000kb via gel electrophoresis and was originally used to separate intact chromosomes of 
Saccharomyces cerevisiae. The technique uses alternatively pulsed, perpendicularly oriented 
electrical fields at least one of which is inhomogeneous. The duration of the electrical pulses is 
varied from 1 second to 90 seconds to achieve optimal separations of DNA molecules ranging 
from 30 to 2000 kb in size (210). For fingerprinting of bacterial genomes the bacterial 
chromosome is fragmented using a restriction enzyme that cuts the genome at a small number of 
restriction sites (158). Following digestion, DNA is subjected to PFGE as described above and the 
position of fragments on a gel, which indicates the size of the fragments, is used to cluster 
bacterial isolates. PFGE has been used in typing GBS isolates to show that isolates within the same 
serotype show considerable genetic variation (58), that particular fragments detected can be 
linked with virulent isolates from CSF samples (194) and has clustered 35% of macrolide-resistant 
isolates into one PFGE type (44). PGFE is also useful for identifying chromosomal insertions or 
deletions, for example Bohnsack et al. used PFGE to show the presence of two GBSil introns in 
serotype III GBS isolates by selecting relevant bands in the PGFE profiles where these introns may 
exist on the basis of their size and then confirmed their presence by subtractive hybridization (18). 
Martins et al. have also used PFGE to aid in the identification of rare capsule switching events in 
GBS (155).
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1.2.1.2.3 MLST
MLST is a sequence based molecular typing system in which a number of conserved housekeeping 
genes, usually seven, are sequenced and used to place strains into clusters known as sequence 
types. MLST was originally developed by Maiden et al. for Neisseria meningitidis (146) and to date 
has been used on more than 80 different species.  --------- —
In the GBS MLST scheme (103) fragments of 7 housekeeping genes involved in intermediary 
metabolism are sequenced (adhP, atr, glcK, glnA, pheS, sdhA and tkt). These loci were selected for 
their presence in all GBS strains (as evidenced by their use in MLEE typing systems) and their 
chromosomal location, since loci too close together cannot be used because recombination 
events may exaggerate evolutionary relationships (103). The sequenced loci are assigned an allele 
type on the basis of similarity to previously identified alleles using the online MLST database 
(101). Additionally in this method allelic sequences can be concatenated and used for 
phylogenetic analysis to study the relationships between strains. However, using concatenated 
sequences of the MLST loci to infer phylogeny has been shown to poorly reflect whole genome 
phylogeny in E. coli (119).
The advantages of using sequence data is that it is comparable between laboratories worldwide, 
whereas gel based methods such as RAPD and PFGE often show inter-laboratory variation. MLST 
also gives a larger number of unique sequence types when compared to either RAPD or PFGE. 
However, there are limitations to its discriminatory power as it clusters large number of isolates 
together. For example, the initial work when the GBS MLST scheme was developed examined 152 
isolates and placed them into only 29 sequence types with the majority of isolates (101/152) 
placed into only 4 sequence types (103). Further work using 338 strains gave an additional 29 
sequence types with the top 6 sequence types (all containing > 25 isolates) containing 281/388  
(72%) of all isolates (149).
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1.2.1.2.4 Molecular Serotyping
Molecular serotyping is a sequence-based method which aims to reproduce conventional 
serotyping by sequencing capsular polysaccharide (cps) gene clusters (115) as well as the genes 
encoding the cell surface antigens C, R and X (114). This method has been used successfully to 
serotype isolates that are non-typeable by immunological serotyping and could assign molecular 
serotype to 98.5% of isolates (116). However, the molecular serotypes assigned may not agree 
with conventional serotyping as demonstrated by Manning et al. who showed that molecular 
serotypes la and III could show either conventional serotype (149). Chaffin et al. demonstrated 
that this was due to the cpsH gene controlling CPS expression independent of the rest of the CPS 
operon (30). Molecular serotyping has been applied to a number of other organisms including E. 
coli (50) and Streptococcus pneumoniae (7).
1.2.1.2.5 Three Set Genotyping
Three set genotyping, proposed by Kong et al. in 2003 (117), is an extension of the molecular 
serotyping system. As well as sequencing cps genes and genes encoding cell surface protein 
antigens, a set of 5 mobile genetic elements (MGE's) are sequenced if they are present. Sequence 
type is assigned on the basis of allele sequence and presence/absence of the five MGE's (117). As 
with MLST large numbers of isolates are placed into a limited number of groups. In one study, the 
three set genotyping system places 83 isolates into 27 genotypes with the top four genotypes 
covering over 60% of tested isolates compared to 24 MLST types with 60% of isolates being found 
in the top four genotypes (228).
44
1.2.1.2.6 Sequence Typing using Non-Coding DNA
Various sequence typing methods have been developed using markers from non-coding regions of 
the genome. These include 16S-23S rRNA gene internal transcribed spacer (ITS) (66,199)/ Multi 
Spacer Typing (MST) (47) and Multiple Loci VNTR Analysis (MLVA) (144,240,245). The assumption 
behind sequence typing methods from non-coding regions is that non-coding DNA is theoretically 
unaffected by selective pressure and therefore can be more variable and will provide more 
discriminatory strain typing systems (47).
ITS typing was the first one developed and is useful because like the 16S rRNA gene it is common 
to all bacteria with the exception of Rickettsiales (138). It is also present in multiple copies per 
genome (21). Additionally, it is more variable than the 16s rRNA gene making this method more 
discriminatory.
As well as single non-coding regions for typing, multiple regions can be selected for various 
organisms to create Multi Spacer Typing (MST). MST loci can be selected either because of the 
presence of repeat regions which should also be more variable due to replication errors (74) or 
non-coding sequences which show significant variation between different bacterial strains. For 
example MST based on six intergenic spacers divided 36 Y. pestis strains from three biovars from 
dental pulp of patients deceased from plague in the second and third pandemics into 19 sequence 
types (47). MST has also been applied to Rickettsia conorii (63), Rickettsia prowazekii (260), 
Rickettsia sibirica (62), Coxiella burnetii (69), Bartonella henselae (134,136), Bartonella quintana 
(61) and Tropheryma whipplei (137) and when MST schemes are compared to MLST schemes MST 
is shown to be more discriminatory (63,136).
Multiple Loci VNTR Analysis (MLVA) is used to type organisms based on the number of tandem  
repeats found at any given locus that varies in copy number. These repeats and are dispersed 
widely in both human and bacterial genomes (144,240,245). In bacterial genomes, VNTR loci are 
found in non-coding regions as well as in genes and these non-coding VNTRs make good targets 
for strain typing because of their rapid evolution (63,170,240) and therefore MLVA tends to be
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more discriminatory than other methods. For some species which show high levels of homology 
such as Francisella tularensis (57,99), Bacillus anthracis (89,111,140), Yersinia pestis (113), and 
Mycobacterium tuberculosis (129) MVLA typing is considered the gold standard. MLVA has also 
been applied to other important human pathogens with varying levels of success such as 
meticillin-resistant Staphylococcus aureus strains (230), Burkholderia pseudomallei (236), and 
Clostridium difficile (241) and even GBS (186).
The rapidly evolving nature of non-coding loci, particularly repeat regions the main weakness of 
typing using non-coding DNA. For example MLVA typing of Mycobacterium leprae, has shown 
variation in the VNTR pattern between isolates of M. leprae biopsies from the same patient (162). 
Although this effect may be dependent on the species or even the specific target as it has also 
been shown that MLVA for Enterococcus faecium is less discriminatory than PFGE and MLST (253).
1.2.2 Whole Genome Analysis 
The ability to sequence whole genomes has revolutionised microbiology, allowing 
characterisation of bacteria at the genus, species and strain level (231). At the outset of this study 
there were 3 fully sequenced GBS genomes 2603V/R, NEM316 and A909 and 5 partially 
sequenced "shotgun" genomes 18RS21, 515, CB111, COH1 and H36B available. Currently, there 
are an additional 273 partially sequenced genomes that have recently been published by the JCVI.
Sequencing of single genomes allows general features to be characterised. For example, the G+C 
content of GBS strains NEM316 and 2603V/R is 35.6% and 35.7% respectively (68,232). Open 
reading frames (ORF's) in these genome sequences were determined by GLIMMER (40,201) which 
showed 2118 and 2175 protein coding genes in strains NEM316 and 2603V/R respectively. ORF's 
can be placed into families and super-families on the basis of similarity with known protein 
sequences using Markov models such as those used in the programs PFAM (11) and TIGRFAMS 
(78). This allows characterisation of genetic features such as the levels of surface genes and 
potential virulence genes (68,232).
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Comparison of multiple genomes is more informative. The genome sequences of NEM316 was 
compared to the previously sequenced Streptococcus pneumoniae strain TIGR 4 (233) and 
Streptococcus pyogenes strain M l  (60) and showed that out of the 2118 protein coding genes 
1173 and 1139 were shared in S. pneumoniae TIGR4 and S. pyogenes M l respectively. Strain 
2603V/R shared 1236 genes with S. pneumoniae and 1285 genes with 5. pyogenes. Comparison to 
other genomes can also reveal unique genes with links to pathogenesis. For example, analysis of 
strain 2603VR revealed that genes encoding the CPS capsule and genes essential for S. agalactiae 
P-haemolytic activity are unique to S. agalactiae. Analysis of multiple genomes from the same 
species allows the study of the genetic basis of pathogenicity by identifying unique and core 
genes. Core genes between strains of the same species reveal the backbone of the species and 
pathogenic elements common to the species (for example, the CPS capsule), while unique genes 
give clues to the variation in pathogenicity between strains. The core genome of S.agalactiae has 
been defined by a number of methods to be discussed later. Tettelin et al. placed the core 
genome between 1,750-1,841 (~85%) genes (231) and Lefebure et al. placed the number of core 
genes at 1686 (~80%). Konstantinidis et al. showed that strains 2603V/R and NEM316 share 87.5% 
of their genes (120) in his work using Average Nucleotide Identity (ANI) to develop a genomic 
method of taxonomic classification. ANI is a measure of species diversity, it is the average identity 
shared between genes in the core genome and therefore is a measure of how rapidly genomes 
are evolving and it has been shown that the phylogeny of genes with nucleotide identity values 
that correlate to the ANI accurately reflect whole genome phylogeny (119). Additional 
information from the genome of an organism can be discovered by performing genome 
alignments using tools such as the Artemis Comparison Tool (ACT) (28) to show chromosomal 
rearrangements and/or novel genomic islands. For example, Tumapa et al. studied genome 
plasticity in Burkholderia pseudomallei and identified 5 genomic islands (235).
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1.2.3 Virulence Factors 
There are already a large number of known virulence factors in GBS which can be grouped into 
several classes with differing roles in pathogenicity of the organism. The largest group of virulence 
factors are adhesins which are cell surface components involved in binding to host cells (37). GBS 
adhesins include fibrinogen binding proteins A and B (fbsA and fbsB) (212). Both bind human 
fibrinogen (208) but fsbA is attached to the GBS cell wall whereas fbsB is secreted (75,96). The 
pilus islands I and II are genomic islands containing genes which encode and regulate pilus 
structures (127,195,229) that have been shown to adhere to endothelial cells of the blood brain 
barrier (148) and the Lmb lipoprotein which has been shown to aid invasion of damaged 
epithelium (220). GBS also contains a number of exoenzymes which are secreted enzymes that 
break down extra-cellular products including hyaluronidase which degrades hyaluronic acid 
present in the ground substance of connective tissue (93) and streptococcal enolase, a glycolytic 
enzyme which aids GBS binding to plasminogen (173).
A number of GBS virulence factors are categorised by their induction of an immune response. The 
immunoreactive antigens are the C, X and R protein antigens used in serotyping (117) and have 
diverse functions (24,193,224,248). They include the a-C protein which mediates internalisation 
of GBS in human cervical cells (19), the a-like protein which is highly similar to the a-C protein 
except it carries an IgA-binding region similar to the one found in |3-C protein (122), the (3-C 
protein which may aid in preventing opsonophagocytosis (6,98), resistance to proteases (rib) 
protein which is carried by most serotype III GBS isolates and is involved in immune evasion 
(224,248) and the surface immunogenic protein (sip) which is of unknown function but is highly 
conserved in GBS (24,193).
GBS has also been shown to contain genes that are involved in immune evasion. For example the 
capsular polysaccharide locus prevents deposition of complement factor C3b and shields 
immunogenic proteins on the cell surface through molecular mimicry of mammalian sugar 
epitopes (4,46). Additionally C3-degrading protease and C5a peptidase inactivate C3 and C5a 
complement factors respectively (5,35) and serine protease is a surface expressed protein
involved in folding and maturation of secreted proteins and inhibition of genetic competence as 
part of the CiaRH two component regulatory system (94). Finally, haemolysin is a potent cytotoxin 
affecting a broad range of host cells (46) and is responsible for P-haemolysis of red blood cells 
when GBS is plated on blood agar (56).
1.2.4 Regulation and Nucleotide Repeats 
GBS can exist in multiple locations within the body and expresses different proteins at different 
stages in its pathogenesis therefore, different genomic expression profiles can be seen when the 
bacteria is subjected to different conditions. Mereghetti et al. showed that incubation of GBS 
isolates in human blood rapidly changed the transcription profile of the organism when compared 
to growth in laboratory rich medium. Proteins involved in interaction with the host 
coagulation/fibrinolysis system and proteins involved in bacterial-host interactions were rapidly 
up-regulated. Additionally, extensive transcript changes also occurred for genes involved in 
carbohydrate metabolism, probably indicating the relative scarcity of carbohydrates in human 
blood compared to laboratory media, including multi-functional proteins and regulators 
putatively involved in pathogenesis (161). Changes in the transcriptome of GBS can even be seen 
in different growth stages under laboratory conditions with an up-regulation of genes involved in 
virulence factor production and utilization of alternate carbon sources (214). The response of GBS 
to growth in human amniotic fluid has also been studied and showed that the majority of up- 
regulated genes were involved in amino acid and nucleotide production and metabolism, again 
reflecting the levels of available nutrients in laboratory medium compared to practically any 
source where the bacteria will be found in nature. Additionally, multiple virulence genes such as 
adhesins, capsule genes, hemolysin and IL-8 proteinase were shown to be up-regulated 
potentially affecting host-pathogen interactions (213).
Having shown that GBS responds to its environment as would be expected, it is worth considering 
the mechanisms in place to ensure this regulation. Currently, only a limited number of regulatory
methods are understood (187) but a number of genes important in virulence can be shown to be 
regulated by a variety of processes. Samen et al. showed using gene knock out models that the 
rovS gene is involved in regulating genes involved in attachment to human epithelium as well as a 
number of other key virulence genes (202). Rozhdestvenskaya et al. showed that the BgrR/S two 
component regulatory system led to decreased P-antigen expression and also led to reduced 
virulence properties in S. agalactiae (197). Rajagopal et al. have shown that Stkl positively 
regulates transcription of a cytotoxin, p-haemolysin/cytolysin that is critical for survival of GBS in 
the bloodstream and for resistance to oxidative stress (189). To summarise, GBS seems to have a 
repertoire of regulatory mechanism that deal with changes in environmental conditions, which is 
not unsurprising considering the number of different environments GBS can be isolated from.
However, response to the human immune system can often involve other methods of genetic 
regulation. For example Short Sequence Repeats (SSRs) are simple DNA sequence repeats made 
up from motifs of l-6bp that are repeated up to a dozen times (246) and there is evidence that 
these regions play a role in regulation of gene expression (74). Mononucleotide repeats (MNRs) 
have been linked to virulence genes due to their role in phase variation by slipped strand 
mispairing. Evidence for this includes the fact that SSR tracts above 3bp are heavily over 
represented in coding regions of the genome of E. coli (74). Also, on the basis of analysis of 81 
bacterial and 18 archaeal genomes, Orsi et al. suggests that homopolymeric repeats represent a 
general regulatory mechanism in prokaryotes since homopolymeric repeats are over represented 
in the first 10% of genes. This suggests a role in genomic regulation by slipped strand mispairing 
since it would be beneficial to the organism that transcription is terminated earlier in the gene to 
avoid expending resources on a non-functional transcript (171).
1.3 Tools and Technology
1.3.1 Bioinformatics
1.3.1.1 Phylogenetics 
Phylogenetics is defined as the study of evolutionary relatedness among groups of organisms 
which is discovered through molecular sequencing data and morphological data matrices. The 
term phylogenetics is of Greek origin from the terms phyle/phylon meaning "tribe/race" and 
genetikos meaning "relative to birth". Methods for estimating phylogenies include distance-based 
methods such as neighbour-joining and Unweighted Pair Group Method with Arithmetic Mean 
(UPGMA), maximum parsimony, Bayesian phylogenetic inference and Maximum Likelihood.
The distance based methods rely on clustering genetic distance values and therefore require 
either a multiple sequence alignment or a distance matrix as an input (164). Parsimony is a 
method that uses character classes and therefore can be used with both sequence and 
morphological data. It operates by evaluating candidate phylogenetic trees according to an 
explicit optimality criterion which provides a measure of the fit of the data to a given hypothesis, 
the tree with the most favourable score is taken as the best estimate of the phylogenetic 
relationships of the included taxa. DNA can easily be divided into character classes since at any 
given position in an alignment the character can be any IUPAC base (218).
Alternatly, eBURST (59) can be used to determine relationships between molecular typing data 
that defines isolates as strings of integers such as MLST allelic profiles. It works by attempting split 
allele types from sequence typing schemes into groups and then identify the founding sequence 
type of each group. The algorithm then predicts the descent from the predicted founding 
genotype to the other genotypes in the group displaying the output as a radial diagram, centred 
on the predicted founding genotype. Since it used allele type data eBurst is particularly good at 
identifying recombination events. But since it does not use sequence data directly it assumes that 
all allele types are equally related which is a weakness for this particular method (59).
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Maximum Likelihood generates the most likely tree given the confines of a previously selected 
model of evolution (258). Therefore selection of the model of evolution is crucial to creating good 
maximum likelihood trees. The ModelTest software (182) can select the best possible 
evolutionary model using the Akaike Information Criterion. The maximum likelihood process itself 
generates all possible trees and assesses the log likelihood of each tree against the sequence data 
given the selected model of evolution. The most statistically significant log likelihood value is 
considered the most likely tree. Bayesian phylogenetic approaches are computationally similar to 
maximum likelihood approaches with the main difference being the addition of prior and 
posterior probabilities. These are assumptions about the data made before generating a tree. 
Additionally, maximum likelihood generates one optimised tree whereas Bayesian methods 
generate multiple trees and each tree generated is used to generate a final consensus tree. That 
is, rather than the maximum likelihood "hill climbing" algorithm to generate the best possible 
tree, the Bayesian method uses a Markov Chain Monte Carlo (MCMC) algorithm of a large sample 
of highly probably trees to generate a consensus tree (Oliver Gascuel and Manolo Gouy, Personal 
Correspondence April 2009). It is also worth considering the "curse of dimensionality" in regards 
to this data. Since the number of sequences to consider is potentially rather large. The "curse of 
dimensionality" refers to issues that present themselves when analyzing data in high-dimensional 
spaces (such as data with a large number of variables). Essentially, high dimensional data may not 
form sufficiently defined clusters making data difficult to resolve. This becomes more of an issue 
as sample size increases and may be an issue with the number of sequences being analysed here. 
However, there are steps that can be taken to reduce the likelihood that high dimensionality data 
will cause problems.
Firstly we can consider the data we are inputting to the model itself. Since even low dimensional 
data can be turned into high dimensional data by the addition of duplicates only sequences that 
are representative of sequence types were used here therefore limiting the dimensionality.
Also, the curse of dimensionality is essentially a problem of clustering too large of a number of
samples in the same space and subsequent failure to resolve these clusters the selection of more
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variable sequences should somewhat overcome the issue by creating a larger space for variables 
to exist in.
Secondly, the selection of the Maximum Likelihood model somewhat overcomes this issue since 
the MCMC random walk based sampling method moves from point to point which limits the 
issues caused by large uniform clusters. This does make high Dimensionality data more 
computationally intensive as more steps are required before finding theoptimal likelihood but 
since 1) computational power is in abundance and 2) steps have already been taken to reduce the 
dimensionality of this data this is not expected that high dimensionality data will cause significant 
problems. Additionally, since all analyses were confirmed by bootstrapping, analysis problems 
caused by high dimensionality data could be identified by poor bootstrap support for points on 
the tree.
1.3.1.2 Identification  o f  the C ore/Variab le  Genome 
The core genome is defined as the pool of genes shared by all strains of the same bacterial species 
(159) but the term has also been used to describe genes shared within a genus (132).The principle 
behind establishing the core genome is relatively simple although in practice it may be more 
difficult. DNA or protein sequences within a genome are compared to gene or proteins sequences 
from one or more other genomes. Comparison is based on levels of homology which are 
calculated using either alignment algorithms (e.g. FASTA or ClustalW) or the BLAST algorithm. 
Despite the underlying mechanisms being similar different programs use different parameters to 
decide what constitutes a good alignment, each set of parameters are known as scoring matrices. 
Tettelin et al (231). has used three methods to establish the GBS core genome, firstly Smith and 
Waterman protein searches on all of the predicted proteins by using the SSEARCH program (which 
uses alignments created using Smith-Waterman's scoring matrix). Secondly a DNA search of all of 
the predicted ORF's of a strain against the complete DNA sequence of the other strain using the 
FASTA program and finally a translated protein search of all of the predicted proteins of a strain
against the complete DNA sequence of the other strain using the TFASTY program. Three separate 
methods were used to ensure reproducibility of bioinformatic results. When any of the three 
methods identified an alignment with a minimum of 50% sequence homology, over 50% of the 
protein/gene length, that gene was considered core (231). However using three different 
methods and considering genes picked by any one method as core, rather than taking genes 
picked by all three methods, may lead to over overrepresentation of the core genome.
Konstantinidis used a reciprocal best match BLAST approach to establish the core genome (119).
In this method every gene in a reference genome is BLASTed against one or more query genomes 
using homology and length criteria. Genes that meet these criteria in the query genome are 
BLASTed back against the reference genome. If the set criteria are met in both searches then the 
gene is considered core and is used in further analysis. This method is considered robust and 
reproducible and it has been used previously to establish the core genome of four bacterial 
groups Escherichia coii, Salmonella spp., Shewanella spp., and Burkholderia spp (119).
The variable genome is defined as everything in the genome which is not considered core and can 
easily be identified after a core genome analysis has been performed. Studying the variable 
genome allows identification of genes that differ between genomes and may identify potential 
virulence factors present in pathogenic strains that are not present in less/non pathogenic 
bacteria.
Recent advances and reduction in the cost of whole genome sequencing technologies has made 
sequencing of bacterial genomes quicker and cheaper and therefore has led to far higher volumes 
of genome sequences being available making comparative genomic analysis far more important 
and easier to perform. Because of this abundance of data new tools for analysis of the core 
genome are being developed, for example Panseq is an online tool to identify the core and 
accessory genomes using the BLASTn program of any given set of genomes (124) and CoreAligner 
which relies on creating alignments of orthologous groups to identify common regions within 
genomes (237). As whole genome bacterial sequencing becomes more common in research it is
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highly likely that software to perform comparative genomic analysis between next generation 
sequenced genomes will become standardised and even supplied as part of the standard software 
supplied with next generation sequencing platforms.
1.3.2 Sequencing
1.3.2.1 Sanger Di-deoxy Sequencing
Figure 1.9: Representation o f the Sanger sequencing process
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Di-deoxy sequencing is the most established sequencing method. First proposed by Sanger et al. 
in 1975 it works via the chain termination method (203). DNA amplified by PCR is placed into a 
reaction mix containing DNA polymerase, an oligonucleotide primer, a mix of deoxy and di-deoxy 
nucleotides and is subjected to cycle sequencing. As in PCR, DNA polymerase will extend a chain 
of nucleotides complementary to the template DNA. When a di-deoxy nucleotide is incorporated 
into the sequence further extension cannot occur. Within the reaction, this will occur at each 
nucleotide creating fragments at different lengths based on where a di-deoxy nucleotide is
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incorporated and will occur a sufficient number of times for visualisation of each fragment on a 
gel. Traditionally, one di-deoxy nucleotide is used per reaction and each reaction (A, G, C and T) is 
ran on one lane of a gel allowing the sequence to be read from the four lanes on the basis of size 
of DNA fragments (203,204). Sequencing has now been automated and each di-deoxy nucleotide 
is tagged with a different fluorescent dye and all 4 termination reactions are performed in the 
same reaction, analysed by capillary electrophoresis using an automated sequencer and results in 
a chromatograph of peaks corresponding to each base.
Despite di-deoxy sequencing being the gold standard for sequencing and chromatographs being 
accepted by all major sequence repositories, there are disadvantages to the method. The 
throughput is lower than next generation sequencing technologies. Sequencing whole genomes 
using sanger sequencing would require dedicated centres with up to 100 sequencing machines 
running 24 hours a day 365 days a year using a highly automated template preparation process, 
without this set-up, sequencing even the smallest genome would be prohibitively expensive and 
require massive manpower (81). It is also not the best method for sequencing short DNA 
fragments.
1.3.2.2 Sequencing by Synthesis (SbS)/Pyrosequencing  
Sequencing by synthesis is a method for rapidly sequencing short sequences of DNA of up to 
lOObp (157) although this length has been improved using whole genome sequencing platforms. 
This method uses either 3 or 4 enzymatic steps depending on the platform. The four nucleotides 
(dATP, dTTP, dCTP and dGTP) are added sequentially for each base being sequenced. When a 
nucleotide is incorporated into the extending DNA it releases inorganic pyrophosphate (PPi) which 
is converted to adenosine triphosphate (ATP) by ATP sulfurylase. The released ATP causes 
luciferase to emit light which can be detected. The level of light emitted indicates how many 
nucleotides are incorporated (i.e. when dATP is introduced, if there are 5 T nucleotides in the 
complementary sequence then 5 dATP nucleotides will be incorporated emitting 5 times as much
light as the incorporation of one). The fourth enzyme is apyrase which is used to degrade 
unincorporated dNTPs and ATP in the Biotage system, other pyrosequencing based systems such 
as the Roche 454 platform replace this fourth enzyme with a washing step (157). Generally in 
pyrosequencing, sequencing occurs at a speed of ~lbp per minute (105).
Pyrosequencing has been used to type bacteria. Luna et al (143). used pyrosequencing to identify 
atypical bacterial isolates within a children's hospital by sequencing the highly variable V I  and V3 
regions of 16S rRNA gene and Nygren at al (169). used pyrosequencing to differentiate Bordetella 
using a section of the Pertussis Toxin promoter region to differentiate virulent Bordetella pertussis 
from less virulent B. parapertussis and B. bronchiseptica. Sequencing of short fragments was 
shown to identify mutations in B. parapertussis and B. bronchiseptica that rendered the promoter 
region non-functional and therefore prevented expression of Pertussis Toxin. Pyrosequencing was 
selected since a region of the Pertussis Toxin promoter showed sequence compression when 
sequenced by Sanger sequencing due to strong secondary structure formation. Finally,
Wroblewski et al (256). developed a rapid method to characterise Clostridium difficile strains 
using pyrosequencing to sequence fragments of the genes encoding toxins A (tcdA) and B (tcdB) 
and the binary toxin genes (cdtA and cdtB), and detect common deletions in the tcdC gene which 
is thought to be involved in negative regulation of toxin gene expression.
1.3.2.3 Second Generation Whole Genome Sequencing  
Advances in whole genome sequencing technology have allowed sequencing of a large number of 
bacterial genomes leading to increased understanding of bacterial diversity. Currently, the 
sequencing technologies used are referred to as second generation platforms and include the 454 
Genome Sequencer FLX (Roche Applied Science), the lllumina (Solexa) Genome Analyzer and the 
ABI SOLiD System (Applied Biosystems).
The 454 and lllumina platforms both use sequencing by synthesis chemistry in parallel reactions 
to generate large numbers of short sequencing reads (each read for the 454 platform is ~400bp
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whereas the illumina is ~150bp). The 454 platform involves library creation by fragmenting____
genomic DNA to approximately 300-800bp. Short adaptors are added to the 5' and 3' ends of 
each fragment. These adaptors are used to attach DNA fragments to propriety DNA capture 
beads. Each bead will have one fragment attached to it and each bead acts as an individual micro- 
reactor for emulsion PCR meaning each bead contains DNA amplified from the individual 
fragment attached to it. Each amplified bead is then added to PicoTiterPlate device for 
sequencing. The size of the wells means each well will only contain one bead and in each well an 
individual sequencing by synthesis reaction is performed allowing sequencing of 1,000,000 
individual reads with the GS FLX System and 100,000 individual reads with the GS Junior System 
per 10-hour instrument run. The lllumina platform uses the same steps of library creation and 
clonal amplification of DNA fragments but sequencing and amplification of these fragments is 
performed inside flow cells using standard sequencing by synthesis reagents.
The ABI SOLiD platform uses sequencing by ligation chemistry where DNA fragments are ligated to 
beads and clonally amplified. The beads are then enriched to separate the beads with extended 
templates from undesired beads. The template on the selected beads undergoes a 3' modification 
to allow covalent attachment to a glass slide. Sequencing then occurs by ligating a 5bp probe with 
a florescent tag complementary to the first 2bp of sequence to the template strand. Following 
measurement of the florescent tag to determine the first 2bp of the 5bp probe the florescent tag 
is cleaved and the next 5bp tag is bound to the next 5bp of the template sequence. The ligation 
reaction is repeated as required. Following the ligation reactions the extension product is 
removed and the sequencing primer is replaced by a primer complementary to N -l of the first 
primer for a second round of ligation. This allows sequencing of the 2/5 bp of the probe which is 
out of frame by lbp  to the first set of ligation reactions. This process of resetting the primer to the 
n -l position of the previous primer and performing a new series of ligation reactions is repeated 5 
times to sequence all bases of the template DNA.
Having the capability to sequence such a large amount of DNA has allowed researchers to 
perform experiments that would have been prohibitively expensive even a few years ago. For
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example, M orelli et al. used 454 sequencing technology to  sequence seventeen Yersinia pestis 
genomes to  identify 933 SNPs between isolates tha t where then screened using Sequenom 
MassARRAY SNP typing in 286 isolates (163). Holt et al. used lllumina and 454 technology to  
sequence the genomes o f 19 Salmonella enterica  serovar Typhi isolates to  show tha t evolution in 
the Typhi population seems to  be characterized by ongoing loss o f gene function and discovered a 
lack o f evidence fo r antigenic variation driven by immune selection in contrast to  strong adaptive 
selection fo r mutations conferring antib io tic resistance (90). Finally, Gulig et al. used the SOLiD 
system to  sequence four strains o f Vibrio vulnificus, tw o  strains came from  a viru lent population 
and tw o  strains were environmental strains. This revealed eighty genes specific to  the viru lent 
strains (73).
1.3.2.4 Third  Generation Whole Genome Sequencing 
There are currently four th ird  generation sequencing platforms that use single strand DNA 
sequencing the Pacific Biosciences Single Molecule Real Time (SMRT) (figure 1.10-a), the Life 
Technologies FRET sequencing platform  (figure 1.10-b), the Oxford nanopore sequencing p latform  
(figure 1.10-c) and the Ion Torrent sequencing platform  (figure 1.10-d).
Figure 1,10: Four third generation sequencing technologies
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The Pacific Biosciences Single Molecule Real Time (SMRT) achieves single-molecule sequencing,by 
detecting nucleotides which are fluorescently labelled at the terminal phosphate when they are 
held in place by a polymerase during incorporation.
The Life Technologies FRET sequencing platform uses fluorescently labelled nucleotides, a DNA 
polymerase modified with a quantum dot and DNA template molecules immobilized onto a solid 
surface. During incorporation events, energy is transferred from the quantum dot to an acceptor 
fluorescent moiety on each labelled base.
The Oxford Nanopore's platform uses an exonuclease coupled to a modified a-hemolysin 
nanopore which is positioned within a lipid bilayer. As DNA is directed through the a-hemolysin 
each nucleotide is cleaved sequentially. As single bases fall into the pore, they transiently interact 
with the cyclodextrin moiety which disturbs current through the nanopore in a manner which is 
unique for each base. (198).
The Ion Torrent sequencing platform uses a semiconductor-based high-density array of microwell 
reaction chambers positioned above an ion-sensitive layer and an ion sensor. As single 
nucleotides are sequentially incorporated the release of hydrogen ions is measured to identify the 
incorporated nucleotide.
1.3.2.5  Sequence Analysis by M ALDl-TO FM S  
Matrix Assisted Laser Deabsorption/Ionisation Time of Flight (MALDl-TOF) mass spectrometry has 
been used for sequencing and Single Nucleotide Polymorphism (SNP) detection. MALDl-TOF is a 
form of mass spectrometry which uses laser pulses directed at a crystallised mix of analyte and a 
chemical matrix molecule. When a laser pulse is directed at this mix, energy is transferred to the 
matrix molecule causing the analyte and matrix to be ionised. The ionised analyte is carried by an 
electromagnetic field to a detector. The time it takes the ionised analyte to reach the detector is 
used to calculate its mass (87). There are two Sequenom applications used in genotyping DNA, the
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iSEQ system which sequences loci using base specific cleavage and the iPLEX system which is used 
for SIMP genotyping.
The iSEQ. system uses RNA fragments generated through base specific cleavage of reverse 
transcribed PCR amplified DNA (225). Cleavage occurs at the C and T (U) bases in the forward and 
reverse strands of RNA giving 4 reactions per sequence. The size of fragments in each reaction is 
then-compared to a reference sequence. Variations in sequence are discovered by identifying 
which fragments in the reference sequence do not appear as expected, the software then 
calculates the new sequence on the basis of mass fragments that are not matched to the 
reference sequence. Since there are 4 cleavage reactions per sequence all nucleotide variations 
are proved since they are replicated within the experiment. The iSEQ system has been used to 
perform MLST typing of N. meningitidis and produced results consistent with di-deoxy sequencing 
(91) and to characterise SNPs in the genome of JC polyomavirus (12).
The iPLEX system is used for genotyping SNPs and uses a primer designed immediately upstream 
of a SNP. The primer is then extended by one nucleotide complementary to the template strand 
and differences in mass between the extended primers allow SNP typing. Recently, this 
application has become more popular than the iSEQ since it can genotype up to 40 SNPs per well 
in a 384well plate, allowing up to 15360 SNPs genotyped per plate making it ideal for studies of 
SNPs located through whole genome sequencing. For example, Morelli et al. (163) used 454 
sequencing to sequence 17 Yersina pestis genomes and using the data generated identified 933 
SNPs which were then profiled in 286 Y. pestis using the iPLEX platform. Clawson et al. sequenced 
pooled DNA from 91 human E. coli 0157.H7 infections and 102 E coli 0157.H7 isolates from cattle 
which identified 16,218 putative polymorphisms. From those, 178 were genotyped using the 
iPLEX platform which allowed differentiation of human and bovine isolates (34).
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1.4 Aims and Objectives
GBS normally exists as a commensal organism of the gastrointestinal and genitourinary tracts but 
in a small number of cases the bacteria can be passed to the neonate during childbirth to cause 
systemic disease. To aid in the understanding of why some bacteria cause infection and others do 
not, a method of generating DNA profiles which accurately reflect phylogeny and give indications 
of potential virulence are required. The aim of this project is to develop a two component 
molecular profiling system to address these issues. The first component will look at sections of the 
genome that are evolving at the same rate of the organism as a whole and the second component 
will look at regions of the genome containing MNR repeat regions around or within virulence 
genes.
The first component of this profiling system will be developed by:
•  Adapting a method which was developed to select targets for sequence typing at the 
genus level (119) to a select targets at the strain level.
•  This method will use reciprocal BLAST to identify the core genome which will be analysed 
to calculate the Average Nucleotide Identity (ANI) of the core genome which will be 
correlated to the evolutionary distances generated from Maximum Likelihood analysis of 
each core gene
•  The assumption is that genes with a strong correlation to the rate the genome is evolving 
at the average rate will more accurately reflect the evolution of the organism.
•  Selected targets will be sequenced from a collection of UK clinical isolates and compared 
to sequence type and levels of diversity of the loci of the GBS MLST scheme (103).
The second component of this project will look at the presence/abundance of Mononucleotide 
Repeats (MNRs) in the genome as:
•  MNRs have been shown to be a genomic regulator in both coding (74) and non-coding 
(184) DNA meaning analysis of MNR repeats within or around virulence associated genes 
may allow predictions of virulence.
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•  Previous studies have demonstrated that these MNR containing regions could be suitable 
profiling markers (42).
•  Within the core-genome MNRs will be assessed by developing Perl workflows to assess 
the presence, abundance and homology between MNR repeats, focusing specifically on 
virulence genes. .
•  MNR repeats will also be assessed within non-coding DNA, focusing on non-coding DNA at 
the 5' and 3' of known virulence factors.
•  Selected targets will be assessed as profiling markers and results compared to the existing 
MLST scheme and first component of the profiling system
In the final stage, analysis will be carried out to find the optimal way to combine the two 
components to develop an optimal profiling system for GBS which is able to accurately reflect the 
evolution of the organism, discriminate more accurately than the currently used MLST scheme 
and provide indicators of the virulence of the organism.
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Materials and Methods
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2.0 Materials and Methods
2.1 Laboratory Methods
2.1.1 Strain Collection 
This study uses a collection of 134 GBS isolates consisting of 48 reference strains (including 8 
genome sequenced isolates) and 86 clinical isolates from the UK. The collection represents 
capsular serotypes IA, IB and ll-VIII and examples of the immunoreactive antigens C, R and X as 
shown in Appendix 9.1. A summary of the serotypes of the isolates is shown in table 2.1.
Table 2.1: Serotypes o f clinical isolates used in this study_____________
Serotype Frequency
IA 18
IB 14
1 (Other) 3
II 17
III 18
IV 12
V 14
VI 5
VII 7
VIII 4
NT 22
Subtypes
C 19
R 3
X 3
2.1.2 Bacterial Culture 
Each strain was plated from Protect bacterial preservation system beads (Technical Science 
Consultants Ltd., Heywood, UK) stored at -80°C onto Columbia agar with Defibrinated Horse Blood 
(HPA Media Department, London, UK), Plates were first checked for purity and then streaked to 
provide single colonies and grown overnight at 37°C. Single colonies were then picked and sub­
cultured overnight for DNA extraction.
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2.1.3 DNA Extraction 
DNA extraction was performed with the Qiagen DNeasy Blood & Tissue kit using a modified Gram 
positive extraction protocol (Qiagen Ltd, Crawley, UK). A lOpI loop of cells were taken from the 
agar plate and re-suspended in 1ml phosphate buffered saline (PBS) (HPA media department) and 
centrifuged for 10 minutes at 7500rpm using a Sigma l-15p centrifuge (Scientific Laboratory 
Supplies Ltd., Nottingham, UK). The supernatant was removed and the pellet was re-suspended in 
180pl enzymatic lysis buffer consisting of 20mM Tris-CI (pH 8.0), 2 mM sodium EDTA, 1.2% Triton® 
X-100, lysozyme at 20mg/ml and mutanolysin at 50pg/ml which was incubated at 37°C for 30 
minutes. Twenty five microlitres proteinase K and 200pl Buffer AL were then added, mixed by 
vortexing and incubated for 1 hour at 56°C. Following incubation 200pl 96-100% ethanol (Sigma- 
Aldrich Co.Ltd, Gillingham, UK) was added and mixed by vortexing. The mixture from this step was 
added to a DNeasy Mini spin column placed in a 2 ml collection tube and centrifuged at 6000xg 
(8000 rpm) for 1 minute after which the flow-through and collection tube were discarded. The 
spin column was then placed into a new collection tube and 500pl of buffer AW1 was added to 
the spin column which was centrifuged at 6000xg (8000rpm) for 1 minute. Again, the collection 
tube was discarded and the spin column was placed in a new collection tube and 500pl of buffer 
AW2 was added to the spin column which was centrifuged for 3 min at 20,000xg (14,000 rpm).
The collection tube was again discarded and the spin column was placed into a 1.5ml 
microcentrifuge tube (Eppendorf UK Ltd, Cambridge, UK) with the cap removed. lOOpI buffer AE 
was added directly to the spin column membrane and centrifuged at 6000xg (8000rpm) for 1 
minute, this stage was then repeated to ensure maximum DNA elution. The 200pl eluted product 
was then transferred to a screw-topped microcentrifuge tube for storage at -20°C.
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2.1.4 DNA Quantification 
Extracted DNA was quantified using the NanoDrop ND-8000 spectrophotometer (Labtech 
International Ltd, Ringmer, UK). Three microlitres of DNA from each sample was transferred to a 
96 well skirted PCR plate (Abgene, Epsom, UK). Two microlitres of water was used to initialise the 
instrument, this was cleaned off using lint free wipes (Kimberly-Clarke Professional) and replaced - 
with 2|il of Qiagen DNeasy buffer AE and the instrument was "blanked" i.e. a sample of elution 
buffer was used to provide a set of spectral measurements that are assumed to contain no DNA. 
DNA samples were then added to the 8 channels and the absorbance at frequencies A230, A260 
and A280 were measured. The A260 measurement is used by the software to calculate the 
concentration of DNA (measured in ng/pl) by using the Beer-Lambert equation which states that 
A = E x b x c where A is the absorbance, E is the extinction coefficient, b is the length of the wave 
path and c is the analyte concentration. The A260/280 ratio is expected to be around 1.8 for pure 
DNA, if the ratio is lower, it could indicate the presence of protein, phenol or other contaminants 
that absorb strongly at or near 280 nm and the A260/230 is a secondary measure of DNA purity 
and is typically between 1.8-2.2, lower values may indicate the presence of co-purified 
contaminants. After measurements are taken the 8 channels are cleaned again and this stage is 
repeated until all samples are processed.
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2.1.5 PCR
All PCR reactions were performed using Qiagen HotStar Taq 2x Master Mix (Qiagen) 
supplemented with l.OmM MgCI2 (final MgCI2 concentration of 2.5mM). Primer concentrations 
were 0.2pM for all primer pairs except the T7/SP6 tagged glnA sequencing primers used in the
Sequenom amplification reaction which were used ata  concentration of 0.3pM. Early  ~
optimisation of the MLST primer pairs showed that cycling conditions of an initial 15 minute 
denaturation followed by 30 cycles of a 30 second denaturation at 95°C, a 30 second annealing 
step at 55°C and a 1 minute elongation step at 72°C was optimal. After 30 cycles there was a 7 
minute final elongation stage at 72°C. These conditions were used as standard for all further 
primer pairs unless they did not produce sufficient product. The non-coding primer pairs (see 
table 2.2) did not produce sufficient product until the annealing temperature was raised to 60°C.
2.1.5.1 Prim ers
All primers were synthesised by Eurofins MWG Operon (Eurofins MWG Operon, Ebersberg, 
Germany). Primers are dispatched as lyophilised powder and are made up to a stock 
concentration of lOOpmol/pl and stored at -20°C. For use, PCR primers are made to a working 
concentration of 0.2 or 0.3pM (see above). The sequence of each amplification primer used is 
shown in table 2.2.
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2.1.5.2  PCR Set-Up Using the Corbett Robotics CAS4200 
The CAS4200 (Qiagen) is an automated high throughput PCR laboratory robotic system which was 
used to prepare PCR reactions for Sequenom iSEQ sequencing and Sanger Di-Deoxy sequencing. 
The program Robotics4 (Qiagen) was used to program the plate layout to configure the master 
mix ingredients, sample locations (and in some cases the sample concentrations) and determine 
the order of reagent, reaction mix and/or sample addition.
Additionally the CAS4200 was used to normalise DNA concentrations to ensure a constant 5ng/pl 
DNA concentration in Sequenom PCR reactions.
2.1.6 Gel Electrophoresis 
Gel electrophoresis was performed in a Sub-Cell Model 96 Cell Submerged Horizontal 
Electrophoresis Tank using a 25x15cm gel caster and two standard 50 well combs (Bio-Rad 
Laboratories Ltd., Hemel Hampstead, UK). Each gel was made to a thickness of 5mm using 2% 
UltraPure agrose (Life Technologies, Paisley, UK) in 0.5x TBE (Life Technologies). A BioMarker ext 
plus 50-2500bp ladder (Cambio Ltd., Cambridge, UK) was used to size DNA products. One 
microlitre of PCR reaction product was added to 5pl lx  BlueJuice loading buffer (Life 
Technologies) before being run for 1 hour at 120V with a maximum current of 100mA in 0.5x TBE 
running buffer (Life Technologies). Gels were stained in 500ml 0.5mg/l ethidium bromide solution 
and visualised using a Gel-Doc 2000 (Bio-Rad).
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2.1.7 Sequenom iSEQ Re-sequencing
2.1.7.1 Experim ental Design
2.1.7.1.1 PCR Primers and Tags 
Due to the reverse transcription stage in the iSEQ workflow PCR primers need to be tagged with 
reverse transcriptase promoter sequences. The primers used were the MLST sequencing primers 
from the pubMLST website (http://Dubmlst.org/sagalactiae/info/primers.shtmh where the 
forward primers are tagged with a T7 polymerase promoter and the reverse primers tagged with a 
SP6 polymerase promoter (see table 2.3). All primers where synthesised by Eurofins MWG 
Operon and prepared and stored as above.
Table 2.3: iSEQ tagged MLST sequencing primers. The polymerase promoters are in lowercase 
and the loci specific section o f the primers are in uppercase._____________________ __________
Primer Forward/T7 (5' - 3') Reverse/SP6 (5' - 3')
Product
Length
(bp)
adhP
cagtaatacgactcactatagggagaagg
ctGGTGTGTGCCATACTGATTT
cgatttaggtgacactatagaagagaggctACA 
G CAGT CACAACCACT CC
498
atr
cagtaatacgactcactatagggagaagg 
ct AT G GTT GAG CCAATTATTT C
cgatttaggtgacactatagaagagaggctCCT 
TG CT CAACAATAATG CC
501
glcK
cagtaatacgactcactatagggagaagg
ctGGTATCTTGACGCTTGAGGG
cgatttaggtgacactatagaagagaggctATC 
GCTGCI 1 IAATGGCAGA
459
glnA
cagtaatacgactcactatagggagaagg 
ct AATAAAG CAAT GTTTG AT G G
cgatttaggtgacactatagaagagaggctGCA 
TTGTT CCCTT CATTAT C 498
pheS
cagtaatacgactcactatagggagaagg 
ct ATAT CAACT CAAG AAAAG CT
cgatttaggtgacactatagaagagaggctTGA
TGGAATTGATGGCTATG
501
sdhA
cagtaatacgactcactatagggagaagg 
ct AACATAG CAG AG CT CAT GAT
cgatttaggtgacactatagaagagaggctGG
GACTTCAACTAAACCTGC
549
tkt
cagtaatacgactcactatagggagaagg 
ct ACACTT CAT G GTG ATG GTT G
cgatttaggtgacactatagaagagaggctTGA
CCTAGGTCATGAGCTTT
480
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2.1.7.1.2 Reference Database Design 
The MLST reference sequences fo r each of the 7 loci were obtained from  pubMLST (101). 
However, since these reference sequences were generated by Sanger Sequencing the sequence 
from  the end o f the reference sequences to the forward and reverse primers was not present, 
since this is required fo r iSEQ re-sequencing the missing sequence was filled in w ith  consensus 
sequence from  the whole genome sequence 2603V/R (232) as previously described (91).
2.1.7.2 PCR Am plification  
PCR amplification was performed as standard (see 2.1.5) w ith  some modifications. Ninety five 
lOpI PCR reactions and one negative control were set up in a 384 well PCR plate (ABgene) using 
the Corbett Robotics CAS4200 (Qiagen) in an interleaved configuration w ith  each sample added 
sequentially (see figure 2.1). Also, the PCR amplification used the T7/SP6 RNA polymerase 
promoters (see 2.1.7.1.1). Finally tem plate DNA concentrations where normalised to  a constant 
5ng/pl. PCR amplification was performed in a 384 well GenAmp 9700 therm al cycler (Life 
Technologies).
Figure 2.1: PCR plate set-up, coloured wells indicate active wells whereas blank wells are left 
empty.
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2.1.7.3 Clean-up Using SAP T reatm ent
Each reaction was treated with 5|il of 0.04U/pl Shrimp Alkaline Phosphatase (SAP) to 
dephosphorylate any remaining unincorporated nucleotides and render them unavailable in 
downstream reactions. The SAP solution was added to each well in a Sarstedt 96 well V-bottom 
plate which was distributed to the active wells in the 384 well PCR reaction plate using the Matrix 
Plate Mate Liquid Handler (Thermo Fisher Scientific, Hemel Hampstead, UK). Following 
distribution the PCR plate was sealed and incubated in a 384 well GenAmp 9700 thermal cycler 
(Life Technologies) at 37°C for 20 minutes followed by 85°C for 10 minutes.
2.1.7.4  Reverse Transcription and  Cleavage
Each SAP-treated PCR reaction is split into four 2pl aliquots in a new 384 well PCR plate (ABgene) 
for the four separate cleavage reactions (C Forward, C Reverse, T Forward and T Reverse) as 
described in figure 2.2. Each reaction contains 1.08pl RNA free ddH20, 0.9pl polymerase buffer, 
0.12pl C or T cleavage mixture depending on the reaction, 0.14pl of lOOmM DDT, 0.22pl of T7 or 
SP6 polymerase depending on the reaction and 0.04pl of 0.08 mg/ml RNase A. 4 96 reaction 
master mixes (CF, CR, TF, TR) were made and each one is distributed to a Sarstedt 96 well V- 
bottom plate. The Matrix Plate Mate Liquid Handler (Thermo Fisher Scientific) was then used to 
dispense 2.5pl of cleavage reactions to the appropriate well of the plate which contained 2pl of 
SAP treated PCR product. The transcription/cleavage reaction plates were sealed and incubated 
for 3 hours at 37°C for 3 hours in a 384 well GenAmp 9700 thermal cycler.
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Figure 2.2: Lay out o f a 384 well plate containing reaction mixes fo r  the 4 cleavage reactions 
and SAP treated PCR product where yellow wells correspond to C Forward, Green to C Reverse, 
Blue to T Forward and Pink to T Reverse.
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2.1 .7 .5  Conditioning the Plates  
Conditioning the reaction mixes de-salts the reactions for use in Mass Spectrometry. The Matrix 
Plate Mate Liquid Handler (Thermo fisher Scientific, Loughborough, UK) was used to dilute the 
samples by adding 21.5pl of nano-pure H20  to each transcription/cleavage reaction. 6 mg of Clean 
Resin (Sequenom, San Diego CA, USA) was allowed to air dry for 15 minutes before addition to the 
diluted sample mixes. The plate was sealed and rotated for 10 minutes to agitate the resin in the 
wells before the plate was centrifuged in a Heraeus Megafuge 11 plate centrifuge (Thermo Fisher 
Scientific) for 5 minutes at 4000xg for 5 minutes to sink the resin to the bottom of the w e ll.
2.1.7 .6  Chip Spotting Using the Nano Dispenser 
Conditioned RNA cleavage products and a 4 point size calibrant (Sequenom) were spotted onto 
SpectroCHIPS (Sequenom) using the NanoDispenser (Samsung, Seoul, South Korea). Seventy 
microlitres calibrant was added to the calibrant well, the conditioned RNA cleavage products on a 
384 well plate were placed into the plate holder at position "MTP-1" and the SpectroCHIP was 
placed into a chip holder at position at "scout plate 1". The pin head was conditioned in 50% 
ethanol for 30 minutes before the chip spotting program was ran.
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2 .1.7 .7  Mass Spectrom etry ofRNA fragm ents  
Using the iSEQ software Plate Editor (Sequenom) the position of each sample, the reference set 
each sample uses and the reaction transcription/cleavage reaction for each well on the 384 well 
plate used to spot the chips (see 2.1.7.6) was mapped. This map was exported to the RT 
workstation which was used to program the MassARRAY compact (Bruker, Billerica MA, USA) 
using the SpectroACQUIRE software to acquire spectra from the cleavage reactions imprinted 
onto the SpectroCHIPs (Sequenom). Spectra are obtained in real time and displayed as the MALDI- 
TOF process progresses.
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2.1.7 .8  Generating Sequence D ata  fro m  Spectra  
Generated spectra were imported into the iSEQ Analyser software (Sequenom) which was used to 
calculate the mass of each ionised RNA fragment corresponding to a peak. The size of fragments 
from which the mass can be inferred reliably is between 4 and 25bp. The mass of each ionised 
fragment was compared to fragments generated from the in-silico reference sets generated from 
the reference DNA sequences and the closest matching reference sequence (the one containing 
the most simulated to observed peak matches) is selected as the closest matching reference 
sequence. Since the analysis is based on the size of a fragment rather than its composition it is 
worth considering the probability of a fragment being confused for one of equal mass. Essentially, 
this can be considered the number of combinations of nucleotides in a given fragment versus the 
number of permutations. For a single fragment the probability of a fragment matching a different 
one of the same mass ranged from 13.7% for four nucleotide fragments to 2.9xlO'10for a 25 
nucleotide fragment. However, since the iSEQ system uses 4 reactions the probability of all four 
reactions identifying the wrong 4 fragments ranges from 0.0003% for four nucleotide fragments 
to 7 .17xl0‘47for a 25 nucleotide fragment making either event unlikely.
The software analysed the closest matching reference sequence compared to the observed peak 
pattern and assigned probability values referring to the chance of the sequence being correct and 
to the chance of any variation that has not being observed in the sequence, with a value <0.05 
being considered a reliable sequence match.
2.1.8 Sanger Di-deoxy Sequencing
2.1.8.1 Sequencing Prim ers  
All primers were synthesised by Eurofins MWG Operon. Primers are dispatched as lyophilised 
powder and are made up to a stock concentration of 100pmol/pl and stored at -20°C. For use 
sequencing primers are made to a concentration of 0.2pM. The sequence of each sequencing 
primer used is shown in table 2.4
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2.1.8.2 PCR Product Clean-up Using AM Pure  
PCR product clean up was performed using AMPure (Beckman Coulter, High Wycombe, UK) 
reagents either manually or automated using the Biomek NXP (Beckman Coulter) laboratory 
automation workstation. Both methods are detailed below.
To perform PCR product clean up manually first PCR product was transferred to a MicroAmp 
optical 96 well reaction plate (Life Technologies) and 45pl of AMPure beads were added to each 
25pl reaction, mixed by pipetting then incubated for 5 minutes to allow PCR product to bind to 
the magnetic beads. The PCR plate was then placed onto a magnetic SPRIPIate (Beckman Coulter) 
and incubated until magnetic beads were visibly bound to the outside of the PCR plate 
(approximately 5-10 minutes). Cleared solution from the PCR plate was aspirated and discarded 
and two 200pl 70% ethanol washes were performed. After the second ethanol aspiration the PCR 
plate was air dried for 20 minutes. The beads were then eluted in 40pl dH20  and mixed by 
pipetting 10 times to ensure PCR product released from the beads. Whilst on the magnetic plate, 
35pl of the eluted product were transferred to a fresh 96 well MicroAmp optical reaction plate 
(Life Technologies) for sequencing.
Automated PCR product clean up uses the same chemistry on the Biomek NXP (Beckman Coulter) 
laboratory automation workstation with two changes to protocol incubation times. Firstly, the 
time to bind beads to the side of the well after AMPure addition was seven and a half minutes 
(opposed to between 5-10 minutes with visual verification of bead binding). Secondly, after the 
ethanol washes the plate is dried for 15 minutes opposed to 20 in the manual reaction. Programs 
for performing AMPure clean up were supplied with the equipment by the manufacturer and 
controlled using the Biomek software (Beckman Coulter).
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2.1.8.3  Cycle Sequencing
Cycle sequencing used BigDye v l . l  and v3.1 (Life Technologies) chemistry were used, the reaction 
mixes were the same for both versions. Cycle sequencing plates were set up using the QIAgility 
PCR robotics platform (Qiagen). Each reaction contained lp l BigDye (Life Technologies), 1.5pl 5x 
Sequencing Buffer (Life Technologies), lp l Sequencing Primer (0.2pM), 3pl AMPure cleaned up 
PCR product (containing between 5 and 20ng DNA) and 3.5pl molecular biology grade H20  (Fisher 
Scientific). Cycle sequencing reactions were performed using either a GenAmp 9700 96 well 
thermal cycler or a Veriti 96 well cycler (Life Technologies). Cycling conditions were an initial 
denaturation of 1 min at 96°C followed by 25 cycles of a 10 second denaturation at 96°C, a 5 
second annealing at 55°C and a 4 minute extension at 60°C for the GenAmp 9700 thermal cycler, 
the Veriti thermal cycler uses the same conditions except for a shorter extension time of 1 minute 
15 seconds.
2.1.8.4  Cycle Sequencing Product Clean-up Using CleanSEQ 
Cycle sequencing product clean up was performed both manually and automated using the 
Biomek l\IXp (Beckman Coulter) laboratory automation workstation.
Manual cycle sequencing product clean up was performed using cleanSEQ (Beckman Coulter). 
lOpI of cleanSEQ beads and 42pl of 85% ethanol were added to each lOpI cycle sequencing 
reaction in a MicroAmp optical 96 well reaction plate (ABI). The mixture was pipette mixed until 
the solution was homogenous and the reaction place was placed onto a SPRIPIate (Beckman 
Coulter) until magnetic beads were visibly bound to the outside of the PCR plate (approximately 
3-5 minutes). The cleared solution from the PCR plate was aspirated and discarded and two 85% 
ethanol washes were performed. The plate was then left to air dry for 10 minutes and the beads 
were eluted in either formamide or molecular biology H20  depending on the length of time from 
clean up to sequencing, i.e. clean up performed the same day was sequencing was eluted in 
water, for a longer time between clean up and sequencing formamide was used. The eluted
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product was then placed onto a SPRIPIate (Beckman Coulter) until the beads were bound to the 
side of the PCR plate and 35pl was removed and added to a clean PCR plate for sequencing.
Automated cycle sequencing product clean up uses the same chemistry on the Biomek NXP 
(Beckman Coulter) laboratory automation workstation. One change to the incubation times was 
made from the manual reaction and the beads where left for three minutes (opposed to between 
■three and five minutes with visual verification). Programs for performing cleanSEQ clean up were 
supplied with the equipment by the manufacturer and controlled using the Biomek software 
(Beckman Coulter).
2.1.8 .5  C apillary Electrophoresis Using A B l 3130x1 /3730  
Sequencers
Sequencing was performed by capillary electrophoresis using either the 3130x1 or 3730 genetic 
analyser (Life Technologies). Either 35pl of cleaned up cycle sequencing product without magnetic 
beads in a 96 well MicroAmp optical reaction plate (Life Technologies) were placed in a plate 
retainer or 80pl of cleaned up cycle sequencing product with magnetic beads, also in a 96 well 
MicroAmp optical reaction plate (Life Technologies) were placed onto a direct inject plate (ABl) 
and assembled with a plate retainer. Sequencing was performed using a 3 second injection time 
and the standard Genomic Sequencing Service (GSU) analysis protocol specific to either V I .1 or 
v3.1 BigDye (Life Technologies) chemistry was used to base-call and trim sequence using a rule of 
>4 bases out of 20 had to have a quality value (QV) >20.
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2.1.8.6  Trace Assessment and  Assembly 
Trace files were checked using Sequence Scanner vl.O (Life Technologies) to assess trace quality 
by ensuring the quality values (a numerical value between 1-100 assigned to each base in 
chromatogram that shows the level of confidence in that base) over the length of the sequence 
are >20 and by comparing the experimentally determined contiguous read length to the expected 
read length. Forward and reverse reactions were assembled into contigs using SeqMan in the 
Lasergene 8 software package (DNASTAR, Madison, Wl, USA) where sequences are trimmed down 
to good quality bases and the forward and reverse strand are checked for conflicts and manually 
base called.
2.2 Bioinformatic Methods
2.2.1 Sequenced Genomes Used
Three fully sequenced S. agalactiae genomes, serotype V 2603V/R (232), serotype III NEM316 (68) 
and serotype IA A909 (231) as well as five whole genome shotgun sequences 18RS21, 515,
□ B i l l ,  COH1 and H36B (231) with the serotypes II, IA, V, III and IB respectively were obtained 
from GenBank (http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi) for use in this study.
2.2.2 Core Genome Analysis
The core genome was extrapolated and analysed as described by Konstantinidis (119) by 
identifying the core genome using reciprocal BLAST, performing maximum likelihood analysis of 
each core gene, determining the Average Nucleotide Identity (ANI) of the genome and selecting 
profiling targets by correlating each core gene to the ANI using a number of methods. The 
overview of this process is shown in figure 2.3
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Figure 2.3: Overview of the target selection process
Reciprocal BLAST searching to 
determine genes considered core 
using the 50% homology over 
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(ANI) (9.8.4)
Data Mining of GenBank files to 
obtain coding sequences in 
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Reverse complementing coding 
sequences that appear on the 
negative strand to produce 
accurate alignments (9.8.2)
Target selection based on Kendall’s t scores and 
analysis of levels of nucleotide diversity to select 
targets which closely model the ANI and targets which 
are both highly correlated to the ANI and have a high 
level of nucleotide variation.
Correlation of each of the core gene distance values to 
the ANI using Kendall’s t rank correlation co-efficient 
(Value Range = - 1 - 1 . 1  = Perfect correlation) and 
where differentiation between these scores was 
necessary by analysis of the raw distance values.(9.8.6 
and 9.8.7)
The selected targets are sequenced and analysed by 
generation of a matrix of every combination of 3 genes. 
Each set of 3 genes is concatenated and clustered to 
provide the number of unique sequence types. The 3 
genes which provide the highest discriminatory power 
are used in further analyses.
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2.2.2.1 D ata-M in in g  GenBank Files fo r  Coding Sequences 
Coding sequences from the GenBank files of the three fully sequenced genomes were extracted 
using a custom PERL script adapted from a previous study (1) which used the PERL modules SeqIO 
and AnnotationCollectionl to identify coding sequences (appendix 9.8.1), and their locus tag and 
output these sequences in FASTA format. For the five whole genome shotgun genomes the cDNA 
regions were taken directly from NCBI in FASTA format and custom PERL scripts were used to split 
each coding region into a separate file and change the NCBI reference identifiers to the assigned 
locus tags.
2.2.2.2 Reciprocal BLAST
Reciprocal BLAST was used to identify the core genome of 1) the three fully sequenced S. 
agalactiae genomes and 2) all 8 S. agalactiae genomes. In both cases all coding sequences were 
concatenated into a singe Fasta file and BLAST databases were constructed using formatdb 
including the -o  option to generate additional indexing files, a custom PERL script from a previous 
study (appendix 9.8.2) was then adapted to perform reciprocal BLAST using the genome 2603V/R 
as a reference genome. Each gene from the 2603V/R genome was BLASTed against each of the 
test genomes and a gene was considered core if it had hits in all other genomes that were 50% 
homologous over 70% of the gene length and each hit would meet the same criteria when 
BLASTed back against the reference genome.
2 .2 .2 3  D eterm in ing  the COG Categories o f  Core Genes 
Cluster of Orthologous (COG) categories for each gene in the reference genome 2603V/R were 
taken from NCBI (http://www.ncbi.nlm.nih.gov/sutils/coxik.cgi7gis252) and concatenated into a 
single Excel worksheet, core gene locus tags were added and the VLOOKUP function was used to 
identify the core genes in the list of all COG categorised genes and therefore isolate COG 
categories of each core gene.
83
2 .2 .2A  A ltern a te  Methods f o r  D eterm in ing  the Core Genome 
Two alternate methods where used to identify the core genome to confirm reciprocal BLAST 
results. Firstly, the Multi-Genome Homology Comparison tool (JCVI, http://cmr.icvi.org/cgi- 
bin/CMR/shared/MakeFrontPages.cgi?page=circular display) which used protein sequences to 
determine homology. A 50% sequence identity criteria was used to identify the core genome of ~ 
both the three fully sequenced genomes and of all eight S. agalactiae genomes. Secondly the 
Panseq online tool (124) was used to identify the core genome of the three fully sequenced 
strains. However, the output of this is a core genome alignment, so it identifies potential coding 
sequences and the GLIMMER software (40,201) was then used to identify the genes within one 
core genome alignment ortholog.
2.2 .2 .5  Reverse Com plem enting N egative S trand  Genes
Core genes are often found on different strands and therefore could not be aligned accurately 
without ensuring all genes were in the correct orientation, the fully sequenced genomes were all 
orientated correctly however the whole genome shotgun genes, because of the way in which they 
were extracted needed to be manually checked using BioEdit and re-aligned if necessary.
2 .2.2 .6  A lignm ent Using C lustalW
A custom PERL script adapted from a previous study (appendix 9.8.3) was used to align each set of 
core gene orthologs using the ClustalW PERL module and output the alignment in Nexus file 
format for use with the PAUP* program for maximum likelihood analysis.
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2.2 .2 .7  Calculating the Average Nucleotide Id en tity  (AN I)
The ANI of the core genome was calculated using a custom PERL script which used AlignlO 
(appendix 9.8.4) to calculate the number of identical bases between each ortholog pair for each 
core gene. The ANI between each ortholog pair was then calculated using the equation below.
„  (Number o f Identical Bases\
_  \  Alignment Length )
• Number o f Core Genes
The output was a file containing the average nucleotide identity between each pair of genomes 
and the ANI was calculated by taking the average of these values.
2.2.2 .8  M axim um  Likelihood Analysis o f  Each Core Gene
A custom PERL script (appendix 9.8.5) was used to perform maximum likelihood analysis on each 
core gene by taking each gene and using PAUP* (254) to generate a file containing the 
information necessary for ModelTest v3.7(182) (Gamma Shape Parameter, Proportion of 
Invariable Sites, Base Pair Frequency, ti/tv  ratios and log likelihood values). This information was 
then used to analyse each gene against 56 models of evolution to determine the most likely 
model using the Akaike information criterion. The best model for each individual core gene is then 
inputted back into PAUP* using the PAUP block to perform maximum likelihood analysis using the 
most likely model of evolution. The output of this is a set of files for each core gene which 
contains the evolutionary distance values between each ortholog of each core gene.
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2.2.2.9 Target Selection
2.2.2.9.1 Kendal's Rank Correlation Coefficient 
The Kendall rank correlation coefficient (also known as the Kendall's tau (t) coefficient) is a 
statistic used to measure the correlation between two measured quantities. It is a non-parametric 
hypothesis test for statistical dependence which measures the similarity of the order of given data 
(i.e. a rank correlation).
The evolutionary distance values were formatted for use in the Stata program (StataCorp) using 
custom PERL scripts (appendix 9.8.6 and 9.8.7) to add the genome distance values (ANI) to each 
core gene file and changing the file name to an ordered numerical value and creating a file key 
(the new file number and its corresponding locus tag). These files were then analysed using a 
Stata script to measure the TauA and TauB statistics between each core gene and the ANI.
2.2.2.9.2 Absolute Subtraction
The Kendal's Tau test was used to identify genes that are closely related to the whole genome 
average. However, using the three fully sequenced genomes Kendal's Tau gave insufficient 
discriminatory power and so the Absolute Subtraction method was devised. The distance values 
of the ANI and each core genome ortholog were totalled using a custom PERL script (appendix 
9.8.8) and in Excel the total core genome ortholog distance value was absolutely subtracted (i.e. 
negative results were converted to a positive result) and therefore Absolute Subtraction scores 
close to zero are more closely related to the ANI.
2.2.2.9.3 Analysis of the Average Number of SNP's 
Selected core gene orthologs were aligned in BioEdit and a distance matrix was created. The 
distance matrix was used to calculate the Average Number of SNP's per ortholog and per lOObp 
per ortholog using Excel.
2.2.2.9A Clustering of Sequence Data
Sequence data was analysed using CD-Hit est software (135) to determine the number of unique 
allele types in a given set of sequences using a homology criteria of 1.00 (100%) and a word size of 
9. Concatenated DNA sequences of multiple DNA targets were also analysed using CD-Hit est 
using the same criteria. Here a custom PERL script was used to automate the use of the script 
fastaConcat.pl, written by D. Wolf and N. Takebayashi (Institute of Arctic Biology) and 
downloaded from (http://hi.baidu.com/cnelonll33/blog/item/ab545dfll883eacf7931aabb.htm l 
accessed March 2008), to concatenate every combination of sequenced DNA from selected loci, 
input each sequence into CD-Hit and return an output of the combination of loci and the number 
of unique sequence types.
2 .2.2 .10  Analysis o f  Sequence D ata
2.2.2.10.1 jModelTest
jModelTest (181) was used for sequence data analysis in place of ModelTest v3.7 (182) since it is 
independent of PAUP*, uses an intuitive graphical user interface (GUI) and was shown to be 
faster. Phylogenetic model selection was performed by inputting Fasta sequence files and 
selecting "compute likelihood scores" (which performs the same function as PAUP* did for 
ModelTest) using the default settings. Following computation of likelihood scores AIC calculations 
are performed to select the most likely model of evolution for use in phyML.
2.2.2.10.2 phyML
DNA sequences were converted from FASTA into phylip format using Seaview v4 (70) and entered
into phyML (72). Trees were constructed using either a default model (GTR with optimised
gamma shape parameter over 4 sites, optimised proportion of invariable sites and empirical base
frequencies) or using the model selected using JModelTest. The selected model was inputted by
selecting custom model and inputting the correct substitution code (for example, phyML does not
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have the TIM3ef model whose substitution code is 012032), inputting the jModelTest selected 
ti/tv  rates which is the ratio of the number of transition (purine-purine or pyrimidine-pyrimidine) 
to transversion (purine- pyrimidine or vice versa) substitutions that appear to have occurred since 
two sequences separated from a common ancestor and base frequencies, if necessary specifying 
the gamma shape parameter and proportion of invariable sites. All trees were bootstrapped 100 
times.
2.2.2.10.3 BioNJ
BioNJ (67) was used to create distance trees using the ANI distance values. BioNJ uses a neighbor 
joining algorithm which is a bottom-up clustering method for the creation of phylogenetic trees 
created by Saitou and Nei (200). The method works by creating a "Q matrix" from the distance 
values and joining the two most closely related taxa based on these scores. The distance of the 
new node created from these joined taxa to the rest of the tree is then calculated. This process is 
repeated using the new node and the closest taxa to it as a new pair until the tree is fully 
resolved. Here the ANI script output was converted into phylip format and inputted into the BioNJ 
program and trees were constructed using the default settings (i.e. A Jukes-Cantor substitution 
model, a Gamma Distribution Parameter of 1 and a ti/tv  ratio of 2).
2.2.2.10.4 pubMLST
Assignment of MLST allele types and sequence types was performed using the 5. agalactiae 
database on the pubMLST website (http://pubmlst.org/sagalactiae/) (101). Fasta formatted DNA 
sequences were aligned against allele type 1 for all loci and trimmed to the correct length and 
inputted as a "single locus batch query". Results for each loci are saved and stored in an excel 
worksheet. Complete sets of allele types for each strain are then entered as a "batch profile 
query" to obtain the sequence type for each strain.
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„ 2.2.2.10.5 „ _ .START2 „ ,______ ______ _____________
START2 (Sequence Type Analysis and Recombinational Tests Version 2) (102) was used to 
measure Linkage Disequilibrium between allele types of each combination of profiling loci. Each 
profiling scheme was also tested for potential recombination sites between alleles of each 
sequenced loci using a Maximum Chi squared test.
To calculate linkage disequilibrium, for each profiling scheme the complete collection of allelic 
profiles/ST assignments and DNA sequences of each allele type were inputted into the software. 
Two separate Index of Association tests were performed, a "Classical" (Maynard Smith) and a 
"Standardized" (Haubold) test was performed and it was considered evidence for/against linkage 
disequilibrium if both tests were in agreement (102).
The Maximum Chi squared test was performed by inputting sequence data as above and running 
a batch Maximum Chi squared test to identify potential recombination sites between every 
combination of alleles.
2.2.3 Analysis of Mono-Nucleotide Repeats (MNRs)
2.2.3.1 Identification  o f  Virulence Factors  
Virulence factors of the three fully sequenced S. agalactiae genomes were obtained from VFDB 
(Virulence Factors Database) (31). To obtain virulence factors for the partially sequenced genomes 
each virulence factor from the genome 2603V/R was BLASTed against a database of all coding 
sequences from the 5 wgs genomes and homologues matching with an e value of > 105 were 
considered homologues and therefore virulence factors. Selected loci from A909 and NEM316 
were also blasted against the wgs coding sequence database if these loci did not have a 
homologue in 2603V/R.
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2.2.3.2  Location o /M N R s  
MNRs were identified in non-coding and coding DNA regions as potential profiling markers. 
Analysis of non-coding DNA was performed using the three fully sequenced genomes and analysis 
of coding DNA was performed using the protein coding DNA sequences from all eight genomes.
Non-coding DNA was investigated for MNR tracts using custom PERL scripts (appendix 9.9.1, 9.9.2 
and 9.9.3) designed to separate the coding sequences on the positive and negative strand of the 
chromosome, format the coding sequences into tab delimitated format containing the locus tag 
and the sequence of each gene on a separate line of a new file. These files were used to replace 
the coding DNA minus 20bp at each end of the coding gene (to overcome overlapping coding 
genes not being replaced and as a site for primer design) in the sequenced genome file with the 
appropriate locus tag, meaning the remaining DNA was either non-coding or coding for a protein 
on the opposite strand (this problem was solved by only using non-coding DNA between 200- 
300bp and manually checking selected markers using BLAST). Each region of DNA between 2 locus 
tags was cut out and stored to a separate file with each non-coding region on a separate line 
along with the locus tags at the 5' and 3' ends of the DNA. Each non-coding region was then used 
in a custom designed MNR finder script which returns the 5' and 3' locus tags, the length and base 
composition of any MNRs found and the length of the non-coding region.
Coding DNA was analysed by modifying the custom MNR script above (appendix 9.9.4) to analyse 
the tab delimitated coding sequences (also above) and identify MNRs in coding DNA and return 
the locus tag, any repeats found, the position of the start of the repeat and the length of the 
sequence. Another custom PERL script was developed to locate any of the 3 stop codons (TAA, 
TAG and TGA) in all open reading frames (ORFs) and return the locus tag, position and which stop 
codon was located.
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2.2.3.3  Identification  o f  Genes Containing Hom opolym eric tracts  
Previous work has shown that homopolymeric tracts represent a general regulatory mechanism in 
prokaryotes (171) and the most reliable indicator or a MNR tract that may be regulated by slipped 
strand mispairing is a repeat occurring in the first 10% of the gene length. The tab delimitated file 
from above was imported into an excel worksheet and the position of the repeat was calculated 
as a percentage of the total gene length for each gene. Each list of genes was correlated to known 
virulence factors and any virulence factor with repeats in the first 10% of the gene was considered 
to potentially be regulated by slipped strand mispairing.
2.2.3 .4  Identification  o f  Non-coding Regions f o r  Profiling  
The locus tags at the 5' and 3' ends of non-coding regions of between 200 and 300bp which 
contained MNR repeat tracts were correlated to known virulence factors gained from VFDB (31) 
using Excel. Non-coding regions with a virulence factor at either the 5' and/or 3' of the gene were 
considered suitable for sequence analysis (see above). Additionally, three random non-coding 
DNA sequences between 200-300bp in length that had no MNRs and were not associated with 
any virulence factors were selected as controls.
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Chapter 3 
MLST Profiling
3.0 MLST Profiling
3.1 Introduction
MLST is currently the gold standard technique for typing GBS (103). This was performed on the 
strain collection of 135 clinical and reference strains to determine whether the Sequenom iSEQ. 
platform was suitable for re-sequencing GBS and to provide comparative data for novel methods 
that were developed.
The Sequenom iSEQ platform is a re-sequencing technology that uses Matrix Assisted Laser 
Deabsorption/Ionisation Time of Flight Mass Spectrometry (MALDI-TOF MS). In this method PCR 
product reverse transcribed into RNA and cleaved in four separate reactions at T and C bases on 
the forward and reverse strand (figure 3.1) and the mass of each cleavage fragment is measured 
using MALDI-TOF MS. MALDI-TOF MS measures the mass of fragments by directing a laser pulse 
at a chemical matrix molecule which absorb UV from the laser leading to the ablation of the upper 
layer of the matrix material which produces a hot plume of matrix which transfers charge to the 
RNA fragments. The ionised RNA fragments are then carried through a vacuum by an 
electromagnetic field to a detector. The time it takes the ionised RNA fragments to reach the 
detector is used to calculate their mass (87). The fragment sizes are then compared to a simulated 
cleavage pattern (figure 3.2) from a user generated in-silico reference set, the more observed 
fragments matching the simulated fragments the higher the probability of a confident match. The 
iSEQ platform has previously been demonstrated as suitable for MLST on Neisseria meningitidis 
(91,109) and should therefore be suitable for application to the GBS MLST scheme.
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Figure 3.1: The iSEQ experimental process
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Figure 3.2: Generating simulated fragment patterns from a user supplied reference set
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3.1.1 Assessing the iSEQ Platform for MLST Profiling 
Initially, to  test the system and to  get an indication o f fa ilure rates, each MLST loci was sequenced 
fo r six clinical isolates by both Sanger sequencing and using the iSEQ. platform . For iSEQ 
sequencing the MLST sequencing primers (103) were tagged w ith  the T7 and SP6 tags and DNA 
was amplified, reverse transcribed and cleaved at T and C bases on the forward and reverse 
strands in four separate reactions before being conditioned and spotted to spectroCHIPS fo r 
analysis by MALDI-TOF MS. Sanger sequencing was performed as previously described except the 
sequencing primers were also used fo r amplification (103). Using the iSEQ platform  sequences 
were generated fo r 35/42 targets (83%) and fo r Sanger sequencing sequences were generated fo r 
34/42 targets (80%), showing a similar failure rate between the tw o  methods. The targets tha t 
failed to  sequence were repeated and sequences from  each method were compared showing tha t
the sequences generated from the iSEQ. platform were identical to the sequences identified using 
Sanger sequencing. This initial assessment suggest that the platform is suitable for MLST profiling 
of GBS.
3.1.2 Optimisation of iSEQ for MLST Profiling 
The 7 loci of the MLST scheme were re-sequenced for 135 isolates using the Sequenom iSEQ. 
system and profiles were obtained for 134 (one isolate was a mixed sample and a profile could 
not be obtained) and were matched to existing sequence types taken from pubMLST (101). Each 
sequence match is placed into one of three categories, a confident match, a sequence that shows 
a significant probability (>0.05) of sequence variation from the closest reference sequence or a 
bad assay indicating the reaction has either failed or the sequence is so divergent that the 
sequence cannot be matched to any reference sequence.
The first step was to determine if the iSEQ. results were correct. Sequenom states that a confident 
match is a match to a reference sequence with a sequence variation probability less than 0.05, 
however over half of the sequences generated (55%) were shown to have a significant chance of 
sequence variability. For the 7% of sequences that failed after being sequenced twice using iSEQ 
Sanger sequencing was performed (table 3.1).
Table 3.1: The number o f sequences p erio d  falling into each o f the three match categories
Loci
Confident
Matches
Probability of Sequence 
Variation >0.05
Sanger
Sequenced Other Information
adhP 46 72 16
atr 6 120 8
glcK 59 70 1 4 Loci contained 2KB inserts
glnA 96 34 4
pheS 19 112 3
sdhA 106 6 22
tkt 16 104 14
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From the 55% of sequences showing significant chance of sequence variability it is unlikely that ... 
they are not present in the MLST database, especially since in the MLST profiles database the vast 
majority of profiles are made up of allele types discovered in the original MLST paper (103). For 
example, the prevalence of allele type 1 in allelic profiles for each loci ranges from 20% {tkt) to 
71% (pheS) suggesting that allele types discovered.early on account for a high proportion.of allele 
types. It was therefore necessary to determine why such a large amount of sequences were falling 
into this category.
Loci showing more variation should be easier to discriminate using the iSEQ platform. Thus the 
level of nucleotide variation was measured between all identified sequence types of all loci of the 
GBS MLST scheme. They were compared to the same information from the successful N. 
meningitidis MLST scheme (91). This showed significantly higher levels of average nucleotide 
variation between all loci of the N. meningitidis MLST scheme (tables 3.2 and 3.3). The GBS loci 
ranged from 0.65-1.04 SNPs per lOObp wheras the N. meningitidis ranged from 2.7-11.84 SNPs 
per lOObp. So even the lowest variation observed in a N. meningitidis loci is significantly higher 
than the GBS loci and this may be contributing to the low level of confidence in the GBS iSEQ. 
results.
The average AT content of all previously identified sequence types from all loci of both the GBS 
and N. meningitidis MLST schemes were also compared. T bases do not fly well in a mass 
spectrometer due to T bases not accepting charge and therefore fragments containing an 
abundance of T bases may not be identified by MALDI-TOF MS (C. Honisch, Personal 
Correspondence). This could lead to incorrect sequence type assignments or affect the statistics 
relating to the confidence of a match. This analysis showed that the AT content was significantly 
lower in the loci of the N. meningitidis MLST scheme (table 3.4)
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Table 3.2: The number of reference sequences, length of loci and SNP's per sequence/perlOObp
fo r the GBS reference set______________________________________
Locus Sequence Types Length Average SNP's SNP/lOObp
adhP 78* 498 4.46* 0.9
atr 53 501 5.21 1.04
glcK 39 459 3.77 0.82
glnA 46 498 3.32 0.67
pheS 31 501 3.25 0.65
sdhA .40 519 5.25 1.01
Tkt 33 480 4.2 0.88
*adhP allele types 49 + 54 removed due to a 163bp deletion which would disproportionately bias
the SNP scores
Table 3.3: The number o f reference sequences, length o f loci and SNP's per sequence/per lOObp 
fo r  the N. meningitidis reference set. ________ _________________ ____________
Locus Sequence Types Length Average SNP's SNP/lOObp
adcZ 454 433 29.14 6.73
adk 307 465 18.23 3.92
aroE 514 490 58.02 11.84
fumC 461 465 12.56 2.7
gdh 496 501 31.9 6.37
pdhC 478 480 26.42 5.5
pgm 474 450 30.25 6.72
Table 3.4: The A T content o f each target o f the GBS MLST scheme compared to the A T  content o f 
the N. meningitidis MLST scheme loci________ ____________________
GBS
Loci AT Content
adhP 56.22
atr 62.67
glcK 57.52
glnA 64.06
pheS 62.87
sdhA 58.58
tkt 60.83
N. meningitidis
Loci AT Content
adcZ 48.5
adk 47.74
aroE 42.66
fumC 42.37
gdh 48.1
pdhC 46.46
pgm 45.56
All targets in the N. meningitidis MLST scheme are significantly more variable than the targets of 
the GBS MLST set and the AT content is on average 15% higher in the GBS MLST set. The 
combination of this data suggests a possible explanation as to why the GBS scheme is not 
performing as well on the iSEQ. platform as the published N. meningitidis MLST scheme. Initial
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testing did show that the sequences generated by theJSEQ platform matched sequences ____
generated by Sanger sequencing. Since that used only a limited number of isolates it is still 
possible that the sequences were being incorrectly identified or that the statistics the software 
uses were not suited to these loci despite the sequences being identified correctly. To investigate 
further a selection of 30 isolates where Sanger sequenced for the atr,pheS and tkt loci, the'loci 
which demonstrated the highest number of matches with significant sequence variation 
probabilities. The results are shown in tables 3.5, 3.6 and 3.7.
Table 3.5: Comparison ofiSEQ assigned sequence types to Sanger sequencing for the a tr loci
Strain Sequenom ST Confidence Score P Variation Match?
0933 *atr_-6 Sequence variations 0.921 0.219 Yes
8186 *atr_-6 Sequence variations 0.938 0.063 Yes
8188 atr_ -l Sequence variations 0.879 0.894 Yes
00/46 *atr_-2 Sequence variations 0.934 0.079 Yes
00/465 *atr_-2 Sequence variations 0.921 0.227 Yes
03/0477/GB *atr_-6 Sequence variations 0.913 0.342 Yes
03/226 *atr_-3 Sequence variations 0.915 0.295 Yes
03/270 *atr_-3 Sequence variations 0.895 0.685 Yes
03/414 atr_-4 Sequence variations 0.887 0.973 No
03/427 atr_-4 Sequence variations 0.914 0.753 Yes
03/438 atr_-2 Sequence variations 0.925 0.147 Yes
03/439 *atr_-3 Sequence variations 0.936 0.048 Yes
03/451 *atr_-6 Sequence variations 0.915 0.295 Yes
03/460 atr_-4 Sequence variations 0.9 0.916 Yes
03/464 atr_ -l Sequence variations 0.914 0.316 Yes
03/467 *atr_-2 Sequence variations 0.894 0.689 Yes
03/471 *atr_-2 Sequence variations 0.915 0.303 Yes
03/474 *atr_-3 Sequence variations 0.921 0.212 No
03/478/GB *atr_-3 Sequence variations 0.909 0.402 Yes
515 *atr_-6 Sequence variations 0.929 0.12 Yes
GBS III a tr_ -l Sequence variations 0.933 0.106 Yes
GBS IV atr_-4 Sequence variations 0.911 0.819 Yes
GBS VII *atr_-2 Sequence variations 0.926 0.174 Yes
GBS VIII *atr_-2 Sequence variations 0.926 0.168 Yes
GBS X *a tr_ -l Sequence variations 0.856 0.996 Yes
H03420043 atr_ -l Sequence variations 0.935 0.085 Yes
H034540119 atr_-4 Sequence variations 0.905 0.934 Yes
H035140030 atr_-4 Sequence variations 0.916 0.654 Yes
H040200291 *atr_-3 Sequence variations 0.913 0.337 Yes
H040540417 atr_ -l Sequence variations 0.923 0.209 Yes
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Table 3.6: Comparison ofiSEQ assigned sequence types to Sanger sequencing for the pheS loci
Sample Sequenom ST Confidence Score P Variation Match?
0933 pheS-4 Sequence variations 0.93 0.109 Yes
8186 pheS-4 Sequence variations 0.928 0.202 Yes
8188 *pheS-l Sequence variations 0.857 0.997 Yes
00/46 *pheS-l Sequence variations 0.917 0.259 Yes
00/465 *pheS-l Sequence variations 0.918 0.257 Yes
03/0477/GB pheS-4 Sequence variations 0.936 0.075 Yes
03/226 *pheS-l Sequence variations 0.939 0.328 Yes
03/270 pheS-1 Sequence variations 0.937 0.061 Yes
03/414 *pheS-l Sequence variations 0.902 0.513 Yes
03/427 *pheS-l Sequence variations 0.926 0.158 Yes
03/438 *pheS-l Sequence variations 0.93 0.12 Yes
03/439 *pheS-l Sequence variations 0.937 0.089 Yes
03/451 pheS-4 Sequence variations 0.912 0.346 Yes
03/460 *pheS-l Sequence variations 0.923 0.203 Yes
03/464 *pheS-l Sequence variations 0.879 0.876 Yes
03/467 *pheS-l Sequence variations 0.917 0.264 Yes
03/471 *pheS-l Sequence variations 0.92 0.204 Yes
03/474 *pheS-l Sequence variations 0.909 0.401 Yes
03/478/GB *pheS-l Sequence variations 0.928 0.134 Yes
BAA1177(515) * pheS-4 Sequence variations 0.942 0.067 Yes
GBS III *pheS-l Sequence variations 0.934 0.134 Yes
GBS IV pheS-1 Sequence variations 0.946 0.054 Yes
GBS VII pheS-1 Sequence variations 0.941 0.083 Yes
GBS VIII pheS-1 Match 0.957 0.022 Yes
GBS X *pheS-l Sequence variations 0.891 0.74 Yes
H03420043 pheS-1 Sequence variations 0.942 0.11 Yes
H034540119 *pheS-4 Sequence variations 0.912 0.34 Yes
H035140030 *pheS-l Sequence variations 0.936 0.09 Yes
H040200291 *pheS-l Sequence variations 0.938 0.067 Yes
H040540417 pheS-3 Sequence variations 0.925 0.162 Yes
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Table 3.7: Comparison ofiSEQ assigned sequence types to Sanger sequencing for the tktloci
Sample Sequenom ST Confidence Score P Variation Match?
0933 *tkt_-3 Sequence variations 0.873 0.749 Yes
8186 tkt_-3 Sequence variations 0.957 0.053 Yes
8188 tk t_ -l Sequence variations 0.941 0.49 Yes
00/46 *tkt_-2 Sequence variations 0.906 0.207 Yes
00/465 *tkt_-2 Sequence variations 0.973 0.019 Yes
03/0477/GB *tkt_-3 Sequence variations 0.895 0.372 Yes
03/226 *tkt_-2 Sequence variations 0.92 0.08 Yes
03/270 *tkt_-2 Sequence variations 0.965 0.044 Yes
03/414 *tkt_-2 Sequence variations 0.888 0.634 Yes
03/427 *tkt_-2 Sequence variations 0.955 0.118 Yes
03/438 *tkt_-5 Sequence variations 0.9 0.257 No
03/439 *tkt_-2 Sequence variations 0.972 0.021 Yes
03/451 tkt_-3 Sequence variations 0.894 0.342 Yes
03/460 *tkt_-5 Sequence variations 0.902 0.235 No
03/464 *tk t_ -l Sequence variations 0.879 0.986 Yes
03/467 *tkt_-2 Sequence variations 0.885 0.575 Yes
03/471 *tkt_-2 Sequence variations 0.887 0.45 Yes
03/474 *tkt_-2 Sequence variations 0.963 0.053 Yes
03/478/GB *tkt_-5 Sequence variations 0.961 0.06 No
BAA1177(515) tkt_-3 Sequence variations 0.958 0.051 Yes
GBS III tkt_-5 Match 0.97 0.006 Yes
GBS IV *tkt_-2 Sequence variations 0.973 0.004 Yes
GBS VII tkt_-2 Match 0.977 0.003 Yes
GBS VIII *tkt_-2 Sequence variations 0.962 0.013 Yes
GBS X tk t_ -l Sequence variations 0.921 0.234 Yes
H03420043 *tk t_ -l Sequence variations 0.888 0.633 Yes
H034540119 tkt_-3 Sequence variations 0.933 0.128 Yes
H035140030 *tkt_-2 Sequence variations 0.957 0.094 Yes
H040200291 *tkt_-2 Sequence variations 0.888 0.44 Yes
H040540417 *tk t_ -l Sequence variations 0.888 0.752 Yes
The results show that the majority of sequences were correctly identified by the iSEQ platform 
with 93.3% of atr loci, 100% of pheS loci and 90% of tkt loci being correctly identified with an 
average 94.4%. This is a comparable level of accuracy to the N. meningitidis MLST set (91). 
However, this only assessed loci where sequences almost exclusively had a high sequence 
variation probability. When most sequence variation probabilities were high it is possible that the 
scoring is incorrect. However, if the proportion of confident matches to matches with a significant 
proportion of sequence variation is roughly even then it was unclear if the scoring was incorrect 
or if the sequenced loci were not present in the reference database. This is what had occurred
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with the glcK locus with 59 confident matches and 70 matches with a significant probability of 
sequence variation. Therefore to investigate the accuracy of the iSEQ system further all isolates 
were Sanger sequenced for the glcK locus. The glcK loci iSEQ. sequences matched the Sanger 
sequence 97.7% of the time, 3 sequences out of 130 did not match the predicted sequence type 
and 4 were shown to contain a 2kb insert. Table 3.8 shows the three samples where the di-deoxy 
sequencing did not match the iSEQ sequencing results.
Table 3.8: The non-matching sequences from sequencing allg lcK  loci
Strain Loci Sequenom ST Confidence Score P Variation Match?
03/414 glcK glcK-3 Sequence variations 0.906 0.931 No
03/474 glcK *glcK-2 Sequence variations 0.933 0.222 No
NEM316 glcK *glcK-2 Sequence variations 0.95 0.05 No
Sequence variation probabilities of incorrect iSEQ. allele type assignments does not reveal any 
particular pattern (table 3.8), for example the variation probabilities for incorrectly matched 
reference sequences were not all scored as very high and range from 0.05 to 0.931 and sequences 
that match the Sanger sequence can have sequence variation probabilities as high as 0.996. 
Therefore, the sequence variation probabilities were not a reliable indication of the accuracy of an 
identified sequence. Consequently, the sequence variation probabilities were not able to identify 
loci that have been incorrectly sequenced it was necessary to identify a marker to select 
incorrectly assigned sequence types. Out of the ten sequences identified as being incorrect by 
iSEQ. profiling 7 of these were in new sequence types that were not present in the pubMLST 
database but when the correct sequence was identified through Sanger sequencing the allele type 
was corrected to a previously identified allele type. Therefore, it is highly likely that allelic profiles 
that are not present in the MLST database contain incorrectly assigned allele types. Each allelic 
profile not present in the MLST database was searched using the allelic profile query on the 
pubMLST website, this revealed a list of sequence types that had an allelic profile close to that of 
the submitted sequence type and allowed the identification of allele types that are likely to be
incorrectly assigned. For example, table 3.9 shows the list of allelic profiles close to the profile _r_. 
given for the isolate 8190 (1,1,2,8,1,2,2) which was not found in the MLST profile database.
Table 3.9: Comparison o f allelic profiles sim ilar to the profile fo r  isolate 8190 which was not 
found in the database__________  ~ ~ ..............
ST adhP pheS atr glnA sdhA glcK tkt
NEW ST 8190 1 1 2 8 1 2 2
1 1 1 2 1 1 2 2
50 1 1 2 11 1 2 2
97 1 1 2 18 2 2
251 1 1 2 27 1 2 2
297 1 1 2 2 1 2 2
383 1 1 2 42 1 2 2
413 1 2 4 1 2 2
429 1 1 2 46 1 2 2
463 1 1 2 3 1 2 2
478 1 1 2 5 1 2 2
From this analysis only the glnA allele differs from the allelic profile of 10 known sequence types 
suggesting that the glnA allele may have been incorrectly assigned. The same analysis was 
performed for all 17 allelic profiles that were not identified as a known allele type. The alleles that 
differed from closely related allele types were Sanger sequenced. In total 30 alleles were Sanger 
sequenced (9 adhP, 2 atr, 1 glcK, 4 glnA, 2 pheS, 3 sdhA and 9 tkt) and of these alleles, 16 
matched the iSEQ allele type assignment and 14 did not match. The 14 non-matching sequences 
corrected the allele types of 12 previously unidentified allele types and placed them into the 
correct group, a further 5 previously unidentified allele types were shown to be correct and are 
therefore new allele types.
In conclusion, the iSEQ system can correctly identify the alleles of the MLST scheme. The platform 
will correctly identify 95.5% of sequences, which is comparable to other work (91). It is possible 
when using the MLST set to identify sequences that are more likely to be incorrectly identified. 
However, this approach for identifying incorrectly assigned sequences could not be applied to any
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new sequence typing methods developed since there would be no existing database for 
comparison. Therefore, the iSEQ method was not used in further work.
3.1.3 MLST Profiles 
The iSEQ data combined where necessary with Sanger sequencing was used to determine the 
sequence type of each isolate in the strain collection using the pubMLST website (101). The 134 
clinical isolates were separated into 43 unique sequence types (summary in table 3.10 and figure 
3.3. Full results with allelic profiles and serotype data is in Appendix 9.2). The relationships 
between the sequence types is shown using a maximum likelihood tree (figure 3.4).
Table 3.10: Summary o f MLST sequence types
ST Frequency
1 9
2 6
6 5
7 5
8 5
9 2
10 5
12 3
14 1
17 9
19 5
22 4
23 15
24 2
25 3
26 1
28 5
44 2
48 1
51 1
61 4
67 2
ST Frequency
110 1
144 2
172 1
174 2
182 1
186 9
196 2
200 1
268 1
277 5
293 2
297 1
333 1
389 1
Insert 1 2
Insert 2 2
NEW-1 1
NEW-2 1
NEW-3 1
NEW-4 1
NEW-5 1
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Figure 3.4: A maximum likelihood tree indicating the relationships between MLST sequence
types using the GTR model, optimised proportion o f invariable sites and optimised gamma shape
parameter
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Figure 3.4 shows the relationship between the sequence types generated in this study and was 
calculated by performing maximum likelihood analysis on the concatenated allele sequences of all 
7 loci. The 4 isolates that contained 2kb inserts in the glcK loci were removed from the analysis. 
The tree shows that the new sequence types are distributed throughout the tree. That they are 
not located in their own clade suggests that these 5 strains are not a novel lineage but considering 
the high levels of recombination observed previously between MLST loci (221) it is highly likely 
that there have been recombination events which created novel allelic profiles. The four most 
commonly isolated sequences types 1,17, 23 and 186 are also distantly related suggesting these 
are separate lineages which have become prevalent independently and are not descended from a 
recent common ancestor. Finally, the three sequence types 24,25 and 144 are closely related to 
the invasive sequence type ST-23, suggesting these may also be invasive sequence types.
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3.2 Discussion of MLST Profiling
MLST is currently the gold standard molecular typing scheme for GBS (103) and is used for 
profiling in clinical research and epidemiology settings. According to the current version of the 
pubMLST database the GBS MLST scheme is reasonably well represented with 559 unique 
sequence types and an average of 46 unique allele types per loci (min = 45, max = 105) which 
places the GBS MLST scheme as the 16th largest scheme out of 80 meaning it is already well 
established. The largest MLST scheme is the Neisseria species MLST scheme which has 9060 
unique sequence types and as has been shown to use alleles that are far more variable than the 
alleles of the GBS MLST scheme. Sequence typing of N. menginitidis was also the scheme used to 
demonstrate that the Sequenom iSEQ platform could be used for accurate sequence typing (91). 
The MLST scheme was used to test the iSEQ platform for sequence typing and to provide a point 
of reference for comparison with new sequence typing schemes developed.
The distribution of MLST sequence types generated in this study showed a higher number of 
unique sequence types and a lower number of isolates were placed into the top four sequence 
types compared to other studies (103,104). Here 31% of isolates were placed into the top 4 
sequence types and 43 sequence types were identified. This suggests that the strain collection 
used was more variable than strain collections used in previous studies. This is understandable 
since previous studies used strains from single regions or hospitals, compared to this study in 
which the isolates came from across the UK. The most prevalent sequence type in this strain 
collection was the hyper-virulent ST-23 (15/134 isolates) which is unsurprising in a collection of 
clinical isolates and the top four sequences types in this study 1,17, 23 and 186 are also known to 
be common sequence types in neonatal infection as demonstrated in other studies 
(17,23,103,104,125,141,152,156). Statistical analysis of the data generated in this study showed 
that the isolates were not randomly distributed and that the MLST data is therefore indicating 
some kind of evolutionary relationship. Additionally, phylogenetic analysis revealed that the four 
most commonly isolated sequence types are distantly related which suggests that these are 
separate lineages which have become prevalent independently. Potentially they have each
acquired a novel feature that increased virulence and allowed these isolates to successfully 
disseminate by to clonal expansion. However, since it was shown that these four sequence types 
are not closely related according to the MLST data that would mean that either a common feature 
that causes enhanced virulence was acquired by a distant common ancestor which has been 
conserved by Strong selective pressure whilst the rest of the organism changes. It is also possible 
that each sequence type has independently acquired separate features that enhance virulence 
and allowed each sequence type to become prevalent. The final possibility is that the MLST 
scheme is not correctly establishing the relationships between a particularly subsets of GBS 
clinical isolates and hence why a new profiling method for GBS is required.
To test the potential of a new profiling method requires comparison to an existing method, in this 
case to MLST. Therefore the strain collection was typed using the existing MLST scheme and this 
was performed using the iSEQ system for comparative sequence analysis.
As shown in the results section (3.1.2) the platform had difficulty in assessing the probability of a 
given sequence being correct. However, Sanger sequencing confirmed the majority of the 
sequences generated by the iSEQ. platform and showed that no new allele types were generated. 
This is unsurprising because although these isolates have not been previously characterised by 
MLST a large number of UK clinical isolates have (103,104) and these isolates would not be 
expected to be so different. There are several potential reasons why the iSEQ. system was not able 
to analyse the data. Firstly it has previously been shown that AT rich regions do not sequence well 
in the iSEQ platform since T bases do not accept charge and fly well in a spectrometer (C. Honsich 
Personal Correspondence). This would make GBS a particularly poor organism to be sequenced 
using the iSEQ platform as the average AT content of GBS is approximately 65%, and analysis of 
MLST targets showed that they are on average around 10% more AT rich than those of the N. 
meningitidis MLST scheme. The second reason is that the GBS MLST scheme is far less variable 
than the N. meningitidis MLST scheme which, combined with the problems in AT rich fragments 
not flying well in a spectrometer means the platform will be less able to differentiate between
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highly similar alleles. If there was limited variation and that variation occured in an AT rich region 
it would be less likely to be identified.
iSEQ sequencing did show that the vast majority of isolates were identified with comparable 
results to those previously generated using the Sequenom (91). Despite it being difficult to 
identify which isolates were sequenced correctly using the iSEQ platforms statistics it was 
observed that sequences that were identified incorrectly had a much higher chance of being in 
allele types that have not previously been identified in the online MLST allele database (101). For 
this reason, any isolate that was identified as a new allele type was sequenced using Sanger 
sequencing. From this the number of isolates found to be new allele types was reduced from 30 
to 5 which is in line with previous research (91). This means that analysis of the sequencing results 
could correct the problems with the analysis of GBS sequences to give a similar accuracy rate to 
the N. meningitidis MLST scheme used by Honisch et al. (91). For these reasons it is believed that 
the MLST sequence data generated was correct and could be used as a comparison for future new 
targets. However, since these problems were identified in targets that already have a large 
reference database which allowed identification of atypical isolates, using this platform on 
completely novel targets developed in the next section would mean that to be sure the correct 
sequence type was assigned to each isolate they would have to be identified by Sanger 
sequencing anyway, therefore making the iSEQ platform unsuitable for further use in this project. 
Additionally, even towards the end of this project the costs of Sanger sequencing had decreased 
below the point of the initially cheaper iSEQ. platform and advances in automation and capacity of 
Sanger sequencing technology had increased to make the Sequenom platform obsolete for 
sequencing.
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Chapter 4 
Analysis of the Core Genome
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4.0 Analysis of the Core Genome
4.1 Introduction
The aim of this work was to discover phylogenetically representative target markers that better 
represent the relationships shared by the whole genomes of GBS. To do this a method that has 
previously been developed for sequence typing at the genus level (119).was adapted to develop a 
sequence typing method at the strain level. Reciprocal BLAST was used to extrapolate the core 
genomes of 1) three fully sequenced GBS genomes (2603V/R, A909 and NEM316) and 2) the three 
fully sequenced genomes plus five whole genome shotgun (wgs) sequenced genomes (18RS21, 
515, CJB111, COH1 and H36B). The core genome was then used to generate the ANI which was 
correlated to distance values between each ortholog of each core gene. The aim was to create a 
strain typing system that was not only more representative of the whole genome but which is also 
able to provide comparable or improved discriminatory power when compared to the current 
gold standard MLST scheme (103).
4.1.1 Data Mining of Sequenced Genomes 
The coding sequences from the three fully sequenced and five wgs genomes were identified 
(Table 4.1). The average number of genes across the 8 genomes was 2198 with a minimum of 
1999 coding genes (A909) to a maximum of 2376 (COH1 and H36B).
Table 4.1: The total number o f coding DNA sequences for each genome___________
Genome Number of Coding Sequences Method of Sequencing
2603V/R 2121 Fully Sequenced
A909 1996 Fully Sequenced
NEM316 2094 Fully Sequenced
515 2275 Whole Genome Shotgun
18RS21 2146 Whole Genome Shotgun
CJB111 2197 Whole Genome Shotgun
COH1 2376 Whole Genome Shotgun
H36B 2376 Whole Genome Shotgun
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4.1.2 Reciprocal BLAST Results 
Reciprocal best match BLAST is an implementation of the BLAST DNA alignment algorithm which 
is used to identify user generated DNA sequences by performing short alignments over a given 
sequence database and identifying sequences with a specified level of consecutive alignments. 
Reciprocal best match BLASTS a reference DNA sequence against a set o f query genomes using 
defined length and homology criteria to determine any DNA sequences in the reference DNA 
sequences that meet the set length and homology criteria. Of the hits that meet the criteria, the 
most similar was taken as the best match. This best match was then realigned and searched 
against the initial reference sequence to confirm it meets the length and homology criteria. 
Reciprocal best match BLAST was used here to identify the core genomes of the three fully 
sequenced genomes and of all eight GBS genomes.
To ensure that no one genome was having a disproportionate effect on the size of the core 
genome (since wgs sequences have gaps and there is no guarantee that coding sequences do not 
occur inside those gaps) the core genome was calculated for all strains by adding in each strain 
sequentially. That is, 2603V/R was used as the reference sequence as it was the largest genome of 
the fully sequenced genomes and reciprocal BLAST was carried out on the genome NEM316. The 
number of genes returned as core between these two genomes was recorded. Then the core 
genome of all three sequenced genomes was calculated by performing reciprocal BLAST using 
2603V/R as the reference and the genomes A909 and NEM316 as query genomes. Again, the 
number of core genes was recorded. Following this, 5 more reciprocal BLAST searches were 
preformed adding each of the whole genome shotgun genomes sequentially from smallest to 
largest (i.e., COH1, H36B, 515, CJB111,18RS21). At each reciprocal BLAST search the number of 
core genes identified was recorded to confirm that no genomes from the whole genome shotgun 
set were missing a disproportionate number of coding sequences that would affect the size of the 
core genome. This showed a broadly linear trend (Figure 4.1) suggesting that the reduction in the 
number of core genes when new sequences are added is not a result of missing coding sequences
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from the wgs genomes, although a limited number of missing coding sequences cannot be ruled 
out.
Figure 4.1: A graph indicating the number o f core genes found when new genomes are added to 
calculating the core genome.
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After it was shown that no one genome has a disproportionate effect on the size of the core 
genomes, two datasets were used for further analysis. The first dataset comprised the core 
genome of the three fully sequenced genomes (2603V/R, NEM316 and A909) and had a core 
genome containing 1684 genes and the second dataset comprised core genes from all the 
sequenced genomes and had a core genome containing 1179 genes (Appendix 9.10.1 and 9.10.2 
for the full list of core genes for the 3 and 8 core genome datasets respectively). The proportion of 
core genes in each dataset was calculated as shown in tables 4.2 and 4.3. For both datasets, the 
largest genomes (2603V/R and COH1 and H36B) had the lowest percentage of core genes and the 
smallest genome (A909) has the highest level. This suggests that the core genome is quite small 
with a large accessory genome and as more GBS genomes are sequenced the size of the core 
genome will continue to fall. Theoretically, after 18.49 genomes the core genome will contain no 
genes, although it is obvious that at some point before that the number of core genes reach a 
minimum level which would cover the "true" core genome for GBS. Compared to E. Coli this is a 
rather low number of genomes before reaching the theoretical zero point. Lukjancenko et al.
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(142) showed that in E. coli at the same number of genomes the core-genome still accounts for a 
large proportion of individual strains.
Table 4.2: Core genes in the fully sequenced genomes
Strain Total Gene Content: % Core % Variable
2603V/R 2124 79.3 20.7
NEM316 2093 80.5 19.5 '
A909 1996 84.4 15.6
Table 4.3: Core genes in all sequenced genomes
Strain Total Gene Content: % Core % Variable
COH1 2376 49.6 50.4
H36B 2376 49.6 50.4
515 2275 51.8 48.2
□ B i l l 2197 53.7 46.3
18RS21 2146 54.9 45.1
2603V/R 2124 55.5 44.5
NEM316 2093 56.3 43.7
A909 1996 59.1 40.9
Each gene in the core genome was assigned to a cluster of orthologs groups (COG) category and 
plotted as a percentage of the total number of genes in that COG category in the reference 
genome 2603V/R to identify how different COG categories are represented in the core genome 
(Figure 4.2 and Table 4.4).
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Figure 4.2: The percentage o f each COG category present in each o f the two core genome 
datasets
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Table 4.4: The total number o f genes from each category in the 2603V/R genome and the
COG Genes in COG (2603V/R) Description
J 152 Translation
K 160 Transcription
L 144 Replication, recombination and repair
D 24 Cell cycle control, mitosis and meiosis
V 45 Defence mechanisms
T 74 Signal transduction mechanisms
M 114 Cell wall/m em brane biogenesis
N 8 Cell m otility
U 27 Intracellular trafficking and secretion
0 57 Posttranslational m odification, protein turnover, chaperones
C 61 Energy production and conversion
G 153 Carbohydrate transport and metabolism
E 160 Amino acid transport and metabolism
F 74 Nucleotide transport and metabolism
H 51 Coenzyme transport and metabolism
1 51 Lipid transport and metabolism
P 109 Inorganic ion transport and metabolism
Q 27 Secondary metabolites biosynthesis, transport and catabolism
R 247 General function prediction only
S 166 Function unknown
- 444 Not in COGs
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The proportion of genes from each COG category was relatively evenly distributed across both the 
datasets with some notable exceptions. Genes that do not feature in the COG database were 
underrepresented in both core genomes with only 41% of genes not in the COG database present 
in the 3 genome core dataset and 25% in the 8 genome core dataset. In the 3 genome core 
dataset two COG categories have all their genes in the core (Nucleotide transport and metabolism 
and Coenzyme transport and metabolism) and a further 11 categories had over 90% of their 
genes in the core genome (Translation, Defence mechanisms, Signal transduction mechanisms, 
Posttranslational modification, protein turnover and chaperones, Energy production and 
conversion, Carbohydrate transport and metabolism, Amino acid transport and metabolism, Lipid 
transport and metabolism, Inorganic ion transport and metabolism, Secondary metabolites 
biosynthesis, transport and catabolism and General function prediction only). The 8 genome core 
dataset showed a relatively consistent fall in the proportion of each COG category (average 25%) 
with a few notable exceptions. Only two categories showed more than a 30% reduction in the 
proportion of COG categories found in the 8 genome core dataset opposed to the 3 genome core 
dataset, function unknown (33.5%) and inorganic ion transport and metabolism (34.4%) and only 
5 categories showed less than a 20% reduction, transcription (17.4%), cell cycle control, mitosis 
and meiosis (17.4%), coenzyme transport and metabolism (17.7%), lipid transport and metabolism 
(18%) and not in COG (16%).
4.1.3 Alternate Core Genomes
To confirm the core genome identified here using reciprocal BLAST two separate methods were
used. Firstly, the Panseq online tool (124) was used to create an alignment of the core genomes of
the three fully sequenced genomes (unfortunately this method could not be applied to the five
whole genome shotgun sequences). One ortholog of the alignment was then used in glimmer to
identify potential open reading frames, the number of which was taken to be the core genome.
This gave a core genome of 1809 sequences. However, not all predicted ORFs are necessarily
actual genes. Secondly, the Multi-Genome Homology Comparison tool (JCVI) was used to identify
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the core genome of both the three genome dataset and the eight genome dataset using a 50% 
sequence identity cut off as in the reciprocal BLAST approach. This identified a core genome of 
1713 genes for the three genome dataset and a core genome of 1485 genes for the eight genome 
dataset.
4.1.4 ANI Calculation Results 
ANI is the Average Nucleotide Identity between each ortholog in a concatenated alignment of a 
core genome. It has been used previously to investigate the species definition within a genus 
(120) and as a way to select genes that are evolving at the same rate as the core genome in 
development of genus level sequence typing methods (119). Here, the ANI will be correlated to 
the nucleotide identities of every core gene in both core genome datasets to allow selection of 
profiling markers at the strain level.
The level of nucleotide identity between each genome pair from both datasets was calculated and 
is shown in the distance tables 4.5 and 4.6 respectively.
Table 4.5: The nucleotide identities o f the core genome pairs o f the three genome core dataset
1________ 2________ 3
2603V/R '
NEM316
A909
100
98.1
97.9
100
98.4 100
Table 4.6: The nucleotide identities o f the 8  genome core dataset
1 2 3 4 5 6 7 8
1 515 100
2 18RS21 98.77 100
3 2603VR 98.66 99.19 100
4 A909 98.48 98.64 98.56 100
5 CJB111 98.57 98.7 98.64 98.99 100
6 COH1 98.34 98.43 98.49 98.35 98.33 100
7 H36B 98.30 98.61 98.36 99.54 98.85 98.21
8 NEM316 99.29 98.92 98.78 99.54 98.68 98.42
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From these values the ANI was calculated by averaging the distance values between each genome 
pair. For the three genome core dataset this was 98.11% and for the 8 genome core dataset was 
98.68%. An ANI value of >94% corresponds to the traditional species definition of 70% DNA-DNA 
re-association and genomes from the same species have been shown to have ANI values between 
98 and 99% (120). This is confirmed for the GBS genomes.
The ANI values of the core genome of all 8 strains were converted into a Phylip formatted DNA 
distance matrix and used in the BioNJ program (67) to generate a neighbour joining tree of the 
core genomes which essentially clusters the isolates based on the hierarchy of the level of identity 
between isolates calculated based on the distance values (Figure 4.3).
Figure 4.3: A neighbourjoining tree o f the core genome o f  GBS.
! 10.2
COM
18RS21
CJB111 •
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A309
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1As shown in the tree the most closely related genomes are A909 to H36Band NEM316.The core_. 
genomes of H36B and NEM316 share 99.54% homology to core genome of A909. The most 
distantly related genomes are H36B and COH1 which are 98.21% homologous. The genome 
sequenced strains represent seven GBS serotypes. Three of these serotypes appear twice in the 
tree (la, III and V). It is therefore possible to speculate on the correlation between genomic 
relationship and serotype for these three serotypes. The strains A909 and 515 are both serotype 
la and are separated by three common ancestors as are the serotype V strains 2603VR and 
□ B i l l .  The serotype III strains COH1 and NEM316 are separated by four common ancestors. The 
higher levels of variation shown between genomes sharing the same serotype indicate, that 
serotype is not correlated to relationships of whole genomes as suggested by other studies 
(150,219).
4.1.5 Maximum Likelihood 
Maximum likelihood analysis was performed for each core gene from both datasets as previously 
done by Konstantinidis et al. (119) using a custom Perl script (appendix 9.8.5) to automate the use 
of PAUP* and ModelTest v3.7. The evolutionary distance values from this process were used to 
correlate the relationship between each core gene ortholog to the ANI to aid in the selection of 
phylogenetically representative targets.
Of the 1684 genes from the 3 genome core dataset 1341 gave evolutionary distance values. From 
the 8 genome dataset 1119/1179 core genes gave evolutionary distance values. The remaining 
core genes (343 for the 3 genome dataset and 60 for the 8 genome dataset) could not be 
analysed due to high levels of homology between each ortholog and where either identical across 
all loci or differed by only lbp. These loci were therefore removed from further analysis since loci 
that display a high level of homology would make poor profiling markers.
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4.1.6 Kendal's x Rank Correlation Co-efficient 
The Kendal's x rank correlation co-efficient is a non-parametric hypothesis test and is used to 
measure the association between two quantities. Specifically, it is a measure ranking correlation, 
i.e. the correlation between the rank given to a piece of data in two separate lists. Here, the 
distance value between each pair of orthologs of the ANI is ordered and is correlated to the rank 
order of each core gene. Genes that are highly correlated to the ANI using the Kendal's x rank 
correlation co-efficient are therefore evolving in the same way as the average for the core 
genome and should provide an accurate measure of phylogeny.
The distance values from each gene in both the three genome and eight genome core datasets 
were correlated to the ANI using the Kendal's x rank correlation co-efficient. There are two 
Kendal's x rank correlation co-efficient scores, tau-a and tau-b, the stata software package 
calculates both. However, the tab-b score was used for target selection since it corrects for ties 
between values and is suited to square tables, i.e. distance matrix. Tau-a/b scores range from 1 
(100% correlation) to -1 (0% correlation).
Correlation of the 3 genome core dataset to its ANI split 1341 core genes into 7 separate groups 
(the maximum mathematically possible considering the number of different potential ranks 
compared to the ANI). From this 66 core genes were placed into the top scoring tau-1 group 
(Table 4.7).
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Table 4.7: All core genes from the 3 genome core dataset that have a Kendal's r  score o f l
Locus Tag Product Name Locus
SAG1305 homocysteine methyltransferase m muM
SAG0445 valyl-tRNA synthetase valS
SAG1241 IS3 family transposase OrfA -
SAG2110 50S ribosomal protein L33 rpmG
SAG1334 peptide deformylase -
SAG1145 sodiumralanine symporter family protein -
SAG0705 glycosy hydrolase family protein -
SAG1777 ribosome-associated GTPase -
SAG1085 xanthine permease ~ pbuX
SAG1070 ABC transporter, ATP-binding/permease protein -
• SAG0420 ribonucleotide-diphosphate reductase subunit alpha nrdE-1
SAG1320 hypothetical protein SAG1320 -
SAG1193 TPR domain-containing protein -
SAG0685 hypothetical protein SAG0685 -
SAG1372 thiamine biosynthesis protein Thil thil
SAG0137 hypothetical protein SAG0137 -
SAG0142 hypothetical protein SAG0142 -
SAG0047 adenylosuccinate lyase purB
SAG1321 hypothetical protein SAG1321 -
SAG0096 heat shock protein GrpE grpE
SAG1307 hypothetical protein SAG1307 -
SAG0701 glucuronate isomerase uxaC
SAG0107 CTP synthetase pyrG
SAG1096 hypothetical protein SAG1096 -
SAG1160 UDP-N-acetylglucosamine-2-epimerase NeuC neuC
SAG1785 hypothetical protein SAG1785 -
SAG1171 glycosyl transferase CpsE cpsE
SAG0696 sugar transporter, putative -
SAG1172 cpsD protein cpsD
SAG1403 hypothetical protein SAG1403 -
SAG1047 orotidine 5'-phosphate decarboxylase pyrF
SAG2106 hypothetical protein SAG2106 -
SAG1108 spermidine/putrescine ABC transporter, spermidine/putrescine-binding protein potD
SAG1319 hemolysin III, putative -
SAG1736 x-prolyl-dipeptidyl aminopeptidase pepX
SAG1077 peptide chain release factor 1 prfA
SAG1094 inorganic polyphosphate/ATP-NAD kinase ppnK
SAG1117 folylpolyglutamate synthase folC
SAG1323 isopentenyl pyrophosphate isomerase -
SAG0405 protein of unknown function/lipoprotein, putative
SAG1154 DNAtopoisomerase IV subunit B parE
SAG0102 hypothetical protein SAG0102 -
SAG1155 putative glycerol-3-phosphate acyltransferase PIsY -
SAG1118 rarD protein rarD
SAG0406 UTP-glucose-1-phosphate uridylyltransferase galU
SAG1137 gls24 protein, putative -
SAG1202 hypothetical protein SAG1202 -
SAG0123 DNA-binding response regulator -
SAG0135 amino acid ABC transporter, ATP-binding protein -
SAG1115 dihydropteroate synthase folP
SAG1246 hypothetical protein SAG1246 -
SAG0392 cell wall surface anchor family protein -
SAG1198 dTDP-glucose 4,6-dehydratase rfbB
SAG0228 hypothetical protein SAG0228 -
SAG0043 phosphoribosylamine-glycine ligase purD
SAG0025 phosphoribosylformylglycinamidine synthase, putative -
SAG0027 phosphoribosylaminoimidazole synthetase purM
SAG0086 putative lipoprotein -
SAG0566 prophage LambdaSal, single-strand binding protein ssb-2
SAG0606 hypothetical protein SAG0606 -
SAG1984 hypothetical protein SAG1984 -
SAG1863 prophage LambdaSa2, single-strand binding protein ssb-4
SAG1980 ABC transporter, ATP-binding protein -
SAG1982 Cro/CI family transcriptional regulator -
SAG1245 hypothetical protein SAG1245 -
SAG1971 hypothetical protein SAG1971 -
Performing the Kendal's t test to correlate the 8 genome core dataset to the ANI provided better 
discrimination splitting 1119 core genes into 826 unique tau-b scores however, no tau-b scores 
were perfectly correlated to the ANI. Table 4.8 shows the top 15 profiling markers.
Table 4.8: The top 15 potential profiling markers from the 8  genome core dataset
Locus Tag - • Product Name Locus tau-a score tau-b score
SAG1470 GTPase ObgE obgE 0.6587301 0.7080954
SAG1894 cyclic nucleotide-binding domain-containing protein - 0.5820106 0.69342
SAG2058 major facilitator family protein - 0.5820106 0.69342
SAG1816 hypothetical protein SAG1816 - 0.5714286 0.6885933
SAG1808 Lacl family sugar-binding transcriptional regulator - 0.5555556 0.677296
SAG1834 alkyl hydroperoxide reductase, subunit F ahpF 0.5079365 0.6682031
SAG1970 hypothetical protein SAG1970 - 0.5079365 0.6682031
SAG1824 Hsp33-like chaperonin hsIO 0.5899471 0.6565586
SAG1033 FtsK/SpolllE family protein - 0.6481481 0.655986
SAG2033 acetyltransferase - 0.5079365 0.6478174
SAG1392 iron compound ABC transporter, ATP-binding protein - 0.5767196 0.6407914
SAG1965 phosphate ABC transporter, permease protein - 0.5767196 0.632602
SAG1825 NifR3/Smm l family protein - 0.5291005 0.6303818
SAG2047 hypothetical protein SAG2047 - 0.5291005 0.6303818
SAG1826 deoxynucleoside kinase family protein - 0.5793651 0.6285582
4.1.7 Absolute Subtraction 
Since the three genome core dataset gave 66 top scoring core genes a further method was 
required to provide further discrimination. In this method the distance values for the ANI and 
each core gene were totalled and the total distance value for each core gene was absolutely 
subtracted from the total distance value of the ANI. This means that absolute subtraction (Abs) 
scores close to zero are closer to the ANI and are therefore evolving at a rate closer to the whole 
genome average. Abs scores were calculated using a custom Perl script (appendix 9.8.8) for all 
core gene distance values for both datasets. The Kendal's Tau scores were still the primary 
method of target selection, therefore for the three genome dataset, potential profiling markers 
were selected from the 66 genes with a Kendal's Tau score of 1 and an Abs score close to zero.
The Abs scores from the eight genome dataset were used to confirm the Kendal's Tau scores. 
Tables 4.9 and 4.10 shown the top 15 targets selected by absolute subtraction and the Kendal's i  
test for the three genome and eight genome dataset respectively.
123
, Table 4.9: The Kendal's t  score and absolute subtraction score o f the top 15 targets from  the 
three genome core dataset____________________________________
Locus Tag Product Name Locus
tau-a
score
tau-b
score Abs Score
SAG1305 homocysteine methyltransferase m muM 1 1 0.0114
SAG0445 valyl-tRNA synthetase valS 1 1 0.0120
SAG1241 IS3 family transposase OrfA - 1 1 0.0126
SAG2110 50S ribosomal protein L33 rpmG 1 1 0.0158
SAG1334 peptide deformylase - 1 0.0174
SAG1145 sodiumralanine symporter family protein - 1 1 0.0224
SAG0705 glycosy hydrolase family protein - 1 1 0.0258
SAG1777 ribosome-associated GTPase - 1 1 0.0259
SAG1085 xanthine permease pbuX 1 1 0.0298
SAG1070 ABC transporter, ATP-binding/permease protein - 1 1 0.0300
SAG0420 ribonucleotide-diphosphate reductase subunit alpha nrdE-1 1 1 0.0302
SAG1320 hypothetical protein SAG1320 - 1 1 0.0303
SAG1193 TPR domain-containing protein - 1 1 0.0304
SAG0685 hypothetical protein SAG0685 - 1 0.0312 :
SAG1372 thiamine biosynthesis protein Thil thil 1 1 0.0318
Table 4.10: The Kendal's r  score and absolute subtraction score o f the top 15 targets from  the 
eight genome core dataset______________________________________________________________
Locus Tag Product Name Locus
tau-a
score
tau-b
score Abs Score
SAG1470 GTPase ObgE obgE 0.6587301 0.7080954 0.1258582
SAG1894 cyclic nucleotide-binding domain-containing protein - 0.5820106 0.69342 0.1713396
SAG2058 major facilitator family protein - 0.5820106 0.69342 0.1856244
SAG1816 hypothetical protein SAG1816 - 0.5714286 0.6885933 0.0731777
SAG1808 Lacl family sugar-binding transcriptional regulator - 0.5555556 0.677296 0.1763721
SAG1834 alkyl hydroperoxide reductase, subunit F ahpF 0.5079365 0.6682031 0.1215686
SAG1970 hypothetical protein SAG1970 - 0.5079365 0.6682031 0.1960784
SAG1824 Hsp33-like chaperonin hsIO 0.5899471 0.6565586 0.0687286
SAG1033 FtsK/SpolllE family protein - 0.6481481 0.655986 1.7331175
SAG2033 acetyltransferase - 0.5079365 0.6478174 0.1316873
SAG1392 iron compound ABC transporter, ATP-binding protein - 0.5767196 0.6407914 0.1060607
SAG1965 phosphate ABC transporter, permease protein - ■ 0.5767196 0.632602 0.143535
SAG1825 NifR3/Smm l family protein - 0.5291005 0.6303818 0.1005128
SAG2047 hypothetical protein SAG2047 - 0.5291005 0.6303818 0.1163121
SAG1826 deoxynucleoside kinase family protein - 0.5793651 0.6285582 0.1064163
Interestingly, the top targets by the Kendal's x score of the 8 genome dataset had significantly 
higher Abs scores than the top scoring targets of the three genome dataset suggesting that the 
highest scoring genes from the eight genome dataset were evolving at a faster or slower rate than
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the average. However, this is more likely because the top scoring group for the three genome 
dataset contains 70 genes and therefore a wider range of distance values are available.
4.1.8 Bioinformatic Target Selection 
The top two targets based on the Kendal's Tau scores and the Absolute Subtraction scores from 
each core genome dataset, valS and mmuM  from the three genome dataset and obgE and 
SAG1894 from the eight genome dataset and two core virulence genes cylB and cpsL from a 
previous study (261) were selected for sequence analysis. The levels of nucleotide variation per 
100 base pairs and the number of unique clusters for the orthologs of each core gene was 
calculated and compared to the nucleotide variation and the number of unique clusters for the 
core gene orthologs of the MLST genes (Table 4.11).
Table 4.11: The bioinformatically selected targets compared to the MLST loci.
Gene Dataset SNPs/lOObp Unique Allele Types
mmuM 3 Genome Core 1.89 5
valS 3 Genome Core 0.79 7
obgE 8 Genome Core 0.72 5
SAG 1894 8 Genome Core 0.61 3
cylB Virulence Loci 0.12 4
cpsL Virulence Loci 1.61 6
adhP MLST 0.73 6
atr MLST 0.85 5
glcK MLST 0.35 2
glnA MLST 0.37 3
pheS MLST 0.34 2
sdhA MLST 0.88 3
tkt MLST 0.59 4
This shows that the 4 targets selected through the bioinformatic approach are more variable than 
all but two of seven MLST loci and the targets selected from the three genome dataset are more 
variable than the targets selected using the eight genome dataset. However, there is not 
necessarily a correlation between nucleotide variation and the number of unique allele types, for
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example, the target with the highest level of nucleotide variation per lOObp (mmuM) will spljt 
into 5 unique allele types whereas valS which has nucleotide variation per lOObp, which is less 
than half that of mmuM, splits the eight genome sequenced orthologs into 7 unique allele types. 
This is based on a limited amount of available sequence data and by sequencing the targets from 
a larger strain collection the benefit of applying a bioinformatic approach to selecting sequence 
typing markers will be informed.
In conclusion, this section has shown that the methods used to establish the core genome and 
analyse each gene compared to the core genome can identify targets more variable in terms of 
SNPs and in terms of the number of unique allele types that the loci of the MLST scheme. It has 
also revealed information about the gene contents of the core genome as additional sequences 
are added and potentially highlighted an issue with using incomplete genome sequences when 
identifying the core genome. However, a bioinformatics approach alone, using a relatively small 
number of genomes is not sufficient to design a new sequence-typing system and the potential 
targets identified here need to be tested in a collection of clinical isolates.
In conclusion, this section has shown that the methods used to establish the core genome and 
analyse each gene compared to the core genome can identify targets more variable in terms of 
SNPs and in terms of the number of unique allele types that the loci of the MLST scheme. It has 
also revealed information about the gene contents of the core genome as additional sequences 
are added and potentially highlighted an issue with using incomplete genome sequences when 
identifying the core genome. However, a bioinformatics approach alone, using a relatively small 
number of genomes is not sufficient to design a new sequence-typing system and the potential 
targets identified here need to be tested in a collection of clinical isolates.
126
4.2 Sequence Analysis of the Core Genome
As mentioned, a purely bioinformatics approach using a limited number of genomes would not 
alone be sufficient to develop a new profiling scheme. And since the reason for developing this 
new profiling scheme is to develop a tool that will better represent the relationships between 
clinical isolates each target was tested against a collection of clinical isolates similar to what 
would be expected to be analysed in a national reference laboratory.
4.2.1 Core Genome Sequencing 
To test the discriminatory power of the 6 targets selected using a bioinformatics approach the 
targets were sequenced for 79 isolates from the collection. The level of nucleotide identity and 
the number of unique allele types were compared to the loci of the MLST scheme (Table 4.12). 
The new targets split the 79 isolates into either equivalent or more unique allele types than all 
MLST loci except adhP which resulted in 9 unique sequence types whereas mmuM  and obgE 
formed only 8 and 7 unique allele types respectively. However, the best performing loci using 
these criteria was cpsL which was selected from a set of core genome virulence genes which split 
79 isolates into 18 unique allele types. The next best performing targets were valS (12 unique 
allele types) and SAG1894 (10 unique allele types) which were from the 3 genome and 8 genome 
datasets respectively. The worst selected target was cylB which split 79 isolates into only five 
unique sequence types and also had the highest level of nucleotide identity out of all sequenced 
loci. This loci was therefore removed from further analysis.
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Table 4.12: The level o f nucleotide identity and the number o f unique allele types between each 
sequenced loci_______________
Loci Length (bp) Unique Allele Types Percent Identity Source
adhP 498 9 97.99 MLST
atr 501 6 98.00 MLST
glcK 459 6 98.04 MLST
glnA 498 7 98.59 MLST
pheS 501 4 98.80 MLST
sdhA 519 6 97.50 MLST
tkt 480 7 98.13 MLST
cpsL 502 18 85.66 Core Virulence
cylB 501 5 99.21 Core Virulence
valS 476 12 95.17 3 Genome Core
mmuM 429 8 93.94 3 Genome Core
obgE 512 7 98.05 8 Genome Core
SAG 1894 451 10 97.56 8 Genome Core
The data also showed that the relationship between nucleotide identity and the number of 
unique allele types is not clear; that is, a higher level of nucleotide variation does not always lead 
to a larger number of unique allele types. For example, the target SAG1894 is the third best 
performing target in terms of unique allele types but only the 5th most variable target with two 
targets showing higher levels of nucleotide variation but splitting the isolates into significantly 
lower levels of unique allele types (mmuM  and sdhA).
The sequences from each dataset were subsequently concatenated and clustered to identify 
which dataset produces the most discriminatory targets (Table 4.13). Analysis showed that the 
genes selected from the three genome core dataset split the 79 isolates into 20 unique allele 
types compared to the to the eight genome dataset which split the same isolates into 15 unique 
allele types. The targets selected from the three genome dataset also show a higher level of 
nucleotide variation than the genes selected from the eight genome core dataset. Additionally, all 
four targets were concatenated and clustered, which showed that these four targets had equal 
discriminatory power to the MLST set.
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Table 4.13: The number o f unique allele types and the percent identity o f each concatenated set 
o f loci _________ _______________
Loci Length (bp) Unique Allele Types . Percent Identity
MLST 3456 31 98.15
mmuM, valS, obgE, SAG 1894 1868 31 96.25
mmuM, valS 905 20 94.59
obgE, SAG 1894 963 15 97.82
All four selected targets concatenated together have equal discriminatory power to the MLST 
scheme. However, the aim of this work was to create a three gene typing system that represents 
the phylogeny of the whole genome but also has improved discriminatory power to the MLST 
scheme. This combination of loci shows equal discrimination to the MLST scheme but selection of 
alternative markers may improve discriminatory power further. The targets from the three 
genome dataset are more discriminatory than the targets selected from the eight genome dataset 
and the three genome core dataset has 66 genes which were placed into the top scoring Kendal's 
Tau test category therefore the further targets were selected from this dataset. All of these 66 
genes with an alignment length greater than 500bp (n= 50) were analysed to determine the level 
of SNP's per lOObp. For any genes that were also in the 8 genome core dataset the orthologs 
where used to determine the number of SNPs and for genes in the three genome dataset only, 
the number of SNPs was calculated from the three fully sequenced genome orthologs (Table 
4.14). The level of nucleotide variation was used as an additional method for target selection 
since it was expected that higher levels of variation would make more discriminatory targets.
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Table 4.14: The level of nucleotide variation between orthologs fo r the 50 genes > 500bp from
Locus Tag Gene Name
Number of 
Genomes Alignment Length (bp) Average SNP's SNP/lOObp
SAG0027 purM 8 915 53.8 5.88
SAG0043 purD 8 1263 49.2 3.90
SAG0025 - 8 3612 124.8 3.46
SAG0047 purB 8 1299 32 2.46
SAG1198 rfbB 8 1047 23.9 2.28
SAG1305 mmuM 8 945 17.9 1.89
SAG1096 - 8 591 7.3 1.24
SAG1145 - 3 1346 15.3 1.14
SAG0137 - 3 1884 20.7 1.10
SAG0420 nrdE-1 J 8 2169 19.4 0.89
SAG0685 - 3 1419 12 0.85
SAG1372 thil 8 1155 9.6 0.83
SAG1777 - 8 831 6.7 0.81
SAG0445 valS 8 1965 15.6 0.79
SAG0705 - 8 1791 13.4 0.75
SAG1070 - 8 1734 12.5 0.72
SAG1321 - 8 855 6.1 0.71
SAG1085 pbuX 8 1275 9 0.71
SAG0107 pyrG 3 1605 11.3 0.70
SAG1193 - 8 1227 8.5 0.69
SAG1160 neuC 3 1155 8 0.69
SAG1320 - 8 915 6.3 0.69
SAG 1171 cpsE 8 1107 6.8 0.61
SAG 1047 pyrF 8 702 4.3 0.61
SAG0142 - 8 1263 7.6 0.60
SAG0696 - 3 1551 9.3 0.60
SAG0701 uxaC 8 1401 8.2 0.59
SAG1172 cpsD 8 544 2.8 0.51
SAG1307 - 8 651 3.3 0.51
SAG1154 parE 8 1929 9.5 0.49
SAG1202 - 8 789 3.8 0.48
SAG 1319 - 8 564 2.7 0.48
SAG 1403 - 8 585 2.8 0.48
SAG1117 folC 8 1182 5.6 0.47
SAG0405 - 3 1044 4.7 0.45
SAG1155 - 3 624 2.7 0.43
SAG2106 - 8 945 3.9 0.41
SAG1736 pepX 8 2286 9.1 0.40
SAG1077 prfA 8 1080 4.1 0.38
SAG1108 potD 8 1074 4 0.37
SAG1137 - 3 543 2 0.37
SAG0406 gaiu 3 900 3.3 0.37
SAG1323 - 8 996 3.6 0.36
SAG0123 - 3 672 2 0.30
SAG0392 - 8 1489 4.4 0.30
SAG1118 rarD 8 888 2.6 0.29
SAG1115 folP 8 804 2.2 0.27
SAG0135 - 3 741 2 0.27
SAG1785 - 3 1293 2.17 0.17
SAG1246 - 3 1170 1.3 0.11
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The four most variable genes from this list were selected for further analysis (SAG0027, SAG0043, 
SAG0025 and SAG0047, highlighted in red in Table 4.14) and primers were designed to amplify the 
most variable regions of the gene. The previously sequenced targets mmuM  and valS were also 
found in this list at position 6 and 14 respectively, suggesting it is unlikely that there are more 
variable targets than the targets selected here and the targets already analysed.
The new targets were sequenced for the same 79 isolates. The nucleotide identity and the 
number of unique allele types were calculated for each target individually and for all 4 targets 
concatenated, and compared to the MLST scheme (Table 4.15).
Table 4.15: Analysis o f the four highly variable selected targets __________________
Loci Length (bp) Unique Allele Types Percent Identity
SAG0025 501 9 87.82
SAG0027 (purM) 506 8 82.81
SAG0043 (purD) 513 12 85.96
SAG0047 (purB) 488 10 91.80
Concatenated Loci 2008 22 87.05
Surprisingly, the four highly variable targets concatenated together produce less unique allele 
types than the MLST set (22 compared to 31 for MLST). They also produce less allele types than 
the concatenated mmuM, valS, obgE and SAG1894 targets (22 compared to 31) despite the four 
highly variable targets forming on average more unique allele types and having a higher level of 
nucleotide variation.
The locus tags suggest the four highly variable genes must be located relatively close to each 
other on the genome. A GenBank file modified to contain only annotations for the 17 loci 
sequenced in this study was imported into CLC Sequence Viewer (CLC bio) to generate a 
chromosome map (Figure 4.4).
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Figure 4.4: A chromosome map of all sequenced targets. Red indicates the highly variable 
genes, Yellow indicates the MLST loci, Blue indicates the initial screening targets and Green 
indicates the core virulence genes.
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The map shows that the four highly variable genes are located very close together on the 
chromosome compared to the loci of the MLST set and the other 4 core genome targets. This 
suggests that these four targets were evolving at the same rate due to their proximity on the 
chromosome and that they are all part of the purine biosynthetic pathway (188). The high levels 
of nucleotide variation observed do produce a higher number of allele types but when 
concatenated produced a limited number of very well defined sequence types.
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4.2.2 Selection o f 3 P ro filin g  M a rk e r Genes 
The combination of markers used was not more discriminatory than the MLST set. However, the 
majority of the markers selected were more variable and form more unique clusters than the 
targets in the MLST set. Since at this point a large number of potential profile markers had already 
been sequenced at this point it was decided to combine each of the new markers to determine ; 
the optimum combination for enhanced discriminatory power using fewer genetic markers. The 
initial clustering data was used to select the first marker (i.e. cpsL formed most unique allele types 
and was therefore the first marker for the proposed profiling system). Every combination of cpsL 
and another one of nine of the sequenced alleles (cylB was excluded due to its extremely low 
levels of variation and poor discriminatory power) was concatenated together and clustered using 
the CD hit program. The sequence that generated the most new unique allele types was selected 
as the second profiling marker, this process was repeated until each of the 9 genes had been 
concatenated and clustered. This allowed the selection of the ideal number of markers by 
measuring the effect of the addition of a new marker to the profiling scheme (Figure 4.5). 
Additionally, every combination of targets was concatenated and clustered for a three and four 
gene typing system which showed the same markers were selected using this alternate clustering 
method. The sequential clustering results are shown here as they allow more discussion of the 
sequence typing targets and they are able to show falling returns on sequencing new targets.
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Figure 4.5: The number o f unique sequence types generated by concatenated profiling markers
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Figure 4.5 shows that the number of new sequence types starts to be reduced at the addition of 
SAG1894 (37 unique sequence types, 5 new) and valS (41 unique sequence types, 4 new) and 
addition of further new targets creates at best 2 new sequence types (SAG0025) and at worst no 
new sequence types (SAG0027).
To inform the number of profiling markers to use, the targets cpsL, SAG0043, SAG1894 and valS 
were sequenced for the remaining 55 isolates in the strain collection. A three gene profiling 
method (consisting of cpsL, SAG0043 and SAG1894) was compared to a four gene profiling 
method (three targets above plus valS). The four gene approach was included since it is unclear 
from the clustering of 79 isolates the benefit of the addition of the valS loci. Sequencing this 
fourth locus from a larger number of isolates would confirm if a three gene system was 
sufficiently discriminatory. These results showed that the addition of the valS locus split 134 
isolates into 69 sequence types compared to 61 for the three gene profiling method alone 
(summary shown in figures 4.6 and 4.7 and the full results by isolate are shown in Appendix 9.3
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and 9.4). The sequence types of the three gene profiling method that were split into new 
sequence types by the addition of valS are highlighted in green in Figure 4.6.
Figure 4.6:Summary o f sequence typing using the loci cpsL, SAG1894 and SAG0043 fpurD].
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Figure 4.7: Sequence typing using the loci cpsL, SAG1894, purD and valS.
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These results show that the addition of the valS loci generated an extra eight sequence types 
compared to the three gene profiling system. Of these eight sequence types, six sequence types 
of the three gene profiling system (ST-13, ST-18, ST-33, ST-34, ST-45 and ST-47) were split into one 
additional sequence type when valS was added. All of these new sequence types contained only 
one isolate. The largest sequence type, ST-16 (n=17) was split into three new sequence types (the 
4 gene profiling sequencing sequence types are ST-17, ST-18 and ST-19) which may be useful.
Since in total only 8 new sequence types were created the additional discriminatory power of 
adding valS is not sufficient to justify using a four gene profiling system.
4.2.3 Comparison of MLST to Novel Profiling Markers 
The sequences from each loci of the MLST set and the 3 gene profiling method were 
concatenated separately and aligned. They were then analysed for the nucleotide identity, the 
number of unique allele types produced and the number of informative sites (Table 4.16). The 
alignments were also used to generate a maximum likelihood phylogenetic tree demonstrating 
the relationships of MLST (Figure 4.8) and 3 gene (Figure 4.9) sequence types. Also the isolates 
contained within each sequence type in each clade of the MLST and 3 gene profiling phylogenetic 
trees were compared to identify clades which were homologous between sequence typing 
methods.
Table 4.16: The discriminatory power, nucleotide identity and number o f informative sites o f  
each profiling scheme._________________________________________________________________
Scheme
Number of 
Loci
Total
BP
Nucleotide
Identity
Unique Allele 
Types
Number of Informative 
Sites*
MLST 7 3456 97.97 43 66
3 gene 3 1472 88.25 61 142
* The Number of informative sites corresponds to the number of phylogenetically informative
columns in an alignment
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Figure 4.8: A maximum likelihood tree indicating the relationships between MLST sequence
types using the GTR model, optimised proportion of invariable sites and optimised gamma shape
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0.001
ST-25
ST-24
ST-144
ST-48
ST-17
ST-22
ST-174
ST-61
ST-67
80
ST-172
NEW-4 
ST-186 
— ST-277
76
■ST-14
tF '6
73
HI1ST-7ST-51
84
81
76
—NEW-1 
— ST-44 
ST-297 
ST-1
ST-293
— ST-28 
ST-19
— ST-182
— ST-110
— ST-389
— NEW-5
ST-196
ST-333
NEW-2 
ST-200 
— ST-8 
— ST-9 
ST-10
H IST-12ST-268
—NEW-3
ST-2
138
Figure 4.9: A maximum likelihood tree indicating the relationships between 3 gene profiling
method sequence types using the GTR model, optimised proportion of invariable sites and
optimised gamma shape parameter. Highlighted is a potentially virulent clade.
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These results showed that the relationship between sequence types of the three gene profiling 
method (Figure 4.9) has stronger bootstrap support than the corresponding tree of the MLST set 
(Figure 4.8) when using the same maximum likelihood settings.
Also, comparing isolates found within clades showed a strong correlation between a clade in the 3 
gene profiling tree to a clade in the MLST tree that contains sequence types previously identified 
as virulent (highlighted clades in figures 4.8 and 4.9) as these dades share 83% of isolates. 
Therefore, the three gene profiling system was similar to the MLST scheme in the ability to 
identify virulent strains.
The three gene sequencing method represents the phylogeny much better with the two main 
clades in the tree mirroring the two halves of the ANI tree. More specifically, the relationships 
between pairs of most sequenced genomes seems correct, A909 and H36B are indicated as being 
closely related according to the ANI and MLST trees, as are the strains 515 and NEM316. Using 
this method the strains 2603V/R, 18RS21 and GB111 are all closely related and found in the same 
sub-clade of clade 2 and although the 3 gene sequencing tree showed that 2603V/R and QB111 
are more closely related than 2603V/R and 18RS21, which is shown in the ANI tree, the 
relationship is still closer than that indicated by the MLST tree. Interestingly, although COH1 is 
indicated as being related to 2603V/R, 18RS21 and QB111 by one common ancestor, in the 3 
gene tree it is found in a separate sub clade of clade 2. Despite this, the 3 gene tree more closely 
models the relationships between the sequenced genomes according to a tree based on the core 
genome. It is also worth considering that the core genome identified for the 8 genomes may not 
be accurate due to missing coding regions from the partially sequenced genomes. However, in the 
absence of other data this method has to be considered as a reference for the accuracy of other 
data.
The MLST scheme and the 3 gene profiling method were both analysed using the START2 
(Sequence Type Analysis and Recombination Tests version 2) to determine if there is linkage 
disequilibrium between the loci. This was performed because proving linkage disequilibrium
would prove that the loci of each typing method are linked and therefore evolving at the same 
rate, i.e. if an allele type from one loci is more likely to be associated with a specific allele type 
from another loci, and these loci are sufficiently far apart on the chromosome to not be affected 
by chromosomal rearrangement then it is likely that that hypothetical pair of loci are evolving at 
the same rate relative to other lineages. To test for linkage disequilibrium a classical (Maynard- 
Smith) and Standardised (Haubold) index of association test was performed on the allelic profiles 
of all available sequence types and for both profiling methods. Both index of association tests 
demonstrated a significant probability of linkage disequilibrium. This suggested that both profiling 
schemes were modelling evolution and not random change. This was further supported by the 
ratio of non-synomous to synomous mutation rates (dN/dS) also calculated using START2 in the 
selected loci. All dN/dS ratios were all <1 which suggested purifying selection.
The combination of the bioinformatic method used to select the targets of the three gene system 
has created a sequence typing system that improves on the discriminatory power of the MLST 
scheme using less targets. The proven linkage disequilibrium and the fact that all loci are under 
purifying evolutionary pressure suggests that the three genome method is modelling whole 
genome evolution. The MLST scheme however, is already acknowledged as modelling evolution 
over longer terms, as shown in this study by lower rates of variation in the MLST loci. Therefore, 
whilst both methods model evolution, and will usually agree on which isolates are related to each 
other, the new three gene profiling method developed here is more likely to be modelling recent 
evolution making it more useful as an epidemiological method for either surveillance or outbreak 
studies whereas the MLST scheme maybe better for identifying specific lineages (for example 
differentiating between bovine and human isolates (16)).
To summarise, the three gene profiling set provides increased discriminatory power. The level of 
nucleotide variation and the number of informative sites between orthologs of the loci of the 
three gene profiling method were significantly higher when compared to the MLST scheme and 
the number of unique allele types was also significantly higher (Figure 4.6). This method of target 
selection should identify the targets more representative of whole genome evolution and the
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three targets selected were spread throughout the genome of 2603VR and therefore sequence 
types should not be biased by recombination events (Figure 4.10).
Figure 4.10: The position o f each loci o f the three genome profiling method on the 2603V /R  
chromosome
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4.3 Discussion of the Analysis of the Core Genome
There have already been a substantial number of studies to learn more about the population 
structure of GBS using MLST in different countries. These include the United Kingdom (103,104), 
the United States (17), Sweden (141), Portugal (156), France (125), Israel (152), the Central African 
Republic and Senegal (23). In all of these studies the sequence types 1 ,17 ,1 9  and 23 appear 
prominently, although with some variation. How likely would it be that GBS isolates from four out 
of seven continents, or even from within one country, were genetically .identical as indicated by 
the MLST results produced? This would imply that either GBS is a very old and very slowly 
evolving pathogen that grew alongside human populations or that being primarily a 
gastrointestinal bacterium that most of the world is consuming a food source infected with- 
bacteria from the same source. The latter is not very likely. The more probable explanation is of 
course that the MLST scheme lacks resolution and is not differentiating between genomically 
different GBS isolates and suggests that the housekeeping loci of the scheme are very well 
adapted to their function and are under strong positive selection. These issues have been 
previously observed in other organisms (83) and are partly why whole genome sequencing, which 
gives higher resolution, is becoming so popular.
In defence of sequence typing using a limited number of core genes there are existing schemes 
that produce better discrimination and can be used to answer epidemiological questions, if you 
compare the GBS MLST scheme with the Burkholderia pseudomallei MLST scheme you see a more 
realistic distribution of sequence types worldwide. The sequence types generated from the B. 
pseudomallei MLST scheme have been plotted onto a world map using MLST maps 
(http://bpseudomallei.mlst.net/earth/maps/). Each sequence type is confined to one country with 
the exception of ST-40 which is distributed across a number of countries. However even with this 
sequence type it appears there is a pattern with the sequence type originating in China, spreading 
outwards and into the Middle East and into Europe. Obviously this is not a detailed look into B. 
pseudomallei epidemiology but the point here is that for the vast majority of B. pseudomallei
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isolates a sequence type generated using MLST could determine the country of origin of the 
isolate. The data generated from the GBS MLST scheme does not allow this analysis.
The first aim of this project was to analyse the core genome to identify genes that are ljm ore  
discriminatory than that of the GBS MLST scheme. Since a more discriminatory scheme alone 
would increase the probability of identifying different groups of GBS, 2) more phylogenetically 
representative of the whole genome. Thus creating a sequence typing method that more 
accurately reflects the relationships between GBS clinical isolates. This was achieved by adapting 
a method used by Konstantinids et al. (119) which has previously been used to select genomic 
markers for E. coli and the Salmonella, Burkholderia, and Shewanella groups.
Calculating the core genome of two separate datasets of three and eight genomes showed when 
each new genome is added the number of core genomes falls, which is confirmed by the findings 
of Lefebure et al (132). The proportion of core genes across the genome was also confirmed 
using, the Panseq tool (124) and the Multi-Genome Homology Comparison tool (JCVI), which 
showed that the level of core genes produced was similar but not identical. This is unsurprising 
considering that the JCVI method uses the criteria that 50% of the columns in the alignment must 
be shared. This is less stringent than the settings used here. The Panseq tool predicts regions of 
the genome that are core and may or may not be coding regions. Coding regions are then 
identified using GLIMMER which may pick out coding regions incorrectly. For example the 
2603V/R genome has 2126 protein coding genes according to the NCBI database and 2145 
according to GLIMMER. Additionally, the core genome generated by the Reciprocal BLAST method 
was confirmed by other studies that have identified the core genome of GBS. Lefebure et al (132). 
used a similar method except that instead of performing BLAST using length and homology 
criteria, they used an e value of le -5  and an inflation parameter of 1.5. Then when the alignments 
were created using clustalW to impose a cut off that meant any alignments that share less than 
50% of conserved sites were rejected from the core genome. In other words they calculated a 
broad core genome and then removed elements rather than creating a stringent core to begin 
with and analysing it. Tettelin et al (231) also calculated the core genome of GBS using a radically
different method than the one used here.Their approach used three separate analyses, a.Smith . 
and Waterman protein search on all of the predicted proteins by using the SSEARCH program, a 
DNA search of all predicted ORFs of a strain against the complete DNA sequence of the other 
strain using the FASTA program and a translated protein search of all of the predicted proteins of 
a strain against the complete DNA sequence of the other strain using the TFASTY program. This 
resulted in a larger core genome than identified in this study. This is not surprising since they used 
three separate methods and if any one of these methods identified a gene as core it was added to 
the list which may have overestimated the core genome. Particularly as using translated protein 
searches as if the majority of nucleotide differences do not affect the amino acid sequence then 
this may severely underestimate diversity. In conclusion, the core genome extracted here using 
the Reciprocal BLAST method is supported by multiple methods and published literature.
Analysis of what is contained within the core genome using the COG category system revealed 
some interesting results which may have affected previous analysis of the core genome. The data 
showed that the core genome of the 3 genome dataset had 2 categories (nucleotide transport 
and metabolism and the coenzyme transport and metabolism) that had 100% of its genes in the 3 
genome core, however a sharp reduction in the number of these genes was observed in these 2 
categories in the 8 genome dataset. This may suggest that the core genome is being 
underestimated due to core genes being missing from the whole genome shotgun sequences, 
since both of these categories are most likely essential for the survival of the organism. For 
example the atr gene which encodes an amino acid transporter and is used in the MLST scheme is 
not completely present in the 18RS21 genome but there are no examples of this gene being 
missing in any isolates profiled by MLST. Because of this and because it is unlikely that amino acid 
transport is a non-essential function, it is therefore unlikely that this gene, and others like it, are 
not present in all genomes. It is possible that some genomes have separate genetic mechanisms 
for performing the same function. However, such a large number of genes believed to be 
essential to the survival of the organism not being present suggests that the likely explanation is 
that these genes are missing from the partially sequenced genomes. This may be possible because
both of these categories contain genes encoding transport proteins which are known to contain 
repeat regions which can be difficult to assemble into contigs depending on the genome 
sequencing method employed. If the level of decrease in the size of the core genome as new 
sequenced genomes are added is overestimated it would have implications for previous work 
demonstrating that GBS has an open pan-genome (132,231) as the calculation of the rate of 
decrease in the size of the core genome would be incorrect. It would also suggest that the 
estimation of the pan-genome may be overestimated as any genes added to the pan-genome 
based on these analyses could actually be part of the core genome. In fact, Tettelin et al. (231) 
suggest that the findings from their work may challenge the findings of Konstantinidis and Tiedje 
(120) by suggesting that rather than limited variation, bacterial species may be much more 
variable than suggested because of increased variation in the pan-genome. However, if the 
analysis of the core genome was unreliable this would bring that hypothesis into doubt. Yet, 
making this conclusion may be somewhat premature considering this was based on looking at 
different species of bacteria and it is well known that each species may evolve differently and be 
more or less prone to gene acquisition and loss. Secondly, the analysis by Tettelin et al. used 
partially sequenced whole genome shotgun sequences which based on this analysis would 
underestimate the core genome. To confirm this finding would require either completion of the 5 
wgs genomes or analysis of additional genomes which was not possible in this project but it is an 
interesting finding which should be considered in analysis of these core genomes and potentially 
in further work. Fortunately, since this project was completed a large number of new GBS 
genomes have been completed, for example NCBI now shows 143 genomes with data published 
in the wgs database and an additional 105 with data in the Short Read Archive (SRA) The majority 
of these coming from the JCVI which is currently running a project on evolutionary genomics and 
the population structure of pathogenic streptococci and in addition to these genomes is also due 
to publish data on a further 67 genomes.
The ANI calculated using the 3 genome and 8 genome datasets showed that, on average, the core 
genomes are remarkably similar and are well above the 94% ANI value that is viewed as
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equivalent to the traditional 70% DNA-DNA reassociation standard of the current species ,_______ •_
definition (120). It is also significantly higher than ANI values calculated for the four bacterial . 
groups studied previously, which is understandable as a group would be expected to be more 
variable than a species. The ANI value is also higher than that of the E. coli genomes. It has been 
suggested that they have low ANI values and lower percentages of core genes because they cover' 
a larger number of environmental niches and therefore require more variation than a pathogen 
that is restricted to limited hosts. Previous work also showed that the larger the genome of an 
organism the lower the ANI which means GBS with a relatively small genome would be expected 
to have a higher ANI as was shown here. This suggests that the majority of variation in GBS comes 
from recombination and that GBS is a pathogen more highly adapted to its surroundings and 
therefore evolving at a slower rate than organisms that are more promiscuous in their 
environmental niches. It also suggests that selecting housekeeping genes from the core genome is 
likely to give a less discriminatory typing scheme since these genes are likely to be less variable 
than this already highly similar average, as shown with the MLST genes, and traditionally are 
selected for molecular typing schemes for this reason (103,146).
The ANI was also used to generate a tree indicating the relationships of the genome sequences 
using the ANI meaning the tree shows how the core genome is evolving. This showed that genetic 
relationships are not related to serotype as has previously been observed (150,219). A similar 
method has since been used to perform phylogenetic analysis on MRSA isolates from a Thai 
hospital sequenced using the lllumina genome analyser (83) which showed that using core 
genome SNPs differentiated a collection of ST-239 MRSA isolates on the basis of their country of 
origin and even was able to identify differences between isolates from patients from different 
wards of the same hospital suggesting that using core genome SNPs provides a very accurate 
method for phylogenetics and typing. An alternate method for typing using the whole genome 
would be pan-genome typing (79) which has been shown to differentiate between the sequenced 
genomes of six bacterial species. However, using this method to analyse the core genome would 
give no phylogenetic information to allow target selection.
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Since the target selection process was performed on two datasets, one of which contained three 
genomes, an addition to the Konstantinidis method (119) was required to further discriminate 
them since mathematically every possible combination of ranks can only give seven categories 
which needed to be separated out for target selection. This was done by measuring the distance 
between the ANI and the distance value which allowed target selection 1) based on the distance 
value of the target relative to the ANI or 2) to select highly variable targets that are still evolving in 
the same way as the whole genome. This could be useful for design of profiling schemes with only 
a limited number of published sequences although technological advances have made this less of 
an issue.
Targets were not selected solely on the basis of the computational analysis as in Konstantinidis's 
work, rather a selection of targets were chosen and sequenced to determine the variation at the 
locus level and the number of unique allele types produced and then combined to determine how 
discriminatory the targets would be when used together. This showed that the most variable 
targets do not make the most discriminatory profiling scheme. For example, the four most 
variable targets with a Kendal's Tau score of 1 selected from the three genome dataset produced 
even less unique sequence types than the MLST scheme. This is probably because these genes are 
all part of the same biosynthesis pathway (188) and are therefore under the same selective 
pressures and are evolving at the same rate, although quicker than the MLST housekeeping genes. 
Therefore, another variation to the Konstantinidis method (119) was developed to determine the 
most variable combination of sequences, if the targets were selected solely on the basis of 
relationship to the ANI as in the Konstantinidis then the sequence typing system produced would 
have been less discriminatory than the MLST scheme.
Interestingly, after three targets the number of unique allele types generated increased at a
slower rate until adding an extra target did not increase the number of unique sequence types at
all after 8 genes were added to the sequence typing method. This suggests adding further targets
would not significantly improve discrimination. This is in contrast to current methods which
involve expanding the number of housekeeping genes in the MLST scheme as used by Sorrensen
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et al. (219), which would suggest that the level of variation in these genes in insufficient for 
molecular typing.
Reliable interpretations of phylogeny in this strain collection are difficult due to a lack of strain 
information. It is possible however to show how each scheme differentiates between and 
indicates the relationships between the genome sequenced isolates by comparing the trees of 
each method to the tree of the whole genomes as determined by the ANI which indicates the 
relationships between the core genomes.
The tree based on the MLST data showed that the strains COH1, NEM316 and 515 are located in 
the same clade, the whole genome tree indicates that 515 and NEM316 are located together but 
COH1 is more distantly related, meaning MLST is assigning the relationship between COH1 and 
NEM316 and 515 incorrectly. The isolates A909, H36B and 2603V/R are also clustered together 
according to the MLST tree, in the whole genome tree A909 and H36B are closely related but 
2603V/R is much more distantly related. Additionally, the isolate 18RS21 is not particularly closely 
related to any of these groups but is most closely related to the isolates A909 and H36B according 
to the MLST tree but are distantly related according to the whole genome tree. These data 
suggests that the MLST scheme may not be correctly measuring the relationships between 
isolates and is therefore misrepresenting the evolutionary relationship between GBS isolates.
Phylogenetic analysis using these three targets showed that bootstrap support was stronger for 
the three gene tree than the MLST tree. This is most likely because there are more variable sites 
in the three genes than in the seven MLST loci, resulting in more phylogenetic information from 
which to draw conclusions about relationships between isolates. These data shows that the three 
gene profiling method is more discriminatory and generates trees that are more highly supported 
than those generated from the MLST scheme. However, to prove conclusively that this scheme is 
performing better than the MLST scheme it would need to be tested on a larger and more varied 
strain set, ideally with clinical isolates from locations outside the UK to test the theory that better 
targets would discriminate between an isolates country of origin.
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This work has shown that three genes selected using a bioinformatic approach results in sequence 
typing with superior resolution and accuracy compared to the seven genes of the MLST scheme. 
This implies that the method used for selecting targets for sequence typing is more important that 
the number of targets sequenced. That is, as sequencing technology continues to improve and the 
cost of sequencing decreases while the throughput increases, some thought about the markers 
that are being used in sequence typing methods provides a greater improvement in accuracy and 
resolution than a brute force method of sequencing more targets. It has also shown that using a 
bioinformatic method alone would not produce the most efficient typing system and a 
bioinformatic approach must be combined with laboratory testing using clinical isolates, at least 
until there is a higher number of sequenced genomes. Using fewer targets also has implications 
for epidemiological studies and research projects as a higher number of isolates can be studied in 
a shorter time frame with much reduced costs and less analysis required.
150
Chapter 5
Analysis of the MNR repeats
for Profiling
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5.0 Bioinformatic Analysis of MNRs for Profiling
5.1 Aims and Objectives 
In addition to developing an accurate method to assess the phylogeny of GBS clinical isolates this 
section looked at methods to determine potential differences in virulence between different GBS 
clinical isolates. To do this the content of GBS genomes was assessed for virulence factors, since 
these were shown to be homologous between the sequenced genomes the level of 
Mononucleotide Repeats (MNRs) within core genes was assessed with a focus on repeats found in 
known virulence genes as these were shown to be involved in genomic regulation through slipped 
strand mispairing creating truncated gene products (133). Additionally, the presence and 
abundance of MNRs were assessed in non-coding areas of DNA around known virulence factors as 
these have been shown to have an effect on genomic regulation (165,242) and have also been 
shown to be good targets for strain profiling (42). The targets generated were then assessed as 
profiling markers and compared to both the existing MLST scheme and the previously discussed 
three gene profiling method. Final analysis of all profiling markers was also performed.
5.1.1 MNRs Within Coding DNA of Core Genes 
It has previously been shown that MNR repeats are overrepresented in the first 10% of coding 
DNA sequences (171) and it is believed that repeats act as a regulator of transcription through 
slipped strand mispairing causing a frame shift that brings an out of frame stop codon into frame. 
When this occurs earlier in transcription it is better for the organism since it uses less energy in 
creating a non-functioning truncated RNA.
Using a custom peri script (Appendix 9.9.4) each core gene from the 8 genome dataset was 
scanned to identify all MNR repeat regions greater than 6bp in length and used to indicate the 
level of homology of each tract in other words, each MNR tract was scored on how many core 
gene orthologs it was found in. This data was used to identify genes that had MNR repeats in the 
first 10% of the gene and to assess any difference in length and/or presence of repeats in core
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genes. Genes that have previously been identified as virulence factors were considered the most 
important because the majority of GBS virulence factors are present in all strains of the organism 
therefore differences in virulence between strains is most likely due to regulation of transcription.
In total 927/1179 genes contained at least one MNR repeat with the majority (83.3% of MNR 
repeats) being homologous across all genomes, i.e. the MNR repeat region was present at the 
same location and was the same length and composition in all 8 core gene orthologs. The position 
by percentage of gene length of each core gene was then calculated and only genes with MNR 
repeat regions in the first 10% of the gene were analysed. Of the 927 genes containing MNR 
repeats >6bp in length 325 genes were found to contain at least one MNR in the first 10% of the 
coding sequence, meaning a higher than average level of MNR repeats are found in the first 10% 
of genes.
Genes with MNR repeat regions in the first 10% were correlated to known virulence factors since 
regulation of these genes would make the biggest impact in regulation of virulence in the 
organism. Surprisingly only 6 virulence genes were identified with MNR repeat regions in the first 
10% of the gene and all of these repeats were homologous across all sequenced genomes (Table 
5.1).
Table 5.1: Virulence factors with repeats in the first 10% o f the gene
Loci Product Repeat Position
Length
of
Repeat
Number of genomes 
with homologous 
repeat
Length
of
Gene
SAG0667 cylA protein AAAAAAA 26 7 8 929
SAG0668 cylB protein TTTTTT 65 6 8 878
SAG1159 Capsule AAAAAAAA 3 8 8 629
SAG1161 Capsule AAAAAAA 57 7 8 1025
SAG1172 Capsule AAAAAAAA 41 8 8 689
SAG1173 Capsule AAAAAAA 50 7 8 692
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To test the hypothesis tha t genes selected containing MNR regions may be involved in slipped 
strand mispairing the number of NMR containing genes found in each COG category was 
compared. If MNRs were repeatedly found in genes w ith  essential functions, fo r example 
categories J and K (corresponding to  genes involved in translation and transcription respectively) 
compared to  non-essential genes such as category V (defense mechanisms) or genes w ith  no 
known COG category then this method may not be predicting repeat regions tha t are involved in 
genomic regulation, suggesting the repeats were present fo r structural reasons (Table 5.2).
Table 5.2: COG categories o f all genes, all MNR containing genes and genes containing MNRs in
the firs t 10% o f the gene.
COG
Genes in 
COG 
(2603V/R)
Genes in 
COG 
(2603V/R, %)
Genes in 
COG (all 
MNR)
Genes in 
COG (all 
MNR, %)
Genes In 
COG (MNR 
in first 10%)
Genes In 
COG (MNR 
in first 
10%, %)
J 152 6.47 87 8.64 30 8.45
K 160 6.81 76 7.55 26 7.32
L 144 6.13 48 4.77 21 5.92
D 24 1.02 13 1.29 2 0.56
V 45 1.92 23 2.28 11 3.10
T 74 3.15 41 4.07 14 3.94
M 114 4.86 51 5.06 19 5.35
N 8 0.34 4 0.40 1 0.28
U 27 1.15 12 1.19 5 1.41
0 57 2.43 31 3.08 11 3.10
C 61 2.60 30 2.98 12 3.38
G 153 6.52 77 7.65 24 6.76
E 160 6.81 90 8.94 32 9.01
F 74 3.15 38 3.77 13 3.66
H 51 2.17 37 3.67 9 2.54
1 51 2.17 28 2.78 8 2.25
P 109 4.64 49 4.87 19 5.35
27 1.15 9 0.89 2 0.56
R 247 10.52 100 9.93 37 10.42
S 166 7.07 65 6.45 21 5.92
- 444 18.91 97 9.63 37 10.42
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Table 5.2 shows that the majority of COG categories were present at approximately the same ....
proportion in both all MNR repeat containing genes and genes containing MNR repeats in the first 
10% with the only exception being genes not found in any COG category. To show how similar the 
proportion of genes predicted in both MNR datasets were the Kendal Rank correlation coefficient 
was calculated for the total genetic content of 2603V/R and all MNR containing genes and 
between the total genetic content of 2603V/R and genes containing MNRs in the first 10% of the 
gene. This showed a correlation of 0.85 and 0.90 respectively suggesting a strong correlation and 
that MNR repeat regions were found across a wide variety of genes with no particular preference 
for genes likely to undergo regulation by slipped strand mispairing.
Analysis of COG categories of genes and the lack of homology found in MNR repeat regions within 
genes suggests that either this method was not reliable for identifying genes regulated via slipped 
strand mispairing. It is also possible that the collection of sequenced isolates is biased in favour of 
virulent isolates. For this method to be useful genome sequences of non-virulent GBS isolates 
would be required. Therefore, these data were not investigated further.
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5.1.2 MNRs Within Non-Coding DNA 
Mono-Nucleotide Repeats (MNRs) within non-coding DNA have previously been identified as a 
source of hyper-variability with higher rates of variability observed within MNR tracts and in the 
flanking sequences in Escherichia coli when compared to the housekeeping genes of the E. coli 
MLST scheme (42). MNRs in non-coding DNA have also been identified as potential regulatory 
site for virulence genes (184). Therefore, non-coding DNA sequences containing MNRs were 
identified as potential profiling markers.
To identify MNR tracts within the non-coding genome two versions of the genome, one positive 
strand and one negative strand were created that do not contain DNA coding regions for each of 
the three fully sequenced genomes. The strand each coding loci was on was taken from the NCBI 
protein tables. The positive and negative strand coding loci were then separated and this analysis 
showed that the genomes 2603V/R, A909 and NEM316 had 47.8%, 50.8% and 48.3% of their 
coding loci on the positive strand respectively.
Using a custom Perl script (appendix 9.9.1) the coding loci were trimmed by 20bp at the 5' and 3' 
ends to allow replacement of coding sequences that overlapped. This gave an area to design 
primers. These trimmed coding loci were then removed from the chromosomal DNA and replaced 
with the locus tag of the coding DNA. The result was two files containing non-coding regions on 
the positive and negative strands. This resulted in some of the non-coding regions containing 
coding DNA from the opposite strand. These were easily identified by size and by BLASTing 
selected targets against the genome to confirm true non-coding regions and these were removed 
from the analysis.
Another custom Perl script (appendix 9.9.3) was then used to identify any NMR tracts >6bp in 
each non-coding region and to return the 5' and 3' locus tags, the length of the repeat and the 
composition and the length of the non-coding region. Across all genomes this showed a total of 
539, 511 and 534 non-coding regions that contained MNRs for the strains 2603V/R, A909 NEM316 
respectively. However, since these lists include "pseudo non-coding" regions and the targets that
were chosen for this method were designed for short sequencing, only non-coding regions 
between 200-300bp were considered in any further analysis. A summary of the MNR repeat 
containing regions is shown in Table 5.3, and a summary of all MNRs within non coding DNA is 
shown in Table 5.4.
Table 5.3: The number o f MNR repeats in non-coding DNA between 200-300bp.
Nucleotide
Repeat
Length
Frequencey
(2603V/R)
Frequencey
(A909)
Frequencey
(NEM316)
A 6 25 29 27
7 9 9 13
8 1 0 3
9 0 0 0
G 6 1 1 0
7 0 0 0
8 0 0 0
9 0 0 0
C 6 0 0 0
7 0 0 0
8 0 0 0
9 0 0 0
T 6 21 21 20
7 11 7 11
8 1 1 2
9 1 1 1
Total 70 69 77
These potential profiling markers were then correlated to known virulence factors extracted from 
the Virulence Factor Database (31). It is probable that regions of the genome containing virulence 
factors were more variable due to immune evasion factors and also that MNR regions in non­
coding DNA have been linked to regulation of virulence factors (184). This analysis showed that in 
the genomes 2603V/R, A909 and NEM316 there were five, two and three 200-300bp non-coding 
loci which had a virulence factor (VF) at either the 5', 3' or both ends respectively (Table 5.5).
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Table 5.4: A summary of all MNRs found in non-coding DNA
2603VR A909 NEM316
Number of Coding Regions 
Total Non-Coding Regions 
Non-Coding with MNRs 
Non-Coding with MNRs and VF at 5' and/or 3' 
Non-Coding with MNRs and VF at 5' and/or 3' 200 < 300bp
2121
1057
539
17
5
1996
995
511
22
2
2094
1039
534
15
3
Each of the ten potential profiling markers were searched using BLAST against each other to 
remove homologs and to identify loci that were present in all 3 sequenced genomes. Four loci 
were identified that met the above criteria (SAG0032-SAG0033, SAG0649-SAG650, SAG1768- 
SAG1767 and SAG2044-SAG2043) and one locus that showed homology in all genomes but with 
an insertion sequence separating the region found in A909 in the 2603V/R genome (SAKJL320- 
SAK_1319) as shown in Table 5.5.
Table 5.5; Profiling targets selected from  the non-coding regions o f the three fu lly  sequenced 
genomes._____________________________________________________________________________
5' Loci Length Strand 3' Loci VF
Sequenced? Contain MNR 
Repeats
SAG0032 246 + SAG0033 5' S
SAG0649 274 + SAG0650 5' S V
SAG 1768 208 - SAG 1767 5' S V
SAG2044 219 - SAG2043 3' X
SAK_1320 235 - SAK_1319 573'
SAG0106 272 + SAG0107 No X
SAG0043 280 + SAG0044 No X
SAG2143 228 - SAG2142 No X
From these loci, three were selected for sequencing and further analysis (Non coding regions 
between SAG0032-SAG0033, SAG0649-SAG0650, SAG1768-SAG1767). These were compared to 
three randomly selected non-coding sections of DNA that do not contain MNR repeats (Table 5.5). 
The intragenic region between SAK_1320 and SAK_1319 was also selected for sequencing because 
firstly, a MNR repeat region was found in two out of three sequenced genomes and secondly 
because of the presence of an insert in one genome which has previously been linked to increased
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Imb binding which may play a role in enhancing virulence of GBS (2,220). Primers were designed 
~100bp upstream of each of the selected targets to ensure the entire non-coding region was 
sequenced.
5.2 Sequence Analysis of MNRs for Profiling
5.2.1 Comparison of MNR and Non-MNR Non-Coding Loci 
The selected non-coding loci containing MNR repeat regions and the regions without MNR 
repeats were sequenced for all 134 isolates in the strain collection. They were analysed by allele 
typing of each loci, by assessing the level of nucleotide variation between orthologs of each target 
and by sequence typing selected combinations of loci.
The number of unique allele types and the level of nucleotide variation are shown in Table 5.6 and 
it was found that the levels of nucleotide variation and the number of unique allele types were 
relatively consistent across targets containing MNRs and those without. The SAG1768-SAG1767 
intragenic region splits the strains into the highest number of unique allele types (n = 17) with a 
variation rate of 1.02 SNPs/lOObp compared to the SAG0043-SAG0044 intragenic region which 
splits the same strains into 12 unique sequence types but has a level nucleotide variation almost 4 
times higher (3.95 SNPs/lOObp). This suggests that MNR repeat containing regions are better at 
discriminating sequence types than similarly variable regions of non-coding DNA that do not 
contain MNR repeat regions. The allele types were used to place the strains into unique sequence 
types and the ability of MNR containing loci with non MNR containing loci to cluster the tested 
isolates was analysed. The sequence typing using both sets of targets is shown in Appendix 9.5 
and 9.6 and the distribution of isolates across each sequence type is shown in figures 5.1 and 5.2 
respectively.
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Table 5.6: The number o f unique allele types and nucleotide variation o f the selected non-coding 
loci. In the unique allele types column numbers in brackets indicate sequence types that are 
genomic inserts. ____________ . .   .     ,
Loci Source Length
Unique Allele 
Types SNPs/loci SNPs/lOObp
SAG0032-SAG0033 Non-Coding + MNR 246 8 - 1.89 0.77
SAG0649-SAG0650 Non-Coding + MNR 274 3 0.38 0.14
SAG1768-SAG1767 Non-Coding + MNR 208 14 (3) 2.13 1.02
SAK_1320-SAK_1319 Non-Coding + MNR 235 7(2) 1.44 0.61
SAG0043-SAG0044 Non-Coding 280 12 11.06 3.95
SAG0106-SAG0107 Non-Coding 272 6 0.64 0.24
SAG2143-SAG2142 Non-Coding 228 8 2.00 0.88
Figure 5.1: The distribution o f sequence types fo r  the non-coding loci containing MNRs
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Figure 5.2: The distribution of sequence types fo r the non-coding loci not containing MNRs
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Five loci from four strains failed to amplify. This is most likely because of a mutation in the primer 
binding region, because the genes are arranged differently in these strains or because the coding 
regions the primer sites are located in were not present.
In total, profiling using MNR repeat coding regions was able to sequence type 132/134 isolates 
and profiling using non-coding DNA that does not contain MNR repeats was able to sequence type 
131/134 isolates. Using non-coding DNA that contains MNR repeat regions forms more unique 
sequence types (39) than using non-coding DNA that does not contain MNRs (23). The nucleotide 
identity of the MNR containing non-coding DNA targets was calculated and compared to the
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nucleotide identity of the non-coding DNA targets not containing MNR regions. This analysis 
showed that the MNR containing DNA regions were on average more similar with 98.6% 
nucleotide identity compared to 97.7% nucleotide identity for non-coding regions not containing 
MNR repeat regions but was still able to split the isolates into more unique sequence types. 
Figures 5.1 and 5.2 show the distribution of sequence types and for both MNR containing non­
coding DNA and non-coding DNA not containing MNRs the top three sequence types contain a 
large proportion of the isolates (42.5% and 57.5% respectively).
However, neither method using non-coding DNA created more unique sequence types than either 
the MLST scheme of the 3 gene profiling method which gave 43 and 61 unique sequence types 
respectively. Additionally, the top three sequence types of the MLST scheme and the 3 gene 
method contained a smaller percentage of the isolates (24.1% and 29.1% respectively).
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5.3 Discussion of using MNRs for profiling
The second aim of this project was to identify regions of hyper-variability within the GBS genome 
to select variable markers to further discriminate GBS isolates. This was achieved by studying 
MNR tracts as they have previously been shown to be sources of variation due to replication 
errors by slipped strand mispairing, meaning these regions more likely to be prone to mutation 
than average (133). Slipped strand mispairing can occur due to MNRs in the genome forming 
transient mispaired regions during transcription leading to truncated RNA products and during 
replication DNA polymerase may undergo slippage at these locations resulting in either expansion 
or contraction of repeat units in the progeny generation (133). This has been shown that to 
increase the fitness of organisms in general (165,242) and specifically in pathogens including 
Helicobacter pylori (3,205), Haemophilus influenza (92) Neisseria spp (108,217) N. meningitidis 
(153) and Campylobacter jejuni (178,247).
MNR repeats were investigated by two approaches, firstly core genes were studied for the 
presence and homology of MNRs as slipped strand mispairing would cause that changes in the 
length of MNR tracts, causing a frame shift potentially leading to premature termination of the 
gene product by bringing an out of frame stop codon into frame. The position relative to the start 
of a gene was also considered because it has been shown that genes in the first 10% of a coding 
gene are more likely to be involved in slipped strand mispairing, as these repeat regions are likely 
to have evolved to limit the amount of energy the cell expends to create a non-functional 
transcript (171). Also because virulence factors are universal in all sequenced genomes there is 
likely to be regulatory mechanisms to prevent the exposure of surface proteins to the immune 
system. Due to the latter, this work focused specifically focused on virulence genes as any 
occurrences of slipped strand mispairing would have an effect on the virulence of the organism 
due to the regulation of expression of proteins that either come into contact with the immune 
system or affect the pathogenesis of the disease.
The second approach will look at MNR repeats in non-coding DNA as these have been shown to
be involved in genomic regulation (140) and have also been shown to make good typing markers
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due to the instability of the genome and therefore lead to increased variability of these regions 
(55) making them suited to profiling.
The bioinformatics analysis showed that the majority of core genes had an MNR repeats greater 
than 6bp in length but that only 27% of genes had MNR repeats in the first 10% of the gene 
sequence. Of these genes only eight encoded virulence factors, meaning the presence'of MNR 
repeats in this organism are under-represented in these genes compared to the average.
In fact, when the classifications of genes containing MNR repeats were studied there was 
statistical evidence to suggest that there is no preference to genes that would be expected to be 
regulated by slipped strand mispairing. This was because there was no significant increase in the 
number of genes that have a MNR in the first 10% of the gene in genes expected to be regulated 
by slipped strand mispairing such as virulence genes and genes that code for proteins exposed to 
the host immune system and those not be expected to be regulated by slipped strand mispairing 
such as genes involved in transcription and translation.
A study by Janulczyk et al. in 2010 (97) examined the same issues except that they looked at all 
genes for evidence of slipped strand mispairing and not just on virulence genes and found only 39 
genes that contained MNRs that were of a different length in at least one sequenced genome 
suggesting that these 39 genes are the only genes that are under regulation by slipped strand 
misspairing. However, just because there is homology between all other MNR regions in genes 
does not automatically mean that no other genes are under regulation by slipped strand 
misspairing. It is possible that they are not identified in the sequenced genomes since the 
sequencing used would only give the most prevalent length of MNR repeats when sequences are 
assembled into contigs. Considering this, it has been demonstrated that only 1-2% of GBS isolates 
(250) are non-hemolytic which means that if a culture was grown for sequencing a GBS genome, 
only 1-2% of the sequences generated for the MNR tract would have a frameshift mutation 
meaning when the sequences were assembled the MNR repeat region would be identified as 
having the non-frameshift length of nucleotides. The best way to establish if slipped strand
mispairing occurred would be to grow a culture and deep amplicon sequence the selected region . 
to prove that a percentage of sequences have a different number of nucleotides at this repeat 
region. As the availability of wgs increases within the HPA, this may be an area for future work.
The second approach was to look at MNR containing regions of non-coding DNA for use as 
sequence typing markers. Non-coding DNA was selected for two reasons, firstly if may be involved'
in regulation of the upstream genes (184), which would allow profiling with a link to th e   •
phenotype of the organism. Secondly if these non-coding DNA are not involved in regulation it 
would imply that this DNA would be free of selective pressures and free to accumulate mutations 
making these regions a source of increased variability, particularly if these regions contain 
sequence repeats since these regions would still be prone to mutation due to replication errors 
(234). The majority of sequence typing methods that use targets in non-coding DNA use short 
tandem repeats and this method has been applied to Mycoplasma genitalium (145), C. difficile 
(259), 5. aureus (206), M. tuberculosis and M. bovis (222). Using MNR containing non-coding 
region for selecting sequence typing targets has also been successfully applied to £  coli and this is 
the approach which was applied in this study (42).
Since these targets were designed for sequence typing, only non-coding regions between 200- 
300bp were considered. Within these limits, the three fully sequenced genomes on average had 
only 72 non-coding regions containing MNRs and only 3.3 on average between or around 
virulence genes. This suggests a bias in favour of MNR regions within non-coding DNA, which 
suggests evolutionary pressure is being applied despite the fact that these areas of DNA are non­
coding suggesting involvement in genomic regulation, i.e. if these non-coding regions are not 
under selective pressure and are random the probability of a string of repeated bases occurring 
would be small. For example, the probability of a 6bp poly-A repeat occurring would be 0.0002 
and an 8bp poly-A repeat would be 0.00002, meaning these would be expected to appear 
randomly 5 and 0.5 times over the course of a 2.5Mbp genome respectively. Since they appear 
more frequently it suggests that when they appear, they have a function of some description.
165
A selection of non-coding DNA targets containing MNRs but still around virulence factors were 
selected to assess their suitability as profiling targets compared to non-coding regions that did not 
contain MNRs. The results from this were interesting, the target that split the isolate collection 
into the largest number of unique sequence types did contain MNRs but the second highest did 
not contain MNR repeats.
This shows that just because a section of non-coding DNA contains MNRs does not mean it will be 
more variable due to genome instability as suggested previously (74). However, one interesting 
aspect of the MNR containing non-coding regions was that 2/4 targets were found to contain 
various insertion sequences including GBSil, IS1548 and ISSag8 and a 5. equi transposase. This 
suggests that non-coding regions which contain MNR repeats are more likely to contain an 
insertion sequence which makes sense as 1) an insert into non-coding DNA would not inactivate 
an existing gene and 2) because MNR regions may either create an area of instability in the 
genome or may be complementary to the ends of insertion sequences.
The findings here disagree with the work of Diamant et al. (42) who proposed that MNR tracts 
within non-coding DNA are a source of hyper variability. They state that MNR containing non­
coding DNA is more variable than housekeeping genes and the level of variation is independent of 
the variation of surrounding DNA. The data shown here suggest that MNR repeat regions are 
more likely to be variable if the genes surrounding them are highly variable. This was shown by 
the SAG0043-SAG0044 intragenic region which does not contain MNRs but is the most variable 
intragenic region.and it is located near the highly variable targets established during the core 
genome work earlier. The levels of variation within these MNR regions is not significantly different 
to the housekeeping genes of the MLST scheme and is in most cases significantly lower than the 
core genes selected for profiling. Despite this, on average the diversity of the non-coding DNA 
with MNR repeats was higher than the diversity of the non-coding DNA that does not contain 
MNR repeats but not by enough to compensate for other factors such as the variation of DNA 
surrounding the non-coding repeats.
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When looking at the sequences of these targets the variation that was shown was very rarely . 
shown in the length of MNR repeat regions as opposed to the remainder of the sequence which is 
surprising. This may suggest an efficient DNA repair system or that any repeat regions are actively 
selected for which would make sense considering that MNR repeats are overrepresented in non­
coding DNA which would suggest they are being actively selected for. Additionally, one reason for 
looking at MNR containing non-coding DNA regions was to identify targets that would be highly 
variable in a short stretch of sequence. This would allow pyrosequencing to be used, however 
analysis of the targets showed that in the approximately 150bp that could be generated by the 
biotage pyrosequencing platform available there would be insufficient variation to justify using 
these targets as sequence typing markers.
In conclusion, profiling schemes designed using non-coding DNA both with and without MNR 
repeats was unable to create a profiling system more discriminatory than the MLST scheme using 
fewer markers showing that the presence of MNR repeats in non-coding DNA alone is not 
sufficient to select profiling markers. Other work has created non-coding DNA based profiling 
systems by aligning corresponding non-coding DNA regions across a selection of genomes and 
selecting the most variable alignments (47) which would appear to be a better method for 
selecting profiling markers.
However 1) a region that is more variable does not necessarily represent the evolution of the 
species and has already been demonstrated to be inappropriate for long term evolutionary 
studies (136) and 2) if targets are going to be selected on the basis of variability of alignments, 
there is no reason to restrict this analysis to the non-coding genome, there may be coding regions 
that are more variable if that is what is desired.
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Chapter 6
Combining Three Gene 
Profiling with MNR Profiling
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6.0 Combining Three Gene Profiling and MNR profiling 
6.1 Introduction
The aim of this project was to develop a two component profiling system that accurately reflects 
the phylogeny of GBS clinical isolates and gives indications into enhanced virulence. The first 
component of this was achieved by developing a three gene typing system which has been shown 
to be more discriminatory than the current MLST scheme. The second component looked at 
potential regulation of virulence genes by looking at MNR regions in coding and non-coding DNA. 
Although together these MNR containing regions did not produce a typing system to rival existing 
methods, individual targets were able to add discriminatory power and act as a potential 
virulence indicator for GBS.
6.2 Results
The results from profiling using non-coding regions containing MNRs were added to the three 
gene profiling method and the number of sequence types calculated (Figure 6.1). The SAKJL320- 
SAK_1319 (scpB-Imb) intragenic region which equalled the discriminatory power of valS and this 
region gave in combination with the 3 gene profiling markers resulted in 69 unique sequence 
types (Figure 6.1).
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Figure 6.1: The number o f unique sequence types per dataset
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Figure 6.2: Distribution o f Sequence Types using the Three Gene plus Insertion sequence typing 
scheme. Sequence Types comprised o f a GBSil insertion sequence are indicated by Red bars and 
Sequence Types comprised o f an IS1548 insertion sequence are indicated by Green bars.
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These data show that the intragenic region between scpB and Imb does increase discriminatory 
power and results in more unique sequence types. However, two of the allele types found in the 
scpB-Imb intragenic region were the genomic inserts GBSil which were identified in 19 isolates 
and IS1548 which was identified in 7 isolates, giving a total of 26 (19.4%) sequenced isolates 
containing an insertion sequence.
In total 12 three gene sequence types had isolates that contained inserts. Eight of these sequence 
types had an insert found in all strains of that type, of these the sequence types ST-28, ST-32, ST- 
36, ST-41 and ST-59 contained the GBSil insert and the sequence types ST-39, ST-43 and ST-47 
contained the IS1548 insert. Four of the 3 gene sequence types had an insertion sequence in at 
least one isolate, ST-18 (7 isolates) had a GBSil insert in one isolate, ST-33 (3 isolates) had GBSil 
inserts in 2 isolates, ST-34 (9 isolates) had GBSil inserts in 6 isolates and ST-45 (7 isolates) had 
GBSil inserts in five isolates.
Using a loci with a relatively high proportion of insertion sequences means that this loci could not
be used in phylogenetic analyses since any alignment would be misleading as each base is
considered a separate evolutionary event which is not the case with an insertion of DNA
sequence. Despite the limitations in using this marker in phylogenetic typing the presence of two
distinct insertion sequences in a relatively high number of isolates presented a number of
potential advantages. Firstly, figure 6.3 shows that these inserts were not found in the same 3
gene sequence type at this loci suggesting that insertion of either of these insertion sequences
could be a marker of evolutionary lineage. Secondly, it has previously been shown that insertion
sequences at this location may be partly responsible for increased virulence resulting in increased
expression of Imb, a previously identified virulence factor involved in host cell invasion (2). Finally,
the presence of this insert allowed further comparison of the MLST scheme and the 3 gene
profiling method since isolates with insertion sequences would be expected to cluster together
since, even considering GBS's open pan genome, an insertion is more likely to be a single event in
the evolution of a subset of GBS strains. Therefore, mapping insertion sequences to the
phylogenetic trees of the relationship between sequence types using the MLST scheme and the 3
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gene profiling method should give an indication of how each scheme is representing the _ 
phylogeny of GBS strains.
When the sequence types containing inserts are added to the tree showing the relationships of 
the 3 gene sequence types (Figure 6.3), all isolates containing insertion sequences cluster within 
one clade (a section of the tree beginning with a common ancestor), clade A and within clade A 
there are two sub-clades (B and C). Clade B contains 2/3 of the sequence types (4/7 isolates) 
containing the IS1548 insertion sequence and 2/8  sequence types (6/19 isolates) containing the 
GBSil insertion sequence. Clade C contains 6/8 sequence types containing the GBSil insertion 
sequence (12/19 isolates) and 1/3 sequence types (3/7 isolates) containing the IS1548 insertion 
sequence.
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Figure 6.3: The three gene profiling tree including the presence o f inserts between the scpB-lmb 
genes and the number o f isolates per ST with inserts. Points A, B and C indicate clades.
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Finding that these insertion sequences were exclusive to a particular clade may suggest that these
insertion sequences were gained around point A in the evolutionary history of GBS as indicated by
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this tree. However, since these insertions were not present in all isolates after this point may 
suggest that the insertion sequence was either being lost because it was inherently unstable or, if 
this insertion sequence does increase virulence, because of selective pressure placed on the 
organism by treatment or invasive GBS.
When the positions of insertion sequences were mapped onto the MLST tree (Figure 6.4) it is 
clear that the insertion sequences were more spread throughout the tree when compared to the 
position of isolates on the 3 gene phylogenetic tree. Only 38.4% of the insertion sequences are 
found in the potential virulent clade identified earlier (Figure 4.8).
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Figure 6.4 shows the diverse lineages which contain insertion sequences and also shows that 
unlike the three gene profiling method, one sequence type (ST-19) contains isolates containing 
both the GBSil and IS1548 insertion sequences which would not be expected if the sequence type 
is clonal suggesting that the MLST scheme is not accurately identifying phylogenetic lineages.
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6.3 Discussion of Combining Three Gene Profiling and MNR 
Profiling
The aim of this section was to discover if the sequence typing using the three gene profiling 
system could be more discriminatory if supplemented with one of the markers selected from non­
coding DNA. Since even though the MNR containing non-coding regions are not alone suitable for- 
typing GBS, the addition of one of the MNR-targets was shown to improve the discriminatory 
power of the three gene profiling system and provided additional confirmation that this scheme is 
more phylogenetically representative that the existing MLST scheme.
ThescpB-Imb intragenic region in 2/3 of the fully sequenced GBS genomes (A909and NEM316) is 
a 235bp intragenic region containing MNR repeats, whereas in 2603V/R this region contains the 
gbsil insertion sequence. When combined to the three gene profiling method this region also 
produced the largest number of unique sequence types. The disadvantage of using this target is 
that due to the large proportion of insertion sequences this target cannot be used for sequence- 
based phylogenetic analysis. However, the use of this target is justified because the presence of 
IS1548 and GBSil at this location has been shown to increase the level of Imb which is a known 
virulence factor which binds to laminin and is therefore involved in GBS cells invading damaged 
epithelium (220). The two insertion sequences have been shown to increase the level of 
expression or Imb by variable degrees, expression is substantially increased when IS1548 is 
present and increased slightly in the presence of isolates containing the GBSil insertion sequence 
compared to isolates containing no insertion sequence (2). Due to this, the presence of an 
insertion sequence here can be considered a putative indicator of enhanced virulence, although 
the clinical impact is unknown and further work is required to determine this.
Including the presence and absence of insertions in analysis of the three gene sequence typing 
data confirms that the three gene profiling method is more phylogenetically accurate than the 
MLST scheme since the presence of any insertion sequence is limited to one clade in the 3 gene 
tree (Figure 6.3) and spread over the MLST tree (Figure 6.4) which would suggest that the three
gene profiling tree is hinting at a point in the evolution of the organism when it acquired these 
insertion sequences. Additionally, the MLST scheme contains multiple sequence types where the 
isolates within that sequence type contain different types of insertions, that is, a single sequence 
type can contain isolates that contain either the IS1548 or the GBSil insertion sequences at the 
same location. Since the presence of multiple different insertion sequences in sequence types 
that, according to the MLST scheme, are identical it is likely that the MLST scheme is not 
accurately modelling the relationships between these isolates. By contrast, the three gene 
profiling method never showed a sequence type that contained the multiple types of insertion 
sequences. However, it did show sequence types that have an insertion sequence in some but not 
all isolates, although the majority of sequence types are homogenous for insertions with seven 
out of the eleven sequence types that contain an insertion sequence having one in all isolates of 
that sequence type. The fact that this insertion sequence is so unstable at this point in the 
genome could suggest that streptococcal genomes are highly recombinant, as previously 
suggested by Springman et al. (221) or that insertions at this location are inherently unstable. The 
most likely explanation is that the three gene profiling method, while representing phylogeny 
better than the MLST scheme is still not perfect. This is understandable since in a typing scheme 
that perfectly represented the phylogeny it is highly unlikely that any two isolates would ever be 
placed into the same sequence type. This is because any two isolates gathered from different 
infections or even different sites of infection in the same patient are highly likely to show some 
difference at the genome level. A sequence typing system in which all isolates are guaranteed to 
fall into a different sequence type would be redundant as it would be increasingly difficult to 
identify common sources of infection without detailed analysis. The only way to generate a typing 
system that has 100% resolution would be to sequence the genomes. Even then, analyses of 
relationships are difficult. For example, with multiple sequenced genomes there are multiple 
methods for analysing the relationships such as using core genome SNPs in phylogenetic analysis 
(84) or cluster analysis based on genes that are not shared between all isolates (80), neither of 
which use all of the information generated from whole genome sequences.
In conclusion, this work set out to develop new profiling strategies based on different___
bioinformatic methods with varying degrees of success. Combining the elements of the highly 
discriminatory three gene profiling scheme with an element of the non-coding genome has the 
potential to become a profiling scheme that surpasses MLST in discriminatory power and 
accuracy. Combining a locus which may have real clinical implications will allow further study to 
elucidate the pathogenicity of GBS. This has the potential for future development of methods to 
determine if an isolate has the potential to cause disease.
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Chapter 7 
Discussion
7.0 Discussion
The aim of this project was to develop a two component sequence typing method that accurately 
reflects the evolution of GBS, is more discriminatory than the existing MLST scheme and could 
give an indication of the virulence of the organism. This was the goal because bacterial typing is 
one of the cornerstones of microbiology and has been performed by a large number of methods 
over many years. Each method has it's advantages and disadvantages and works differently when 
applied to different organisms. For example, the serotyping of GBS was developed by Rebecca 
Lancefield in 1934 (126) and is still used today to allow for historical comparisons and to allow 
vaccine development. Despite it's advantages, it does not discriminate very well and does not 
reflect the evolution of the organism. Another example is MLST, which despite being useful for 
studying the long term evolution of most organisms it is not as reliable in GBS as in other 
pathogens. This project aims to improve upon this scheme and develop a new sequence typing 
method that accurately reflects the evolution of GBS.
Bacterial typing is performed for a number of reasons. Firstly to differentiate strains of bacteria 
that can cause disease from those that cannot, for example only certain E. coli strains can cause 
disease and these can be differentiated by serotyping of the 0 , K, H and F antigens (14) which is in 
direct contrast to GBS where serotyping for epidemiology has shown that out of the 10 existing 
serotypes, serotypes la, III and V cause the majority of neonatal GBS infections in the West 
opposed to types Vi and VIII in Japan (123), i.e. it appears that most if not all GBS serotype can 
cause disease but the prevalence of serotypes in a given locale is more important, that is, if 
serotypes VI and VIII were more prevalent in the UK then it is unlikely that the disease burden 
would be decreased, rather, the only difference is likely to be that infections show a different 
serotype. Also molecular typing methods have been used to track the spread of outbreaks such as 
Destro et al. who used RAPD and PFGE to trace the dissemination of L monocytogenes in a shrimp 
processing plant (41) and is routinely used to confirm the source of existing outbreaks identified 
through studying the movements of and connections between patients.
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Additionally, in research to answer key questions about the organism, for example, Sorensen et 
al. in 2010 (219) used MLST plus 8 additional housekeeping genes to shown that GBS clones are 
specifically adapted to either bovine or human hosts. However, sequence typing methods have 
been better able to study the population structure of other organisms than the GBS MLST 
scheme, the main sequence typing method for GBS. There are currently many commonly used _ 
methods for bacterial typing including serotyping, which uses antibodies against set proteins; 
phage typing which detects different susceptibilities to attack by certain bacteriophages and 
molecular methods such as PFGE, RAPD or MLST. Other methods are organism-specific and less 
common, for example in GBS three set genotyping (117), molecular serotyping (115) and a 
method referred to here as MLST+ which is MLST plus sequencing of other housekeeping schemes 
to add discriminatory power to MLST (219) all of which may be in response to limitations with the 
MLST scheme. The limitations of sequence typing are firstly lack of discrimination, that is, 
different bacteria that are different being placed into the same category and secondly the 
categories assigned do not represent the links between evolution of the organism as a whole. 
Hence, the goal of this project, to create a new molecular profiling system which is both more 
discriminatory and better represents evolution than the existing MLST scheme for GBS.
The approach used here was to develop bioinformatic pipelines for selecting genomic markers of 
phylogeny and variability in GBS and then test these in a laboratory setting. The methods 
developed here can also be applied to other microorganisms. The first method used was first 
developed by Konstantinidis et al. (119) and selects genomic targets based on their correlation to 
the average rate at which the genome is evolving and has previously been shown to generate a 
much more accurate phylogeny of E. coli and the Salmonella, Burkholderia, and Shewanella 
groups. Here this method is adapted for use at the strain level using an organism in which a large 
number of core genes show a high level of homology. The second is based on research that 
showed that MNR repeat regions are more highly variable that comparable DNA stretches (133) 
and may be involved in genomic regulation through slipped strand misspairing creating truncated 
translation products (165,242) and by other methods in non-coding sections of DNA (184). Also,
since it is known that the vast majority of virulence genes are shared between GBS sequenced 
isolates, work looking at sections of DNA that may be involved in regulation will focus on these. _ 
genes as it may reveal interesting facts about GBS virulence.
Bacterial typing is important for diagnosis, treatment and epidemiological surveillance of 
infections. This is even more important in bacteria which exhibit high levels of antibiotic 
resistance, are involved in nosocomial or pandemic infections or for bacteria that are being 
studied for vaccine development. There are a variety of different typing methods which can 
broadly be split into four categories 1) serological. 2) DNA banding based methods. 3) DNA 
hybridization methods using nucleotide probes. 4) DNA sequencing based techniques. This section 
will discuss the general issues with typing and the advantages and disadvantages of each of the 
methods which have been applied to GBS previously and in this study.
In molecular biology, a bacterial species is defined as a homogeneous population. This can be 
determined experimentally through DNA hybridization which defines bacteria as being in the 
same species if they share at least 70% hybridization of DNA (249), by the homology between the 
16S rRNA gene where an identity over 97% gene sequence similarity shows isolates to be in the 
same species (223) or by the Average Nucleotide Identity of the core genomes of a group of 
isolates where iftheA N I is greater than 94% two genomes can be considered related (121).
Relatively recently there has been a large increase in the number of whole genome sequences 
available as a result of advances in whole genome sequencing technology and the corresponding 
decrease in cost. This has allowed comparative genomic methods to demonstrate that genetic 
diversity within a bacterial species was far greater than previously thought (15,65,132,231). This 
also introduced the concept of the bacterial pan-genome. This is every gene identified in a species 
subdivided into two components, the core-genome, which is comprised of genes shared by all 
sequenced strains in a species, and the accessory genome which is comprised of genes which are 
not found in all strains. Any two strains of the same species of bacteria may differ in gene content 
by as much as 30% and a species may show a much higher level of diversity (65,231). The concept
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of an open or.closed pan-genome has also been introduced. A closed pan-genome is a species 
with a relatively small pan-genome and sequencing of new strains will not add to the pan­
genome. In contrast, an open pan-genome contains a large pan-genome and theoretically, 
sequencing additional strains of the species will result in the size of the pan-genome increasing 
indefinitely. For example, Bacillus genomes have been shown to have a closed pan-genome 
whereas GBS hypothetically has an open pan-genome (231). However, this may be due to 
sampling bias caused by using incomplete genome sequences. Genomic variations and typing can 
therefore be measured in two ways. Firstly variation can be measured by looking at core genes 
using either whole genome sequencing (83) or by using genes selected from the core genome to 
give a representation of genomic diversity such as in MLST (146). Also through more targeted 
methods which use genomic information to select more representative targets such as the typing 
schemes devised by Konstantinidis (118) and by extension of the work presented here. The 
advantage of methods which use the core genome is that it is possible to gain an idea of 
phylogeny and the evolutionary lineage of the species.
In contrast, it is also possible to type strains of bacteria using the pan-genome, for example Hiller 
el al. (88) used microarray analysis to determine the pan-genome of S. pneumoniae isolates and 
revealed that this method was more discriminatory than MLST which is also confirmed by Hall 
(79). However, using pan-genome microrrays for typing has a number of potential problems. 
Firstly, in the case of an open pan-genome it is possible than not all accessory genes will be 
identified in a microarray and secondly information regarding the phylogeny of the organism is 
limited if the core genome is not considered. Although it is possible that these problems will be 
overcome with the increasing use of whole genome sequencing allowing identification of new 
genes and also identifying the core genome of bacterial species so analysis of both core and 
accessory genomes can be performed in unison.
Despite the problems with pan-genome based typing, using the core genome also has its 
problems. The concept of pan-genome typing and the increased availability of whole genome 
sequencing challenges the use of the core genome for bacterial typing, by demonstrating that
typing methods using the core genome may not be able to evaluate the genetic diversity of a 
bacterial species. That is, despite the core genome or the representatives of it selected for strain 
typing such as MLST loci, may show a species to be identical but the strains may still have 
differences routed in its accessory genome. For example, the genomic diversity of GBS based on 
analysis of the whole genome was found to be inconsistent with MLST sequence types (159) and . 
is also confirmed in this work.
This discrepancy may be explained by the fact that housekeeping genes used in MLST are selected 
from the core genome rather than the pan-genome. With a sequence based typing scheme using 
a limited number of genes it is sensible to use genes that will be found in all strains to obtain the 
maximum amount of information. In other words, one sequenced gene allows more potential 
discriminatory power than the presence or absence of one gene. Therefore, for pan-genome 
typing to be an effective typing tool would require either whole genome sequencing or 
microarray analysis which is costly and requires a longer turnaround time than traditional 
methods based on sequencing core genes. Typing based on specific genes from the pan-genome 
may, however, be particularly useful for typing based on genes that are involved with phenotypic 
or clinically important genomic factors.
Because intraspecies/genus diversity can result from SNPs, insertions or deletions, and 
recombination, it is sensible to consider the recombination rate of the selected bacteria when 
designing or selecting typing methods for any group of organisms. For example medically relevant 
pathogens such as species within the Streptococcus genus, the species N. meningitidis, the species 
H. pylori, and bacteria of the Salmonella species show high levels of genetic recombination (179), 
which needs to be considered. The traditional method to take recombination into account when 
developing sequence based typing schemes is to situate profiling loci around the genome so one 
recombination event will not disproportionally affect the overall sequence type as in the 
published MLST schemes and to use methods such as eBURST (59) which provides an analysis 
based on the presence and absence of particular allele types and is therefore ideal for analysis of 
recombination events between loci of sequence typing schemes. The only problem with this
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approach is that allele types are not weighted on nucleotide identity so an allele type that is one 
nucleotide different from another is considered equally related to an allele type that shows 
significant differences at the nucleotide level. An alternative is to include additional profiling 
targets from the pan-genome to give an indication of the effects of recombination on the 
relationship between isolates, ideally ones that are clinically relevant.
Decoding the association between genotypes and phenotypic or epidemiological traits such as 
bacterial virulence, antibiotic resistance, host adaptation, geographic origin, pandemic, or 
epidemic outbreaks, is another major challenge of bacterial genotyping. Genotyping can be 
discriminatory depending on the loci selected for sequence typing. It is however, still important to 
take epidemiological traits into account when determining outbreaks of bacterial infections 
otherwise it is possible to falsely identify outbreaks. Although most typing markers are not genes 
directly responsible for virulence or antibiotic resistance, it is still possible to show correlations 
between specific sequence types and phenotypic or epidemiological traits by correlating 
phylogeny information with epidemiological data. For example, it is widely acknowledged that 
GBS sequence type 23 strains identified by MLST are highly virulent (141). Additionally, regardless 
of the typing method used, a larger collection of strains is also useful for linking genotypes with 
phenotypical and epidemiological traits (29).
Bacterial typing by serological methods is common in microbiology and is one of the oldest 
methods for bacterial typing, for example GBS is serotyped on the basis of ten type specific 
capsular polysaccharides (126,216) and is further subdivided using the localised protein antigens. 
This highlights the weakness of serotyping since using cell capsular polysaccharides GBS can only 
be subdivided into 10 distinct types and addition of the three cell protein markers increases the 
number of potential types to 30. This is a small number compared to the number of sequence 
types generated by both MLST (575 MLST sequence types) and the three gene profiling approach 
from this study (69 sequence types). However, this effect is species dependent. For example the 
Salmonella enterica species has over 2300 serovars split over six different subspecies (enterica, 
salamae, arizonae, diarizonae, houtenae and indica) whereas the MLST scheme contains 1525
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sequence types according to the UCC MLST database. Another limitation of serotyping is that 
isolates can be non-typable, for example one study showed the number of non-typable GBS 
isolates was as high as 12% (116) and serotypes can also show cross reactivity resulting in a non- 
conclusive results.
Serotyping does have its advantages. Firstly, as the oldest typing method any isolates compared 
by this method can be studied relevant to the history of the organism, which is difficult with 
newer molecular profiling schemes, especially since an increase in genomic data is allowing more 
accurate sequence typing targets to be proposed potentially superseding established molecular 
profiling schemes. An additional advantage is that since serotyping markers are accessible to 
antibodies they may make good vaccine candidates. For example a recent meta-analysis has 
shown that the most common GBS serotypes are la, III and V and they account for 72% of 
infectious GBS isolates (95). However, if a trivalent vaccine was developed against these serotypes 
(175) it is likely the other GBS serotypes would increase in prevalence meaning any outbreaks 
would need to be monitored by serotyping to allow for further vaccine development. The GBS 
serotyping scheme is not the most discriminatory typing method available, as demonstrated in 
this work which showed that MLST, 3-gene typing and typing using non-coding DNA containing 
MNRs are all more discriminatory than serotyping, however, since serotyping it is essential for 
vaccine development of CPS based vaccines serotyping is unlikely to be stopped.
The DNA sequence is the primary genetic information of an organism and is used for
differentiation and phylogenetic analysis of bacterial strains. DNA sequence-based genotyping
methods are highly reproducible because they rely on unambiguous DNA sequences that are
easily stored in online or local databases and are therefore easily compared between different
laboratories without the inter-laboratory variation associated with DNA banding based methods.
A number of DNA sequence databases exist, the three most common are GenBank, EMBL, and
DDBJ the largest and most popular of these being NCBI's GenBank, which contains a massive
amount of DNA sequences and is still increasing at an exponential rate. For example, in December
2000 there were lx lO 10 base pairs and currently there is approximately 1.2xlOn bp of sequence
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data. Sequence information is either in the form of complete genomes or locus-specific sequences 
from important targets for almost all known bacteria. Compared with other SNP genotyping 
methods, DNA sequencing is better suited for the identification of multiple SNPs within small 
regions of DNA, in addition to detecting sequence differences used to place bacteria into 
sequence types. The main advantage of DNA sequencing is that it allows the evaluation of the 
evolutionary forces that led to these differences, particularly when combined with phenotypic 
information such as antibiotic resistance. However, the usefulness of DNA sequencing largely 
depends on the targets selected and the desired function of the sequence typing scheme, for 
example 16S rDNA sequencing is ideal for identification at the genus level and at the species level 
but not suitable for differentiation between strains of the same bacteria. Whereas MLST cannot 
be used for identification of bacteria as it is species specific but is better than 16S rDNA 
sequencing at differentiating between isolates of the same species of bacteria.
In addition to these methods, there is MLST which is currently one of the most popular sequence 
typing methods for the characterization of bacterial strains and is currently the reference typing 
method for many bacteria. MLST typically involves the sequencing of 7 loci spread over the 
genome from genes present in all strains of a given bacteria. Because the loci are spread 
throughout the genome this gives the advantage that the results from one of the MLST schemes 
should not be heavily influenced by recombination events. That is, using a single locus could 
identify two isolates that on the whole are closely related as being massively different on the 
basis of one recombination event. Additionally, since loci are spread over the genome and have 
different functions they will not be evolving at the same rate as a genes located close to each 
other on the genome or are involved in the same function and therefore under the same selective 
pressures. As well as sharing the advantages of other sequence typing methods of portability and 
consistency between laboratories, MLST does however have its disadvantages. Firstly, analysis 
using eBURST which is a common method for MLST data analysis relies on alleles which are 
assigned to an arbitrary numbering system i.e. sequence types 1 and 2 are no more or less likely 
to be more related than sequence types 1 and 100, which is a weakness of this form of
phylogenetic analysis (32), of course other phylogenetic methods can be used but the high level of 
homology some MLST schemes show can give less reliable results. Secondly the use of conserved 
genes in MLST schemes often fails to detect the variability between strains which can be quite 
different at the genome level. Finally, sequencing seven loci is costly and time consuming when 
compared to other typing methods although the costs of sequencing have been decreasing for 
quite some time and are continuing to do so.
Most typing of GBS is now performed by MLST, partly because sequenced-based methods avoid 
problems of banding pattern based methods such as inter-laboratory variability and partly 
because of improved discrimination. MLST is now by far the most common GBS typing scheme, 
and as previously mentioned it has already been used in a number of studies on the population 
structure of in different countries including the UK (103,104), the USA (17), Sweden (141),
Portugal (156), France (125), Israel (152), the Central African Republic and Senegal (23). As 
previously discussed the results from these studies suggest that invasive GBS is a worldwide clonal 
population which is highly unlikely. It is possible that using the new 3-gene typing system plus 
analysis of the SAK_1320-SAK_1319 intragenic region will address this problem as it has been 
shown in this study that these targets represent the relationships between the 8 genome 
sequenced strains far better than MLST and that this new scheme is able to discriminate between 
isolates more effectively. However further work on a large and more varied strain collection is 
required to prove this hypothesis fully.
As an alternative to using coding regions for sequence typing various schemes using non-coding
DNA have been developed, the first of these 16S-23S rRNA gene internal transcribed spacer (ITS)
was the first non-coding sequence used for strain typing (66,199). Like the 16S rRNA gene it is
common to all bacteria with the exception of Rickettsiales (138) and is usually present in multiple
copies per genome (21). It is, however, much more variable than the 16S rRNA gene and is most
commonly used for sub-typing bacteria. However, its variability and the fact it exists in multiple
copies and given that the region varies in length between multiple copies in the genome, make
direct sequencing difficult. Cloning based methods can overcome this problem but this makes the
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process more difficult, time consuming and expensive. As well as single non-coding regions for 
typing, multiple regions can be selected for various organisms to create Multi Spacer Typing 
(MST). The assumption behind MST is that non-coding DNA is less affected by selective pressure 
than coding regions and therefore are more variable and will therefore provide more 
discriminatory strain typing systems (47). MST loci are selected either because of the presence of 
repeat regions which should also be more variable due to replication errors (74) or non-coding 
sequences which vary the most between different bacterial strains. This approach has proved 
useful for strain typing, for example MST based on six intergenic spacers divided 36 Y. pestis 
strains from three biovars from dental pulp of patients deceased from plague in the second and 
third pandemics into 19 sequence types (47). Additionally, MST has been applied to Rickettsia 
conorii (63), Rickettsia prowazekii (260), Rickettsia sibirica (62), Coxiella burnetii (69), Bartonella 
henselae (134,136), Bartonella quintana (61) and Tropheryma whipplei (137) and when MST 
schemes are compared to MLST schemes MST is shown to be more discriminatory (63,136). As 
with MLVA typing, it is possible that having incredibly variable loci for typing may make MST 
typing schemes too variable to provide useful evolutionary information. Additionally, since non­
coding regions should not be affected by selective pressure (excluding non-coding DNA involved 
in regulation) it is unlikely that MST typing would give a true evolutionary history.
Multiple Loci VNTR Analysis (MLVA) is used to type organisms based on the number of tandem 
repeats found at any given locus that varies in copy number. These repeats and are dispersed 
widely in both human and bacterial genomes (144,240,245). In bacterial genomes, VNTR loci are 
found in non-coding regions as well as in genes and these non-coding VNTRs make good targets 
for strain typing because of their rapid evolution (63,170,240) and therefore MLVA tends to be 
more discriminatory than other methods.
Since MLVA, first used in 2000 has proven to be a highly discriminatory method for a number of 
bacteria it is now regarded as a reference typing method for many bacterial species, such as 
Francisella tularensis (57,99), Bacillus anthracis (89,111,140), Yersinia pestis (113), and 
Mycobacterium tuberculosis (129). Interestingly, these are usually considered to be highly
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homologous groups that are difficult to type by other methods. MLVA has also been applied to . _ 
other important human pathogens such as meticillin-resistant Staphylococcus aureus strains 
(230), Burkholderia pseudomallei (236), and Clostridium difficile (241). It was recently applied to 
GBS (186) and was able to split a strain collection into almost double the number of sequence 
types when compared to MLST.
However, the rapidly evolving nature of VNTR loci is also the main weakness of MLVA typing, it 
has been shown that VNTR loci may be too variable to provide reliable evolutionary information 
between closely related strains. For example MLVA typing of Mycobacterium leprae, has shown 
variation in the VNTR pattern between isolates of M. leprae biopsies from the same patient (162) 
showing that MLVA may be unsuitable for outbreak investigation and is more than likely 
unsuitable for long-term epidemiological surveillance (139). This effect however, may be species 
dependent as it has also been shown that MLVA for Enterococcus faecium is less discriminatory 
than PFGE and MLST (253). As a result the use of MVLA typing should be considered carefully for 
each organism.
Steps should also be undertaken to ensure than new MLVA schemes carefully select targets based 
on multiple sequenced genomes. Since previous research had shown that non-coding regions that 
contained MNR repeats were more variable than non-coding regions that do not contain them 
(42). This study however, showed that the presence of MNRs was not necessarily a predictor of 
enhanced variability. This could be species dependant because, for example GBS contains better 
DNA proofreading proteins to counter the effects of replication errors and therefore the results 
found in E coli could not be translated to GBS. Alternatively, it is possible the MNR regions are 
not randomly occurring and they are maintained as they play a role in genomic regulation and are 
therefore under selective pressure to maintain relatively homogenous.
The point remains that typing based on the pan-genome will be more highly discriminatory and 
provide more accurate representation of phylogeny than any typing system that uses markers 
selected from the genome. However, it would be even more useful to sequence the whole
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genome, giving scope for analysis.of .the core genome and the variable genome. In fact since the 
beginning of this project the technology for whole genome sequencing has improved dramatically 
and the cost has decreased significantly even to the point that one of the most frequent questions 
about this project is "won't this be irrelevant soon because we will just sequence the genomes of 
everything?" To answer that, the short answer is yes, but the long answer is not for a while. As 
Amara's law states, "We tend to overestimate the effect of a technology in the short run and 
underestimate the effect in the long run."
Whole genome sequencing is already being used to study the evolution of pathogens for example, 
Harris et al. (84) used the illumina genome analyser to generate sequence data for 63 MRSA 
isolates. Further work to elucidate the population structure of GBS should use these methods and 
take advantage of new technologies to sequence a large number of GBS genomes to reveal the 
actual population structure of GBS opposed to the current view from the MLST typing system that 
the worlds GBS population is essentially similar. A number of different methods of analysing the 
data could be employed including looking at the core genome to determine the evolutionary 
history of the organism (83) or typing based on the pan-genome proposed by Hall et al. who used 
a microarray approach to show that pan genome typing is able to differentiate the genome 
sequenced strains (79). This research is possible with current technologies and could be 
performed now especially considering the large number of GBS genomes being published by the 
JCVI recently meaning population structure could be studied by any research group without the 
associated costs of sequencing a large number of genomes.
The holy grail of next generation sequencing in microbiology would be the ability to sequence 
multiple bacterial genomes and deliver and interpret the resultant sequence information in "real­
time" in order to use sequence information for patient management or for high resolution 
outbreak tracking. As recently as May 2012 there was no examples of this occurring (49) but most 
recent reviews agree that the rapid advances in whole genome sequencing will become more and 
more prevalent in clinical microbiology. The advantages of this being that three key areas of
microbiology can be addressed in a single workflow thereby replacing many current complex and
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expensive techniques, firstly, species identification at a much higher resolution than current . 
methods, secondly, an ability to test an organisms properties such as virulence and resistance to 
antibiotics and finally, perhaps most usefully, to monitor the spread and emergence of human 
pathogens (43). Additional advantages to using next generation sequencing technology includes 
clinical metagenomics, a weakness of Sanger sequencing since firstly without expensive and time 
consuming random amplification and cloning techniques (22) only the most prevalent of any 
selected target sequence will be represented compared to NGS platforms that will give all manner 
of information of quasi-species and multiple infections (172).
Despite this technology being difficult to bring into routine clinical microbiology at this time, it is 
already being used frequently for research purposes. For example a recent study by Claudio 
published in June 2012 has used the lllumina MiSeq to sequence 14 MRSA genomes, 7 of which 
were associated with a hospital outbreak and 7 which were associated with carriage of MRSA or 
bacteremia in the same hospital which showed a previously missed transmission event between 
two patients with bacteremia who were not part of the outbreak. Flowever this study did highlight 
difficulties in analysis, epidemiological analyses suggested all seven outbreak strains were linked 
however, sequence analysis showed that one of the outbreak isolates was much more distantly 
related than the other outbreak isolates. This either highlights the difficulty of imposing a simple 
identity based threshold to classify isolates as belonging to the same outbreak or it demonstrates 
that current epidemiological methods can incorrectly place unrelated isolates together. From a 
patient management point of view genomic data also allowed the creation of an artificial 
"resistome" of antibiotic resistance genes which would allow intelligent selection of antibiotics 
(33). However, costs using this approach are still high with each genome sequence costing 
approximately £285 compared to around £12 for sequence typing. Additionally this study was a 
retroactive analysis, whilst the timeframe the study was conducted in, means this method could 
theoretically be applied in a real clinical setting it was not in this case meaning that there is still 
research to be done and a detailed consideration of costs and benefits of using such an approach 
before this type of analysis would be applied routinely in a clinical setting.
That being said currentadvances in whole genome sequencing technology will see sequence___
typing replaced in the near future by diagnostic whole genome sequencing which would provide 
much more information about the genomic aspects of infectious disease and could lead to giant 
leaps in the understanding but these methods are currently not available or cost efficient to most 
laboratories. Another technology that could provide cost efficient real time genomic information 
is the Life technologies Ion PGM (personal genome machine), which in my view is the third 
generation sequencing technology most suited to be used as a solution for microbial whole 
genome sequencing due to its relatively low cost and proven ability to rapidly generate the 
genome sequence of the recent Enterohemorrhagic £  coli O104:H4 isolate responsible for the 
recent outbreak in Germany (160). Despite the potential with this platform, the cost of a GBS 
genome would be £316 using a single 10Mb 314 chip which would theoretically give 
approximately 5x coverage of a GBS genome, but is still a little on the low side practically since the 
above sequencing required the use often 314 chips. However, using the 316 chip which were not 
available when this study was carried out, have a capacity of lOOMBp so the cost of sequencing a 
GBS genome would be £700 and give approximately 50x coverage (Miles Collier, Life 
Technologies, personal correspondence). This would be even cheaper if a number of samples 
could be multiplexed, for example for ~10x coverage using a 316 chip five samples can be 
processed per chip and would cost £140 per genome and there is no reason to believe this cost 
will not fall further since the sequencing capacity of this platform essentially relies on how many 
semiconductors can be placed onto a chip and since Moore's law states that the number of 
transistors that can be placed inexpensively on an integrated circuit doubles approximately every 
two years the capacity of the technology can only increase, decreasing the costs per base.
Although the advantages of whole genome sequencing in clinical microbiology would be 
innumerable several issues must be resolved before whole genome sequencing becomes routine 
in public health. The first of these issues being cost, as discussed above the latest research places 
the cost per genome at £285 per genome and a theoretical lower end of £140 which are both 
higher than the £12 that sequence typing using four targets would cost. Of course there is no
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doubt that the costs of sequencing of whole genomes has fallen dramatically and will continue to 
fall, the only question is which technology will be the first to drop costs enough to make whole 
genome sequencing viable on a routine basis.
Which technology will be the main driver of whole genome sequencing in clinical microbiology is 
still a matter of much debate and from the point of view of the clinician or the technician what 
technology is used is unimportant. However, it is still a question worth considering. A recent 
review by Quail et al. (185) concludes that the Ion Torrent, Pacific Biosciences and lllumina MiSeq 
sequencers all able to generate usable sequence but there are differences in quality of the data 
generated and supported applications. For example, the error rates for the lllumina platforms and 
the Ion Torrent were 0.4% and 1.78% respectively and a rather high 13% for the Pacific 
Biosciences platform. This resulted in the lllumina platform producing 76.45% of reads without a 
single mismatch or indel opposed to 15.92% and 0% error free reads of the Ion Torrent and Pacific 
Biosciences sequencing platforms respectively. These figures taken together should indicate the 
lllumina platform will be the main driver of whole genome sequencing technology. Quail et al. 
(184) found that as long as there was sufficient coverage the errors do not make a significant 
impact on the final analysed sequence. In fact, they conclude for sequencing of microbial 
genomes that either the Ion Torrent or the lllumina platform will work well. They do however 
conclude that the Pacific Biosciences platform is currently unsuitable. Although it is worth noting 
that the lllumina chemistry is a tried and tested formula which although being a field leader now 
did have initial difficulties and the Ion Torrent and Pacific Biosciences platforms may well be at 
that stage of development now and who knows how they will perform in just a few years.
Additional problems with whole genome sequence data in a clinical microbiology setting include, 
there being a lack of staff with the knowledge or experience to deal with large volumes of 
genomic information, although this may be partially overcome with improvements in computer 
technology and software to make large scale analysis more user friendly and faster. It also 
highlights the importance of training staff to carry out bioinformatic analyses as well as the 
importance of the techniques used in this study since the majority of work in the evolution of
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pathogens using whole genome sequence will either use the core genome to perform 
phylogenetic analysis on or the pan-genome to analyse the presence or absence of certain genes.
Finally, data storage is also an issue, for example the Sanger centre has previously had to delete 
experimental data before any meaningful analysis has taken place due to space restrictions (Jose 
Afuso Guerra Assuncao, personal correspondence), although, again, this problem will become less 
of an issue as either technology improves and storage becomes cheaper or scientific centres move 
more towards central data storage and cloud computing. Although there is no reason to believe 
that any of these problems are insurmountable sequence typing based on selected loci will be 
used in clinical microbiology for quite a while.
Therefore, as long as sequence typing is based on sequencing of selected loci, it makes sense to 
select those loci sensibly. This project explored different methods for selecting targets for 
molecular typing systems and from this I showed that it is possible to select markers that are 
more accurate and discriminatory by employing bioinformatics methods. The best of these 
methods being an adaptation of the Konstantinidis method (119) and selecting targets based on 
results from this. However using a bioinformatic approach alone is not always sufficient as I 
demonstrated and any analysis performed in-silico must be confirmed in the laboratory. In this 
study this was demonstrated by showing that performing an analysis and selecting the top 3 
targets is not guaranteed to produce the most effective typing system. It is however an excellent 
starting point but selected targets must be verified experimentally by sequencing a collection of 
isolates and the results compared to an existing gold standard method or if no existing method 
exists by comparing multiple combinations of targets to select the best combination. At the time 
of the study there were only a limited number of sequenced genomes and information revealed 
from these may be applicable in varying degrees to real world isolates however since more 
sequenced genomes are now available the target selection process would be improved. Despite 
that, this project has demonstrated that fully investigating the sequence typing methods, rather 
than simply picking your favourite seven housekeeping genes is worth the effort due to increased 
accuracy in the data generated, decreased cost and time saved.
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7.1 Future Work
Despite what is shown about the benefits of intelligent selection of sequence typing targets in this 
project further work is required to investigate the population structure of GBS and in my opinion 
the best way to do this would be to sequence the genomes of as many GBS isolates as feasible. 
However since this is not yet practical the typing system developed here should be applied to as 
wide a collection of clinical isolates as possible. As mentioned earlier the strain collection used in 
this study was a collection of UK clinical isolates, a more varied strain collection would enable a 
new set of questions to be answered and gain more reliable insight into the population structure 
of GBS. Specifically a collection of isolates from outside the UK would show the ability of this 
scheme to differentiate strains on the basis of country of origin. Other questions that could be 
answered include attempting to differentiate between invasive and non-invasive isolates in order 
to identify infectious vs. non-infectious lineages and would require sequence typing of non- 
invasive isolates which are difficult to obtain. That is, to obtain a sample that is a truly non- 
infectious isolate an expectant mother would have to be screened for GBS, proven positive and 
then refuse or be unable to receive intrapartum antibiotics to prove that infection was not passed 
onto the neonate. But it is also worth noting that not enough is known about host factors to 
estimate if a particular strain would cause infection in a different host. An alternative to this 
would be to use bovine or piscine isolates as a substitute for non-invasive isolates (55) but it is 
again uncertain if these could infect neonates. A recent study has suggested that zoonotic 
infection is possible by comparing colonisation of 68 families with their livestock (151) although 
this study did use a number of typing methods it is possible that lack of discrimination is affecting 
these results.
It would also be valuable to compare all existing GBS typing methods on the same isolates at the 
same time. There are already for example, publications that use MLST and PFGE (156) or MLST 
and serotyping (16) but there is no single comparison of all typing methods and since typing of 
organisms is one of the cornerstones of microbiology it would seem worthwhile comparing all 
typing methods on a selection of isolates isolated from as many different sources as possible to
definitively determine the best typing system, or rather, to know what system gives you what 
information and therefore when each method should be applied. Perhaps through collaboration 
with other national centres to get a generic scheme.
Further work into the affects of MNR repeats on genomic regulation should focus on the cylA and 
cylB genes since there are already a number of genomic controls identified for expression of 
capsule genes (114). This work could proceed in one of two ways. Firstly using a method like 
Fluorescence-activated cell sorting (FACS) to separate cells expressing the cylA and cylB proteins 
from those expressing one or neither followed by sequencing the section of the gene containing 
the MNR repeat region to determine if there is a change in the length of the MNR repeat region 
which would be the most likely cause of a lack of expression. Alternatively, it would be possible to 
try to force phase variation by growing liquid cultures and deep sequencing loci containing MNR 
repeats using 454 amplicon sequencing to determine the proportion of sequences with a frame 
shift mutation since it is already known that 5% of GBS clinical isolates do not show haemolytic 
activity (183).
Further work should also be carried out with other streptococcus species. MLST results for S. 
pneumoniae and 5. pyogenes also seem to have a large proportion of sequence types that are 
widely distributed globally making it difficult to assume that the sequence typing performed on 
these organisms is any more reliable than that of GBS. This would suggest that applying this target 
selection approach on these organisms either at the species level or with all members of the 
streptococcus group could allow study of the population structure of these medically relevant 
pathogens. Advantages of this approach would be the additional information generated from so 
many extra genomes and a stronger evolutionary context to any targets selected and the original 
Konstantinidis method has already been shown to be adept at selecting targets at the genus level 
before the adaptations in this study. The disadvantages of using such a high number of genomes 
is that performing this method on all sequenced streptococcus genomes of which there are nearly 
1,000 in the NCBI genome database may limit discrimination between strains at the species level, 
computationally this analysis would be very expensive and finally the number of core genes may
be reduced to a number that limits target selection. It was suggested by Tettelin et.al. the number 
of core genes will decrease indefinitely as newly sequenced genomes are added (231) and so the 
effects of adding in a large number of general streptococcus genomes could have a big impact. 
Other research has however suggested a pan streptococcus typing system is feasible since it has 
already been shown that 26 streptococcus genomes have a core genome that plateaus at around 
600 genes (132) although further analysis would be required to ensure this number would not fall 
with the addition of so many additional genomes.
Finally, before whole genome sequencing technology is ready to be applied routinely, any new 
sequence typing methods being developed for different organisms should consider using genomic 
information to make informed decisions about target selection. This has been successfully applied 
to GBS in this study and could easily be applied to other organisms.
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Chapter 9 
Appendices
9.0 Appendices
9.1 Strain Collection
Strain Serotype Source Type Year Isolation Site Patient Age
Other
Information
515 IA ATCC Reference Not known Not known Neonate
9933 IA ATCC Reference Not known Not known
6175 NT NCTC Reference 1941 Bovine Not known Bovine mastitis
8017 NT NCTC Reference 1949 Not known Not known Pigmented
8020 NT NCTC - - Reference 1949 Not known Not known Non-pigmented
8100 lc NCTC Reference 1949 Not known Not known
8181 lc NCTC Reference 1949 Milk Not known
8182 Id NCTC Reference 1949 Not known Not known
8183 2a NCTC Reference 1949 Not known Not known
8184 3a NCTC Reference 1949 Not known Not known
8186 3/C NCTC Reference 1950 Not known Not known
8188 6a NCTC Reference 1949 Not known Not known
8190 la NCTC Reference 1949 Not known Not known
8541 NT NCTC Reference 1953 Human Not known Vaginal carrier
8542 NT NCTC Reference 1953 Human Not known Throat carrier
9409 NT NCTC Reference 1953 Human Not known Vaginal carrier
9410 NT NCTC Reference 1953 Human Not known Fatal infection
9411 NT NCTC Reference 1953 Human Not known Throat carrier 
Cervix,
9412 NT NCTC Reference 1953 Human Not known puerperal
sepsis
9415 NT NCTC Reference 1953 Human Not known Nose
9828 R NCTC Reference 1956 Not known Not known
9829 R NCTC Reference 1956 Not known Not known
11080 X NCTC Reference 1976 Bovine Not known Chronic mastitis
11930 IV NCTC Reference 1985 Not known Not known
12906 NT NCTC Reference 2007 Not known Not known
12907 NT NCTC Reference 2007 Not known Not known
01/59 VII HPA Reference Lab Not known 2001 Not known Not known
01/08 VII HPA Reference Lab Clinical 2001 Blood 0 years
01/13 VII HPA Reference Lab Clinical 2001 Placenta 23 years
00/46 VIII HPA Reference Lab Clinical 2000 Blood 0 years
00/465 VII HPA Reference Lab Clinical 2000 CSF ly e a r
01/776 VIII HPA Reference Lab Not known 2001 Not known Not known
01/789 VIII HPA Reference Lab Not known 2001 Not known Not known
03/0021 VII HPA Reference Lab Clinical 2003 Blood 69 years
03/0476 III HPA Reference Lab Clinical 2003 Blood 1 month
03/0477/GB IA HPA Reference Lab Clinical 2003 Blood 66 years
03/177 IV HPA Reference Lab Clinical 2003 Blood 37 years
03/207 VI HPA Reference Lab Clinical 2003 Blood 74 years
03/215 VI HPA Reference Lab Clinical 2003 Blood 42 years
03/226 IV HPA Reference Lab Clinical 2003 Blood 0 years
03/247 IV HPA Reference Lab Clinical 2003 Blood 83 years
03/270 IV HPA Reference Lab Clinical 2003 Urine 17 years
03/323 VII HPA Reference Lab Clinical Not known Not known
03/414 IB HPA Reference Lab Clinical Not known Not known
03/424 V HPA Reference Lab Clinical 2003 Blood 0 years
03/427 IB HPA Reference Lab Clinical 2003 CSF 3 months
03/431 V HPA Reference Lab Not known 2003 Not known Not known
03/438 V HPA Reference Lab Clinical 2003 Swab 0 years
03/439 II HPA Reference Lab Clinical 2003 Not known Not known Post mortem
03/442 IB HPA Reference Lab Clinical 2003 Blood 54 years
03/443 V HPA Reference Lab Clinical 2003 Blood 29 years
03/447 II HPA Reference Lab Clinical 2003 Lung 2 months Post mortem
03/451 IA HPA Reference Lab Clinical 2003 Blood 0 years
03/453 IB HPA Reference Lab Clinical 2003 Blood 0 years
03/460 lb /c HPA Reference Lab Clinical 2003 Blood 22 years
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03/463 IA HPA Reference Lab Clinical 2003 Blood Not known
03/464 III HPA Reference Lab Clinical 2003 Blood 0 years
03 /467 V HPA Reference Lab Clinical 2003 Blood 32 years
03/469 II HPA Reference Lab Clinical 2003 Vaginal Swab 28 years
03 /470 II HPA Reference Lab Clinical 2003 Ear swab 0 years
03/471 IA HPA Reference Lab Clinical 2003 Blood 49 years
0 3/474 IV HPA Reference Lab Clinical 2003 Blood 0 years
03/478/G B III HPA Reference Lab Clinical 2003 Blood 0 years
03/479/G B III HPA Reference Lab Clinical 2003 Blood 74 years
03-0475 III HPA Reference Lab Clinical 2003 Blood 0 years
18RS21 t II NCTC Reference 1976 Human Not known
2603V/R V ATCC Reference 2003 Human Not known
A909 IA NCTC Reference 1976 Not known Not known
CJB111 V ATCC Reference 1990 Human Not known
COH1 III ATCC Reference 1985 Human Not known
GBS X III HPA Reference Lab Reference Not known Not known
GBS-C C HPA Reference Lab Reference Not known Not known
GBS-IA IA HPA Reference Lab Reference Not known Not known
GBS-IB IB HPA Reference Lab Reference Not known Not known
GBS-II II HPA Reference Lab Reference Not known Not known
GBS-III III HPA Reference Lab Reference Not known Not known
GBS-IV IV HPA Reference Lab Reference Not known Not known
GBS-NT-03/454/GB NT HPA Reference Lab Reference Not known Not known
GBS-NT-03/455/GB NT HPA Reference Lab Reference Not known Not known
GBS-R R HPA Reference Lab Reference Not known Not known
GBS-Type NT HPA Reference Lab Reference Not known Not known
GBS-V V HPA Reference Lab Reference Not known Not known
GBS-VI VI HPA Reference Lab Reference Not known Not known
GBS-VII VII HPA Reference Lab Reference Not known Not known
GBS-VI II VIII HPA Reference Lab Reference Not known Not known
H034520043 III HPA Reference Lab Clinical 2003 Blood 25 days
H034540199 IA/C HPA Reference Lab Clinical 2003 Blood 68 years
H034540202 IB/C HPA Reference Lab Clinical 2003 Groin swab 0 days
H034580222 II HPA Reference Lab Clinical 2003 Lung/spleen 8 days
H034600053 ll/C HPA Reference Lab Clinical 2003 Blood 0 days
H034620029 V HPA Reference Lab Clinical 2003 Blood 7 days
H034640397 IB/C HPA Reference Lab Clinical 2003 Lung/spleen 11 days
H034700302 IA/C HPA Reference Lab Clinical 2003 Ear swab 4 days
H034760020 V HPA Reference Lab Clinical 2003 Blood 87 years
H034780226 IA HPA Reference Lab Clinical 2003 Blood 31 years
H034940026 lll/X HPA Reference Lab Clinical 2003 CSF + blood 24 days
H034960218 VI/C HPA Reference Lab Clinical 2003 Blood 63 years
H034980044 NT HPA Reference Lab Clinical 2003
Elbow
aspirate
57 years
H035140030 IB HPA Reference Lab Clinical 2003 Blood 3 months
H040120318 IA HPA Reference Lab Clinical 2004 Blood 89 years
H040200291 II HPA Reference Lab Clinical 2004 Blood 45 years
H040420423 IV/C HPA Reference Lab Clinical 2004 Breast milk 29 years
H040440330 ll/C HPA Reference Lab Clinical 2004 Joint aspirate 81 years
H040540417 ll/C HPA Reference Lab Clinical 2004 Blood 36 years
H040600213 NT HPA Reference Lab Clinical 2004 Blood 69 years
H040680236 IV HPA Reference Lab Clinical 2004 Blood 4 days
H040840193 V HPA Reference Lab Clinical 2004 Blood 74 years
H040880024 IV/C HPA Reference Lab Clinical 2004 Nose swab 18 days
H041060026 ll/C HPA Reference Lab Clinical 2004 Blood 29 years
H041100399 lll/X HPA Reference Lab Clinical 2004 Blood 2 days
H041180103 II HPA Reference Lab Clinical 2004 Blood 25 years
H041200156 III HPA Reference Lab Clinical 2004 CSF 5 days
H041360432 IV/C HPA Reference Lab Clinical 2004 Blood 0 years
H041420037 II HPA Reference Lab Clinical 2004 CSF 11 years
H041420425 IB/C HPA Reference Lab Clinical 2004 Blood 64 years
H041540478 IA HPA Reference Lab Clinical 2004 Blood 77 years
H041740496 II HPA Reference Lab Clinical 2004 Blood 78 years
H041800048 IV HPA Reference Lab Clinical 2004 Blood 8 days
H041860027 V HPA Reference Lab Clinical 2004 Blood Not known
Throat
Blood
Blood
Post mortem  
Post natal
Post natal 
Maternity
Post mortem
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H041960046 IB HPA Reference Lab Clinical 2004 Blood Not known
H041960680 - III HPA Reference Lab Clinical 2004 -Blood 8 days
H042380454 III HPA Reference Lab Clinical 2004 Blood 0 years
H042560014 IB/C HPA Reference Lab Clinical 2004 Blood 3 days . . . . .  :
H042680168 V HPA Reference Lab Clinical 2004 Blood 0 years
H042700323 V HPA Reference Lab Clinical 2004 Blood 6 days
H042760726 IB/C HPA Reference Lab. . Clinical 2004 Blood 60 years
H042880027 IA HPA Reference Lab Clinical 2004 Blood 96 years
H042960014 IA HPA Reference Lab Clinical 2004 Blood 1 month
H043220036 IA HPA Reference Lab Clinical 2004 Blood 41 years Maternity
H043260048 II . HPA Reference Lab Clinical 2004 Blood 0 years Post mortem •
H043340011 Ill HPA Reference Lab Clinical 2004 Blood 74 years
H043340012 IA/C HPA Reference Lab Clinical 2004 Blood 41 years
H36B IB NCTC Reference 1949 Not known N/a . . .  .
NEM316 III NCTC Reference Not known N/a Fatal septicemia
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9.2 MLST Allelic Profiles
Strain adhP pheS otr glnA st/M glcK tkt ST Serotype
01/59 1 1 2 1 2 2 1 VII
00/46 1 1 2 1 1 2 2 1 VIII
00/465 1 1 2 1 1 2 2 VII
03/431 1 1 2 1 1 2 2 1 V
03/467 1 1 2 1 1 2 2 1 V
CJB111 1 1 2 1 1 2 2 V
GBS-VI 1 1 1 2 1 1 2 2 VII
GBS-VIII 1 1 2 1 1 2 2 1 VIII
H041060026 1 1 2 1 1 2 2 ll/C
03/177 1 1 3 1 1 2 2 2 IV
03/247 1 1 3 1 1 2 2 2 IV
03/469 1 1 3 1 1 2 2 2 II
H040440330 1 1 3 1 1 2 2 2 ll/C
03/470 1 1 3 1 1 2 2 2 II
GBS-NT-03/455/GB 1 1 3 1 1 2 2 2 NT
8542 9 1 2 1 3 2 2 6 Unknown
9412 9 1 2 1 3 2 2 ' 6 Unknown
9415 9 1 2 1 3 2 2 6 Unknown
H36B 9 1 2 1 3 2 2 6 IB
GBS-IB 9 1 2 1 3 2 2 6 IB
12907 10 1 2 1 3 2 2 7 Unknown
03/471 10 1 2 1 3 2 2 7 IA
A909 10 1 2 1 3 2 2 7 IA
GBS-C 10 1 2 1 3 2 2 7 C
H041100399 10 1 2 1 3 2 2 7 lll/X
03/427 4 1 4 1 3 3 2 8 IB
03/453 4 1 4 1 3 3 2 8 IB
H035140030 4 4 1 3 3 2 8 IB
H042560014 4 1 4 1 3 3 2 8 IB/C
H041180103 4 1 4 1 3 3 2 8 II
03/460 8 1 4 1 3 3 2 9 Unknown
H042760726 8 1 4 1 3 3 2 9 IB/C
11930 9 1 4 1 3 3 2 10 IV
03/442 9 1 4 1 3 3 2 10 IB
GBS-1V 9 1 4 1 3 3 2 10 IV
H034540202 9 1 4 1 3 3 2 10 IB/C
H041960046 9 1 4 1 3 3 2 10 IB
H040880024 10 1 4 1 3 3 2 12 IV/C
H040600213 10 1 4 1 3 3 2 12 NT
H041420425 10 1 4 1 3 3 2 12 IB/C
GBS-VI 1 1 2 1 5 2 2 14 VI
03/464 2 1 1 2 1 1 1 17 III
COH1 2 1 1 2 1 1 1 17 III
H03420043 2 1 1 2 1 1 1 17 III
H034620029 2 1 1 2 1 1 1 17 V
H034940026 2 1 1 2 1 1 1 17 lll/X
H040420423 2 1 1 2 1 1 1 17 IV/C
H041360432 2 1 1 2 1 1 1 17 IV/C
H041960680 2 1 1 2 1 1 1 17 III
H042380454 2 1 1 2 1 1 1 17 III
8541 1 1 3 2 2 2 2 19 Unknown
18RS21 1 1 3 2 2 2 2 19 II
GBS-II 1 1 3 2 2 2 2 19 II
224
03/478/GB 1 1 3 2 2 2 2 19 III
H040200291 1 1 3 2 2 2 2 19 II
H034600053 13 3 1 3 1 1 1 22 ll/C
H034960218 13 3 1 3 1 1 1 22 VI/C
H040540417 13 3 1 3 1 1 1 22 ll/C
H041420037 13 3 1 3 1 1 1 22 II
8186 5 4 6 3 2 1 3 23 3/C
9409 5 4 6 3 2 1 3 23 Unknown
9410 5 4 6 3 2 1 3 23 Unknown
9411 5 4 6 3 2 1 3 23 Unknown
03/0477/GB 5 4 6 3 2 1 3 23 IA
03/451 5 4 6 3 2 1 3 23 IA
03/463 5 4 6 3 2 1 3 23 IA
H034700302 5 4 6 3 2 1 3 23 IA/C
H041540478 5 4 6 3 2 1 3 23 IA
H042960014 5 4 6 3 2 1 3 23 IA
H043220036 5 4 6 3 2 1 3 23 IA
H043340012 5 4 6 3 2 3 23 IA/C
NEM316 5 4 6 3 2 1 3 23 III
515 5 4 6 3 2 1 3 23 IA
12906 5 4 6 3 2 1 3 23 Unknown
H034540119 5 4 4 3 2 3 24 IA/C
H042880027 5 4 4 3 2 3 24 IA
0933 5 4 6 3 8 1 3 25 IA
GBS-IA 5 4 6 3 8 1 3 25 IA
GBS-Type 5 4 6 3 8 1 3 25 Unknown
GBS-V 1 1 5 4 1 4 6 26 V
03/439 1 1 3 5 2 2 2 28 II
H034580222 1 1 3 5 2 2 2 28 II
H040120318 1 1 3 5 2 2 2 28 IA
03/447 1 1 3 5 2 2 2 28 II
H043260048 1 1 3 5 2 2 2 28 II
03/270 1 1 3 2 1 2 2 44 IV
03/479/GB 1 1 3 2 1 2 2 44 III
03/0476 2 1 1 2 2 1 1 48 III
03/414 10 1 3 1 3 2 2 51 IB
8100 13 1 1 13 1 1 1 61 lc
8181 13 1 1 13 1 1 1 61 lc
8182 13 1 1 13 1 1 1 61 Id
8188 13 1 1 13 1 1 1 61 6a
9828 13 1 1 13 1 1 5 67 R
GBS-R 13 1 1 13 1 1 5 67 R
2603VR 1 1 2 2 9 110 V
8017 5 4 1 3 2 1 3 144 Unknown
8020 5 4 1 3 2 1 3 144 Unknown
H034780226 1 1 1 1 4 172 IA
6175 2 1 1 3 1 1 1 174 Unknown
8184 2 1 1 3 1 1 1 174 3a
03-0475 1 1 3 2 18 2 2 182 III
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Three gene Allelic Profiles
Isolate cpsL SAG0043 SAG 1894 ST
8182 1 7 12 1
11930 2 3 4 2
NEM316 3 4 5 3
12907 4 3 4 4
8542 5 3 4 5
8017 6 4 5 6
01/59 7 1 ‘ 4 7
01/08 7 1 4 7
01/13 7 1 4 7
03-323 7 1 4 7
GBS-VII 7 1 4 7
00-46 7 12 4 8
01-789 8 4. 9
GBS-VIII 8 1 4 9
00-465 8 12 4 10
GBS-VI 9 4 11
01-776 9 2 4 12
03-0021 9 3 4 13
03-215 9 3 4 13
A909 10 3 4 14
12906 10 4 3 15
515 10 4 5 16
993 10 4 5 16
8020 10 4 5 16
8186 10 4 5 16
9409 10 4 5 16
9410 10 4 5 16
9411 10 4 5 16
03-0477-GB 10 4 5 16
03-451 10 4 5 16
03-463 10 4 5 16
GBS-IA 10 4 5 16
GBS-Type 10 4 5 16
H034540119 10 4 5 16
H034700302 10 4 5 16
H041540478 10 4 5 16
H042880027 10 4 5 16
H043220036 10 4 5 16
H042960014 10 17 5 17
H043340012 10 17 5 17
03-177 11 1 4 18
03-226 11 1 4 18
03-270 11 1 4 18
03-474 11 4 18
H040440330 11 1 4 18
H041200156 ...... 11 - 1 4 . .. 18
H041800048 11 1 4 18
03-443 11 5 19
03-247 11 1 6 20
GBS-IV 11 3 4 21
H040840193. .. 11 3 . 4 : 21
03-207 12 1 4 22
9412 13 3 - 4 23
9415 13 3 4 23
03-414 13 3 4 23
03-427 13 3 4 23
03-453 13 3 4 23
GBS-IB 13 3 4 23
H0345020 13 3 4 23
H041180103 13 3 4 23
H041960046 13 3 4 23
H042560014 13 3 4 23
H36B 13 3 4 23
H04276-0726 13 3 14 24
03-460 13 6 4 25
H04142-0425 13 16 2 26
03-424 14 1 4 27
03-431 14 1 4 27
03-467 14 1 4 27
□ B i l l 14 1 4 27
GBS-NT-03-455-
GB 14 1 4 27
H034980044 14 1 4 27
H040680236 14 1 4 27
H041060026 14 1 4 27
H041860077 14 1 4 27
H042680168 14 1 4 27
H042700325 14 1 4 27
2603VR 14 1 5 28
H041100399 14 4 29
GBS-V 14 11 4 30
H034760020 14 14 4 31
03-469 15 1 1 32
03-470 15 1 4 33
H034640397 15 1 4 33
H041740496 15 1 4 33
8541 15 1 5 34
03-439 15 1 5 34
03-447 15 1 5 34
18RS21 15 1 5 34
GBS-II___ 15. . . . . .  1 - 5 34 :
GBS-NT-03-454-
GB 15 1 5 34
H040120318 15 1 5 34
H040200291 15 1 5 34
H043260048 1C 1 A^J.O J 34
03-0476-GB 15 1 7 35
03-438 15 1 IS1381 36
H040600213 15 3 2 ' 37
H040880024 15 3 2 37
8181 15 7 9 38
H034600053 15 7 13 39
H034960218 15 7 13 39
H040540417 15 7 13 39
8100 15 9 10 40
H034580222 15 12 5 41
GBS-X 15 13 10 42
H04142-0037 15 15 13 43
03-442 16 3 4 44
03-464 17 5 8 45
COH1 17 5 8 45
H034620029 17 5 8 45
H034940026 17 5 8 45
H041360432 17 5 8 45
H041960680 17 5 8 45
H042380454 17 5 8 45
03-471 18 3 4 46
03-478-GB 19 1 5 47
03-479-GB 19 1 5 47
H04334-0011 19 1 5 47
11080 20 7 9 48
GBS-III 20 7 9 48
8184 21 5 5 49
6175 21 8 5 50
03-0475 22 7 11 51
H0347800226 23 1 4 52
8183 23 10 4 53
8188 25 7 10 54
8190 26 1 4 55
9828 26 7 4 56
GBS-R 26 7 4 56
H03420043 27 5 8 57
H035140030 28 3 4 58
H040420423 29 5 8 59
9829 30 9 10 60
GBS-C 31 1 4 61
Four Gene Allelic Profiles
Isolate cpsL SAG0043 SAG 1894 valS ST
8182 1 7 12 9 1
11930 2 3 ; 4 2 . 2
NEM316 3 4 5 8 3
12907 4 3 4 2 4
8542 5 . . . . .  3 4 2 5
8017 6 4 5 8 6
01/59 7 1 4 1 7
01/08 7 4 1 7
01/13 7 1 4 1 7
03-323 7 1 4 1 7
GBS-VII 7 1 4 1 7
00-46 7 12 4 1 8
01-789 8 4 9
GBS-VIII 8 1 4 1 9
00-465 8 12 4 1 10
GBS-VI 9 1 4 4 11
01-776 9 2 4 9 12
03-0021 9 3 4 2 13
03-215 9 3 4 5 14
A909 10 3 4 2 15
12906 10 4 3 3 16
H034540119 10 4 5 2 17
H042880027 10 4 5 2 17
515 10 4 5 3 18
03-0477-GB 10 4 5 3 18
03-451 10 4 5 3 18
03-463 10 4 5 3 18
H034700302 10 4 5 3 18
H041540478 10 4 5 3 18
H043220036 10 4 5 3 18
993 10 4 5 8 19
8020 10 4 5 8 19
8186 10 4 5 8 19
9409 10 4 5 8 19
9410 10 4 5 8 19
9411 10 4 5 8 19
GBS-IA 10 4 5 8 19
GBS-Type 10 4 5 8 19
H042960014 10 17 5 3 20
H043340012 10 17 5 3 20
03-177 11 1 4 4 21
03-226 11 1 4 4 21
03-270 11 1 4 4 21
H040440330 11 1 4 . 4 21
H041200156 11 1 4 4 21
H041800048 11 1 4 4 21
03-474 11 1 4 6 22
. 03-443 11 1 5 4 23
03-247 11 1 6 4 24
GBS-IV 11 3 4 2 25
H040840193 11 3 4 2 25
03-207 12 1 4 1 26
9412 13 3 4 2 27
9415 13 3 4 2 27
03-414 13 3 4 2 27
03-427 13 3 4 2 27
03-453 13 3 4 2 27
GBS-IB 13 3 4 2 27
H0345020 13 3 4 2 27
H041180103 13 3 4 2 27
H041960046 13 3 4 2 27
H042560014 13 3 4 2 27
H36B 13 3 4 2 27
H042760726 13 3 14 2 28
03-460 13 6 4 2 29
H041420425 13 16 2 2 30
03-424 14 1 4 1 31
03-431 14 1 4 1 31
03-467 14 1 4 1 31
CJB111 14 1 4 1 31
GBS-NT-03-455-
GB 14 1 4 1 31
H034980044 14 1 4 1 31
H040680236 14 1 4 1 31
H041060026 14 1 4 1 31
H041860077 14 1 4 1 31
H042680168 14 1 4 1 31
H042700325 14 1 4 1 31
2603VR 14 1 5 4 32
H041100399 14 4 8 33
GBS-V 14 11 4 14 34
H034760020 14 14 4 1 35
03-469 15 1 1 4 36
H034640397 15 1 4 1 37
03-470 15 1 4 4 38
H041740496 15 1 4 4 38
8541 15 1 5 4 39
03-439 15 1 5 4 39
03-447 15 1 5 4 39
18RS21 15 1 5 4 39
GBS-II 15 1 5 4 39
GBS-NT-03-454-
GB 15 1 5 4 39
H040120318 15 1 5 4 39
H040200291 15 1 5 4 39
H043260048 15 1 5 16 40
03-0476-GB 15 1 7 2 41
03-438 15 1 IS1381 4 42
H040600213 15 3 2 2 43
H040880024 15 3 2 2 43
8181 15 7 9 9 44
H034600053 15 7 13 15 45
H034960218 15 7 13 15 45
H040540417 15 7 13 15 45
8100 15 9 10 9 46
H034580222 15 12 5 4 47
GBS-X 15 13 10 9 48
H041420037 15 15 13 15 49
03-442 16 3 4 2 50
03-464 17 5 8 4 51
corn 17 5 8 6 52
H034620029 17 5 8 6 52
H034940026 17 5 8 6 52
H041360432 17 5 8 6 52
H041960680 17 5 8 6 52
H042380454 17 5 8 6 52
03-471 18 3 4 7 53
03-478-GB 19 1 5 4 54
H043340011 19 1 5 4 54
03-479-GB 19 1 5 8 55
11080 20 7 9 9 56
GBS-III 20 9 9 56
8184 21 5 5 10 57
6175 21 8 5 10 58
03-0475 22 7 11 4 59
H0347800226 23 1 4 8 60
8183 23 10 4 11 61
8188 25 7 10 9 62
8190 26 1 4 3 63
9828 26 7 4 13 64
GBS-R 26 7 4 13 64
H03420043 27 5 8 6 65
H035140030 28 3 4 2 66
H040420423 29 5 8 6 67
9829 30 9 10 9 68
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9.5 MNR Repeat Containing Non coding Region Allelic Profiles
Isolate SAG0032 SAG0649 SAG 1768 SAK_1320 ST
03-437 1 1 1 GBSil 1
01/59 1 1 2 1 2
01/08 1 1 2 1 2
01/13 1 1 2 1 2
00-46 1 1 2 2
00-465 1 1 2 1 2
01-789 1 2 1 2
03-207 1 1 2 1 2
03-323 1 1 2 1 2
03-424 1 1 2 1 2
03-431 1 1 2 1 2
03-443 1 2 1 2
03-467 1 1 2 1 2
CJB111 1 2 1 2
GBS-NT-03-455-
GB 1 1 2 2
GBS-VI 1 1 2 1 2
GBS-VII 1 1 2 1 2
GBS-VIII 1 1 2 1 2
H034760020 1 1 2 1 2
H0347800226 1 1 2 1 2
H034980044 1 1 2 1 2
H040680236 1 1 2 1 2
H041060026 1 1 2 1 2
H041200156 1 1 2 1 2
H041800048 1 1 2 1 2
H041860077 1 1 2 1 2
H042700325 1 1 2 1 2
H042680168 1 1 2 5 3
03-469 1 2 GBSil 4
03-470 1 1 2 GBSil 4
H034640397 1 1 2 GBSil 4
8183 1 1 4 1 5
8190 1 1 4 1 5
8541 1 1 5 1 6
GBS-II 1 1 5 i au
H040120318 1 1 5 1 6
03-439 1 1 5 GBSil 7
03-447 1 1 5 GBSil 7
18RS21 1 1 5 GBSil 7
2603VR 1 1 5 GBSil 7
GBS-NT-03-454-
GB 1 1 5 GBSil 7
H034580222 1 1 5 GBSil 7
H043260048 1 1 5 GBSil 7
233
03-478-GB 1 5 IS1548 8
H043340011 1 1 5 IS1548 8
03-479-GB i 1 14 IS1548 9
03-177 1 2 2 1 10
03-226 1 2 2 1 10
03-247 1 2 2 1 10
03-270 1 2 2 1 10
03-464 2 2 1 10
9409 1 2 4 11
9410 1 . . 2 4 1 11
9411 1 2 4 1 11
NEM316 1 2 4 1 11
8017 1 2 4 7 12
8020 1 2 4 7 12
GBS-C 1 2 9 13
H041740496 1 NA 2 1 NA
11930 2 1 2 1 14
12907 2 1 2 1 14
03-414 2 1 2 1 14
03-442 2 1 2 1 14
03-453 2 2 1 14
03-471 2 2 1 14
A909 2 1 2 1 14
GBS-IV 2 1 2 1 14
H0345020 2 1 2 1 14
H035140030 2 1 2 1 14
H040600213 2 1 2 1 14
H040840193 2 2 1 14
H040880024 2 1 2 1 14
H041180103 2 1 2 1 14
H041420425 2 1 2 1 14
H041960046 2 2 1 14
H042760726 2 1 2 1 14
01-776 2 1 2 2 15
03-215 2 1 2 2 15
03-460 2 1 2 3 16
H042560014 2 2 4 17
GBS-IB 2 1 2 7 18
03-0021 2 1 3 2 19
03-427 2 1 13 1 20
9412 2 2 2 1 21
8542 2 2 2 7 22
9415 2 2 2 7 22
H36B 2 2 2 7 22
H041100399 2 3 2 1 23
515 3 1 4 1 24
8100 3 1 4 1 24
11080_____ -  3 1 - 4 1 _.24
03-0477-GB 3 1 4 1 24
03-451^ - 3 4 1 24
GBS-III 3 1 4 1 24
GBS-R 3 4 1 24
H034540119 3 1 4 1 24
H034700302 3 4 1 24
H041540478 3 1 4 24
H042880027 3 1 4 24
H042960014 3 1 4 1 24
H043220036 3 1 4 1 24
H043340012 3 1 4 1 24
8181 3 1 7 1 25
GBS-X 3 1 GBSil 1 26
9829 3 2 2 1 27
993 3 2 4 1 28
8186 3 2 4 1 28
9828 3 2 4 1 28
03-463 3 2 4 1 28
GBS-IA 3 2 4 1 28
GBS-Type 3 2 4 1 28
12906 3 2 4 29
8188 3 2 8 1 30
03-0475 3 2 ISSag8 31
8182 3 2 5. equi transposase 1 32
03-0476-GB 4 1 5 1 33
H040200291 4 NA 5 GBSil NA
H03420043 5 1 5 1 34
H041360432 5 1 5 1 34
03-474 5 1 5 GBSil 35
COH1 5 1 5 GBSil 35
H034620029 5 1 5 GBSil 35
H034940026 5 1 5 GBSil 35
H040420423 5 1 5 GBSil 35
H041960680 5 1 5 GBSil 35
H042380454 5 1 5 GBSil 35
6175 5 1 6 1 36
8184 5 1 g 1J. o r30
GBS-V 6 1 10 1 37
H040440330 7 2 1 38
H034600053 8 1 11 IS1548 39
H034960218 8 1 11 IS1548 39
H040540417 8 1 11 IS1548 39
H041420037 8 1 11 IS1548 39
Non coding Regions without MNR repeat Allelic Profiles
Isolate SAG0043 SAG0106 SAG2143 ST
03-0021 1 2 2 1
03-215 1 2 2 1
8542 1 2 5 2
9412 1 2 5 2
9415 1 : 2 5 2
11930 1 2 5 2
12907 1 2 5 2
03-427 1 2 5 2
03-442 1 2 5 2
03-453 1 2 5 2
03-460 2 5 2
03-471 1 2 5 2
A909 1 2 5 2
GBSJB 1 2 5 2
GBSJV 1 2 5 2
H0345020 1 2 5 2
H035140030 1 2 5 2
H040600213 1 2 5 2
H040840193 1 2 5 2
H040880024 1 2 5 2
H041100399 1 2 5 2
H041420425 1 2 5 2
H041960046 1 2 5 2
H042560014 1 2 5 2
H042760726 1 2 5 2
H36B 1 2 5 2
03-414 2 2 5 3
6175 3 1 3 4
8184 3 1 3 4
H034620029 3 1 3 4
H034940026 3 1 3 4
H041360432 3 1 3 4
03-474 3 4 3 5
COH1 3 4 3 5
H03420043 3
3
4 3 5
H040420423 4 3 5
H041960680 3 4 3 5
H042380454 3 4 3 5
9828 4 1 1 6
GBS_R 4 1 1 6
8100 4 1 7 7
8181 4 1 7 7
8182 4 1 7 7
8188 4 1 7 7
9829 4 1 7 7
11080
03-0475
GBSJII
GBS_X
H034600053
H034960218
H040540417
H041420037
4
4
4
4
4
4
4
4
1
1
1
1
1
1
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
H041180103 5 5 8
8183 6 1 1 9
01/59 6 1 1 9
01/08 6 1 9
01/13 6 1 1 9
00-46 6 1 1 9
00-465 6 1 1 9
01-789 6 1 1 9
03-177 6 1 9
03-207 6 1 1 9
03-247 6 1 1 9
03-270 6 1 1 9
03-323 6 1 1 9
03-424 6 1 1 9
03-431 6 1 9
03-437 6 1 1 9
03-443 6 1 1 9
03-464 6 1 1 9
03-467 6 1 1 9
CJB111 6 1 1 9
GBS_C 6 1 1 9
GBS_NT_03-455- 6 1 1 9GB
GBS_VII 6 1 1 9
GBS_VIII 6 1 1 9
H034640397 6 1 1 9
H034760020 6 1 1 9
H034980044 6 1 1 9
H040440330 6 1 1 9
H040680236 6 1 1 9
H041060026 6 1 1 9
H041200156 6 1 1 9
H041800048 6 1 1 9
H041860077 6 1 1 9
H042680168 6 1 1 9
H042700325 6 1 1 9
8541 6 1 3 10
03-447 6 1 3 10
03-478-GB 6 1 3 10
03-479-GB 6 1 3 10
2603VR 6 1 3 10
H043260048 . 
H043340011
6
6 1
- 3 
3
10
10
03-226 6 4 11
03-469 6 1 6 12
03-470 6 1 6 12
18RS21 6 1 8 13
GBS-II 6 1 8 13
GBS-VI-------- 6 - ------ 2 ..... ----- 3 — 14
03-0476-GB 6 3 3 15
H04020-0291 6 3 3 15
8190 6 6 1 16
03-0477-GB 7 2 3 17
03-439 8 1 3 18
515 9 2 3 19
993 9 2 3 19
8186 9 2 3 19
9409 9 2 3 19
9410 9 2 3 19
9411 9 2 3 19
12906 9 2 3 19
03-451 9 2 3 19
03-463 9 2 3 19
GBSJA 9 2 3 19
GBS_Type 9 2 3 19
H03454-0119 9 2 3 19
H03470-0302 9 2 3 19
H04154-0478 9 2 3 19
H04288-0027 9 2 3 19
H04296-0014 9 2 3 19
H04322-0036 9 2 3 19
H04334-0012 9 2 3 19
NEM316 9 2 3 19
8017 9 5 3 20
8020 9 5 3 20
GBS-NT-03-454- 10 211 3GB
H034580222 11 1 3 22
H040120318 11 1 3 22
H0347800226 12 1 1 23
H041740496 NA 1 1 NA
GBS-V NA 1 2 NA
01-776 NA 2 3 NA
9.7 Allele Typing Results for the Three Gene plus Insertion
Sequence Typing
Isolate cpsL SAG0043 SAG 18 94 SAK_1320 ST
8182 1 7 12 1 1
11930 2 3 4 1 2
NEM316 3 4 5 1 3
12907 4 3 : 4 1 4
8542 5 3 4 7 5
8017 6 4 - 5 7 6
21551 7 1 4 7
40756 7 1 4 1 7
41275 7 1 4 1 7
03-323 7 4 1 7
GBS-VII 7 1 4 1 7
00-46 7 12 4 1 8
01-789 8 4 9
GBS-VII1 8 4 1 9
00-465 8 12 4 1 10
GBS-VI 9 1 4 1 11
01-776 9 2 4 2 12
03-0021 9 3 4 2 13
03-215 9 3 4 2 13
A909 10 3 4 1 14
12906 10 4 3 6 15
515 10 4 5 1 16
993 10 4 5 1 16
8186 10 4 5 1 16
9409 10 4 5 1 16
9410 10 4 5 1 16
9411 10 4 5 1 16
03-0477-GB 10 4 5 1 16
03-451 10 4 5 1 16
03-463 10 4 5 1 16
GBS-IA 10 4 5 1 16
GBS-Type 10 4 5 1 16
H034540119 10 4 5 1 16
H034700302 10 4 5 1 16
H041540478 10 4 5 1 16
H042880027 10 4 5 1 16
H043220036 10 4 5 1 16
8020 10 4 5 7 17
H042960014 10 17 5 1 18
H043340012 10 17 5 1 18
03-177 11 1 4 1 19
03-226 11 1 4 1 19
03-270 11 1 4 1 19
H040440330 11 1 4 1 19
H041200156 11 1 4 1 19
H041800048 11 1 4 1 19
03-474 11 1 4 GBSil 20
03-443 11 5 1 21
03-247 11 1 6 1 22
GBS-IV 11 3 4 1 23
239
H040840193 11 3 4 1 23
03-207 12 1 4 1 24
9412 13 3 4 1 25
03-414 13 3 4 1 25
03-427 13 3 4 1 25
03-453 13 3 4 1 25
H0345020 13 3 4 1 25
H041180103 13 3 4 1 25
H041960046 13 3 4 1 25
H042560014 13 3 4 4 26
9415 13 3 4 7 27
GBS-IB 13 3 - 4 7 27
H36B 13 3 4 7 27
H04276-0726 13 3 14 1 28
03-460 13 6 4 3 29
H04142-0425 13 16 2 1 30
03-424 14 1 4 1 31
03-431 14 1 4 1 31
. 03-467 14 1 4 1 31
□ B i l l 14 1 4 1 31
GBS-NT-03-455-GB 14 1 4 1 31
H034980044 14 1 4 1 31
H040680236 14 1 4 1 31
H041060026 14 1 4 1 31
H041860077 14 1 4 1 31
H042700325 14 1 4 1 31
H042680168 14 1 4 5 32
2603VR 14 1 5 GBSil 33
H041100399 14 4 1 34
GBS-V 14 11 4 1 35
H034760020 14 14 4 1 36
03-469 15 1 1 GBSil 37
H041740496 15 4 1 38
03-470 15 1 4 GBSil 39
H034640397 15 1 4 GBSil 39
8541 15 1 5 1 40
GBS-II 15 1 5 1 40
H040120318 15 1 5 1 40
03-439 15 1 5 GBSil 41
03-447 15 1 5 GBSil 41
18RS21 15 1 5 GBSil 41
GBS-NT-03-454-GB 15 1 5 GBSil 41
H040200291 15 1 5 GBSil 41
H043260048 15 1 5 GBSil 41
03-0476-GB 15 1 7 1 42
03-438 15 1 IS1381 GBSil 43
H040600213 15 3 2 1 44
H040880024 15 3 2 1 44
8181 15 7 9 1 45
H034600053 15 7 13 IS1548 46
H034960218 15 7 13 IS1548 46
H040540417 15 7 13 IS1548 46
8100 15 9 10 1 47
H034580222 15 12 5 GBSil 48
GBS-X 15 13 10 1 49
H04142-0037 15 15 13 IS1548 , 50
03-442 16 3 4 1 51
03-464 17 5 8 1 52
H041360432 17 5 8 1 52
COH1 17 5 8 GBSil 53
H034620029 17 . 5 8 GBSil : 53
H034940026 17 5 8 GBSil 53
H041960680 17 5 8 GBSil 53
H042380454 17 5 8 GBSil : 53
03-471 18 3 4 1 54
03-478-GB 19 1 5 IS1548 55
03-479-GB 19 1 * ’ 5 IS1548 : 55
H04334-0011 19 1 5 IS1548 55
11080 20 7 9 1 56
GBS-III 20 7 9 1 56
8184 21 5 5 1 57
6175 21 8 5 1 58
03-0475 22 7 11 1 59
H0347800226 23 1 4 60
8183 23 10 4 1 61
8188 25 7 10 62
8190 26 1 4 1 63
9828 26 7 4 1 64
GBS-R 26 7 4 1 64
H03420043 27 5 8 1 65
H035140030 28 3 4 1 66
H040420423 29 5 8 GBSil 67
9829 30 9 10 1 68
GBS-C 31 1 4 1 69
9.8 Core Genome Scripts
9.8.1 Gene Extraction Script
# ! / u s r / b i n / p e r l  
#
#
#
# g e n e e x t r a c t i o n . p i
# R e m o v e s  CDS f o m  g e n b a n k  f i l e
# u s e  l i b  " / u s r / l o c a l / s h a r e / p e r l / 5 . 8 . 8 / B i o " ;  
use B i o : : S e q I O ;
use B i o : : A n n o t a t i o n C o l l e c t i o n I ; 
c h d ir  " / h o m e / r i c h a r d / S e q u e n c e s _ 2 / " ;
0 f i l e n a m e =  < * . g b > ;
# 0 f i l e n a m e = ( " B _ h a l o d u r a n s . g b k " ,
" B _ l i c h e n i f o r m i s _ A E 0 1 7 3 3 3 . g b k " , " B _ l i c h e n i f o r m i s _ C P 0 0 0 0 0 2 . g b k " , " B _ t h u r i n g i e n s i s . g b k " ) ;
# 0 f i l e n a m e =  ( " B _ t h u r i n g i e n s ' i s . g b k " ) ; 
fo re a c h  $ f i l e n a m e ( 0 f i l e n a m e )  {
m y  $ s e q i o = B i o : : S e q I O - > n e w  • ( 1- f o r m a t ’ = > ’ G e n B a n k * , - f i l e = >  $ f i l e n a m e ) ;  
m y  $ s e q = $ s e q i o - > n e x t _ s e q ;
0 f e a t s  =  $ s e q - > g e t _ S e q F e a t u r e s ;  
fo re a c h  $ f e a t u r e ( 0 f e a t s )  {
$ t a g  =  $ f e a t u r e - > p r i m a r y _ t a g ;  
i f  ( $ t a g = ~ / C D S / ) {
0 t a g v a l u e s  =  $ f e a t u r e - > g e t _ t a g _ v a l u e s  ( * l o c u s _ t a g ’ ) ;
$ 1 o c u  s _ n a m e = " " ;
fo re a c h  $ t a g v a l u e ( 0 t a g v a l u e s ) {
$ lo c u s _ n a m e  =  $ lo c u s _ n a m e  . $ t a g v a l u e ;  
p r in t  " $ t a g v a l u e \ n " ;
}
$ l o c u s _ n a m e = ~ s / \ / / / g ;  # t h i s  w i l l  r e m o v e  a n y  e x t r a  s l a s h e s  ( f o r w a r d )  t h a t  
m i g h t  b e  p r e s e n t  i n  t h e  l o c u s  n a m e  a s  t h i s  w i l l  t h r o w t h e  s c r i p t  o f f  t r a c k  a s  
c a n t  p r o c e s s  t h i s
$ l o c a t i o n  =  $ f e a t u r e - > l o c a t i o n ;
$ s t a r t  =  $ l o c a t i o n - > s t a r t ;
$ e n d  =  $ l o c a t i o n - > e n d ;
$ l o c u s = $ s e q - > t r u n c ( $ s t a r t , $ e n d ) , " \ n " ; #  g e t s  s e q u e n c e  o f  g e n e  f r o m  s t a r t  t o  e n d  
l o c a t i o n  a s  a  SEQ O B J E C T  
$ l o c u s - > d i s p l a y _ i d ( $ l o c u s _ n a m e )  ;
$ p r e f i x = $ f i l e n a m e ;
$ p r e f i x = ~ s / . g b $ / _ g e n e / ; #  t h i s  w i l l  t a k e  e a c h  f i l e  n a m e  a n d  a s s i g n  t o  n e w  
v a r i a b l e  ( $ p r e f i x )
# e a c h  f i l e  n a m e  ( v a r i a b l e ) i s  t a k e n  a n d  w h e r e  t h e r e  i s  a  . g b k  a t  t h e  e n d  
( / . g b k $ / ) o f  t h e  f i l e n a m e  i t  i s  s u b s t i t u t e d  ( s )  w i t h  n o t h i n g  ( / / )  
$ l o c u s _ s e q I O = B i o : : S e q I O - > n e w ( - f i l e = > " > / h o m e / r i c h a r d / g b s _ a l l / $ l o c u s _ n a m e . f a s " , 
- f o r m a t = > ’ f a s t a ' ) ;
$ l o c u s _ s e q I O - > w r i t e _ s e q ( $ l o c u s ) ;
}
}
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9.8.2 Reciprocal BLAST Script
# ! / u s r / b i n / p e r l  
#
#
#
# b l a s t . p l
# P e r f o r m s  r e c i p r i c o l  b l a s t
# u s e  l i b  " / . u s r / l o c a l / s h a i ; e / p e r l / 5  . 8 . 8 / B i o " ;  
f u s e  l i b  " / u s r / l o c a l / s h a r e / p e r l / 5  . 8 . - 8 / B i o / T o o l s / R u n " ;  
f u s e  l i b  " / h o m e / r i c h a r d / p e r l _ m o d u l e s / T o o l s / B P l i t e / " ;  
u s e  B i o : : S e q I O ;
u s e  B i o : : T o o l s : : R u n : : S t a n d A l o n e B l a s t ;
u s e  B i o : : T o o l s : : B P l i t e : : H S P ;
my $ p o s i t i v e = 0 ;
my $ n e g a t i v e = 0 ;
c h d i r  " . . / g b s _ a 1 1 _ 2 / 2  6 0 3 V R / " ;
0 f a s t a _ s e q = < * . f  a s > ;
F A S T A _ S E Q _ L 0 0 P : f o r e a c h  my $ f a s t a _ s e q ( 0 f a s t a _ s e q ) {
my $ s e q i o = B i o : : S e q I O - > n e w  ( ' - f o r m a t ' = > ' f a s t a ' , - f i l e = > $ f a s t a _ s e q ) ;
# s e q io : m a k e s  n e w  s e q u e n c e  o b j e c t .  T h e  i n d i v i d u a l  f a s t a  f i l e s  f o r  s u b t i l i s  g e n e s  a r e  
u s e d  a s  r e f  g e n o m e  s e q u e n c e s ,  
my $ s e q = $ s e q i o - > n e x t _ s e q ;  
p r i n t  $ s e q - > i d , " \ n " ;
# 0 d a t a b a s e = ( " B _ a n t h r a c i s _ a m e s " , " B _ a n t h r a c i s _ A m e s A n t ” , " B _ a n t h r a c i s _ S t e r n e " , " B _ c e r e u s _ 1 0  98 
7 " , " B _ c e r e u s _ 1 4 5 7  9 " , " B _ c e r e u s _ E 3 3 L " , " B _ c l a u s i i " , " B _ h a l o d u r a n s " , " B _ l i c h e n i f o r m i s _ A E 0 1 7 3 3 3  
" , " B _ l i c h e n i f o r m i s _ C P 0 0 0 0 0 2 " , " B _ t h u r i n g i e n s i s " ) ;
0 d a t a b a s e = ( " A 9 0 9 " , " N E M 3 1 6 " , " 5 1 5 " , " 1 8 R S 2 1 " , " C J B 1 1 1 " , " C 0 H 1 " , "H 3  6 B " ) ; #  r e s u l t s _ 3  
# a r r a y  o f  e a c h  i n d i v i d u a l  c o n c a t a n a t e d  g e n e  d a t a b a s e  
my @ s u b j e c t _ h i t s = ( ) ; 
f o r e a c h  $ d a t a b a s e ( © d a t a b a s e ) {
my $ d a t a b a s e _ p a t h = " . . / g b s _ c a t _ 2 / $ d a t a b a s e / " ; # s p e c i f i e s  t h e  p a t h  t o  t h e  d a t a b a s e  
my $ t o p _ h i t = l o c a l b l a s t ( $ s e q , $ d a t a b a s e _ p a t h ) ; # e a c h  g e n e  i s  t h e n  f e d  i n t o  e a c h  
d a t a b a s e  
i f  ( ! $ t o p _ h i t ) {
p r i n t  " n o  h i t \ n " ;
$ n e g a t i v e + + ;
n e x t  FAS T A _ S  E Q _LO O  P ;
}
$ h i t _ l e n g t h = 0 ;
$ h i t _ i d e n t i c a l _ r e s = 0 ;
$ t o p _ h i t _ n a m e = $ t o p _ h i t - > n a m e ;
w h i l e  ( $ h s p = $ t o p _ h i t - > n e x t _ h s p ) { # g e t  t h e  t o p  H S P  f r o m  t h e  t o p  h i t  
$ h s p _ l e n g t h = $ h s p - > h s p _ l e n g t h ;
$ h s p _ p e r c e n t = $ h s p - > p e r c e n t _ i d e n t i t y ;
$ h s p _ i d e n t i c a l _ r e s i d u e s = $ h s p _ p e r c e n t / 1 0 0 * $ h s p _ l e n g t h ;
$ h i t _ i d e n t i c a l _ r e s = $ h i t _ i d e n t i c a l _ r e s + $ h s p _ i d e n t i c a l _ r e s i d u e s ; # a d d s  t h e  n o  o f  
r e s i d u e s  f o r  e a c h  h s p  i n  o n e  t o p  h i t  t o g e t h e r
$ h i t _ l e n g t h = $ h i t _ l e n g t h + $ h s p _ l e n g t h ;  # a d d s  t h e  l e n g t h s  o f  a l l  t h e  H S P  f o r  o n e  
h i t  t o g e t h e r
}
$ t o t a l _ p e r c e n t _ h o m o l o g y = $ h i t _ i d e n t i c a l _ r e s / $ h i t _ l e n g t h * 1 0 0 ;
$ r e f _ l e n = $ s e q - > l e n g t h ; # o r i g i n a l  r e f  g e n e  l e n g t h
$ t o t a l _ p e r c e n t _ l e n g t h = $ h i t _ l e n g t h / $ r e f _ l e n * 1 0 0 ; # w o r k  o u t  % l e n g t h  o f  g e n e  c o v e r e d
i f  ( $ t o t a l _ p e r c e n t _ h o m o l o g y > 5 0  &&  $ t o t a l _ p e r c e n t _ l e n g t h  > 7 0 ) ( # i f  H S P  % i s  m o r e  
t h a n  5 0  t h e n  p a s s  t h r u  l o o p  t h e n  p a s s  t h r u  n e x t  l o o p  a n d  H S P  l e n g t h  i s  >  70% o f  
t h a t  o f  g e n e  t h e n  p a s s  t h r u  l o o p  a n d  p r i n t  
}
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e ls e {
p r in t  " p e r c e n t  m a t c h  e r r o r , $ t o p _ h i t _ n a m e \ n " ,
" $ t o t a l _ p e r c e n t _ h o m o l o g y , $ t o t a l _ p e r c e n t _ l e n g t h \ n " ;
$ n e g a t i v e + + ;
n e x t F A S T A _ S E Q _ L O O P ;
my $ s u b j e c t _ g e n e _ f i l e = " / h o m e / r i c h a r d / g b s _ a l l _ 2 / $ d a t a b a s e / $ t o p _ h i t _ n a m e . f a s " ;  
m y  $ s u b j e c t _ s e q i o = B i o : : S e q I O - > n e w  ( ' - f o r m a t ' = > ' f a s t a ' , - f i l e = > $ s u b j e c t _ g e n e _ f i l e ) ; 
my $ s u b j  e c t _ s e q = $  s u b j  e c t _ s e q i o - > n e x t _ s e q ; 
my $ r e f _ d a t a b a s e = " . . / g b s _ c a t _ 2 / 2 6 0 3 V R " ;
$ t o p _ h i t = l o c a l b l a s t ( $ s u b j e c t _ s e q , $ r e f _ d a t a b a s e ) ;
$ r e f _ s e q _ n a m e = $ s e q - > i d ;  
i f  ( $ t o p _ h i t _ n a m e = $ r e f _ s e q _ n a m e )  {
}
e ls e  { • •
p r in t  " $ t o p _ h i t _ n a m e , $ r e f _ s e q _ n a m e \ n " ; # p r i n t s  t h i s  i f  n e g  r e s u l t  f o r  r e v e r s e  
b l a s t
$ n e g a t i v e + + ;
n e x t F A S T A _ S E Q _ L O O P ;
y
p u s h ( @ s u b j e c t _ h i t s , $ s u b j  e c t _ s e q )  ;
}
$ p o s i t i v e + + ;
u n s h if t  ( @ s u b j e c t _ h i t s , $ s e q ) ;
# m y  $ s e q o u t = B i o : : S e q I O - > n e w
( ' - f o r m a t ' = > ' f a s t a ' , - f i l e = > " > / h o m e / f 0 / n a d i a / r e s u l t s _ t o t a l _ h s p / $ r e f _ s e q _ n a m e . f a s " ) ;  
my $ s e q o u t = B i o : : S e q I O - > n e w  ( ' - f o r m a t ' = > ' f a s t a ' , - f i l e = >  
" > / h o m e / r i c h a r d / g b s _ c o r e _ 3 / $ r e f _ s e q _ n a m e . f a s " ) ; 
fo re a c h  $ s e q _ s e t ( @ s u b j e c t _ h i t s ) {
$ s e q o u t - > w r i t e _ s e q ( $ s e q _ s e t ) ;
y 
y
p r in t  " $ p o s i t i v e , $ n e g a t i v e \ n " ;
# l o c a l b l a s t  s c r i p t
sub l o c a l b l a s t {  # s u b : s u b r o u t i n e  f o l l o w e d  b y  n a m e  u  g i v e  i t  e g  l o c a l b l a s t ( t h i s  s u b r o u t i n e  
n a m e  i s  t h e n  u s e d  a b o v e  t o  r u n  t h i s  p a r t  o f  t h e  s c r i p t )
my ( $ r e f _ s e q , $ d a t a b a s e ) = 0 _ ; # @ _ :  t a k e s  t h e  i n p u t  t h a t  i s  g o i n g  t h r u  t h e  s u b r o u t i n e  a n d
p a s s e s  i t  i n t o  t h e  l o o p
$ d a t a b a s e = " / h o m e / r i c h a r d / g b s _ c a t _ 2 / " . $ d a t a b a s e ; # d b  l o c a t i o n
0 p a r a m e t e r s =  ( ' p r o g r a m ' = >  ' b l a s t n ' , ' d a t a b a s e ' = >  $ d a t a b a s e , 'X ' = > 1 5 0 ,  ' q ’ = >  - 1 ,  ' F ' = > " F  
,_ R E A D M E T H O D = >  ' B l a s t ' ) ;
# 0 p a r a m e t e r s : p a r a m e t e r s  f o r  t h e  b l a s t
my $ b l a s t o b j  =  B i o : : T o o l s : : R u n : : S t a n d A l o n e B l a s t - > n e w  ( © p a r a m e t e r s ) ;
# d e f i n e s  n e w  b l a s t o b j  w i t h  t h e  p a r a m e t e r s  d e f i n e d  a b o v e
$ b l a s t _ r e p o r t =  $ b l a s t o b j - > b l a s t a l l  ( $ r e f _ s e q ) ; # t a k e s  e a c h  s e q  i n  t u r n  a n d  b l a s t s  
a g a i n s t  d b
my $ b l a s t _ r e s u l t = $ b l a s t _ r e p o r t - > n e x t _ r e s u l t ; # g e t s  b l a s t  r e s u l t  
$ t o p _ h i t = $ b l a s t _ r e s u l t - > n e x t _ h i t ; # t a k e s  t o p  h i t  f r o m  b l a s t  r e s u l t  
r e tu r n  $ t o p _ h i t ;
y
9.8.3 Alignment Script
# ! / u s r / b i n / p e r l  
#
#
#
# c l u s t a l _ c o r e . p l  .
# P e r f o r m s  a l i g n m e n t s
use B i o : : T o o l s : : R u n : : A l i g n m e n t : : C l u s t a l w ;  
c h d i r " . . / g b s _ s h o t g u n _ c o r e _ £ . 9 0 9 r e f / " ;
0 c o r e _ g e n e _ s e q = < * . f a s > ;
fo re a c h  my $ c o r e _ g e n e _ s e q ( 0 c o r e _ g e n e _ s e q ) { 
my 0 p r o t _ o b j ;  
my % s e q _ o b j ;
my $ s e q i o = B i o : : S e q I O - > n e w  ( ' - f o r m a t ' = > ' f a s t a ' , - f i l e = > $ c o r e _ g e n e _ s e q ) ; # c r e a t e s  s e q I O  
o b j e c t  w h i c h  i n  t h i s  c a s e  i s  t h e  f a s t a  f i l e  o f  e a c h  c o r e  g e n e
w h ile  (my $ s e g = $ s e q i o - > n e x t _ s e q ) { i w h i l e  t h e r e  i s  a  s e q u e n c e  . i n  t h e  f i l e  c r e a t e  a 'n e w  
s e q  o b j ( $ s e q  i s  t h e  s e q  o b j )
$ s e q _ o b j { $ s e q - > i d } = $ s e q ;
$ p r o t _ o b j = $ s e q - > t r a n s l a t e ;
p u s h ( 0 p r o t _ o b j , $ p r o t _ o b j ) ; #  p u s h  h a s  t o  b e  w i t h i n  t h e  w h i l e  l o o p  s o  i n s i d e  t h e  
c u r l y  b r a c k e t s
>
0 p a r a m s = ( ' q u i e t '  = > l ) ; # t h i s  w i l l  s e t  t h e  p a r a m e t e r s  f o r  t h e  c l u s t a l . ,  i f  n o n e  s e t  t h e n  
w i l l  r u n  a t  d e f a u l t
$ f a c t o r y = B i o : : T o o l s : : R u n : : A l i g n m e n t : : C l u s t a l w - > n e w ( 0 p a r a m s ) ; # f a c t o r y  o b j e c t  c r e a t e d  
$ p r o t _ o b j _ r e f = \ 0 p r o t _ o b j ; i a r r a y  o f  a l i g n l O  o b j e c t s  t o  b e  u s e d  i n  t h e  c l u s t a l  a l i g n m e n t  
$ a l n = $ f a c t o r y - > a l i g n ( $ p r o t _ o b j _ r e f ) ; #  $ a l n  i s  a  s i m p l e a l i g n  o b j e c t
$ C O D O N S IZ E  =  3 ;
my $ d n a a l i g n  =  n e w  B i o : : S i m p l e A l i g n ;  
my $ s e q o r d e r  = 0 ;  
my $ a l n l e n  =  $ a l n - > l e n g t h ;  
fo re a c h  my $ s e q  (  $ a l n - > e a c h _ s e q  ) { 
my $ n e w s e q ;
$ p r o t _ s e q _ n a m e  =  $ s e q - > i d ;  
i p r i n t  $ p r o t _ s e q _ n a m e , " \ n " ;
fo re a c h  my $ p o s  ( l . . $ a l n l e n  ) {
my $ l o c  =  $ s e q - > l o c a t i o n _ f r o m _ c o l u m n ( $ p o s ) ;  
my $ d n a  =  '  ' ;
i f (  ! d e fin e d  $ l o c  | |  $ l o c - > l o c a t i o n _ t y p e  ne 'E X A C T ' ) {
$ d n a  =  '  '  ;
} e ls e  (
# t o  r e a d j u s t  t o  c o d o n  b o u n d a r i e s
#  e n d  n e e d s  t o  b e  + 1  s o  w e  c a n  j u s t  m u l t i p l y  b y  
C O D O N S IZ E
# t o  g e t  t h i s
my ( $ s t a r t , $ e n d )  =  ( ( ( $ l o c - > s t a r t  -  1 ) * $ C 0 D 0 N S IZ E )  + 1 ,  ( 
$ l o c - > e n d ) * $ C O D O N S I Z E ) ;
i f (  S s t a r t  < = 0  | |  $ e n d  >  $ s e q _ o b j { $ p r o t _ s e q _ n a m e > - >  
l e n g t h ( )  ) {
p r in t  " s t a r t  i s  " ,  $ l o c - > s t a r t ,  "  e n d  i s  " ,  
$ l o c - > e n d ,  " \ n " ;  
w a rn ( " c o d o n s  d o n ' t  s e e m  t o  b e  m a t c h i n g  u p  
f o r  $ s t a r t , $ e n d " ) ;
$ d n a  =  ' -------' ;
} e ls e  {
245
$ d n a  =  $ s e q _ o b j { $ p r o t _ s e q _ n a m e ) - > s u b s e q  
( $ s t a r t , $ e n d ) ;
}
}
S n e w s e q  . =  $ d n a ;
}
$ s e q o r d e r + + ;
#  f u n k y  l o o k i n g  m a t h ' i s  t o  r e a d j u s t  t o  c o d o n  b o u n d a r i e s  a n d  d e a l
# w i t h  f a c t  t h a t  s e q u e n c e  s t a r t  w i t h  1
m y  $ n e w d n a  =  n e w  B i o : : L o c a t a b l e S e q ( - d i s p l a y _ i d  = >  $ s e q - > i d ( ) ,
- s t a r t  = >  ( ( $ s e q - > s t a r t : -  1 )  *  $ C O D O N S IZ E ) +  1 ,
- e n d  = >  ( $ s e q - > e n d  *  $ C O D O N S IZ E ) ,
- s t r a n d  = >  $ s e q - > s t r a n d ,
- s e q  = >  $ n e w s e q ) ;
$ d n a a l i g n - > a d d _ s e q ( $ n e w d n a ) ;
}
m y  $ c o r e _ g e n e _ n a m e = $ c o r e _ g e n e _ s e q ;
$ c o r e _ g e n e _ n a m e = ~ s / \ . f a s $ / / ;
$ a l i g n o u t =  B i o : : A l i g n I O - > n e w ( - f i l e = > " > / h o m e / f 0 / r l o y / s h o t g u n _ n e x u s / $ c o r e _ g e n e _ n a m e . n e x " , 
- f o r m a t  —> ' n e x u s ' ) ;
$ a l i g n o u t - > w r i t e _ a l n ( $ d n a a l i g n ) ;  
p r i n t  $ c o r e  g e n e  n a m e , " \ n " ;
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9.8.4 ANI Script
# ! / u s r / b i n / p e r l  
#
#
#
, # A N I . p l  ’ ’
# C a l c u l a t e s  A N I
u s e  B i o : : A l i g n I O ;
c h d i r " . . / s h o t g u n _ d i s t a n c e _ p o r r e c t e d " ;
@ n e x u s = < * . n e x > ;
% a l n _ l e n = { } ;
% i d e n t i c a l _ b a s e s = { } ;  
f o r e a c h  m y  $ n e x u s ( 0 n e x u s ) { 
p r i n t  $ n e x u s , " \ n " ;
$ n e x u s _ I O = B io : : A l i g n I O - > n e w ( - f i l e = > " $ n e x u s " , - f o r m a t  = > ' n e x u s ’ ) ; 
m y  $ n e x u s _ a l n = $ n e x u s _ I O - > n e x t _ a l n ;  
m y  $ n u m b e r _ o f _ s e q u e n c e s = $ n e x u s _ a ln - > n o _ s e q u e n c e s ; 
f o r  (m y  $ i = l ; $ i < $ n u m b e r _ o f _ s e q u e n c e s ; $ i + + )  {
f o r  (m y  $ j  =  $ i + l ;  $ j  < =  $ n u m b e r _ o f _ s e q u e n c e s ;  $ j + + )  (  
m y  $ s e q l =  $ n e x u s _ a l n - > g e t _ s e q _ b y _ p o s ( $ i ) ;
m y  $ s e q 2 =  $ n e x u s _ a l n - > g e t _ s e q _ b y _ p o s ( $ j ) ;
m y  $ a l n  =  n e w  B i o : : S i m p l e A l i g n ( ) ;
$ a l n - > a d d _ s e q ( $ s e q l ) ;
$ a l n - > a d d _ s e q ( $ s e q 2 ) ;
m y  $ p e r c e n t _ i d  =  $ a l n  - >  o v e r a l l _ p e r c e n t a g e _ i d e n t i t y ( ) ;
m y  $ p e r c e n t _ i d _ o u t p u t  =  s p r i n t f  " % . 2 f " ,  $ p e r c e n t _ i d ;
# p r i n t  " P e r c e n t  i d  b e t w e e n  " ,  $ s e q l - > i d  ,  "  a n d  "  ,  $ s e q 2 - > i d  
$ p e r c e n t _ i d _ o u t p u t \ n " ;
$ a l n _ l e n = $ a l n - > l e n g t h ;
$ n u m b e r _ i d e n t i c a l _ b a s e s = ( $ p e r c e n t _ i d _ o u t p u t / 1 0 0 ) * $ a l n _ l e n ;  
# p r i n t  " n u m b e r  o f  i d e n t i c a l  b a s e s  i s , $ n u m b e r _ i d e n t i c a l _ b a s e s \  
$ g e n o m e l = $ s e q l - > i d ;
$ g e n o m e 2 = $ s e q 2 - > id ;  
i f  ( $ g e n o m e l = ~ / S A G \ d / ) (
$ g e n o m e l= " 2 6 0 3 V R " ;
}
e l s i f  ( $ g e n o m e l = ~ / C O H l _ \ d / ) {
$ g e n o m e l= " C O H l" ;
>
e l s i f  ( $ g e n o m e l = ~ / C J B l l l _ \ d / ) {
$ g e n o m e l= " C J B 1 1 1 " ;
}
e l s i f  ( $ g e n o m e l = ~ / H 3 6 B _ \ d / ) {
$ g e n o m e l= " H 3 6 B " ;
}
e l s i f  ( $ g e n o m e l = ~ / g b s \ d / ) {
$ g e n o m e l= " N E M 3 1 6 " ;
}
e l s i f  ( $ g e n o m e l = ~ / S G B _ \ d / ) {
$ g e n o m e l= " 5 1 5 " ;
)
e l s e  {
$ g e n o m e l= " A 9 0 9 " ;
}
i f  ( $ g e n o m e 2 = ~ / S A G \ d / ) {
$ g e n o m e 2 = " 2  6 0 3 V R " ;
}
e l s i f  ( $ g e n o m e 2 = r / C 0 H l _ \ d / ) {
$ g e n o m e 2 = " C 0 H l" ;
}
e l s i f  ( $ g e n o m e 2 = ~ / C J B l l l _ \ d / )  {
$ g e n o m e 2 = " C J B l l l " ;
>
e l s i f  ( $ g e n o m e 2 = ~ / H 3 6 B _ \ d / )  (
$ g e n o m e 2 = " H 3  6 B " ;
}
e l s i f  ( $ g e n o m e 2 = ~ / g b s \ d / ) {
$ g e n o m e 2 = " N E M 3 1 6 " ;
} ‘ '
e l s i f  ( $ g e n o m e 2 = ~ / S G B _ \ d / ) {
$ g e n o m e 2 = " 5 1 5 " ;
>
e ls e  {
$ g e n o m e 2 = " A 9 0 9 " ;
}
$ a l n _ l e n { " $ g e n o m e l - $ g e n o m e 2 " } + = $ a l n _ l e n ;
$ a l n _ l e n { " $ g e n o m e 2 - $ g e n o m e l " } + = $ a l n _ l e n ;
$ i d e n t i c a l _ b a s e s { " $ g e n o m e l - $ g e n o m e 2 " } + = $ n u m b e r _ i d e n t i c a l _ b a s e s ;
$ i d e n t i c a l _ b a s e s { " $ g e n o m e 2 - $ g e n o m e l " } + = $ n u m b e r _ i d e n t i c a l _ b a s e s ;
o p e n  (O U T , " > A N I . t x t " ) ;
p r i n t  O UT ’^ e O S V R - C O H lX t " ,  1 - ( $ i d e n t i c a l _ b a s e s { ' 2 6 0 3 V R - C O H 1 ' } / $ a l n _ l e n ( ' 2 6 0 3 V R - C O H 1 ' } )  
" \ n " ;
p r i n t  O UT " 2 6 0 3 V R - C J B l l l \ t " ,  1 - ( $ i d e n t i c a l _ b a s e s { ' 2 6 0 3 V R - C J B 1 1 1 ' } / $ a l n _ l e n {
' 2 6 0 3 V R - C J B 1 1 1 ' } ) ,  " \ n " ;
p r i n t  O UT " 2 6 0 3 V R - H 3 6 B \ t " ,  1 - ( $ i d e n t i c a l _ b a s e s { ’ 2 6 0 3 V R - H 3 6 B ’ } / $ a l n _ l e n ( ' 2 6 0 3 V R - H 3 6 B ' } )  
" \ n " ;
p r i n t  O UT " 2 6 0 3 V R - N E M 3 1 6 \ t " ,  1 - ( $ i d e n t i c a l _ b a s e s { ' 2 6 0 3 V R - N E M 3 1 6 ' } / $ a l n _ le n {
' 2 6 0 3 V R - N E M 3 1 6 '} ) ,  " \ n " ;
p r i n t  O UT " 2 6 0 3 V R - 5 1 5 \ t " , 1 - ( $ i d e n t i c a l _ b a s e s { 12 6 0 3 V R - 5 1 5 ' } / $ a l n _ l e n { ' 2 6 0 3 V R - 5 1 5 ’ } )  , 
" \ n " ;
p r i n t  O UT " 2 6 0 3 V R - A 9 0 9 \ t " ,  1 - ( $ i d e n t i c a l _ b a s e s { ’ 2 6 0 3 V R - A 9 0 9 1 } / $ a l n _ l e n { ' 2 6 0 3 V R - A 9 0 9 ’ } )  
"  \  n  " ;
p r i n t  O UT " C O H 1 - C J B l l l V t " ,  1 - ( $ i d e n t i c a l _ b a s e s { ' C O H 1 - C J B 1 1 1 ' } / $ a l n _ l e n { ’ C O H 1 - C J B 1 1 1 ' } )  
" \ n " ;
p r i n t  O UT " C 0 H l - H 3 6 B \ t " , 1 - ( $ i d e n t i c a l _ b a s e s { ' C O H 1 -H 3 6 B ' } / $ a l n _ l e n { ' C O H 1 -H 3 6 B ' } ) ,  " \ n "  
p r i n t  O UT " C O H l - N E M 3 1 6 \ t " ,  1 - ( $ i d e n t i c a l _ b a s e s { ’ C O H 1 -N E M 3 1 6 ' } / $ a l n _ l e n { ’ C O H 1 -N E M 3 1 6 ' } )  
" \ n " ;
p r i n t  O UT " C 0 H 1 - H 3 6 B \ t " , 1 - ( $ i d e n t i c a l _ b a s e s { 1C O H 1 -H 3 6 B ' } / $ a l n _ l e n { ' C O H 1 -H 3  6 B ' J ) ,  " \ n "  
p r i n t  O U T " C O H l - N E M 3 1 6 \ t " ,  1 - ( $ i d e n t i c a l _ b a s e s { ’ C O H 1 - N E M 3 1 6 ' } / $ a l n _ le n ( 'C O H 1 - N E M 3 1 6 ' } )  
" \ n " ;
p r i n t  O UT " C O H l - 5 1 5 \ t " ,  1 - ( $ i d e n t i c a l _ b a s e s { 'C O H 1 - 5 1 5 • } / $ a l n _ l e n { ’ C O H 1 - 5 1 5 ' } )  ,  " \ n " ;  
p r i n t  O UT " C O H 1 - A 9 0 9 \ t " , 1 - ( $ i d e n t i c a l _ b a s e s { ’ C O H 1 - A 9 0 9 ’ } / $ a l n _ l e n { ’ C O H 1 - A 9 0 9 * } ) ,  " \ n "
p r i n t  O UT " C J B l l l - H 3 6 B \ t " ,  1 - ( $ i d e n t i c a l _ b a s e s { ' C J B 1 1 1 - H 3 6 B * } / $ a l n _ l e n { ’ C J B 1 1 1 - H 3 6 B  '  } )  
" \ n " ;
p r i n t  O UT " C J B 1 1 1 - N E M 3 1 6 \ t " ,  1 - ( $ i d e n t i c a l _ b a s e s { ' C J B 1 1 1 - N E M 3 1 6 ' } / $ a l n _ l e n {
' C J B 1 1 1 - N E M 3 1 6 ' } ) ,  " \ n " ;
p r i n t  O UT " C J B 1 1 1 - 5 1 5 \ t " , 1 - ( $ i d e n t i c a l _ b a s e s { ' C J B 1 1 1 - 5 1 5 ' } / $ a l n _ l e n { ’ C J B 1 1 1 - 5 1 5 ' > )  , 
" \ n " ;
p r in t  O UT " C J B 1 1 1 - A 9 0 9 \ t _ "  , . . 1 -  ( $ . i d e n t i c a l _ b a s e s {  ’ C J B 1 1 1 - A 9 0 9 '  } / $ a l n _ l e n {  'C J B 1 1 1 - A 9 0 9 ' } )  
" \ n " ;
p r i n t  O UT " H 3 6 B - N E M 3 1 6 \ t " ,  1 - ( $ i d e n t i c a l _ b a s e s { ’ H 3 6 B - N E M 3 1 6 ' } / $ a l n _ l e n ( 'H 3 6 B - N E M 3 1 6 'J) 
" \ n " ;
p r in t  O UT " H 3 6 B - 5 1 5 \ t " ,  1 - ( $ i d e n t i c a l _ b a s e s { ’ H 3 6 B - 5 1 5 ' } / $ a l n _ l e n { ' H 3 6 B - 5 1 5 ' } )  , " \ n " ;  
p r in t  O U T " H 3 6 B - A 9 0 9 \ t " , 1 - ( $ i d e n t i c a l _ b a s e s { • H 3 6 B - A 9 0 9 ' } / $ a l n _ l e n { 'H 3 6 B - A 9 0 9 ' ) ) ,  " \ n "  
p r in t  O UT "N E M 3 1 6 - 5 1 5 \ . t " /  l - ( $ i d e n t i c a l _ b a s e s { ' N E M 3 1 6 - 5 1 5 ' } / $ a l n _ l e n { 'N E M 3 1 6 - 5 1 5 ’ } ) ,  
" \ n " ;
p r in t  O U T " N E M 3 1 6 - A 9 0 9 \ t " , 1 - ( $ i d e n t i c a l _ b a s e s { 1N E M 3 1 6 - A 9 0 9 ' } / $ a l n _ l e n { ' N E M 3 1 6 - A 9 0 9 ' } )  
" \ n " ;
9.8.5 Distance Analysis Script
# ! / u s r / b i n / p e r l  
#
#
#  ' 
# d i s t a n c e . p l
# C o o r d i n a t e s  M o d e lT e s t  a n d  P a u p  t o  p e r f r o m  a n a l y s i s
c h d i r  " / h o m e / f 0 / r l o y / g b s _ c o r e _ 8 _ t i ; i m m e d _ f a i l e d / ' 
@ n e x u s = < * . n e x > ;
$ d i r = " / h o m e / f 0 / r l o y / g b s _ c o r e _ 8 _ t r i m m e d _ f a i l e d / " ; 
f o r e a e h  $ n e x u s ( © n e x u s ) {
$ f i l e p r e f i x = $ n e x u s ;
$ f i l e p r e f i x = - s / \ . n e x $ / \ . s c o r e s / ; 
i f  ( - e  $ f i l e p r e f i x ) { n e x t ; }
$ f i l e p r e f i x = ~ s / \ . s c o r e s / _ c o m m a n d \ . t x t / ;  
i f  ( ! - e  $ f i l e p r e f i x )  {
o p e n  ( I N , " p r e f i x . t x t " ) ;
© p r e f i x = < I N > ;  
c l o s e  I N ;
o p e n ( I N , " s u f f i x . t x t " )  ;
@ s u f f i x = < I N > ;  
c l o s e  I N ;
$ n e x u s = ~ s / \ . n e x $ / _ c o m m a n d \ . t x t / ;  
o p e n  ( O U T , " > $ n e x u s " ) ;  
p r i n t  OUT © p r e f i x ;
$ n e x u s = ~ s / _ c o m m a n d . t x t $ / \ . n e x / ; 
p r i n t  OUT " e x e c u t e  $ n e x u s ; \ n " ;  
0 n e w _ s u f f i x = ( ) ; 
f o r e a e h  m y  $ l i n e ( © s u f f i x ) {
$ l i n e = ~ s / m o d e l \ . s c o r e s / $ d i r $ n e x u s / ; 
$ l i n e = ~ s / \ . n e x / X . s c o r e s / ; 
p u s h  ( @ n e w _ s u f f i x , $ l i n e ) ;
>
p r i n t  O UT @ n e w _ s u f f i x ;  
c l o s e  O U T ;
}
$ n e x u s = ~ s / \ . n e x $ / _ c o m m a n d \ . t x t / ; 
p r i n t  " $ n e x u s \ n " ;
' / u s r / l o c a l / b i n / p a u p  - n  <  $ d i r $ n e x u s  ' ;
J
@ m a t c h _ s c o r e s = < * . s c o r e s > ;  
f o r e a e h  $ m a t c h _ s c o r e s ( @ m a t c h _ s c o r e s ) { 
$ m o d e l _ t e s t = $ m a t c h _ s c o r e s ;
$ m o d e l _ t e s t = ~ s / \ . s c o r e s / X . o u t / ;
' m o d e l t e s t  < $ d i r $ m a t c h _ s c o r e s > $ m o d e l _ t e s t ' ;
}
@ m o d e l_ t e s t = < * . o u t > ;  
f o r e a e h  $ m o d e l _ t e s t ( @ m o d e l _ t e s t ) { 
o p e n ( I N , $ m o d e l _ t e s t ) ; 
u n t i l ( $ l i n e = ~ / A I C / ) {
$ l i n e = < I N > ;
}
u n t i l ( $ l i n e = - / B E G I N  P A U P ; / ) {
$ l i n e = < I N > ;
>
@ p a r a m s = ( ) ;
p u s h ( © p a r a m s , $ l i n e ) ;
$ m o d e l  t e s t = ~ s / \ . o u t $ / \ . n e x / ;
p u sh ( @ p a r a m s , " e x e c u t e  $ m o d e l _ t e s t ; \ n " ) ; 
u n t i l  ( $ l i n e = ~ / E N D / ) {
$ l i n e = < I N > ;
pu sh ( S p a r a m s , $ l i n e ) ;
}
$ m o d e l _ t e s t = ~ s / \ . n e x $ / _ p a r a m s \ . t x t / ; 
pop S p a r a m s ;
open ( O U T , " > $ m o d e l _ t e s t " ) ; 
p r in t  O UT @ p a ra m s ;
p r in t  O UT " s e t  c r i t e r i o n = l i k e l i h o o d ; \ n " ; 
p r in t  O UT " h s ; \ n " ;
$ m o d e l _ t e s t = ~ s / _ p a r a m s \ . t x t / \ . d i s t / ;
p r in t  OUT " s a v e d i s t  f i l e = ' / h o m e / f 0 / r l o y / g b s _ c o r e _ 8 _ t r i m m e d _ f a i l e d / $ m o d e l _ t e s t ' ; \ n " ;  
p r in t  OUT "LOG STOP;\ n " ;  
p rin t-O U T  "END;\ n " ;  
c lo s e  OUT;
$ m o d e l _ t e s t = ~ s / \ . d i s t / _ p a r a m s \ . t x t / ;
' /u s r / lo c a l /b in /p a u p  -n  < $ d ir$ m o d e l_ te s t>  l o g . f i l e ' ;  
p r in t  " $ m o d e l _ t e s t \ n " ;
p r in t  " d o n e  a t  l a s t \ ! \ ! \ ! \ ! \ n " ;
251
9.8.6 Script for Stata Input Formatting
# ! / u s r / b i n / p e r l  
#
#
#
# s t a t a . p l
# f o r m a t s  d i s t a n c e  d a t a  f o r  s t a t a
# c h d i r  ' C : \ M o d e l t e s t \ t e s t \ r i c h a r d ^ _ d i s t a n c e _ t a b l e ' ;
# c h d i r  ' C t X M o d e l t e s t X t e s t X c o n c a ^ a l i g n X d i s t ^ a b l e ' ; 
c h d ir  * / h o m e / f 0 / r l o y / g b s _ c o r e _ 8 _ t r i m m e d _ d i s t t a b l e / ' ;  
# o p e n  ( O U T , " > $ f i l e _ n u m b e r " ) ;  
open ( I N ,  " A N I . t x t " ) ;
@ a n i = ( )  ;
w h ile  ( $ l i n e = < I N > ) { 
c h o n ^ s  $ l i n e ;
( $ g e n o m e _ n a m e ,  $ a n i ) = s p l i t ( / \ t / , $ l i n e ) ;  
p u s h ( @ a n i , $ a n i ) ;
}
@ d i s t _ t a b l e = < * . d i s t > ;
$ c o u n t e r = 0 ;
open ( O T , " > f i l e _ t a b l e . t x t " ) ;  
fo re a e h  $ d i s t _ t a b l e ( @ d i s t _ t a b l e ) {
@ g e n e _ d i s t = ( ) ;
$ c o u n t e r + + ;  
p r in t  " $ c o u n t e r \ n " ;  
p r in t  O T " $ c o u n t e r \ t $ d i s t _ t a b l e \ n " ;  
open ( I N ,  " $ d i s t _ t a b l e " ) ;  
w h ile  ( $ l i n e _ 2 = < I N > ) { 
chomp $ l i n e _ 2 ;
( $ g e n e _ n a m e ,  $ g e n e _ d i s t ) = s p l i t ( / \ t / , $ l i n e _ 2 ) ;  
p u s h ( 0 g e n e _ d i s t , $ g e n e _ d i s t ) ;
}
# p r i n t  s c a l a r ( 0 a n i ) ;
open ( O U T , " > $ c o u n t e r . t x t " ) ;
p r in t  O UT " g e n e " , " \ t " , " g e n o m e " ,  " \ n " ;
f o r ( $ i = 0 ; $ i < s c a l a r ( 8 a n i )  ; $ i + + )  {
p r in t  OUT " $ g e n e _ d i s t [ $ i ] " , " \ t " , " $ a n i [ $ i ] " , " \ n " ;
>
}
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9.8.7 Stata Input Script
f o r v a l  x = l / 7  9 4 {  
c l e a r
l o c a l  f i l e n a m e = " C : \ M o d e l t e s t \ t e s t \ R P L \ \ ' x ' . t x t "
i n s h e e t  u s i n g  ' f i l e n a m e '
k t a u  g e n e  g e n o m e
g e n e r a t e  f i l e = ' x '
g e n e r a t e  t a u _ a = r ( t a u _ a )
g e n e r a t e  t a u r b - r  { t a u  b )   , . • ;
k e e p  t a u _ a  t a u _ b  f i l e   ' .
k e e p  i f  _ n = = l  
d i s p l a y  f i l e
s a v e  " C : \ M o d e l t e s t \ t e s t \ R P L \ k e n d a l l _ t e m p " , r e p l a c e  
i f  ' x ' = = l {
o u t s h e e t  u s i n g  ” C : \ M o d e l t e s t \ t e s t \ R P L \ k e n d a l l _ c o e f f . t x t " , r e p l a c e
}
e l s e {
c l e a r
i n s h e e t  u s i n g  " C : \ M o d e l t e s t \ t e s t \ R P L \ k e n d a l l _ c o e f f . t x t "  
a p p e n d  u s i n g  " C : V M o d e l t e s t \ t e s t \ R P L \ k e n d a l l _ t e m p "  
o u t s h e e t  u s i n g  " C : \ M o d e l t e s t \ t e s t \ R P L \ k e n d a l l _ c o e f f . t x t " , r e p l a c e  
} --------
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9.8.8 Script to Calculate Summation of Distance Values
# ! / u s r / b i n / p e r l  
#
#
#
# s u m _ d i s t a n c e  . p i  ' .
# w o r k s o u t  s u m  d i s t a n c e  f o r  a l l  c o r e  g e n e s  f o r  A B S  c a l c u l a t i o n .
use w a r n i n g s ;  - 
use s t r i c t ;  ,
c h d i r " / h o m e / f 0 / r l o y / g b s _ c o r e _ 8 _ t r i m m e d _ d i s t t a b l e / " ;
my @ d i s t f i l e  =  < * . d i s t > ;  
my $ d i s t f i l e  =  ( 0 d i s t f i l e ) ;
fo re a e h  m y  $ d i s t f i l e ( @ d i s t f i l e ) {
m y  S o u t p u t  =  " > / h o m e / f 0 / r l o y / g b s _ c o r e _ 8 _ t r i m m e d _ d i s t t a b l e / $ d i s t f i l e \ _ s u m " ;  
open ( O U T P U T ,  " S o u t p u t " ) ;  
open ( D I S T A N C E ,  " S d i s t f i l e " ) ;
■ w h ile  ( m y  $ r e p l a c e  =  < D I S T A N C E > ) (
$ r e p l a c e  = ~  s / 5 1 5 - 1 8 R S 2 1 \ s * / / g ;
$ r e p l a c e  = ~  s / 5 1 5 - 2 6 0 3 V R \ s * / / g ;
$ r e p l a c e  = ~  s / 5 1 5 - A 9 0 9 \ s * / / g ;
$ r e p l a c e  = ~  s / 5 1 5 - C J B l l l \ s * / / g ;
$ r e p l a c e  = ~  s / 5 1 5 - C O H l \ s * / / g ;
$ r e p l a c e  = ~  s / 5 1 5 - H 3 6 B \ s * / / g ;
$ r e p l a c e  = ~  s / 5 1 5 - N E M 3 1 6 \ s * / / g ;
$ r e p l a c e  = ~  s / 1 8 R S 2 1 - 2 6 0 3 V R \ s * / / g ;
S r e p l a c e  = ~  s / 1 8 R S 2 1 - A 9 0 9 \ s * / / g ;
S r e p l a c e  = ~  s / 1 8 R S 2 1 - C J B l l l \ s * / / g ;
$ r e p l a c e  = ~  s / 1 8 R S 2 1 - C O H l \ s * / / g ;
$ r e p l a c e  = ~  s / 1 8 R S 2 1 - H 3 6 B \ s * / / g ;
S r e p l a c e  = ~  s / 1 8 R S 2 1 - N E M 3 1 6 \ s * / / g ;
S r e p l a c e  = ~  s / 2 6 0 3 V R - A 9 0 9 \ s * / / g ;
$ r e p l a c e  = ~  s / 2 6 0 3 V R - C J B l l l \ s * / / g ;
S r e p l a c e  = ~  s / 2 6 0 3 V R - C O H l \ s * / / g ;
S r e p l a c e  = ~  s / 2 6 0 3 V R - H 3 6 B \ s * / / g ;
S r e p l a c e  = ~  s / 2 6 0 3 V R - N E M 3 1 6 \ s * / / g ;
S r e p l a c e  = ~  s / A 9 0 9 - C J B l l l \ s * / / g ;
S r e p l a c e  = * •  s / A 9 0 9 - C O H l \ s * / / g ;
S r e p l a c e  = ~  s / A 9 0 9 - H 3 6 B \ s * / / g ;
S r e p l a c e  = ~  s / A 9 0 9 - N E M 3 1 6 \ s * / / g ;
S r e p l a c e  = ~  s / C J B l l l - C O H l \ s * / / g ;
S r e p l a c e  = ~  s / C J B l l l - H 3 6 B \ s * / / g ;
S r e p l a c e  = ~  s / C J B l l l - N E M 3 1 6 \ s * / / g ;
S r e p l a c e  = ~  s / C O H l - H 3 6 B \ s * / / g ;
S r e p l a c e  = ~  s / C O H l - N E M 3 1 6 \ s * / / g ;
S r e p l a c e  = -  s / H 3 6 B - N E M 3 1 6 \ s * / / g ;
S r e p l a c e  = ~  s / \ n / : / g ;
p r in t  O U T P U T  ( " S r e p l a c e " ) ;
}
)
my 0 s u m  =  < * . d i s t _ s u m > ;  
my $ s u m  =  0 s u m ;
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m y  " $ d i s t l  =  0 ;  
m y  $ d i s t 2  =  0 ;  
m y  $ d i s t 3  =  0 ;  
m y  $ d i s t 4  =  0 ;  
m y  $ d i s t 5  =  0 ;  
m y  $ d i s t 6  =  0 ;  
m y  $ d i s t 7  =  0 ;  
m y  $ d i s t 8  =  0 ;  
m y  $ d i s t 9  =  0 ;
my $ d i s t l 0 = 0
my $ d i s t l l = 0
my $ d i s t l 2 = 0
my $ d i s t l 3 = 0
my $ d i s t l 4 = 0
my $ d i s t l 5 = 0
my $ d i s t l 6 = 0
my $ d i s t l 7 = 0
my $ d i s t l 8 = 0
my $ d i s t l 9 = 0
my $ d i s t 2 0 = 0
my $ d i s t 2 1 = 0
my $ d i s t 2 2 = 0
my $ d i s t 2 3 = 0
my $ d i s t 2 4 = 0
my $ d i s t 2 5 = 0
my $ d i s t 2 6 = 0
my $ d i s t 2 7 = 0
my $ d i s t 2 8 = 0
my 0 s u m _ d i s t  =  q w / / ;
fo re a e h  $ s u m ( @ s u m ) { 
open ( S U M ,  " $ s u m " ) ;
w h ile  (my $ v a l u e s  =  < S U M > ) { 
chomp $ v a l u e s ;
( $ d i s t l ,  $ d i s t 2 ,  $ d i s t 3 ,  $ d i s t 4 ,  $ d i s t 5 ,  $ d i s t 6 ,  $ d i s t 7 ,  $ d i s t 8 ,  $ d i s t 9 ,  $ d i s t l 0 ,  
$ d i s t l l ,  $ d i s t l 2 ,  $ d i s t l 3 ,  $ d i s t l 4 ,  $ d i s t l 5 ,  $ d i s t l 6 ,  $ d i s t l 7 ,  $ d i s t l 8 ,  $ d i s t l 9 ,  
$ d i s t 2 0 ,  $ d i s t 2 1 , $ d i s t 2 2 ,  $ d i s t 2 3 ,  $ d i s t 2 4 ,  $ d i s t 2 5 ,  $ d i s t 2 6 ,  $ d i s t 2 7 ,  $ d i s t 2 8 )  =  
s p l i t  / : / ,  $ v a l u e s ;
p r in t  " $ d i s t l  $ d i s t 2  $ d i s t 3  $ d i s t 4  $ d i s t 5  $ d i s t 6  $ d i s t 7  $ d i s t 8  $ d i s t 9  $ d i s t l 0  $ d i s t l l  
$ d i s t l 2  $ d i s t l 3  $ d i s t l 4  $ d i s t l 5  $ d i s t l 6  $ d i s t l 7  $ d i s t l 8  $ d i s t l 9  $ d i s t 2 0  $ d i s t 2 1  $ d i s t 2 2  
$ d i s t 2 3  $ d i s t 2 4  $ d i s t 2 5  $ d i s t 2 6  $ d i s t 2 7  $ d i s t 2 8 ; \ n " ;
m y  $ t o t a l = $ d i s t l  +  $ d i s t 2  +  $ d i s t 3  +  $ d i s t 4  +  $ d i s t 5  +  $ d i s t 6  +  $ d i s t 7  +  $ d i s t 8  +  $ d i s t 9  +  
$ d i s t l 0  +  $ d i s t l l  +  $ d i s t l 2  +  $ d i s t l 3  +  $ d i s t l 4  +  $ d i s t l 5  +  $ d i s t l 6  +  $ d i s t l 7  +  $ d i s t l 8  +  
$ d i s t l 9  +  $ d i s t 2 0  +  $ d i s t 2 1  +  $ d i s t 2 2  +  $ d i s t 2 3  +  $ d i s t 2 4  +  $ d i s t 2 5  +  $ d i s t 2 6  +  $ d i s t 2 7  +  
$ d i s t 2 8 ;
p r in t  " $ t o t a l \ n " ;
push ( @ s u m _ d i s t ,  $ t o t a l ) ;
)
)
fo re a e h  my $ s u m _ d i s t ( @ s u m _ d i s t ) {
my $ s u m _ o u t p u t  =  " » / h o m e / f 0 / r l o y / g b s _ c o r e _ 8 _ t r i m m e d _ d i s t t a b l e / d i s t _ s u m _ a l l . t x t " ;  
open ( S U M _ O U T P U T ,  " $ s u m _ o u t p u t " ) ;
p r in t  S U M _ O U T P U T  ( " $ s u m _ d i s t \ n " ) ;
}
fo re a e h  $ d i s t f i l e ( 0 d i s t f i l e ) {
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my $ f i l e _ k e y  =  " » / h o m e / f O / r l o y / g b s _ c o r e _ 8 _ t r i m m e d _ d i s t t a b l e / f i l e _ k e y . t x t ”  
open ( F I L E _ K E Y ,  " $ f i l e _ k e y " )  ;
p r in t  F I L E _ K E Y  ( " $ d i s t f i l e \ n " ) ;
)
' rm. * .  d is t_ s u m ';
p r i n t  " T e m p o r a r y  F i l e s  R e m o v e d \ n "
9.9 MNR Analysis Scripts
9.9.1 Script to Remove Coding Sequences from  the Genome
# ! / u s r / b i n / p e r l  
#
#
#
# c o d i n g _ s e q _ r e p l a c e . p l  ' ‘ -
# R e m o v e s  C o d i n g  S e q u e n c e s  f r o m  b a c t e r i a l  g e n o m e
# u s e  w a r n i n g s ;  - . .
f u s e  s t r i c t ;
c h d i r " / h o m e / r i c h a r d / M N R _ f i n a l / N E M 3 1 6 / n e g a t i v e _ s t r a n d / " ;
m y  $ g e n o m e  =  " / h o m e / r i c h a r d / M N R _ f i n a l / N E M 3 1 6 / n e g a t i v e _ s t r a n d / N E M 3 1 6 _ n e g a t i v e _ o n e l i n e . f a s t a "  
o p e n  (G E N O M E ,  " $ g e n o m e " ) ;  
m y  $ o u t p u t  =
" > / h o m e / r i c h a r d / M N R _ f i n a l / N E M 3 1 6 / n e g a t i v e _ s t r a n d / N E M 3 1 6 _ n o n c o d i n g _ i m p r o v e d . f a s t a " ;  
o p e n  ( O U T P U T ,  " S o u t p u t " ) ;
my $coding =
" / h o m e / r i c h a r d / M N R _ f i n a l / N E M 3 1 6 / n e g a t i v e _ s t r a n d / N E M 3 1 6 _ n e g a t i v e _ s t r a n d _ c o d i n g . t x t " ;  
open ( C O D I N G ,  " $ c o d i n g " ) ;
my @list = < C O D I N G > ;  
my $key = 0 ;  
my $value = 0; 
my %hash = {); 
my $locus = 0 ;  
my $sequence = 0 ;
fo re a e h  my $ l i s t ( @ l i s t ) {
($locus, $sequence) = s p l i t  /\t/, Slist;
$ h a s h { $ l o c u s )  =  $ s e q u e n c e ;
}
w h ile  (my $replace = < G E N 0 M E > ) { 
chomp Sreplace;
w h ile  ((my $key, my Svalue) = each(% hash)) { 
chomp Svalue;
my $ t r i m  =  s u b s t r (S v a l u e ,  2 0 ) ;  
my $ t r i m 2  =  s u b s t r ( $ t r i m ,  0 ,  - 2 0 ) ;
Sreplace =~ s/$trim2/$key/gim;
Sreplace =~ s/\n//gim;
Sreplace =~ s/\r//gim;
}
chomp Sreplace;
p r in t  O U T P U T  ("Sreplace");
}
9.9.2 Script to Parse Non-Coding Regions
# ! / u s r / b i n / p e r l  
#
#
#
# g e t _ n o n c o d i n g . p i
# Q u i c k  p a r s e r  t o  g e t  e a c h  n o n  c o d i n g  r e g i o n  o n t o  s e p e r a t e  l i n e ,  
f u s e  w a r n i n g s ;
f u s e  s t r i c t ; ; ............................   ; ■ .
c h d i r " / h o m e / r i c h a r d / M N R _ f i n a l / N E M 3 1 6 / n e g a t i v e _ s t r a n d / " ;  
my S g e n o m e  =
" / h o m e / r i c h a r d / M N R _ f i n a l / N E M 3 1 6 / n e g a t i v e _ s t r a n d / N E M 3 1 6 _ n o n c o d i n g _ i m p r o v e d . f a s t a " ;  
open (G E N O M E ,  " S g e n o m e " ) ;  
m y S o u t p u t  =
" > / h o m e / r i c h a r d / M N R _ f i n a l / N E M 3 1 6 / n e g a t i v e _ s t r a n d / N E M 3 1 6 _ n e g a t i v e _ n o n c o d i n g _ r e g i o n s . f a s t a "  
open ( O U T P U T ,  " S o u t p u t " ) ;  
my S s t r i n g  =  < G E N O M E > ;
w h ile  ( S s t r i n g  = ~  m / ( g b s \ d \ d \ d \ d [ A G C T R Y S W K M B D H V N ] * g b s \ d \ d \ d \ d ) / g ) {
p r in t  " $ l \ n " ;
p r in t  O U T P U T  ( " $ l \ n " ) ;
}
9.9.3 Script to Identity MNR Tracts in Non-Coding DNA
# ! / u s r / b i n / p e r l  
# '
#
#
# M N R _ f i r i d e r _ n o n c o d i n g . p i
# I d e n t i f i e s  N o n - C o d i n g  r e g i o n s  c o n t a i n i n g  a n  MN R t r a c t  
# u s e  w a r n i n g s ;  ,
# u s e  s t r i c t ;  /  ;
c h d i r " / h o m e / r i c h a r d / M N R _ f i n a l / N E M 3 1 6 / n e g a t i y e _ s t r a n d " ;  
my S n o n c o d i n g  =
" / h o m e / r i c h a r d / M N R _ f i n a l / N E M 3 1 6 / n e g a t i v e _ s t r a n d / N E M 3 1 6 _ n e g a t i v e _ n o n c o d i n g _ r e g i o n s . f a s t a " ;  
open ( N O N C O D I N G , '  " $ n o n c o d i n g " ) ; 
my 0 a r r a y  =  < N O N C O D I N G > ;  
my S o u t p u t  =
" > / h o m e / r i c h a r d / M N R _ f i n a l / N E M 3 1 6 / n e g a t i v e _ s t r a n d / N E M 3 1 6 _ n e g a t i v e _ n o n c o d i n g _ N M R _ n e w . t x t " ;  
open ( O U T P U T ,  $ o u t p u t ) ;
fo re a e h  my $ s e q u e n c e ( @ a r r a y )  {
chomp S s e q u e n c e ;
w h i le ( $ s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A A A A A A A A [ T G C N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \  
d ) $ / g m ) ( p r in t  " $ l \ t l 5 \ t A \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " }  
w h i le ( $ s e q u e n c e  = ~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A A A A A A A [ T G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d  
) $ / g m ) ( p r in t  " $ l \ t l 4 \ t A \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " }  
w h i le ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A A A A A A [ T G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d )  
$ / g m ) ( p r in t  " S l \ t l 3 \ t A \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " )  
w h i le ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A A A A A [ T G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ 
/ g m ) ( p r in t  " $ l \ t l 2 \ t A \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " )  
w h i le ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A A A A [ T G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ /  
g m ) ( p r in t  " $ l \ t l l \ t A \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " )  
w h i le ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A A A [ T G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g  
m ) ( p r in t  " $ l \ t l O \ t A \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " )  
w h i le ( S s e q u e n c e  = ~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A A [ T G C N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m  
) ( p r in t  " $ l \ t 9 \ t A \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " } 
w h i le ( S s e q u e n c e  = ~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A [ T G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m  
) ( p r in t  " $ l \ t 8 \ t A \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " )  
w h i le ( S s e q u e n c e  = ~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A [ T G C N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m  
) ( p r in t  " S l \ t 7 \ t A \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " } 
w h i le ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d )  [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A [ T G C N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m )  { 
p r in t  " S l \ t 6 \ t A \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " }
w h i le ( S s e q u e n c e  = ~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T T T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \  
d ) $ / g m ) ( p r in t  " $ l \ t l 5 \ t T \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " ) 
w h i le ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d
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. ) $ / g m ) { p r i n t  " S l \ t l 4 \ t T \ t $ 3 \ t " ,  l e n g t h  (Ssequence)- 1 4 , " \ n " }  
w h i l e ($sequence =~
m / ( A g b s \ d \ d \ d \ d )  [A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T T T T T T  [ A G C N ]  ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d )  
$ / g m ) { p r i n t  " S l \ t l 3 \ t T \ t $ 3 \ t " ,  l e n g t h  (Ssequence)- 1 4 ,"\n") 
w h i l e ($sequence =~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ 
/ g m ) { p r i n t  " $ l \ t l 2 \ t T \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " }
W h i l e (Ssequence =~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$ /  
gm) ( p r i n t  " $ l \ t l l \ t T \ t $ 3 \ t " ,  l e n g t h  (Ssequence)- 1 4 , "\n") 
w h i l e (Ssequence =~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T T T [ A G C N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g  
m ) ( p r i n t  " $ l \ t l O \ t T \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " }  
w h i l e ( S s e q u e n c e  = ~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$/gro 
) ( p r i n t  " $ l \ t 9 \ t T \ t $ 3 \ t " ,  l e n g t h  (Ssequence)- 1 4 , "\n") 
w h i l e (Ssequence =~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m  
) ( p r i n t  " $ l \ t 8 \ t T \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " }  
w h i l e ( S s e q u e n c e  = ~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$/gm 
) ( p r i n t  " $ l \ t 7 \ t T \ t $ 3 \ t " ,  l e n g t h  (Ssequence)- 1 4 , "\n") 
w h i l e (Ssequence =~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$/gm){ 
p r i n t  " $ l \ t 6 \ t T \ t ' $ 3 \ t " ,  l e n g t h  (Ssequence)- 1 4  ,  "\n"}
w h i le (Ssequence =~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C C C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\ 
d)$/gm)( p r in t  ” $ l \ t l 5 \ t C \ t $ 3 \ t " ,  le n g th  (Ssequence) - 1 4 , "\n"} 
w h i le (Ssequence =~
m / ( Ag b s \d \d \d \d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * (g b s \d \d \d \d  
)$ /g m ) (p r in t  " $ l \ t l 4 \ t C \ t $ 3 \ t " ,  le n g th  (Ssequence)- 1 4 , "\n"} 
w h i le (Ssequence =~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d) 
$/gm)( p r in t  " $ l \ t l 3 \ t C \ t $ 3 \ t " ,  le n g th  (Ssequence)- 1 4 , "\n"} 
w h i le (Ssequence =~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$ 
/gm)( p r in t  " $ l \ t l 2 \ t C \ t $ 3 \ t " ,  le n g th  (Ssequence)- 1 4 , "\n" } 
w h i le (Ssequence =~
m / ( Agbs\d\d\d\d) [A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$ /  
gm)( p r in t  " $ l \ t l l \ t C \ t $ 3 \ t " ,  le n g th  (Ssequence)- 1 4 ,"\n") 
w h i le (Ssequence =~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C C C [ A G T N ] ) [ A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$ / g  
m) ( p r in t  " $ l \ t l O \ t C \ t $ 3 \ t " ,  le n g th  (Ssequence)- 1 4 , "\n"} 
w h ile  (Ssequence =■»
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$/gm 
) ( p r in t  " $ l \ t 9 \ t C \ t $ 3 \ t " ,  le n g th  (Ssequence)- 1 4 ,"\n") 
w h i le (Ssequence =~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$/gm 
) ( p r in t  " $ l \ t 8 \ t c \ t $ 3 \ t " ,  le n g th  (Ssequence)- 1 4 , "\n"} 
w h i le (Ssequence =~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)S/gm 
) ( p r in t  " $ l \ t 7 \ t C \ t $ 3 \ t " ,  le n g th  (Ssequence)- 1 4 , "\n") 
w h i le (Ssequence =~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * ( gbs\d\d\d\d)$/gm){ 
p r in t  " $ l \ t 6 \ t C \ t $ 3 \ t " ,  le n g th  (Ssequence)- 1 4 ,"\n")
w h i l e ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [A C T N ] G G G G G G G G G G G G G G G [A C T N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \
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d ) S / . g m ) { p r i n t  " S l \ t l 5 \ t G \ t $ 3 \ t " ,  l e n g t h  ( $ s e q u e n c e ) - 1 4 , " \ n " }  . 
w h i l e ( $ s e q u e n c e  = ~
m / ( Agbs\d\d\d\d) [A G C T R Y S W K M B D H V N ] * ( [ A C T N ] G G G G G G G G G G G G G G [ A C T N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d 
) $ / g m ) ( p r i n t  " $ l \ t l 4 \ t G \ t $ 3 \ t " ,  l e n g t h  (Ssequence)- 1 4 , "\n"} 
w h i l e (Ssequence =~
m / ( Agbs\d\d\d\d) [A G C T R Y S W K M B D H V N ] * ( [A C T N ] G G G G G G G G G G G G G [ A C T N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d) 
$/gm){ p r i n t  " $ l \ t l 3 \ t G \ t $ 3 \ t " ,  l e n g t h  (Ssequence)- 1 4 , "\n"} 
w h i l e (Ssequence =~
m / ( Agbs\d\d\d\d) [A G C T R Y S W K M B D H V N ] * ( [ A C T N ] G G G G G G G G G G G G [ A C T N ] ) [ A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$ 
/gm) ( p r i n t  " $ l \ t l 2 \ t G \ t $ 3 \ t " ,  l e n g t h  (Ssequence)- 1 4 , "\n"} 
w h i l e (Ssequence =~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A C T N ] G G G G G G G G G G G [ A C T N ] ) [ A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$ /  
gm) ( p r i n t  " $ l \ t l l \ t G \ t $ 3 \ t " ,  l e n g t h  (Ssequence)- 1 4 , "\n"} 
w h i l e (Ssequence =~
m / ( Agbs\d\d\d\d) [A G C T R Y S W K M B D H V N ] * ( [ A C T N ] G G G G G G G G G G [ A C T N ] ) [ A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$/g 
m ) ( p r i n t  " $ l \ t l O \ t G \ t $ 3 \ t " ,  l e n g t h  (Ssequence)- 1 4 ,"\n") 
w h i l e (Ssequence =~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A C T N ] G G G G G G G G G [ A C T N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m  
) ( p r i n t  " $ l \ t 9 \ t G \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " }  
w h i l e ( S s e q u e n c e  = ~
m / ( Agbs\d\d\d\d) [A G C T R Y S W K M B D H V N ] * ( [ A C T N ] G G G G G G G G [ A C T N ] ) [ A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$/gm 
) ( p r i n t  " $ l \ t 8 \ t G \ t $ 3 \ t " ,  l e n g t h  (Ssequence)- 1 4 , "\n"} 
w h i l e (Ssequence =~
m / ( Agbs\d\d\d\d) [A G C T R Y S W K M B D H V N ] * ( [ A C T N ] G G G G G G G [ A C T N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$/gm 
) ( p r i n t  "SlXtTXtGXtSSXt",  l e n g t h  (Ssequence)-1.4, "\n"} 
w h i l e (Ssequence =~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] G G G G G G [ A C T N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m ) { 
p r i n t  " $ l \ t 6 \ t G \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " }
# # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # B e l l o w = T e x t f i l e O u t p u t # # A b o v e = S c r e e n O u t # # # #  
##########################################################
w h i l e ( S s e q u e n c e  = -
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A A A A A A A A [ T G C N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \  
d ) $ / g m ) ( p r i n t  O U T P U T  ( " $ l \ t l 5 \ t A \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) } 
w h i l e ( S s e q u e n c e  = ~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A A A A A A A [ T G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d  
) $ / g m ) ( p r i n t  O U T P U T  ( " $ l \ t l 4 \ t A \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) }  
w h i l e ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A A A A A A [ T G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d )  
$ / g m ) ( p r i n t  O U T P U T  ( " $ l \ t l 3 \ t A \ t $ 3 \ t ” ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) } 
w h i l e ( S s e q u e n c e  = ~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A A A A A [ T G C N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ 
/ g m ) ( p r i n t  O U T P U T  ( " $ l \ t l 2 \ t A \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) ) 
w h i l e ( S s e q u e n c e  = ~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A A A A [ T G C N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ /  
g m ) ( p r i n t  O U T P U T  ( " $ l \ t l l \ t A \ t S 3 \ t ” ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) } 
w h i l e ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A A A [ T G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g  
m ) ( p r i n t  O U T P U T  ( " S l \ t l O \ t A \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) } 
w h i l e ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A A [ T G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m  
) ( p r i n t  O U T P U T  ( " $ l \ t 9 \ t A \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) ) 
w h i l e ( S s e q u e n c e  = ~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A A [ T G C N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m  
) ( p r i n t  O U T P U T  ( " S l \ t 8 \ t A \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) }  
w h i l e ( $ s e q u e n c e  = ~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A A [ T G C N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m
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) { p r i n t  O U T P U T  ( " S l X t 7 \ t A \ t $ 3 \ t " ,  l e n g t h  - ( S s e q u e n c e ) - 1 4 , " \ n " ) } -  . .
w h i l e ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ T G C N ] A A A A A A [ T G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m ) ( 
p r i n t  O U T P U T  ( " $ l \ t 6 \ t A \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~
m / ( A g b s \ d \ d X d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T T T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \  
d ) $ / g m ) { p r i n t  O U T P U T  ( " $ l \ t l 5 \ t T \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) ) 
w h i l e ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T T T T T T T [ A G C N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d  
) $ / g m ) { p r i n t  O U T P U T  ( " $ l \ t l 4 \ t T \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) }
w h i l e ( S s e q u e n c e ■= ~ "  ............... .................................................................................. .................... ...... ...
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d )  
$ / g m ) { p r i n t  O U T P U T  ( " $ l X t l 3 \ t T X t $ 3 X t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " X n " ) } 
w h i l e  ( S s e q u e n c e  = ~  . . . . . .
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T T T T T [ A G C N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d X d \ d \ d ) $  
/ g m ) { p r i n t  O U T P U T  , ( " $ l \ t l 2 X t T \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) } 
w h i l e ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ /  
g m ) { p r i n t  O U T P U T  ( " $ l \ t l l \ t T X t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , ” \ n " ) } 
w h i l e ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g  
m ) { p r i n t  O U T P U T  ( " $ l \ t l O \ t T X t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) } 
w h i l e ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m  
) { p r i n t  O U T P U T  ( " $ l X t 9 \ t T \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , n \ n " ) } 
w h i l e ( S s e q u e n c e  = ~
m / ( A g b s X d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / gm 
) { p r i n t  O U T P U T  ( " S l \ t 8 \ t T \ t $ 3 X t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) } 
w h i l e ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d X d \ d \ d ) $ / g m  
) { p r i n t  O U T P U T  ( " S l \ t 7 \ t T X t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " \ n " ) } 
w h i l e ( S s e q u e n c e  = ~
m / ( A g b s X d \ d X d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G C N ] T T T T T T [ A G C N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m ) { 
p r i n t  O U T P U T  ( " $ l \ t 6 \ t T \ t $ 3 \ t " ,  l e n g t h  ( S s e q u e n c e ) - 1 4 , " X n ” ) }
while(Ssequence =~
m/(AgbsXd\dXdXd) [A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C C C C C C C C [ A G T N ] ) [ A G C T R Y S W K M B D H V N ] * (gbs\d\dXd\ 
d)$/gm){print O U T P U T  ( " $ l \ t l 5 \ t C \ t $ 3 \ t " ,  length (Ssequence)- 1 4 , "\n")} 
while(Ssequence =~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d X d \ d  
)$/gm){print O U T P U T  ( " S l \ t l 4 \ t C \ t $ 3 \ t " /  length ( S s e q u e n c e ) - 1 4 , " \ n " ) }  
while ( S s e q u e n c e  = ~
m / ( Agbs\d\d\d\d) [A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d) 
$/gm){print O U T P U T  ("$lXtl3\tC\t$3Xt", length (Ssequence)- 1 4 , "Xn")) 
while(Ssequence =~
m/ ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C C C C C [ A G T N ] ) [ A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d)$  
/gm){print O U T P U T  ( " $ l \ t l 2 \ t C \ t $ 3 \ t " , length ( S s e q u e n c e ) - 1 4 , " X n " ) } 
while ( S s e q u e n c e  = ~
m / ( AgbsXd\d\d\d) [A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\dXd\d\d)$ /  
gm){print O U T P U T  ( " $ l \ t l l \ t C \ t $ 3 \ t " ,  length (Ssequence)- 1 4 , "Xn"))  
while(Ssequence =~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C C C [ A G T N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g  
m ) {print O U T P U T  ( " S l X t l O X t C \ t $ 3 \ t " ,  length ( S s e q u e n c e ) - 1 4 , " \ n " )  ) 
while ( S s e q u e n c e  = ~
m /  ( A g b s \ d \ d \ d X d )  [A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m  
) {print O U T P U T  ( " S l \ t 9 \ t C \ t $ 3 \ t " ,  length ( S s e q u e n c e ) - 1 4 , " X n " ) } 
while ( S s e q u e n c e  = ~
m /  { A g b s X d \ d \ d \ d )  [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m  
) {print O U T P U T  ( " S l \ t 8 X t c X t $ 3 \ t " ,  length ( S s e q u e n c e ) - 1 4 , " \ n " ) )
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w h ile  ( S s e q u e n c e  =~        . .
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C C [ A G T N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) S / g m  
) [ p r in t  O U T P U T  ( " $ l \ t 7 \ t C \ t $ 3 \ t " ,  le n g th  ( $ s e q u e n c e ) - 1 4 , " \ n " ) } 
w h i le ( S s e q u e n c e  = ~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] C C C C C C [ A G T N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m ) ( 
p r in t  O U T P U T  ( " $ l \ t 6 \ t C \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " ) }
w h i le (Ssequence =~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [A C T N ] G G G G G G G G G G G G G G G [A C T N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\ 
d)$/gm)[ p r in t  O U T P U T  ( " $ l \ t l 5 \ t G \ t $ 3 \ t " ,  le n g th  (Ssequence)- 1 4 , "\n")} 
w h i le (Ssequence= ~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [A C T N ]G G G G G G G G G G G G G G [ A C T N ] ) [A G C T R Y S W K M B D H V N ] * (gbs\d\d\d\d 
)$/gm)[ p r in t  O U T P U T  ( " $ l \ t l 4 \ t G \ t $ 3 \ t " ,  le n g th  (Ssequence)- 1 4 , "\n")}  ' 
w h i le (Ssequence =~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [A C T N ]G G G G G G G G G G G G G [A C T N ] ) [A G C T R Y S W K M B D H V N ]* (gbs\d\d\d\d) 
$/gm)[ p r in t  O U T P U T  ( " $ l \ t l 3 \ t G \ t $ 3 \ t " ,  le n g th  (Ssequence)- 1 4 , "\n")) 
w h i le (Ssequence =~
m / ( Agbs\d\d\d\d) [ A G C T R Y S W K M B D H V N ] * ( [ A C T N ] G G G G G G G G G G G G [ A C T N ] ) [A G C T R Y S W K M B D H V N ]* (gbs\d\d\d\d)$  
/gm)[ p r in t  O U T P U T  ( " $ l \ t l 2 \ t G \ t $ 3 \ t " ,  le n g th  (Ssequence)- 1 4 , "\n")} 
w h i le (Ssequence =~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A C T N ] G G G G G G G G G G G [ A C T N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ /  
g m ) ( p r in t  O U T P U T  ( " $ l \ t l l \ t G \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " ) } 
w h i le ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A C T N ] G G G G G G G G G G [ A C T N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g  
m ) ( p r in t  O U T P U T  ( " S l \ t l O \ t G \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " ) } 
w h i le ( S s e q u e n c e  = ~
m / ( A g b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A C T N ] G G G G G G G G G [ A C T N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m  
) ( p r in t  O U T P U T  ( " S l \ t 9 \ t G \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " ) }  
w h i le ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A C T N ] G G G G G G G G [ A C T N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m  
) ( p r in t  O U T P U T  ( " S l \ t 8 \ t G \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " ) }  
w h i le ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A C T N ] G G G G G G G [ A C T N ] ) [ A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m  
) ( p r in t  O U T P U T  ( " S l \ t 7 \ t G \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n ” ) }  
w h i le ( S s e q u e n c e  = ~
m / ( Ag b s \ d \ d \ d \ d ) [ A G C T R Y S W K M B D H V N ] * ( [ A G T N ] G G G G G G [ A C T N ] ) [A G C T R Y S W K M B D H V N ] * ( g b s \ d \ d \ d \ d ) $ / g m ) ( 
p r in t  O U T P U T  ( " $ l \ t 6 \ t G \ t $ 3 \ t " ,  le n g th  ( S s e q u e n c e ) - 1 4 , " \ n " ) )
}
263
9.9.4 Script to Identify MNR Tracts in Coding DNA
# ! / u s r / b i n / p e r l  
#
#
#
# M N R _ f i n d e r _ c o d i n g . p i
i l d e n t i f i e s  MNR t r a c t s  i n  C o d i n g  r e g i o n s
# u s e  w a r n i n g s ;
# u s e  s t r i c t ;
c h d ir " / h o m e / r i c h a r d / g b  s _ a 1 1 / 2  6 0 3 V R / " ;
my © c o d i n g  =  < * . f a s > ;
# m y  S c o d i n g  =  ( 0 c o d i n g ) ;
fo re a e h  my S c o d i n g ( © c o d i n g ) {
my S o u t p u t l  =  " » / h o m e / r i c h a r d / M N R _ f i n a l / c o d i n g / 2 6 0 3 V R / c o d i n g _ r e p e a t s / 2 6 0 3 V R _ a l l "  
open ( 0 U T P U T 1 ,  " S o u t p u t l " ) ;  
open ( C O D I N G ,  ” $ c o d i n g ” ) ;
w h ile  (my S r e p l a c e  =  < C O D I N G > ) { •
S r e p l a c e  = ~  s / > / / g m ;
S r e p l a c e  = ~  s /  S t r e p t o c o c c u s  a g a l a c t i a e  2 6 0 3 V \ / R ,  c o m p l e t e  
g e n o m e . \ s * \ n / \ t / g m ;
S r e p l a c e  = ~  s /  / \ t / g m ;
S r e p l a c e  = ~  s / \ n / / g m ;
S r e p l a c e  = ~  s / \ r / / g m ;
S r e p l a c e  = ~  s / S A G / \ n S A G / g m ;
p r in t  0 U T P U T 1  ( " S r e p l a c e " ) ;
}
}
#################################
c h d ir " / h o m e / r i c h a r d / M N R _ f i n a l / c o d i n g / 2 6 0 3 V R / c o d i n g _ r e p e a t s / " ;
my S l i s t  =  " 2 6 0 3 V R _ a l l " ;  
open ( H A S H _ F I L E ,  " S l i s t " ) ;
my © h a s h  =  < H A S H _ F I L E > ; 
my $ k e y  =  0 ;  
my S v a l u e  =  0 ;
fo re a e h  my $hash(©hash){
my ©split = s p l i t ( / \ t / ,  $hash);
##print "©split[0],©split[1]\n";
my %hash = () ; 
my Slocus = ©split [0]; 
my Ssequence = @split[l];
$hash{Slocus} = Ssequence;
w h ile  ((my Skey, my Svalue) = each(% hash)) {
# p r i n t  " $ k e y \ t $ v a l u e " ;
m y  S o u t p u t  =  " > / h o m e / r i c h a r d / M N R _ f i n a l / c o d i n g / 2 6 0 3 V R / c o d i n g _ r e p e a t s _ l e n g t h / $ l o c u s " ;  
o p e n  ( O U T P U T ,  " $ o u t p u t " ) ;
p r i n t  O U T P U T  ( " L o c u s  T a g \ t N u c l e o t i d e \ t R e p e a t  L e n g t h \ t P o s i t i o n \ t G e n e  L e n g t h \ n " ) ;  
w h i l e ( $ s e q u e n c e  = ~  m / [ A G C N \ s ] T T T T T T T T T T T T T T T [ A G C N \ s ] / g m )  { p r i n t  O U T P U T  ( 
" $ l o c u s \ t T \ t l 5 \ t " ,  p o s  ( S s e q u e n c e ) - 1 5 , " \ t " ,  l e n g t h  ( S s e i q u e n c e ) , " \ n " ) } 
w h i l e ( S s e q u e n c e  = ~  m / [ A G C N \ s ] T T T T T T T T T T T T T T [ A G C N \ s ] / g m )  { p r i n t  O U T P U T  ( 
" $ l o c u s \ t T \ t l 4 \ t " ,  p o s  ( S s e q u e n c e ) - 1 4 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) )
w h i l e ( S s e q u e n c e  = -  m / [ A G C N \ s ] T T T T T T T T T T T T T [ A G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t T \ t l 3 \ t "  
,  p o s  ( S s e q u e n c e ) - 1 3 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ A G C N \ s ] T T T T T T T T T T T T [ A G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t T \ t l 2 \ t " , 
p o s  ( S s e q u e n c e ) - 1 2 , " \ t " , l e n g t h  ( S s e q u e n c e )  , " \ n " )  ) 
w h i l e ( S s e q u e n c e -  = ~  m / [ A G C N \ s ] T T T T T T T T T T T [ A G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ - l o c u s \ t T \ t l l \ t " ,  
p o s  ( S s e q u e n c e ) - 1 1 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) )
w h i l e ( S s e q u e n c e  = ~  m / [ A G C N \ s ] T T T T T T T T T T [ A G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t T \ t l O \ t " ,  
p o s  ( S s e q u e n c e ) - 1 0 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) )
w h i l e ( S s e q u e n c e  = ~  m / [ A G C N \ s ] T T T T T T T T T [ A G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " S l o c u s \ t T \ t 9 \ t " ,  p o s  
( S s e q u e n c e ) - 9 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }  
w h i l e ( S s e q u e n c e  = ~  m / [ A G C N \ s ] T T T T T T T T [ A G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t T \ t 8 \ t " ,  p o s  
( S s e q u e n c e ) - 8 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ A G C N \ s ] T T T T T T T [ A G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t T \ t 7 \ t " ,  p o s  ( 
S s e q u e n c e ) - 7 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ A G C N \ s ] T T T T T T [ A G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t T \ t 6 \ t " ,  p o s  ( 
S s e q u e n c e ) - 6 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
# w h i l e ( S s e q u e n c e  = ~  m / [ A G C N \ s ] T T T T T [ A G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t T \ t 5 \ t " ,  p o s  
( S s e q u e n c e ) - 5 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
# w h i l e ( S s e q u e n c e  = ~  m / [ A G C N \ s ] T T T T [ A G C N A s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t T \ t 4 \ t " ,  p o s  
( S s e q u e n c e ) - 4 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
# w h i l e ( S s e q u e n c e  = ~  m / [ A G C N \ s ] T T T [ A G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t T \ t 3 \ t " ,  p o s  
( S s e q u e n c e ) - 3 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ T G C N \ s ] A A A A A A A A A A A A A A A [ T G C N \ s ] / g m )  { p r i n t  O U T P U T  ( 
" S l o c u s \ t A \ t l 5 \ t " ,  p o s  ( S s e q u e n c e ) - 1 5 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }  
w h i l e ( S s e q u e n c e  = ~  m / [ T G C N \ s ] A A A A A A A A A A A A A A [ T G C N \ s ] / g m )  { p r i n t  O U T P U T  ( 
" S l o c u s \ t A \ t l 4 \ t " ,  p o s  ( S s e q u e n c e ) - 1 4 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ T G C N \ s ] A A A A A A A A A A A A A [ T G C N \ s ] / g m )  ( p r i n t  O U T P U T  ( " $ l o c u s \ t A \ t l 3 \ t "  
,  p o s  ( S s e q u e n c e ) - 1 3 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ T G C N \ s ] A A A A A A A A A A A A [ T G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t A \ t l 2 \ t " ,  
p o s  ( S s e q u e n c e ) - 1 2 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) ) 
w h i l e ( S s e q u e n c e  = ~  m / [ T G C N \ s ] A A A A A A A A A A A [ T G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t A \ t l l \ t " ,  
p o s  ( S s e q u e n c e ) - 1 1 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ T G C N \ s ] A A A A A A A A A A [ T G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t A \ t l O \ t " ,  
p o s  ( S s e q u e n c e ) - 1 0 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ T G C N \ s ] A A A A A A A A A [ T G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " S l o c u s \ t A \ t 9 \ t " ,  p o s  
( S s e q u e n c e ) - 9 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) ) 
w h i l e ( S s e q u e n c e  = ~  m / [ T G C N \ s ] A A A A A A A A [ T G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " S l o c u s \ t A \ t 8 \ t " ,  p o s  
( S s e q u e n c e ) - 8 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) )
w h i l e ( S s e q u e n c e  = ~  m / [ T G C N \ s ] A A A A A A A [ T G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t A \ t 7 \ t " ,  p o s  ( 
S s e q u e n c e ) - 7 , " \ t " ,  l e n g t h  ( S s e q u e n c e )  , " \ n " )  )
w h i l e ( S s e q u e n c e  = ~  m / [ T G C N \ s ] A A A A A A [ T G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t A \ t 6 \ t " ,  p o s  ( 
S s e q u e n c e ) - 6 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
# w h i l e ( S s e q u e n c e  = ~  m / [ T G C N \ s ] A A A A A [ T G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t A \ t 5 \ t " ,  p o s  
( S s e q u e n c e ) - 5 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n ” ) }
# w h i l e ( S s e q u e n c e  = ~  m / [ T G C N \ s ] A A A A [ T G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t A \ t 4 \ t " ,  p o s  
( S s e q u e n c e ) - 4 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
# w h i l e ( S s e q u e n c e  = ~  m / [ T G C N \ s ] A A A [ T G C N \ s ] / g m )  { p r i n t  O U T P U T  ( " S l o c u s \ t A \ t 3 \ t " ,  p o s  
( S s e q u e n c e ) - 3 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ T A G N \ s ] C C C C C C C C C C C C C C C [ T A G N \ s ] / g m )  { p r i n t  O U T P U T  (
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" $ l o c u s \ t C \ t l 5 \ t " ,  p o s  ( S s e q u e n c e ) - 1 5 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) ) 
w h i l e ( $ s e q u e n c e  = ~  m / [ T A G N \ s ] C C C C C C C C C C C C C C [ T A G N \ s ] / g m )  { p r i n t  O U T P U T  ( 
" $ l o c u s \ t C \ t l 4 \ t " ,  p o s  ( S s e q u e n c e ) - 1 4 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) )
w h i l e ( S s e q u e n c e . = ~  m / [ T A G N \ s ] C C C C C C C C C C C C C [ T A G N \ s ] / g m )  { p r i n t  O U T P U T  { " $ l o c u s \ t C \ t l 3 \ t "  
,  p o s  ( $ s e q u e n c e ) - 1 3 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ T A G N \ s ] C C C C C C C C C C C C [ T A G N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t C \ t l 2 \ t " , 
p o s  ( S s e q u e n c e ) - 1 2 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) ) 
w h i l e ( S s e q u e n c e  = ~  m / [ T A G N \ s ] C C C C C C C C C C C [ T A G N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t C \ t l l \ t " ,  
p o s  ( S s e q u e n c e ) - 1 1 , " \ t ” ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ T A G N \ s ] C C C C C C C C C C [ T A G N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t C \ t l O \ t " ,  
p o s  ( S s e q u e n c e ) - 1 0 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ T A G N \ s ] C C C C C C C C C [ T A G N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t C \ t 9 \ t " ,  p o s  
( S s e q u e n c e ) - 9 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }  
w h i l e ( S s e q u e n c e  = ~  m / [ T A G N \ s ] C C C C C C C C [ T A G N \ s ] / g m )  { p r i n t  O U T P U T  ( " S l o c u s \ t C \ t 8 \ t " ,  p o s  
( S s e q u e n c e ) - 8 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) )
w h i l e ( S s e q u e n c e  = ~  m / [ T A G N \ s ] C C C C C C C [ T A G N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t C \ t 7 \ t " ,  p o s  ( 
S s e q u e n c e ) - 7 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ T A G N \ s ] C C C C C C [ T A G N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t C \ t 6 \ t " ,  p o s  ( 
S s e q u e n c e ) - 6 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
# w h i l e ( S s e q u e n c e  = ~  m / [ T A G N \ s ] C C C C C [ T A G N \ s ] / gm ) { p r i n t  O U T P U T  ( " $ l o c u s \ t C \ t 5 \ t " ,  p o s  
( S s e q u e n c e ) - 5 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
# w h i l e ( S s e q u e n c e  = ~  m / [ T A G N \ s ] C C C C [ T A G N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t C \ t 4 \ t " ,  p o s  
( S s e q u e n c e ) - 4 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
# w h i l e ( S s e q u e n c e  = ~  m / [ T A G N \ s ] C C C [ T A G N \ s ] / gm.) { p r i n t  O U T P U T  ( " S l o c u s \ t C \ t 3 \ t " ,  p o s  
( S s e q u e n c e ) - 3 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ T A C N \ s ] GGGGGGGGGGGGGGG[ T A C N \ s ] / g m ) { p r i n t  O U T P U T  ( 
" $ l o c u s \ t G \ t l 5 \ t " ,  p o s  ( S s e q u e n c e ) - 1 5 , ” \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) } 
w h i l e ( S s e q u e n c e  = ~  m / [ T A C N \ s ] GGGGGGGGGGGGGG[ T A C N \ s ] / gm) { p r i n t  O U T P U T  ( 
" $ l o c u s \ t G \ t l 4 \ t " ,  p o s  ( S s e q u e n c e ) - 1 4 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) )
W h i l e ( S s e q u e n c e  = ~  m / [ T A C N \ s ] GGGGGGGGGGGGG[ T A C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t G \ t l 3 \ t "  
,  p o s  ( S s e q u e n c e ) - 1 3 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ T A C N \ s ] G G G G G G G G G G G G [ T A C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t G \ t l 2 \ t " ,  
p o s  ( S s e q u e n c e ) - 1 2 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) } 
w h i l e ( S s e q u e n c e  = ~  m / [ T A C N \ s ] G G G G G G G G G G G [ T A C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t G \ t l l \ t ” ,  
p o s  ( S s e q u e n c e )  - 1 1 , " \ t " ,  l e n g t h  ( S s e i q u e n c e )  ,  " \ n " )  }
w h i l e ( S s e q u e n c e  = ~  m / [ T A C N \ s ] GGGGGGGGGG[ T A C N \ s ] / g m )  { p r i n t  O U T P U T  ( " S l o c u s \ t G \ t l O \ t " ,  
p o s  ( S s e q u e n c e ) - 1 0 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ T A C N \ s ] G G G G G G G G G [ T A C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t G \ t 9 \ t " ,  p o s  
( S s e q u e n c e ) - 9 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) ) 
w h i l e ( S s e q u e n c e  = ~  m / [ T A C N \ s ] G G G G G G G G [ T A C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t G \ t 8 \ t " ,  p o s  
( S s e q u e n c e ) - 8 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) )
w h i l e ( S s e q u e n c e  = ~  m / [ T A C N \ s ] G G G G G G G [ T A C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t G \ t 7 \ t " ,  p o s  ( 
S s e q u e n c e ) - 7 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
w h i l e ( S s e q u e n c e  = ~  m / [ T A C N \ s ] G G G G G G [ T A C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t G \ t 6 \ t " ,  p o s  ( 
S s e q u e n c e ) - 6 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) )
# w h i l e ( S s e q u e n c e  = ~  m / [ T A C N \ s ] G G G G G [ T A C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t G \ t 5 \ t " ,  p o s  
( S s e q u e n c e ) - 5 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
# w h i l e ( S s e q u e n c e  = ~  m / [ T A C N \ s ] G G G G [ T A C N \ s ] / g m )  { p r i n t  O U T P U T  ( " $ l o c u s \ t G \ t 4 \ t " ,  p o s  
( S s e q u e n c e ) - 4 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
# w h i l e ( S s e q u e n c e  = ~  m / [ T A C N \ s ] G G G [ T A C N \ s ] / g m )  { p r i n t  O U T P U T  ( " S l o c u s \ t G \ t 3 \ t " ,  p o s  
( S s e q u e n c e ) - 3 , " \ t " ,  l e n g t h  ( S s e q u e n c e ) , " \ n " ) }
266
9.10 GBS Core Genomes
9.10.1 Three Genome Dataset Core Genome
Locus Tag Gi
5AGG001 22536186
SAG0002 22536187
SAG0003 22536188
SAG0004 22536189
SAG0006 22536191
SAG0007 22536192
SAG0008 22536193
SAG0010 22536195
SAG0011 22536196
SAG0012 22536197
SAG0013 22536198
SAG0014 22536199
SAG0015 22536200
SAG0016 22536201
SAG0017 22536202
SAG0018 22536203
SAGOO19 22536204
SAG0020 22536205
SAG0021 22536206
SAG0022 22536207
SAG0023 22536208
SAG0024 22536209
SAG0025 22536210
SAG0026 22536211
SAG0027 22535212
SAG0028 22536213
SAG0029 22536214
SAG0030 22536215
SAG0031 22536216
SAG0032 22536217
SAG0033 22536218
SAG0034 22536219
SAG0035 22536220
SAG0036 22536221
SAG0037 22536222
SAG0038 22536223
SAG0039 22536224
SAG0040 22536225
5AG0041 22536226
SAG0042 22536227
SAG0043 22536228
SAG0044 22536229
SAG0045 22535230
SAG0047 22536232
SAG0049 22536234
SAG0050 22536235
SAG0051 22536236
SAG0052 22536237
SAG0O53 22536238
SAG0054 22536239
SAG0055 22536240
SAG0056 22536241
SAG0057 22536242
SAG0058 22536243
SAG0059 22536244
SAG0060 22536245
SAG0061 22536246
SAG0062 22536247
SAG0063 22536248
SAG0064 22536249
SAG0065 22536250
SAG0066 22536251
SAG0067 22536252
SAG0068 22536253
SAG0069 22536254
SAG0070 22536255
Locus Tag Gi
SAG0071 22536256
SAG0072 22536257
SAG0073 22536258
SAG0074 22536259
SAG0075 22536260
SAG0076 22536261
SAG0077 22536262
SAG0078 22536263
5AG0079 22536264
SAG0080 22536265
SAG0082 22536267
SAG0083 161485618
SAG0084 22536269
SAG0085 22536270
SAG0086 22536271
SAG0089 22536274
SAG0090 22536275
SAG0091 22536276
SAG0092 22536277
SAG0093 22536278
SAG0094 22536279
SAG0095 22536280
SAG0096 22536281
SAG0097 22536282
SAG0098 22536283
SAG0099 22536284
SAG0100 22536285
SAG0101 22536286
SAG0102 22536287
SAG0103 22536288
SAG0104 22536289
SAG0105 22536290
SAG0106 22536291
SAG0107 22536292
SAG0108 22536293
SAG0109 22536294
SAG0110 22536295
SAG0111 22536296
SAG0112 22536297
SAG0113 22536298
SAG0114 22536299
5AG0115 22536300
SAG0116 22536301
SAG0117 22536302
SAG0118 22536303
SAGQ119 22536304
SAG0121 22536306
SAG0122 22536307
SAG0123 22536308
SAG0124 22536309
SAG0125 22536310
SAG0126 22536311
SAG0127 22536312
SAG0128 22536313
SAG0129 22536314
SAG0130 22536315
SAG0131 22536316
SAG0132 22536317
SAG0135 22536320
SAG0136 22536321
SAG0137 22536322
SAG0138 22536323
SAG0139 22536324
SAG0140 22536325
SAG0141 22536326
SAG0142 22536327
Locus Tag Gi
SAG0143 22536328 .
SAG0144 22S36329
SAG0145 22536330
SAG0146 22536331
SAG0147 22536332
SAGO148 22536333
SAG0149 22536334
SAG0150 22536335
SAG0151 22536336
SAG0152 22536337
SAGQ153 22536338
SAG0154 22536339
SAG0155 22536340
SAG0156 22536341
SAG0158 22536342
SAG0159 22536343
SAG0160 22536344
SAG0161 22536345
SAG0162 22536346
SAG0163 22536347
SAG0164 22536348
SAG0165 22536349
SAG0166 22536350
SAG0167 22536351
SAG0168 22536352
SAG0169 22536353
SAG0171 22536355
SAG0172 22536356
SAG0173 22536357
SAG0174 22536358
SAG0175 22536359
SAG0176 22536360
SAG0177 22536361
SAG0178 22536362
SAG0179 22536363
SAG0180 22536364
SAG0181 22536365
SAG0182 22536366
SAG0183 22536367
SAG0184 22536368
SAGO185 22536369
SAG0187 22536371
SAG0188 22536372
SAG0189 22536373
SAG0190 22536374
SAG0191 22536375
SAG0192 22536376
SAG0193 22536377
SAG0194 22536378
SAG0196 22536380
SAG0197 22536381
SAG0198 22536382
SAG0199 22536383
SAG0200 22536384
SAG0201 22536385
SAG0202 22536386
SAG0203 22536387
SAG0204 22536388
SAG020S 22536389
SAG0206 22536390
SAG0207 22536391
SAG0208 22536392
SAG0209 22536393
SAG0210 22536394
SAG0211 22536395
SAG0214 22536398
Locus Tag Gi
SAG0215 22536399
SAG0217 22536401
SAG0220 22536404
SAG0222 22536406
SAG0223 22536407
SAG0224 22536408
SAG0225 22536409
SAG0226 22536410
SAG0227 22536411
SAG0228 22536412
SAG0229 22536413
SAG0230 22536414
SAG0231 22536415
SAG0232 22536416
SAG0234 22536418
SAG0235 22536419
SAG0239 22536423
SAG0240 22536424
SAG0241 22536425
SAG0242 22536426
SAG0243 22536427
SAG0244 22536428
SAG0252 22536436
SAG0253 22536437
SAG0254 22536438
SAG0255 22536439
SAG0256 22536440
SAG0257 22536441
SAG0258 22536442
SAG0259 22536443
SAG0260 22536444
SAG0263 22536447
SAG0264 22536448
SAG0265 22536449
SAG0266 22536450
SAG0267 22536451
SAG0268 22536452
SAG0269 22536453
SAG0270 22536454
SAG0271 22536455
SAG0272 22536456
5AG0273 22536457
SAG0274 22536458
SAG0275 22536459
SAG0276 22536460
SAG0277 22536461
SAG0278 22536462
SAG0279 22536463
SAG0280 22536464
SAG0281 22536465
SAG0282 22536466
SAG0283 22S36467
SAG0284 22536468
SAG028S 161485617
SAG0286 22536470
SAG0287 22536471
SAG0288 22536472
SAG0289 22536473
SAG0290 22536474
SAG0291 22536475
SAG0292 22536476
SAG0293 22536477
SAG0294 22536478
SAG0295 22536479
SAG0296 22536480
SAG0297 22536481
Locus Tag Gi
SSS0M8- - 22S35?S2'
SAG0299 22536483
5AG0300 22536484
SAG0302 22S36486
SAG0303 22536487
SAG0304 22536488
SAG0305 22536489
SAG0306 22536490
5AG0308 22536492
SAG0309 22536493
SAG0310 22536494
SAG0312 22536495
SAG0313 22536496
5AGQ314 22536497
SAG0315 22536498
SAG0316 22536499
SAG0317 22536500
SAG0318 22536501
SAG0319 22536502
SAG0320 22536503
SAG0321 22536504
SAG0322 22536505
SAG0323 22536506
SAG0324 22536507
SAG0325 22536508
SAG0326 22536509
SAG0327 22536510
SAG0328 22536511
SAG0329 22536512
SAG0330 22536513
SAG0331 22536514
SAG0332 22536515
SAG0333 22536516
SAG0334 22536517
SAG0335 22536518
SAG0336 22536519
SAG0337 22536520
SAG0338 22536521
SAG0339 22536522
SAG0340 22536523
SAG0342 22536525
SAG0343 22536526
SAG0344 22536527
SAG0345 22536528
SAG0346 22536529
SAG0347 22536530
SAG0348 22536531
SAG0349 22536532
SAG0350 22536533
SAG0351 22536534
SAG0352 22536535
SAG0353 22536536
SAG0354 22536537
SAG0355 22536538
SAG0356 22536539
SAG0357 22536540
SAG0358 22536541
SAG0359 22536542
SAG0360 22536543
SAG0361 22536544
SAG0362 22536545
SAG0363 22536546
SAG0364 22536547
SAG0365 22536548
SAG0366 22536549
5AG0367 22536550
Locus Tag Gi
“ 5AG0368 22536551
SAG0369 22536552
5AG0370 22536553
SAG0371 22536554
SAG0373 22536556
SAG0374 22536557
SAG0375 22536558
SAG0376 22536559
SAG0377 22536560
SAG0378 161485616
5AG0379 22536562
SAG0380 22536563
SAG0381 22536564
5AG0382 22536565
SAG0383 22536566
SAG0384 22536567
SAG0385 22536568
SAG0386 22536569
SAG0387 22536570
SAG0388 22536571
SAG0389 22536572
SAG0390 22536573
SAG0391 22536574
SAG0392 22536575
5AG0393 22536576
SAG0394 22536577
SAG0395 22536578
SAG0396 22536579
SAG0397 22536580
SAG0398 22536581
SAG0399 22536582
SAG0400 22536583
SAG0402 22536585
SAG0403 22536586
SAG0404 22536587
SAG0405 22536588
SAG0406 22536589
SAG0407 22536590
SAG0408 22536591
SAG0409 22536592
SAG0410 22536593
SAG0411 22536594
SAG0412 22536595
SAG0413 22536596
SAG0414 22536597
SAG0415 22536598
SAG0417 22536600
SAG0418 22535601
SAG0419 22536602
SAG0420 22536603
SAG0421 22536604
SAG0422 22536605
SAG0423 22536606
SAG0425 22536608
SAG0426 22536609
SAG0430 22536613
SAG0431 22536614
SAG0432 22536615
SAG0440 22536620
SAG0441 22536621
SAG0442 22536622
SAG0443 22536623
SAG0445 22536625
5AG0446 22536626
SAG0447 22536627
SAG0449 22536629
Locus Tag Gi
SAG0450 22536630
SAG0451 22536631
SAG0452 22536632
SAG0454 22536634
SAG0455 22536635
SAG0457 22536636
SAG0458 22536637
SAG0459 22536638
SAG0460 22536639
SAG0461 22536640
SAG0462 22536641
SAG0463 22536642
SAG0464 22536643
SAG0465 22536644
SAG0467 22536646
SAG0468 22536647
5AG0469 22536648
SAG0470 22536649
SAG0471 22536650
SAG0472 22536651
SAG0473 22536652
SAG0474 22536653
SAG0475 22536654
SAG0476 225366S5
SAG0477 22536656
SAG0478 22S36657
SAG0479 22536658
5AG0480 22536659
SAG0481 22536660
SAG0482 22536661
SAG0483 22536662
SAG0484 22536663
SAG0485 22536664
SAG0486 22536665
SAG0487 22536666
SAG0488 22536667
SAG0490 22536669
SAG0491 22536670
SAG0492 22536671
SAG0493 22536672
SAG0494 22536673
SAG0495 22536674
SAG0496 22536675
SAG0497 22536676
SAG0498 22536677
SAG0499 22536678
SAG0500 22536679
SAG0501 22536680
SAG0502 22536681
5AG0503 22536682
SAG0504 22536683
SAG0505 22536684
SAG0506 22536685
SAG0507 22536686
SAG0508 22536587
SAG0509 22536688
SAG0510 22536689
SAGOS 11 22536690
SAG0512 22536691
SAGOS 13 22536692
SAG0514 22536693
SAG0516 22536695
SAG0517 22536696
SAG0519 22536697
SAG0520 22536698
SAG0521 22536699
Locus Tag Gi
SA<S0522 12535700
SAG0523 22536701
SAG0524 22536702
SAG0525 22536703
SAG0526 22536704
SAG0527 22536705
SAG0528 22536706
SAG0530 22536708
SAG0531 22535709
SAG0532 22536710
SAG0533 22536711
SAG0534 22536712
SAG0535 22536713
SAG0536 22536714
SAG0537 22536715
SAG0538 22536716
SAG0539 22536717
SAG0540 22536718
SAG0541 22536719
SAG0544 22536722
SAG0566 22536744
SAG0606. 22536782
SAG0610 22536785
SAG0612 22S36786
SAG0613 22536787
SAG0614 22536788
SAG0615 22536789
SAG0616 22536790
SAG0617 22536791
SAG0619 22536792
SAG0621 22536794
SAG0622 22535795
SAG0623 22536796
SAG0624 22536797
SAG0625 22536798
SAG0626 22536799
SAG0627 22536800
SAG0628 22536801
SAG0629 22536802
SAG0630 22536803
SAG0631 22536804
SAG0632 22536805
SAG0633 22536806
SAG0634 22536807
SAG0635 22536808
SAG0636 22536809
SAG0640 22536811
SAG0645 22536814
SAG0646 22536815
SAG0647 22536816
SAG0648 22536817
SAG0649 22536818
SAG0651 22536820
SAG0657 22536824
SAG0658 22536825
SAG0659 22536826
SAG0660 22536827
SAG0661 22536828
SAG0662 22536829
SAG0663 22536830
SAG0664 22536831
SAG0665 22536832
SAG0666 22536833
SAG0667 22536834
SAG0668 22536835
SAG0669 22536836
Locus Tag Gi
SAG0670 22555837
SAG0671 22536838
SAG0672 22536839
SAG0673 22536840
SAG0684 22536849
SAG0685 22536850
SAG0686 22536851
SAG0687 22536852
SAG0688 22535853
SAG0689 22536854
SAG0690 22536855
SAG0691 22536856
SAG0692 22536857
5AG0695 22536859
SAG0696 22536860
SAG0697 22536861
SAG0698 22536862
SAG0699 22536863
SAG0700 22536864
SAG0701 22536865
SAG0702 22536866
SAG0703 22536867
SAG0704 22536868
SAG0705 22536869
SAG0706 22536870
SAG0707 22536871
SAG0708 22536872
SAG0709 22536873
SAG0710 22536874
SAG0711 22536875
SAG0712 22536876
SAG0713 22536877
SAG0714 22536878
SAG0715 22536879
SAG0716 22536880
SAG0717 22536881
SAG0718 22536882
SAG0719 22536883
SAG0720 22536884
SAG0721 22536885
SAG0722 22536886
SAG0723 22536887
SAG0724 22536888
SAG0725 22536889
SAG0726 22536890
SAG0727 22536891
SAG0728 22536892
SAG0729 22536893
SAG0730 22536894
SAG0731 22536895
SAG0732 22536896
SAG0733 22536897
SAG0734 22536898
5AG0736 22536900
SAG0737 22536901
SAG0738 22536902
SAG0739 22536903
SAG0740 22536904
5AG0741 22536905
SAG0742 22536906
SAG0743 22536907
SAG0744 22536908
SAG0745 22535909
SAG0746 22536910
SAG0747 161485615
SAG0748 22536912
Locus Tag Gi
SAG0749 "22536913"
SAG0750 22536914
5AG0751 22536915
SAG0752 22536916
SAG0753 22536917
SAG0754 22536918
SAG0755 22536919
SAG0756 22536920
SAG0757 22536921
SAG0758 22536922
SAG0759 22536923
SAG0761 22536925
SAG0762 22536926
SAG0763 22536927
SAG0764 22536928
SAG0765 22536929
SAG0766 22536930
SAG0767 22536931
SAG0768 22536932
SAG0769 22536933
SAG0770 22536934
SAG0771 22536935
SAG0772 22536936
SAG0773 22536937
SAG0774 22536938
SAG0775 22536939
SAG0776 22536940
SAG0777 22536941
SAG0778 22536942
SAG0779 22536943
SAG0780 22536944
SAG0781 22536945
SAG0782 22536946
SAG0783 22536947
SAG0784 22536948
SAG0785 22536949
SAG0786 22536950
SAG0787 22536951
SAG0788 22536952
SAG0789 22536953
SAG0790 22536954
SAG0791 22536955
SAG0792 22536956
SAG0793 22536957
SAG0794 22536958
SAG0795 22536959
SAG0796 22536960
SAG0797 22536961
SAG0798 22536962
5AG0799 22536963
SAG0800 22536964
SAG0801 22536965
SAG0803 22536967
SAG0804 22536968
SAG0805 22536969
SAG0806 22536970
SAG0807 22536971
SAG0808 22536972
SAG0809 22536973
SAG0810 22536974
SAG0811 22536975
SAG0812 22536976
SAG0814 22536978
SAG0815 22536979
SAG0816 22536980
SAG0817 22536981
Locus Tag Gi
SAG0818 22536982
SAG0819 22536983
SAG0820 22536984
SAG0821 22536985
SAG0822 22536986
SAG0823 22536987
SAG0824 22536988
SAG0825 22536989
SAG0826 22536990
SAG0827 -22536991
SAG0828 22536992
SAG0830 22536994
SAG0831 22536995
SAG0833 22536997
SAG0834 22536998
SAG0835 22536999
5AG0836 22537000
SAG0837 22537001
SAG0838 22537002
SAG0839 22537003
SAG0840 22537004
SAGQ841 22537005
SAG0842 22537006
SAG0843 22537007
SAG0844 22537008
SAG0845 22537009
SAG0846 22537010
SAG0847 22537011
SAG0848 22537012
SAG0849 22537013
SAG0850 22537014
SAG0851 22537015
SAG0852 22537016
SAG0853 22537017
SAG0854 22537018
SAG0856 22537019
SAG0857 22537020
SAG08S8 22537021
5AG0859 22537022
SAG0860 22537023
SAG0861 22537024
SAG0862 22537025
SAG0863 22537026
SAG0864 22537027
SAG0866 22537029
SAG0867 22537030
SAG0868 22537031
SAG0869 22537032
SAG0870 22537033
SAG0871 22537034
SAG0873 22537036
SAG0874 22537037
SAG0875 22537038
SAG0876 22537039
SAG0877 22537040
SAG0878 22537041
SAG0879 22537042
SAG0880 22537043
SAG0881 22537044
SAG0882 22537045
SAG0883 22537046
SAG0884 22537047
SAG0885 22537048
SAG0886 22537049
SAG0887 22537050
SAG0888 22537051
Locus Tag Gi
SAG0889 22537052
SAG0890 22537053
SAG0891 22537054
SAG0892 22537055
SAG0893 22537056
SAG0894 22537057
SAG0895 22537058
SAG0896 22537059
SAG0897 22537060
SAG0905 22537068
5AG0906 22537069
SAG0907 22537070
SAG0908 22537071
SAG0909 22537072
SAG0910 22537073
SAG0911 22537074
SAG0912 22537075
SAG0913 22537076
SAG0914 22537077
SAG0938 22537099
SAG0939 22537100
SAG0940 22537101
SAG0941 22537102
SAG0942 22537103
SAG0944 22537105
SAG0946 22537107
SAG0947 22537108
SAG0948 22537109
SAG0949 22537110
SAG0950 161485614
SAG0951 22537112
SAG0952 22537113
SAG0953 22537114
SAG0954 22537115
SAG0955 22S37116
SAG0956 22537117
SAG0957 22537118
SAG0958 22537119
SAG0959 22537120
SAG0960 22537121
SAG0961 22537122
SAG0962 22537123
SAG0963 22537124
SAG0964 22537125
SAG0967 22537128
SAG0968 22537129
SAG0969 22537130
SAG0970 22537131
SAG0971 22537132
SAG0974 22537134
SAG0975 22537135
SAG0976 22537136
5AG0977 22537137
SAG0978 22537138
SAG0979 22537139
SAG0980 22537140
SAG0981 22537141
SAG0982 22537142
SAG0983 22537143
SAG0984 22537144
SAG0985 22537145
SAG0986 22537146
SAG0987 22537147
SAG0988 22537148
SAG0989 22537149
SAG0990 22537150
Locus Tag Gi Locus Tag Gi Locus Tag Gi Locus Tag Gi
5KS0991 22537151 SAG 1075 22537233 “ 5AG1149 “ 22537307 5A61225 22537381'
SA6Q992 22537152 SAG 1076 22537234 SAG1150 22537308 SAG1226 22537382
5AG0993 22537153 SAG1077 22537235 SAG1151 22537309 SAG1227 22537383
SAG0994 22537154 SAG1078 22537236 -SAG1152 22537310 -SAG 1228 22537384
SAG0995 22537155 SAG1079 22537237 SAG1153 22537311 SAG1229 22537385
SAG0996 22537156 SAG1081 22537239 SAG1154 22537312 SAG1230 22537386
SAG0997 22537157 SAG1082 22537240 SAG1155 22537313 SAG1233 22537387
SAG0998 22537158 SAG 1083 22537241 SAG1156 22537314 SAG 1234 22537388
SAG0999 22537159 SAG1084 22537242 SAG1157 22537315 SAG1237 22537390
SAG1000 22537160 SAG1085 -22537243 SAG1158 22537316 SAG 1241 22537393
SAG 1001 22537161 SAG1086 22537244 SAG1159 22537317 SAG1243 22537394
SAG1002 22537162 SAG1087 22537245 SAG1160 22537318 SAG 1244 22537395
SAG1003 22537163 SAG1088 22537246 SAG1161 22537319 SAG1245 22537396
SAG1004 22537164 SAG1089 22537247 SAG1162 22537320 SAG 1246 22537397
SAG1005 22537165 SAG1090 22537248 SAG1163 22537321 SAG1247 22537398
SAG 1006 22537166 SAG1091 22537249 SAG1170 22537328 SAG1301 22537448
SAG1007 22537167 SAG1092 22537250 SAG1171 22537329 SAG 1302 22537449
SAG 1008 22537168 SAG1093 22537251 SAG1172 22537330 SAG1303 22537450
SAG1009 22537169 SAG1094 22537252 SAG1173 22537331 SAG1305 22537452
SAG1010 22537170 SAG1095 22537253 SAG1174 22537332 SAG 1306 22537453
SAG 1011 22537171 SAG1096 22537254 SAG1175 22537333 SAG 1307 22537454
5AG1012 22537172 SAG1097 22537255 SAG1176 22537334 SAG1310 22537457
5AG1013 22537173 SAG1098 22537256 SAG1178 22537336 SAG1311 22537458
SAG 1014 22537174 SAG1099 22537257 SAG1179 22537337 SAG 1312 22537459
SAG 1015 22537175 SAG1100 22537258 SAG1180 22537338 SAG1314 22537461
5AG1016 22537176 SAG1101 22537259 SAG1181 22537339 SAG1315 22537462
SAG1017 22537177 SAG1102 22537260 SAG1182 22537340 SAG 1316 22537463
SAG1027 22537186 SAG1103 22537261 5AG1183 22537341 SAG1317 22537464
SAG1032 22537191 SAG1104 22537262 SAG1184 22537342 SAG1318 22537465
SAG1033 22537192 SAG 1105 22537263 SAG1185 22537343 SAG1319 22537466
SAG1034 22537193 SAG1106 22537264 SAG1186 22537344 SAG1320 22537467
SAG 1035 22537194 SAG1107 22537265 SAG1187 22537345 SAG 13 21 22537468
SAG1036 22537195 SAG1108 22537266 SAG1188 22537346 SAG1322 22537469
SAG1037 22537196 SAG 1109 22537267 SAG1189 22537347 SAG1323 22537470
SAG1038 22537197 SAG1110 22537268 SAG1190 22537348 SAG 13 24 22537471
SAG1039 22537198 SAG1111 22537269 SAG1191 22537349 SAG 13 25 22537472
SAG1040 22537199 SAG1112 22537270 SAG1192 22537350 SAG1326 22537473
SAG1041 22537200 SAG1113 22537271 SAG1193 225373S1 SAG1327 22537474
SAG1042 22537201 SAG1114 22537272 SAG1194 22537352 SAG1328 22537475
SAG1043 22537202 SAG1115 22537273 SAG1195 22537353 SAG 13 29 22537476
SAG1044 22537203 SAG1116 22537274 SAG1196 22537354 SAG 1332 22537479
SAG 1045 22537204 SAG1117 22537275 SAG1197 22537355 SAG1333 22537480
SAG1046 22537205 SAG1118 22537276 SAG1198 22537356 SAG1334 22537481
SAG 1047 22537206 SAG1119 22537277 SAG1199 22537357 SAG1335 22537482
SAG1048 22537207 SAG1120 22537278 SAG1200 22537358 SAG 1336 22537483
SAG1049 22537208 SAG1124 22537282 SAG1201 22537359 SAG1337 22537484
SAG1051 22537209 SAG1125 22537283 SAG1202 22537360 SAG1338 22537485
SAG1052 22537210 SAG1126 22537284 SAG1203 22537361 SAG1339 22537486
SAG1054 22537212 SAG1130 22537288 SAG1204 22537362 SAG 1340 22537487
SAG1055 22537213 SAG1131 22537289 SAG1205 22537363 SAG1341 22537488
SAG1056 22537214 SAG1132 22537290 SAG1206 22537364 SAG1342 22537489
SAG1057 22537215 SAG1134 22537292 SAG 1208 22537366 SAG1343 22537490
SAG1058 22537216 SAG1135 22537293 SAG1209 22537367 SAG1344 22537491
SAG1059 22537217 SAG1136 22537294 SAG1210 22537368 SAG1345 22537492
SAG1060 22537218 SAG1137 22537295 SAG1211 22537369 SAG 1346 22537493
SAG1061 22537219 SAG1138 22537296 SAG1212 22537370 SAG 1347 22537494
SAG1062 22537220 SAG1139 22537297 SAG1213 22537371 SAG 1348 22537495
SAG1063 22537221 SAG 1140 22537298 SAG1214 22537372 SAG1349 22537496
SAG1064 22537222 SAG1141 22537299 SAG1215 22537373 SAG1350 22537497
SAG1065 22537223 SAG1142 22537300 SAG1216 22537374 SAG1351 22537498
SAG1066 22537224 SAG 1143 22537301 SAG1218 22537375 SAG1352 22537499
SAG1070 22537228 SAG 1144 22537302 SAG1219 22537376 SAG1353 22537500
SAG1071 22S37229 SAG1145 22S37303 SAG1220 22537377 SAG1354 22537501
SAG1072 22537230 SAG1146 22537304 SAG1222 22537378 SAG1355 22537502
SAG1073 22537231 SAG1147 22537305 SAG1223 22537379 SAG 1356 22537503
SAG1074 22537232 SAG1148 22537306 SAG1224 22537380 SAG1357 22537504
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Locus Tag Gi
SAG1358 22537505
SAG1359 22537506
SAG1360 22537507
SAG1361 22537508
SAG 1362 22537509
SAG1363 22537510
SAG1364 22537511
SAG1365 22537512
SAG1366 22537513
SAG1367 22537514
SAG1368 22537515
SAG1369 22537516
SAG1370 22537517
SAG 1371 22537518
SAG1372 22537519
SAG1373 22537520
SAG1374 22537521
SAG1375 22537522
SAG1376 22537523
SAG 1377 22537524
SAG1378 2253752S
SAG1379 22537526
SAG1380 22537527
SAG1381 22537528
SAG1382 22537529
SAG 1383 22537530
SAG1384 22537531
SAG1385 22537532
SAG1386 22537533
SAG 1387 22537534
SAG1388 22537535
SAG1389 22537536
SAG 1390 22537537
SAG1391 22537538
SAG1392 22537539
SAG 1393 22537540
SAG1394 22537541
SAG1395 22537542
SAG 1396 22537543
SAG1397 22537544
SAG1398 22537545
SAG1399 22537546
SAG 1400 22537547
SAG 1401 22537548
SAG1402 22537549
SAG1403 22537550
SAG 1410 22537556
SAG1411 22537557
SAG1412 22537558
SAG 1413 22537559
SAG1414 22537560
SAG141S 22537561
SAG 1416 22537562
SAG1417 22537563
SAG1418 22537564
SAG 1419 22537565
SAG1420 22537566
SAG 1421 22537567
SAG1422 22537568
SAG1423 22537569
SAG1424 22537570
SAG 1425 22537571
SAG1426 22537572
SAG1427 22537573
SAG 1428 22537574
SAG 1429 22537575
Locus Tag Gi
SAG1430 22537576
SAG1431 22537577
SAG1432 22537578
SAG 1433 22537579
SAG1434 22537580
SAG1435 22537581
SAG1436 22537582
SAG1438 22537584
SAG1439 22537585
SAG1440 22537586
SAG1441 22537587
SAG1442 22537588
SAG1443 22537589
SAG 1444 22537590
SAG1447 22537592
SAG1448 22537593
SAG 1449 22537594
SAG1450 22537595
SAG1451 22537596
SAG1452 22537597
SAG14S3 22537598
SAG1454 22537599
SAG1455 22537600
SAG 1459 22537603
SAG1460 22537604
SAG1461 22537605
SAG1462 22537606
SAG1464 22537607
SAG1465 22537608
SAG1466 22537609
SAG1467 22537610
SAG1469 22537612
SAG1470 161485613
SAG1472 22537615
SAG1473 22537616
SAG1474 22537617
SAG1475 22537618
SAG1476 22537619
SAG1477 22537620
SAG1478 22537621
SAG1479 22537622
SAG1480 22537623
SAG1481 22537624
SAG1482 22537625
SAG1483 22537626
SAG1485 22537628
SAG1486 22537629
SAG1487 22537630
SAG1488 22537631
SAG1489 22537632
SAG1490 22537633
SAG1491 22537634
SAG1495 22537638
SAG1498 22537641
SAG1499 22537642
SAG1500 22537643
SAG1501 22537644
SAG1502 22537645
SAG1505 22537648
SAG1506 22537649
SAG1507 22537650
SAG 1508 22537651
SAG 1509 22537652
SAG1510 22537653
SAG1511 22537654
SAG1512 22537655
Locus Tag Gi
"TAG1513 22537656
SAG1514 22537657
SAG 1515 22537658
SAG1516 22537659
SAG1517 22537660
SAG1518 22537661
SAG1519 22537662
SAG1520 22537663
SAG1521 22537664
SAG1522 22537665
SAG 1523 22537666
SAG1524 22537667
SAG1528 22537671
SAG1529 22537672
SAG1530 22537673
SAG1531 22537674
SAG1532 22537675
SAG1533 22537676
SAG1534 22537677
SAG1535 22537678
SAG1536 22537679
SAG1537 22537680
SAG1538 22537681
SAG1540 22537683
SAG1541 22537684
SAG1542 22537685
SAG1544 22537686
SAG1545 22537687
SAG1546 22537688
SAG 1547 22537689
SAG1551 22537693
SAG1552 22537594
SAG 1553 22537695
SAG1554 22537696
SAG1555 22537697
SAG1556 22537698
SAG1557 22537699
SAG1558 22537700
SAG1559 22537701
SAG1561 22537703
SAG1562 22537704
SAG1563 22537705
SAG1564 22537706
SAG1565 22537707
SAG1566 22537708
SAG1567 22537709
SAG1569 22537710
SAG1572 22537713
SAG1573 22537714
SAG1574 22537715
SAG1575 22537716
SAG1577 22537717
SAG1578 22537718
SAG1579 22537719
SAG1580 22537720
SAG1581 22537721
SAG1583 22537723
SAG1585 22537725
SAG1586 22537726
SAG1587 22537727
SAG1588 22537728
5AG1589 22537729
SAG1590 22537730
SAG1591 22537731
SAG1592 22537732
SAG1593 22537733
Locus Tag Gi
SAG1594 22537734
SAG1595 22S3773S
SAG1596 22537736
SAG1597 22537737
SAG 1598 22537738
SAG 1599 22537739
SAG1600 22537740
SAG1601 22537741
SAG1602 22537742
SAG1603 22537743
SAG1604 22537744
SAG1605 22537745
SAG 1606 22537746
SAG1607 22537747
SAG1608 22537748
SAG1609 22537749
SAG1610 22537750
SAG 1611 22537751
SAG1612 22537752
SAG 1613 22537753
SAG1614 22537754
SAG1615 22537755 .
SAG 1616 22537756
SAG1618 22537758
SAG 16 20 22537760
SAG1621 22537761
SAG 1622 22537762
SAG1623 22537763
SAG1624 22537764
SAG1625 22537765
SAG1626 22537766
SAG1627 22537767
SAG1628 22537768
SAG 16 29 22537769
SAG1630 22537770
SAG 1631 22537771
SAG1632 22537772
SAG1633 22537773
SAG1634 22537774
SAG 163 5 22537775
SAG1637 22537777
SAG 1638 22537778
SAG1639 22537779
SAG1640 22537780
SAG1641 22537781
SAG1642 22537782
SAG 1643 22537783
SAG1645 22537785
SAG1647 22537787
SAG1648 22537788
SAG 1650 22537790
SAG1651 22537791
SAG1652 22537792
SAG1653 22537793
SAG1654 22537794
SAG 1655 22537795
SAG1656 22537796
SAG1657 22537797
SAG1658 22537798
SAG1659 22537799
SAG1660 22537800
SAG1661 22537801
SAG1662 22537802
SAG1663 22537803
SAG 1664 22537804
SAG1665 22537805
Locus Tag Gi
SAG1666 22537806
SAG1667 22537807
SAG1668 22537808
SAG 1669 22537809
SAG 1670 22537810
SAG1671 22537811
SAG1672 22537812
SAG1673 22537813
SAG1674 22537814
SAG1675 22537815
SAG 1676 22537816
SAG1677 22537817
SAG1678 22537818
SAG1679 22537819
SAG1680 22537820
SAG1681 22537821
SAG1682 22537822
SAG 1683 22537823
SAG1684 22537824
SAG1685 22537825
SAG1686 22537826
SAG1687 22537827
SAG1688 22537828
SAG1689 22537829
SAG 1690 22537830
SAG1691 22537831
SAG1692 22537832
SAG1693 22537833
SAG1694 22537834
SAG1695 22537835
SAG1704 22537844
SAG1706 22537845
SAG1707 22537846
SAG 1709 22537848
SAG 1710 22537849
SAG1711 22537850
SAG1712 22537851
SAG1713 22537852
5AG1714 22537853
SAG1715 22537854
SAG1716 22537855
SAG 1717 22537856
SAG1719 22537858
SAG1720 22537859
SAG1721 22537860
SAG1722 22537861
SAG1723 22537862
SAG1724 22537863
SAG 1725 22537864
SAG1726 22537865
SAG1727 22537866
SAG1728 22537867
SAG1729 22537868
SAG1730 22537869
SAG1731 22537870
SAG1732 22537871
SAG 1733 22537872
SAG 1734 22537873
SAG173S 22537874
SAG1736 22537875
SAG1737 22537876
SAG1738 22537877
SAG1739 22537878
SAG1740 22537879
SAG1741 22537880
SAG1742 22537881
Locus Tag Gi
SAG1743 22537882
SAG1744 22537883
SAG 1745 22537884
SAG1747 22537886
SAG1748 22537887
SAG1749 22537888
SAG1750 22537889
SAG1751 22537890
SAG 1752 22537891
SAG 1753 22537892
SAG1754 22537893
SAG1756 22537895
SAG 1757 22537896
SAG1758 22537897
SAG1759 22537898
SAG1760 22537899
SAG1761 22537900
SAG1762 22537901
SAG1763 22537902
SAG1764 22537903
SAG1765 22537904
SAG1766 22537905
SAG1767 22537906
SAG1768 22537907
SAG 1769 22537908
SAG 1770 22537909
SAG1771 22537910
SAG1772 22537911
SAG1773 22537912
SAG 1774 22537913
SAG1775 22537914
SAG1776 22537915
SAG1777 22537916
SAG1778 22537917
SAG1779 22537918
SAG1781 22537920
SAG1782 22537921
SAG1783 22537922
SAG1784 22537923
SAG1785 22537924
SAG1786 22537925
SAG1787 22537926
SAG1788 22537927
SAG1789 22537928
SAG 1790 22537929
SAG1791 22537930
SAG1792 22537931
SAG1793 22537932
SAG1794 22537933
SAG1795 22537934
SAG1796 22537935
SAG1797 22537936
SAG1799 22537938
SAG1800 22537939
SAG1801 22537940
SAG1802 22537941
SAG 1803 22537942
SAG1804 22537943
SAG1805 22537944
SAG1806 22537945
SAG 1807 22537946
SAG1808 22537947
SAG 1809 22537948
SAG1810 22537949
SAG1811 22537950
SAG 1812 22537951
Locus Tag Gi
SAG1813 22537952
SAG1814 22537953
SAG1815 22537954
SAG1816 22537955
SAG 1818 22537957
SAG1819 22537958
SAG 1820 22537959
SAG1821 22537960
SAG1822 22537961
SAG1823 22537962
SAG1824 22537963
SAG1825 22537964
SAG1826 22537965
SAG1827 22537966
SAG1828 22537967
SAG1829 22537968
SAG1830 22537969
SAG1831 22537970
SAG 183 2 22537971
SAG1833 22537972
SAG1834 22537973
SAG1863 22538002
SAG1873 22538011
SAG1887 22538025
SAG1888 22538026
SAG1889 22538027
SAG1890 22538028
SAG1891 22538029
SAG1894 22538032
SAG1895 22538033
SAG1896 22538034
SAG1909 22538047
SAG1910 22538048
SAG1911 22538049
SAG1912 22538050
SAG1913 22538051
SAG1914 22538052
SAG191S 22538053
SAG1916 22538054
SAG1917 225380S5
SAG1918 22538056
SAG1919 22538057
SAG 1920 22538058
SAG1921 22538059
SAG1922 22538060
SAG1923 22538061
SAG1924 22538062
SAG1925 22538063
SAG1926 22538064
SAG1927 22538065
SAG1928 22538066
SAG1929 22538067
SAG1930 22538068
SAG1931 22538069
SAG1932 22538070
SAG1933 22538071
SAG1934 22538072
SAG1935 22538073
SAG1936 22538074
SAG1938 22538075
SAG1939 22538076
SAG1940 22538077
SAG1941 22538078
SAG 1942 22538079
SAG1943 22538080
SAG1944 22538081
Locus Tag Gi
SAG1945 22538082
SAG1946 22S38083
SAG 1947 22538084
SAG1948 22538085
SAG1949 22538086
SAG 1950 22538087
SAG1951 22538088
SAG1952 22538089
SAG1954 22538091
SAG1958 22538094
SAG1959 22538095
SAG1960 22538096
SAG1961 22538097
SAG1962 22538098
SAG1963 22538099
SAG1964 22538100
SAG 1965 22538101
SAG 1966 22538102
SAG1967 22538103
SAG1968 22538104
SAG 1969 22538105
SAG1970 22538106
SAG1971 22538107
SAG1972 22538108
SAG1973 22538109
SAG1974 22538110
SAG1975 22538111
SAG1976 22538112
SAG1977 22538113
SAG 1978 22538114
SAG 1979 22538115
SAG1980 22538116
SAG1982 22538118
SAG 1983 22538119
SAG 1984 22538120
SAG198S 22538121
SAG2026 22538161
SAG2027 22538162
SAG2029 22538164
SAG2030 22538165
SAG2031 22538166
SAG2032 22538167
SAG2033 22538168
SAG2034 22538169
SAG2035 22538170
SAG2037 22538172
SAG2038 22538173
SAG2039 22538174
SAG2040 22538175
SAG2041 22538176
SAG2042 22538177
SAG2043 22538178
SAG2045 22538180
SAG2046 22538181
SAG2047 22538182
SAG2048 22538183
SAG2049 22538184
SAG2050 22538185
SAG2051 22538186
SAG2053 22538188
SAG2054 22538189
SAG2055 22538190
SAG2055 22538191
SAG2057 22538192
SAG2058 22538193
SAG2059 22538194
Locus Tag Gi
SAG2142 22538276
SAG2143 22538277
SAG2144 22538278
SAG2145 22538279
SAG2146 22538280
SAG2147 22538281
SAG2148 22538282
SAG2149 22538283
SAG2150. 22538284
SAG2151 22538285
SAG2152 22538286
SAG2153 22538287
SAG21S4 22538288
SAG215S 22538289
SAG2156 22538290
SAG2157 22538291
SAG2158 22538292
SAG2159 22538293
SAG2160 22538294
SAG2161 22538295
SAG2162 22538296
SAG2163 22538297
SAG2164 22538298
SAG2165 22538299
SAG2166 22538300
SAG2167 22538301
SAG2168 22538302
SAG2169 22538303
SAG2170 22538304
SAG2171 22538305
SAG2172 22538306
SAG2173 22538307
SAG2174 22538308
SAG2175 22538309
Locus Tag Gi
5AG2062 22538197
SAG2064 22538199
SAG2066 22S38201
SAG2067 22538202
SAG2068 22538203
5AG2069 22538204
SAG2070 22538205
SAG2071 22538206
SAG207-2 22538207
SAG2073 22538208
SAG2074 22538209
SAG2075 22538210
SAG2076 22538211
SAG2077 22538212
5AG2078 22538213
SAG2079 22538214
SAG2080 22538215
SAG2081 22538216
SAG2082 22538217
SAG2083 22538218
SAG2084 22538219
SAG2085 22538220
SAG2086 22538221
SAG2087 22538222
SAG2089 22538224
SAG2090 22538225
SAG2091 22538226
SAG2092 22538227
SAG2093 22538228
SAG2095 22538229
SAG2096 22538230
SAG2097 22538231
SAG2098 22538232
SAG2100 22538234
SAG2101 22538235
SAG2102 22538236
SAG2103 22538237
SAG2104 22538238
SAG2105 22538239
SAG2106 22538240
SAG 2107 22538241
SAG2108 22538242
SAG2109 22538243
SAG2110 22538244
SAG2111 22538245
SAG2121 22538255
SAG2122 22538256
SAG2123 22538257
SAG2124 22538258
SAG2125 22538259
SAG2126 22538260
SAG2127 22538261
SAG2128 22538262
SAG2129 22538263
SAG2130 22538264
SAG2131 22538265
SAG2132 22538266
SAG2133 22538267
SAG2134 22538268
SAG2135 22538269
SAG2136 22538270
SAG2137 22538271
SAG2138 22538272
SAG2139 22538273
SAG2140 22538274
SAG2141 22538275
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Locus Tag Gi
SAG0001 22S35185
SAG0002 22536187
SAG0006 22536191
SAG0007 22536192
SAG0011 22536196
SAG0012 22536197
SAG0013 22536198
SAG0014 22536199
SAGOO 15 22536200
SAGOO15 22536201
SAG0017 22536202
SAG 0018 22536203
SAGOO19 22536204
SAG0021 22536206
SAG0022 22536207
SAG0024 22536209
SAG0025 22536210
SAG0027 22536212
SAG0028 22536213
SAG0030 22536215
SAG0031 22536216
SAG0032 22536217
SAG0033 22536218
SAG0034 22536219
SAG0035 22536220
SAG0035 22536221
SAG0037 22536222
SAG0038 22536223
SAG0039 22536224
5AG0040 22536225
SAG0041 22536226
SAG0042 22536227
SAG0043 22536228
SAG0044 22536229
SAG0045 22536230
SAG0047 22536232
SAG0049 22536234
SAG0050 22536235
SAG0052 22536237
SAG0054 22536239
SAG0055 22536240
SAG0055 22536241
SAG0058 22536243
SAG0060 22536245
SAG0061 22536246
SAG0062 22536247
SAG0063 22536248
SAG0064 22536249
SAG0065 22536250
SAG0065 22536251
SAG0067 22536252
SAG0068 22536253
SAG0070 22536255
SAG0072 22536257
SAG0073 22536258
SAG0074 22536259
SAG0075 22536260
SAG0076 22536261
SAG0077 22536262
SAG0078 22536263
SAG0079 22536264
SAG008S 22536270
SAG0086 22536271
SAG0089 22536274
SAG0090 22536275
SAG0091 22536276
Locus Tag Gi
SAG0092 22S36277
SAG0094 22536279
SAG0095 22536280
SAG0096 22536281
SAG0097 22536282
SAG0098 22536283
SAG0099 22536284
SAG0100 22536285
SAG0111 22536296
SAG0112 22536297
SAG0113 22536298
SAG0115 22536300
SAG0116 22536301
SAG0117 22536302
SAG0119 22536304
SAG0121 22536306
SAG0132 22536317
SAG0136 22536321
SAGO138 22536323
SAG0139 22536324
SAG0140 22536325
SAG0141 22536326
SAG0142 22536327
SAG0143 22536328
SAG0144 22536329
SAG0145 22536330
SAG0148 22536333
SAG0150 22536335
SAG0151 22536336
SAG0152 22536337
SAG0154 22536339
SAG0155 22536340
SAG0158 22536342
SAG0159 22536343
SAG0160 22536344
SAG0161 22536345
SAG0162 22536346
SAG0164 22536348
SAG0165 22536349
SAG0167 22536351
SAG0168 22536352
SAG0169 22536353
SAG0172 22536356
SAG0173 22536357
SAG0174 22536358
SAG0176 22536360
SAG0177 22536361
SAG0178 22536362
SAG0179 22536363
SAG0180 22536364
SAG0181 22536365
SAG0182 22536366
SAG0183 22536367
SAG0184 22536368
SAG0185 22536369
SAG0187 22536371
SAG0188 22536372
SAG0189 22536373
SAG0190 22536374
SAG0191 22536375
SAG0194 22536378
SAG0196 22536380
SAG0197 22536381
SAG0198 22536382
SAG0199 22536383
SAG0200 22536384
Locus Tag Gi
SAGOlOl 22536385
SAG0202 22536386
SAG0203 22536387
SAG0204 22536388
SAG0205 22536389
SAG0206 22536390
SAG0207 22536391
SAG0208 22536392
SAG0209 22536393
SAG0210 22536394
SAG0211 22536395
SAG0214 22536398
SAG0215 22536399
SAG0220 22536404
SAG0239 22536423
SAG0241 22536425
SAG0242 22536426
SAG0244 22536428
SAG0252 22536436
SAG0254 22536438
SAG0255 22536439
SAG0256 22536440
SAG0257 22536441
SAG0258 22536442
SAG0264 22536448
SAG0265 22536449
SAG0266 22536450
SAG0268 22536452
SAG0269 22536453
SAG0270 22536454
SAG0271 22536455
SAG0272 22536456
SAG0273 22536457
SAG0274 22536458
SAG0275 22536459
SAG0276 22536460
SAG0277 22536461
SAG0279 22536463
SAG0280 22536464
SAG0281 22536465
SAG0283 22536467
SAG0284 22536468
SAG0285 161485617
SAG0286 22536470
SAG0287 22536471
SAG0288 22536472
SAG0289 22536473
SAG0290 22536474
SAG0291 22536475
SAG0292 22536476
SAG0293 22536477
SAG0294 22536478
SAG0295 22536479
SAG0296 22536480
SAG0297 22536481
SAG0298 22536482
SAG0299 22536483
SAG0300 22536484
SAG03O4 22536488
SAGO305 22536489
SAG0306 22536490
SAG0312 22536495
SAG0313 22536496
SAG0314 22536497
SAG0315 22536498
SAG0316 22536499
Locus Tag Gi
SAG0317 "22536500
SAG0318 22536501
SAG0319 22536502
SAG0320 22536503
SAG0321 22536504
SAG0322 22536505
SAG0323 22536506
SAG0324 22536507
SAG0325 22536508
SAG0326 22536509
SAG0327 22536510
SAG0328 22536511
SAG0329 22536512
SAG0330 22536513
SAG0331 22536514
SAG0332 22536515-
SAG0334 22536517
SAG0335 22536518
SAG0336 22536519
SAG0338 22536521
SAG0339 22536522
SAG0340 22536523
SAG0342 22536525
SAG0343 22536526
SAG0344 22536527
SAG0345 22536528
SAG0346 22536529
SAG0347 22536530
SAG0348 22536531
SAG0349 22536532
SAG0350 22536533
SAG0351 22536534
SAG0352 22536535
SAG0353 22536536
SAG0354 22536537
SAG0355: 22536538
SAG0356 22536539
SAG0357 22536540
SAG0358 22536541
SAG0359 22536542
SAG0360 22536543
SAG0363 22536546
SAG0364 22536547
SAG0365 22536548
SAG0366 22536549
SAG0367 22536550
SAG0368 22536551
SAG0369 22536552
SAG0370 22536553
SAG0371 22536554
SAG0373 22536556
SAG0374 22536557
SAG0375 22536558
SAG0376 22536559
SAG0377 22536560
SAG0378 161485616
SAG0379 22536562
SAG0380 22536563
SAG0382 22536565
SAG0383 22536566
SAG0385 22536568
SAG0386 22536569
SAG0387 22536570
SAG0388 22536571
SAG0389 22536572
SAG0390 22536573
Locus Tag Gi
5AG0391 22536574
SAG0392 22S36575
SAG0393 22536576
SAG0394 22536577
SAG0395 22536578
SAG0397 22536580
SAG0398 22536581
SAG0400 22536583
SAG0402 22536585
SAG0403 22536586
SAG0408 22536591
SAG0409 22536592
SAG0410 22536593
SAG0411 22536594
SAG0412 22536595
SAG0413 22536596
SAG0417 22536600
SAG0418 22536601
SAG0419 22536602
SAG0420 22536603
SAG0421 22536604
SAG0422 22536605
SAG0423 22536606
SAG0431 22536614
SAG0432 22536615
SAG0443 22536623
SAG0445 22536625
SAG0451 22536631
SAG0452 22536632
SAG0454 22536634
SAG0455 22536635
SAG0457 22536636
SAG0458 22536637
SAG0459 22536638
SAG0460 22536639
SAG0461 22536640
SAG0462 22536641
SAG0464 22536643
SAG0465 22536644
SAG0467 22536646
SAG0468 22536647
SAG0469 22536648
SAG0470 22536649
SAG0471 22536650
SAG0472 22536651
SAG0473 22536652
SAG0474 22536653
SAG0475 22536654
SAG0476 22536655
SAG0477 22536656
SAG0478 22536657
SAG0479 22S36658
SAG0480 22536659
SAG0481 22536660
SAG0484 22536663
SAG0486 22536665
SAG0487 22536666
SAG0488 22536667
SAG0490 22536669
SAG0493 22536672
SAG0494 22536673
SAG0495 22536674
SAG0496 22536675
SAG0497 22536676
SAG0498 22S36677
SAG0499 22536678
Locus Tag Gi
SAG0500 22536679
SAG0501 22536680
SAG0503 22536682
5AG0506 22536685
SAG0508 22536687
SAG0509 22536688
SAG0510 22536689
SAG0511 22536690
SAG0512 22536691
SAG0513 22536692
5AG0516 22536695
SAG0517 22536696
SAG0519 22536697
SAG0520 22536698
SAG0521 22536699
SAG0522 22536700
5AG0524 22536702
SAG0525 22536703
SAG0526 22536704
SAG0527 22536705
SAG0528 22536706
5AG0530 22536708
SAG0531 22536709
SAG0532 22536710
SAG0533 22536711
SAG0534 22536712
SAG0536 22536714
SAG0537 22536715
SAG0538 22536716
SAG0544 22536722
SAG0606 22536782
SAG0610 22536785
SAG0612 22536786
SAG0613 22536787
SAG0614 22536788
SAG0616 22536790
SAG0619 22536792
SAG0621 22536794
SAG0622 22536795
SAG0623 22536796
SAG0624 22536797
SAG0625 22536798
SAG0626 22536799
SAG0627 22536800
SAG0628 22536801
SAG0630 22536803
SAG0631 22536804
SAG0632 22536805
SAG0633 22536806
SAG0657 22536824
SAG0658 22536825
SAG0660 22536827
SAG0663 22536830
SAG0665 22536832
SAG0666 22536833
SAG0667 22536834
SAG0668 22536835
SAG0669 22536836
SAG0670 22536837
SAG0671 22536838
SAG0672 22536839
SAG0673 22536840
SAG0684 22536849
SAG0686 22536851
SAG0690 22536855
SAG0691 22536856
Locus Tag Gi
SAG0692 2253685?
SAG0695 22536859
SAG0697 22536861
SAG0698 22536862
SAG0699 22536863
SAG0700 22536864
SAG0701 22536865
SAG0702 22536866
SAG0703 22536867
5AG0704 22536868
SAG0705 22536869
SAG0706 22536870
SAG0707 22536871
SAG0708 22536872
SAG0709 22536873
SAG0711 22536875
SAG0712 22535876
SAG0714 22536878
SAG0715 22536879
SAG0716 22536880
SAG0718 22536882
SAG0719 22536883
SAG0720 22536884
SAG0721 22536885
SAG0722 22536886
SAG0723 22536887
SAG0724 22536888
SAG0725 22536889
SAG0726 22536890
SAG0727 22536891
SAG0728 22536892
SAG0729 22536893
SAG0730 22536894
SAG0731 22536895
SAG0732 22536896
SAG0733 22536897
SAG0736 22536900
SAG0738 22536902
SAG0739 22536903
SAG0741 22536905
SAG0743 22536907
SAG0744 22536908
SAG0745 22536909
SAG0746 22536910
SAG0747 161485615
SAG0748 22536912
SAG0749 22536913
SAG0750 22536914
SAG0751 22536915
SAG0752 22536916
SAG0753 22536917
SAG0757 22S36921
SAG0758 22536922
SAG0759 22536923
SAG0761 22536925
SAG0762 22536926
SAG0763 22536927
SAG0764 22536928
SAG0765 22536929
SAG0766 22536930
SAG0767 22536931
SAG0768 22536932
SAG0770 22536934
SAG0775 22536939
SAG0776 22536940
SAG0777 22536941
Locus Tag Gi
SAG0778 22535932
SAG0779 22536943
SAG0780 22536944
SAG0785 22536949
SAG0786 22536950
SAG0787 22536951
SAG0788 22536952
SAG0789 22536953
SAG0790 22536954
SAG0791 22536955
SAG0793 22536957
SAG0794 22536958
SAG0795 22536959
SAG0796 22536960
SAG0797 22536961
SAG0800 22536964
SAG0809' 22536973
SAG0810 22536974
SAG0811 22536975
SAG0812 22536976
SAG0815 22536979
SAG0818 22536982
SAG0819 22536983
SAG0820 22536984
SAG0822 22536986
SAG0823 22536987
SAG0824 22536988
SAG0825 22536989
SAG0827 22536991
SAG0828 22536992
SAG0830 22536994
SAG0831 22536995
SAG0833 22536997
SAG0835 22536999
SAG0837 22537001
SAG0838 22537002
SAG0839 22537003
SAG0840 22537004
SAG0841 22537005
SAG0842 22537006
SAG0843 22537007
SAG0845 22537009
SAG0846 22537010
SAG0848 22537012
SAG0849 22537013
SAG0850 22537014
SAG0851 22537015
SAG0852 22537016
SAG0853 22537017
SAG0856 22537019
SAG0858 22537021
SAG0859 22537022
SAG0860 22537023
SAG0861 22537024
SAG0862 22537025
SAG0863 22537026
SAG0864 22537027
SAG0867 22537030
SAG0868 22537031
SAG0869 22537032
SAG0877 22537040
SAG0879 22537042
SAG0880 22537043
SAG0881 22537044
SAG0882 22537045
SAG0885 22537048
Locus Tag Gi
SAG (MS 22537049
SAG0887 22537050
SAG0888 22537051
SAG0890 22537053
SAG0891 22537054
SAG0892 22537055
SAG0893 22537056
SAG0896 22537059
SAG0897 22537060
SAG0905 22537068
SAG0906 22537069
SAG0910 22537073
SAG0912 22537075
SAG0913 22537076
SAG0940 22537101
SAG0941 22537102
SAG0942 22537103
SAG0944 22537105
SAG0947 22537108
SAG0948 22537109
SAG0949 22537110
SAG0950 161485614
SAG0951 22537112
SAG0952 22537113
SAG0955 22537116
SAG0955 22537117
SAG0957 22537118
SAG0958 22537119
SAG0960 22537121
SAG0961 22537122
SAG0962 22537123
SAG0967 22537128
5AG0968 22537129
SAG0969 22537130
SAG0970 22537131
SAG0971 22537132
SAG0974 22537134
SAG0976 22537136
SAG0978 22537138
SAG0980 22537140
SAG0981 22537141
SAG0982 22537142
SAG0983 22537143
SAG0984 22537144
SAG0985 22537145
SAG0986 22537146
SAG0987 22537147
SAG0988 22537148
SAG0989 22537149
5AG0990 22537150
SAG0991 22537151
SAG0994 22537154
SAG0999 22537159
SAG1004 22537164
SAG1005 22537165
SAG1006 22537166
SAG1008 22537168
SAG1009 22537169
SAG1010 22537170
SAG 1012 22537172
SAG1013 22537173
SAG1015 22537175
SAG1016 22537176
SAG1027 22537186
SAG1033 22537192
SAG1034 22537193
Locus Tag Gi
5AG1035 22537194
SAG1036 22537195
SAG1041 22537200
SAG1042 22537201
SAG1043 22537202
SAG1044 22537203
SAG1045 22537204
SAG1046 22537205
SAG1047 22537206
SAG1048 22537207
SAG1049 22537208
SAG1052 22537210
SAG1054■ 22537212
SAG1055 22537213
SAG1056 22537214
SAG1058 22537216
SAG1059 22537217
SAG1060 22537218
SAG1061 22537219
SAG1062 22537220
SAG1063 22537221
SAG1064 22537222
SAG1065 22537223
SAG1066 22537224
SAG1070 22537228
SAG1072 22537230
SAG1073 22537231
SAG1074 22537232
SAG1075 22537233
SAG1076 22537234
SAG1077 22537235
SAG1078 22537236
5AG1079 22537237
SAG1081 22537239
SAG1082 22537240
SAG1083 22537241
SAG1084 22537242
SAG1085 22537243
SAG1086 22537244
SAG1087 22537245
SAG1088 22537246
SAG1092 22537250
SAG1093 22537251
SAG1095 22537253
SAG1096 22537254
SAG1097 22537255
SAG1098 22537256
SAG1099 22537257
SAG1100 22537258
5AG1102 22537260
SAG1103 22537261
SAG1104 22537262
SAG1105 22537263
SAG1107 22537255
SAG1108 22537266
5AG1109 22537267
SAG1110 22537268
SAG1111 22537269
SAG1112 22537270
SAG1113 22537271
SAG1114 22537272
SAG1115 22537273
SAG1116 22537274
SAG1117 22537275
SAG1118 22537276
SAG1119 22537277
Locus Tag Gi
“ 5AG1I20 22537278
SAG1124 22537282
5AG1125 22537283
SAG1142 22537300
SAG1143 22537301
SAG1146 22537304
SAG1147 22537305
SAG1148 22537306
SAG1149 22537307
SAG1151 22537309
SAG1153 22537311
SAG11S4 22537312
SAG1156 22537314
SAG1157 22537315
SAG1159 22537317
SAG1161 22537319
SAG1162 22537320
SAG1170 22537328
SAG1171 22537329
SAG1172 22537330
SAG1173 22537331
SAG1174 22537332
SAG1175 22537333
SAG1176 22537334
SAG1178 22537336
SAG1179 22537337
SAG1180 22537338
SAG1181 22537339
SAG1182 22537340
SAG1185 22537343
SAG1188 22537346
SAG1190 22537348
SAG1191 22537349
SAG1192 22537350
SAG1193 22537351
SAG1194 22537352
SAG1195 22537353
SAG1196 22537354
SAG1197 22537355
SAG1198 22537356
SAG1199 22537357
SAG1200 22537358
SAG1201 22537359
SAG1202 22537360
SAG1203 22537361
SAG1204 22537362
SAG1205 22537363
SAG1206 22537364
SAG1210 22537368
SAG1211 22537369
SAG1213 22537371
SAG1214 22537372
SAG 1215 22537373
SAG1218 22537375
SAG1219 22537376
SAG1220 22537377
SAG1228 22537384
SAG1229 22537385
SAG1230 22537385
SAG1233 22537387
SAG1237 22537390
SAG1243 22537394
SAG1244 22537395
SAG1245 22537396
SAG1302 22537449
SAG1305 22537452
Locus Tag Gi
SAG1306 22537453
SAG1307 22537454
SAG1311 22537458
SAG1312 22537459
SAG1314 22537461
SAG1316 22537463
SAG1318 22537465
SAG1319 22537466
SAG1320 22537467
SAG1321 22537468
SAG1322 22537469
SAG1323 22537470
SAG1324 22537471
SAG1325 22537472
SAG1326 22537473
SAG1327 22537474
SAG1328 22537475
SAG1334 22537481
SAG1335 22537482
SAG1336 22537483
SAG1337 22537484
SAG1338 22537485
SAG1340 22537487
SAG1341 22537488
SAG1342 22537489
SAG1344 22537491
SAG 1345 22537492
SAG1347 22537494
SAG1349 22537496
SAG1350 22537497
SAG1351 22537498
SAG1352 22537499
SAG1354 22537501
SAG1363 22537510
SAG1364 22537511
SAG1365 22537512
SAG1366 22537513
SAG 1367 22537514
SAG1368 22537515
SAG1369 22537516
SAG1370 22537517
SAG 1371 22537518
SAG1372 22537519
SAG1373 22537520
SAG1376 22537523
SAG1378 22537525
SAG1379 22537526
SAG1380 22537527
SAG1382 22537529
SAG1384 22537531
SAG1390 22537537
SAG1391 22537538
SAG1392 22537539
SAG1394 22537541
SAG1395 22537542
SAG1396 22537543
SAG1397 22537544
SAG1399 22537546
SAG1400 22537547
SAG1401 22537548
SAG1402 22537549
SAG1403 22537550
SAG1410 22537556
SAG1411 22537557
SAG 1412 22537558
SAG1413 22537559
Locus Tag Gi Locus Tag Gi
SA61414 ”22537500'' SAG1572 ”22537713'
SAG 1415 22537561 SAG1573 22537714
SAG1416 22537562 SAG 1575 22537716
SAG 1417 22537563 5AG1577 22537717
SAG 1418 22537564 SAG1578 22537718
SAG1420 22537566 SAG1579 22537719
SAG1421 22537567 SAG1580 22537720
SAG142S 22537572 SAG1581 22537721
SAG1434 22537580 SAG1583 22537723
SAG1435 22537582 SAG1587 22537727
SAG1448 22537593 SAG1590 22537730
SAG1464 22537607 SAG1591 22537731
SAG1465 22537608 SAG1592 22537732
SAG1466 22537609 SAG1593 22537733
SAG1467 22537610 SAG1596 22537736
SAG1469 22537612 SAG1597 22537737
SAG1470 161485613 SAG1598 22537738
SAG1472 22537615 SAG1602 22537742
SAG1473 22537616 SAG1603 22537743
SAG1474 22537617 SAG1604 22537744
SAG1475 22537618 SAG160S 22537745
SAG1476 22537619 SAG1606 22537746
SAG1477 22537620 SAG1607 22537747
SAG 1478 22537621 SAG1608 22537748
SAG1479 22537622 SAG1609 22537749
SAG1481 22537624 SAG1610 22537750
SAG1482 22537625 SAG1611 22537751
SAG1483 22537626 5AG1612 22537752
SAG1485 22537628 SAG1613 22537753
SAG1499 22537642 SAG1614 22537754
SAG150Q 22537643 SAG161S 22537755
SAG1507 22537650 SAG1616 22537756
SAG1512 22537655 5AG1618 22537758
SAG1513 22537656 SAG1620 22537760
SAG1515 22537658 SAG1621 22537761
SAG1516 22537659 SAG1622 22537762
SAG1517 22537660 SAG1623 22537763
SAG1518 22537661 SAG1625 22537765
SAG1519 22537662 SAG1626 22537766
SAG1523 22537666 SAG1627 22537767
SAG1524 22537667 SAG1628 22537768
SAG1528 22537671 SAG1629 22537769
SAG1534 22537677 SAG1638 22537778
SAG1535 22537678 SAG1639 22537779
SAG1536 22537679 SAG1640 22537780
SAG1537 22537680 SAG 1643 22537783
SAG1538 22537681 SAG1645 22537785
SAG1542 22537685 SAG1647 22537787
SAG1544 22537686 SAG1648 22537788
SAG1545 22537687 SAG1651 22537791
SAG1546 22537688 SAG1652 22537792
SAG1547 22537689 SAG1653 22537793
SAG1551 22537693 SAG 1654 22537794
SAG1552 22537594 SAG1656 22537796
SAG1553 22537695 SAG1657 22537797
SAG1554 22537696 SAG1659 22537799
SAG1555 22537697 SAG1667 22537807
SAG1556 22537698 SAG1668 22537808
SAG 1557 22537699 SAG1669 22537809
SAG1559 22537701 SAG1671 22537811
SAG1561 22537703 SAG1672 22537812
SAG1562 22537704 SAG1676 22537816
SAG1563 22537705 SAG1686 22537826
SAG1564 22537706 SAG 1687 22537827
SAG1567 22537709 SAG1688 22537828
SA61569 22537710 SAG1689 22537829
Locus Tag Gi Locus Tag Gi
SAG1690 22537830 SAG1790 22537929
SAG1691 22537831 SAG1791 22537930
SAG1693 22537833 SAG1792 22537931
SAG1694 22537834 SAG1796 22537935
SAG1695 22537835 SAG1797 22537936
SAG1706 22537845 SAG1799 22537938
SAG1709 22537848 SAG1800 22537939
SAG1710 22537849 SAG1801 22537940
SAG1711 22537850 SAG1802 22537941
5AG1715 22537854 SAG1804 22537943
SAG1716 22537855 SAG1806 22537945
SAG1717 22537856 SAG1808 22537947
SAG1719 22537858 SAG1809 22537948
5AG1720 22537859 SAG1810 22537949
SAG1721 22537860 SAG1811 22537950
SAG1722 22537861 SAG1812 22537951
5AG1723 22537862 SAG1813 22537952
SAG1724 22537863 SAG1814 22537953
SAG1725 22537864 SAG1816 22537955
SAG1726 22537865 SAG1819 22537958
SAG1727 22537866 SAG1821 22537960
SAG1729 22537868 SAG1822 22537961
SAG1730 22537869 SAG1823 22537962
SAG1731 22537870 SAG1824 22537963
SAG1732 22537871 SAG1825 22537964
SAG1733 22537872 SAG1826 22537965
SAG1735 22537874 SAG1827 22537966
SAG1736 22537875 SAG1828 22537967
SAG1737 22537876 SAG1829 22537968
SAG1738 22537877 SAG1830 22537969
SAG1739 22S37878 SAG1832 22537971
SAG1740 22537879 SAG1833 22537972
SAG1741 22537880 SAG1834 22537973
SAG1747 22537886 SAG1888 22538026
SAG1748 22537887 SAG1889 22538027
SAG1750 22537889 SAG1890 22538028
SAG1751 22537890 SAG1891 22538029
SAG1754 22537893 SAG1894 22538032
SAG1756 22537895 SAG1895 22538033
SAG1757 22537896 SAG1896 22538034
SAG1758 22537897 SAG1909 22538047
SAG1759 22537898 SAG1910 22538048
SAG1760 22537899 SAG1911 22538049
SAG1761 22537900 SAG1913 22538051
SAG1762 22537901 SAG1914 22538052
SAG 17 63 22537902 SAG1915 22538053
SAG1764 22537903 SAG1916 22538054
SAG1766 22537905 SAG1918 22538056
SAG1767 22537906 SAG1919 22538057
SAG1771 22537910 SAG1920 22538058
SAG1772 22537911 SAG1921 22538059
SAG1773 22537912 SAG1922 22538060
SAG1774 22537913 SAG1923 22538061
SAG1775 22537914 SAG1924 22538062
SAG1776 22537915 SAG1925 22538063
SAG1777 22537916 SAG1926 22538064
SAG1778 22537917 SAG1927 22538065
SAG1779 22537918 SAG1928 22538066
SAG1781 22537920 SAG1929 22538067
SAG1782 22537921 SAG1930 22538068
SAG1783 22537922 SAG 193 2 22538070
SAG1784 22537923 SAG1934 22538072
SAG1786 22537925 SAG1935 22538073
SAG1787 22537926 SAG1938 22538075
SAG1788 22537927 SAG 193 9 22538076
SAG1789 22537928 SAG1941 22538078
Locus Tag Gi
SAG1942 22538079
SAG1943 22538080
SAG 1944 22538081
SAG 1945 22538082
■ SAG1946 22538083
SAG 1947 22538084
SAG 1948 22538085
SAG1949 22538086
SAG1950 22538087
SAG1951 22538088
SAG1952 22538089
SAG1954 22538091
SAG1958 22538094
SAG1959 22538095
SAG1960 22538096
SAG1961 22538097
SAG1962 22538098
SAG1963 22538099
SAG1964 22538100
SAG1965 22538101
SAG1966 22538102
SAG1968 22538104
SAG1969 22538105
SAG1970 22538106
SAG1972 22538108
SAG1973 22538109
SAG1974 22538110
SAG1975 22538111
SAG 1976 22538112
SAG1977 22538113
SAG1978 22538114
SAG1979 22538115
SAG1980 22538116
SAG1982 22538118
SAG1983 22538119
SAG1984 22538120
SAG2032 22538167
SAG2033 22538168
SAG2034 22538169
SAG2035 22538170
SAG2037 22538172
SAG2038 22538173
SAG2039 22538174
SAG2040 22538175
SAG2043 22538178
SAG2046 22538181
SAG2047 22538182
SAG2049 22538184
SAG2050 22538185
SAG2051 22538186
SAG2053 22538188
SAG205S 22538190
SAG2056 22538191
SAG2057 22538192
SAG2058 22538193
SAG2062 22538197
SAG2064 22538199
SAG2066 22538201
SAG2068 22538203
SAG2069 22538204
SAG2070 22538205
SAG2072 22538207
SAG2073 22538208
SAG2075 22538210
SAG2078 22538213
SAG2079 22538214
Locus Tag Gi
5AG2089 22538224
SAG2090 22538225
SAG2092 22538227
SAG2096 22538230
SAG2100 22538234
SAG2101 22538235
SAG2102 22538236
SAG 2103 22538237
SAG2104 22538238
SAG2105 22538239
SAG2106 22538240
SAG2107 22538241
SAG2108 22538242
SAG2109 22538243
SAG2110 22538244
SAG2121 22538255
SAG2122 22538256
SAG2123 22538257
SAG 2124 22538258
SAG2125 22538259
SAG2126 22538260
SAG2127 22538261
SAG2129 22538253
SAG2131 22538265
SAG2132 22538266
SAG2133 22538267
SAG2134 22538268
SAG2135 22538269
SAG2136 22538270
SAG2137 22538271
SAG2138 22538272
SAG2142 22538276
SAG2143 22538277
SAG2144 22538278
SAG 2145 22538279
SAG 2146 22538280
SAG2147 22538281
SAG2149 22538283
SAG2150 22538284
SAG2152 22538286
SAG2157 22538291
SAG2158 22538292
SAG2160 22538294
SAG2161 22538295
SAG2162 22538296
SAG 2163 22538297
SAG 2165 22538299
SAG2166 22538300
SAG2167 22538301
SAG2168 22538302
SAG2170 22538304
SAG2171 22538305
5AG2172 22538306
SAG2173 22538307
SAG2174 22538308
SAG2175 22538309
